HELICOBACTER PYLORI CAGI REGION

Abstract: Helicobacter pylori is known to cause or be a cofactor in type B gastritis, peptic ulcers, and gastric tumors. In both developed and developing countries, a high percentage of people are infected with this bacterium. The present invention relates generally to a certain H. pylori region located 5' to the CagA gene locus, to proteins encoded thereby, and to the use of these genes and proteins for diagnostic and vaccine applications.

Description: HELICOBACTER PYLORI CAGI REGION 1. Field of the Disclosure The present invention relates generally to certain Helicobacter pylori genetic regions, to the proteins expressed by these regions, and to the use of these genes and proteins for diagnostic and vaccine applications. 2. Brief Description of Related Art Helicobacter pylori is a curved, microaerophilic, gram negative bacterium that has been isolated for the first time in 1982 from stomach biopsies of patients with chronic gastritis, Warren et al., Lancet i: 1273-75 (1983). Originally named Campylobacter pylori, it has been recognized to be part of a separate genus named Helicobacter. Goodwin et al., Int J. Syst. Bacteriol. 39:397-405 (1989). The bacterium colonizes the human gastric mucosa, and infection can persist for decades. During the last few years, the presence of the bacterium has been associated with chronic gastritis type B, a condition that may remain asymptomatic in most infected persons but increases considerably the risk of peptic ulcer and gastric adenocarcinoma. The most recent studies strongly suggest that H. pylori infection may be either a cause or a cofactor of type B gastritis, peptic ulcers, and gastric tumors, see e.g., Blaser, Gastroenterology 93:371-83 (1987); Dooley et al., New Engl. J. ed. 321:1562-66 (1989); Parsonnet et al., New Engl. J. Med. 325:1127-31 (1991). H. pylori is believed to be transmitted by the oral route, Thomas et al., Lancet i:340, 1194 (1992), and the risk of infection increases with age, Graham et al., Gastroenterology 100:1495-1501 (1991), and is facilitated by crowding, Drumm et al., New Engl. J. Med. 4322:359-63 (1990); Blaser, Clin. Infect Dis. 15:386-93 (1992). In developed countries, the presence of antibodies against H. pylori antigens increases from less than 20% to over 50% in people 30 and 60 years old respectively, Jones et al., Med. Microbio. 22:57-62 (1986); Morris et al., N.Z. Med. J. 99:657-59 (1986), while in developing countries over 80% of the population are already infected by the age of 20, Graham et al., Digestive Diseases and Sciences 36:1084-88 (1991). H. pylori factors that have been identified so far include the flagella that are probably necessary to move across the mucus layer, see e.g., Leying et al., Mol. Microbiol. 6:2863-74 (1992); the urease that is necessary to neutralize the acidic environment of the stomach and to allow initial colonization, see e.g., Cussac et al., J. Bacteriol. 174:2466-73 (1992), Perez-Perez et at., J. Infect I rnun. 60:3658-3663 (1992), Austin et al., J. Bacteriol. 174:7470-73 (1992), PCT Publ. No. WO 90/04030; the H. pylori cytotoxin (sometimes referred to as VacA, as it causes vacuolation), see e.g., PCT Publ. No. WO 93/18150, Telford, J.L et al., J. Exp. Med. 179:1653-58 (1994), Cover et al., J. Bio. Chem. 267:10570-75 (1992), Cover et al., J. Clin. Invest. 90:913-18 (1992), Leunk, Rev. Infect Dis. 13:5686-89 (1991); the H. pylori heat shock protein, see e.g., PCT Publ. No. WO 93/18150, Evans et al., Infect. Immun. 60:2125- 27 (1992), Dunn et al., Infect. Immun. 60:1946-51 (1992), Austin et al., J. Bacteriol. 174:7470-73 (1992); and the cytotoxin-associated protein, CagA, see e.g., PCT Publ. No. WO 93/18150, Covacci, A., et al., Proc. Natl. Acad. Sci. USA 90:5791-95 (1993), Tummuru, M.K. et al., Infect. Immun. 61:1799-1809 (1994). Currently, H. pylori strains can be partitioned into at least two major groups, which either express (Type I) or do not express (Type II) the cytotoxin and the CagA proteins. Type I strains contain the CagA and toxin genes and produce active forms of these antigens. Type II strains lack the CagA locus and fail to express the cytotoxin. The association between the presence of the CagA gene and cytotoxicity suggests that the product of the CagA gene is necessary for the transcription, folding, export or function of the cytotoxin. Epidemiological analysis indicate that Type I bacteria are associated with duodenal ulcerations, gastric ulceration and sever forms of active gastritis. For a general review of the pathogenic role of H. pylori in peptic ulcer, see Telford, J.L, et al., TibTech 12:420-426 (1994). SUMMARY OF THE INVENTION The present invention describes nucleotide sequences located at the 5' region of the CagA gene. It has been found that the absence of the CagA gene in Type I strains is associated with the absence of genetic sequences located 5' of the CagA locus. This general region has been designated CagI and may encode virulence factors restricted to Type I strains. Sequences from this region were able to recognize homologous sequences in all Type I strains but failed to hybridize with DNA from Type II strains. Thus, this region has important implications for diagnosis of pathogenic Type I bacteria. The present invention pertains not only to this CagI region, but also to recombinant materials associated therewith, such as vectors, host cells, and proteins encoded by such regions. The understanding at the molecular level of the nature and the role of this region and the availability of recombinant production has important implications for the development of new diagnostics for H. pylori and for the design of vaccines that may prevent H. pylori infection and treat disease. As such, this region has applications for diagnostics and vaccines. The present invention includes methods for diagnosing those diseases associated with H. pylori. As H. pylori has been associated with type B gastritis, peptic ulcers, and gastric adenocarcinoma, it is hoped that the present invention will assist in early detection and alleviation of these disease states. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a schematic diagram of the H. pylori CagI region showing location of specific clones. Fig. 2 is the nucleotide and predicted amino acid sequences, as well as restriction enzyme sites, for the H. pylori CagI locus, as represented by three sequence segments (see below). Fig. 3 is the complete nucleotide sequence for the H. pylori CagI locus (19,932 base pairs). Fig. 4 are the putative open reading frames (ORF) for the CagI locus and their possible homology with other proteins. DETAILED DESCRIPTION OF THE INVENTION A. General Methodology The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, et al., MOLECULAR CLONING; A LABORATORY MANUAL, SECOND EDITION (1989); DNA CLONING, VOLUMES I AND II (D.N Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed, 1984); NUCLEIC ACID HYBRIDIZATION (B.D. Hames & S.J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B.D. Hames & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R.I. Freshney ed. 1986); IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London), Scopes, (1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition (Springer-Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, VOLUMES l-IV (D.M. Weir and C. C. Blackwell eds 1986). Standard abbreviations for nucleotides and amino acids are used in this specification. All publications, patents, and patent applications cited herein are incorporated by reference. B. Definitions "CagI" refers to the genetic regions located 5' to the CagA locus, whose absence correlates with the absence of the CagA gene in Type I bacterial strains. The nucleotide and putative amino acid sequences of CagI are shown in Figs. 2, 3, and 4. Examples of proteins encoded by the CagI region that can be used in the present invention include polypeptides with minor amino acid variations from the natural amino acid sequence of the protein; in particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonably predictable that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological activity. Polypeptide molecules having substantially the same amino acid sequence as the protein but possessing minor amino acid substitutions that do not substantially affect the functional aspects are within the definition of the protein. A significant advantage of producing the protein by recombinant DNA techniques rather than by isolating and purifying a protein from natural sources is that equivalent quantities of the protein can be produced by using less starting material than would be required for isolating the protein from a natural source. Producing the protein by recombinant techniques also permits the protein to be isolated in the absence of some molecules normally present in cells. Indeed, protein compositions entirely free of any trace of human protein contaminants can readily be produced because the only human protein produced by the recombinant non-human host is the recombinant protein at issue. Potential viral agents from natural sources and viral components pathogenic to humans are also avoided. The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature. Thus, this term also encompasses the situation wherein the H. pylori bacterium genome is genetically modified (e.g., through mutagenesis) to produce one or more altered polypeptides. The term "polynucleotide" as used herein refers to a polymeric form of a nucleotide of any length, preferably deoxyribonucleotides, and is used interchangeably herein with the terms "oligonucleotide" and "oligomer." The term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA, as well as antisense polynucleotides. It also includes known types of modifications, for example, the presence of labels which are known in the art, methylation, end "caps," substitution of one or more of the naturally occurring nuc- leotides with an analog, intemucleotide modifications such as, for example, replace¬ ment with certain types of uncharged linkages (e.g., methyl phosphonates, phos- photriesters, phosphoamidates, carbamates, etc.) or charged linkages (e.g., phos- phorothioates, phosphorodithioates, etc.), introduction of pendant moieties, such as, for example, proteins (including nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive species, boron, oxidative moieties, etc.), alkylators (e.g., alpha anomeric nucleic acids, etc.). By "genomic" is meant a collection or library of DNA molecules which are derived from restriction fragments that have been cloned in vectors. This may include all or part of the genetic material of an organism. By "cDNA" is meant a complimentary mRNA sequence that hybridizes to a complimentary strand of mRNA. As used herein, the term "oligomer" refers to both primers and probes and is used interchangeably herein with the term "polynucleotide." The term oligomer does not connote the size of the molecule. However, typically oligomers are no greater than 1000 nucleotides, more typically are no greater than 500 nucleotides, even more typically are no greater than 250 nucleotides; they may be no greater than 100 nucleotides, and may be no greater than 75 nucleotides, and also may be no greater than 50 nucleotides in length. The term "primer" as used herein refers to an oligomer which is capable of acting as a point of initiation of synthesis of a polynucleotide strand when used under appropriate conditions. The primer will be completely or substantially complementary to a region of the polynucleotide strand to be copied. Thus, under conditions conducive to hybridization, the primer will anneal to the complementary region of the analyte strand. Upon addition of suitable reactants, (e.g., a polymerase, nucleotide triphosphates, and the like), the primer will be extended by the polymerizing agent to form a copy of the analyte strand. The primer may be single-stranded or alternatively may be partially or fully double-stranded. The terms "analyte polynucleotide" and "analyte strand" refer to a single- or double-stranded nucleic acid molecule which is suspected of containing a target sequence, and which may be present in a biological sample. As used herein, the term "probe" refers to a structure comprised of a polynucleotide which forms a hybrid structure with a target sequence, due to complementarily of at least one sequence in the probe with a sequence in the target region. The polynucleotide regions of probes may be composed of DNA, and/or RNA, and or synthetic nucleotide analogs. Included within probes are "capture probes" and "label probes". As used herein, the term "target region" refers to a region of the nucleic acid which is to be amplified and/or detected. The term "target sequence" refers to a sequence with which a probe or primer will form a stable hybrid under desired conditions. The term "capture probe" as used herein refers to a polynucleotide probe comprised of a single-stranded polynucleotide coupled to a binding partner. The single-stranded polynucleotide is comprised of a targeting polynucleotide sequence, which is complementary to a target sequence in a target region to be detected in the analyte polynucleotide. This complementary region is of sufficient length and complementarily to the target sequence to afford a duplex of stability which is sufficient to immobilize the analyte polynucleotide to a solid surface (via the binding partners). The binding partner is specific for a second binding partner; the second binding partner can be bound to the surface of a solid support, or may be linked indirectly via other structures or binding partners to a solid support. The term "targeting polynucleotide sequence" as used herein refers to a polynucleotide sequence which is comprised of nucleotides which are complementary to a target nucleotide sequence; the sequence is of sufficient length and complementarily with the target sequence to form a duplex which has sufficient stability for the purpose intended. The term "binding partner" as used herein refers to a molecule capable of binding a ligand molecule with high specificity, as for example an antigen and an antibody specific therefor. In general, the specific binding partners must bind with sufficient affinity to immobilize the analyte copy/complementary strand duplex (in the case of capture probes) under the isolation conditions. Specific binding partners are known in the art, and include, for example, biotin and avidin or streptavidin. IgG and protein A, the numerous known receptor-ligand couples, and complementary polynucleotide strands. In the case of complementary polynucleotide binding partners, the partners are normally at least about 15 bases in length, and may be at least 40 bases in length; in addition, they have a content of Gs and Cs of at least about 40% and as much as about 60%. The polynucleotides may be composed of DNA, RNA, or synthetic nucleotide analogs. The term "coupled" as used herein refers to attachment by covalent bonds or by strong non-covalent interactions (e.g., hydrophobic interactions, hydrogen bonds, etc.). Covalent bonds may be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like. The term "support" refers to any solid or semi-solid surface to which a desired binding partner may be anchored. Suitable supports include glass, plastic, metal, polymer gels, and the like, and may take the form of beads, wells, dipsticks, membranes, and the like. The term "label" as used herein refers to any atom or moiety which can be used to provide a detectable (preferably quantifiable) signal, and which can be at- tached to a polynucleotide or polypeptide. As used herein, the term "label probe" refers to a polynucleotide probe which is comprised of a targeting polynucleotide sequence which is complementary to a target sequence to be detected in the analyte polynucleotide. This complementary region is of sufficient length and complementarily to the target sequence to afford a duplex comprised of the "label probe" and the "target sequence" to be detected by the label. The label probe is coupled to a label either directly, or indirectly via a set of ligand molecules with high specificity for each other, including multimers. The term "multimer," as used herein, refers to linear or branched poly¬ mers of the same repeating single-stranded polynucleotide unit or different single-stranded polynucleotide units. At least one of the units has a sequence, length, and composition that permits it to hybridize specifically to a first single-stranded nucleotide sequence of interest, typically an analyte or a polynucleotide probe (e.g., a label probe) bound to an analyte. In order to achieve such specificity and stability, this unit will normally be at least about 15 nucleotides in length, typically no more than about 50 nucleotides in length, and preferably about 30 nucleotides in length; moreover, the content of Gs and Cs will normally be at least about 40%, and at most about 60%. In addition to such unit(s), the multimer includes a multiplicity of units that are capable of hybridizing specifically and stably to a second single-stranded nucleotide of interest, typically a labeled polynucleotide or another multimer. These units are generally about the same size and composition as the multimers discussed above. When a multimer is designed to be hybridized to another multimer, the first and second oligonucleotide units are heterogeneous (different), and do not hybridize with each other under the conditions of the selected assay. Thus, multimers may be label probes, or may be ligands which couple the label to the probe. A "replicon" is any genetic element e.g., a plasmid, a chromosome, a virus, a cosmid, etc. that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control. This may include selectable markers. "PCR" refers to the technique of polymerase chain reaction as described in Saiki, et al., Nature 324:163 (1986); and Scharf et al., Science (1986) 233:1076- 1078; and U.S. 4,683,195; and U.S. 4,683,202. As used herein, x is "heterologous" with respect to y if x is not naturally associated with y in the identical manner; i.e., x is not associated with y in nature or x is not associated with y in the same manner as is found in nature. "Homology" refers to the degree of similarity between x and y. The cor¬ respondence between the sequence from one form to another can be determined by techniques known in the art. For example, they can be determined by a direct comparison of the sequence information of the polynucleotide. Alternatively, homology can be determined by hybridization of the polynucleotides under conditions which form stable duplexes between homologous regions (for example, those which would be used prior to S 1 digestion), followed by digestion with single-stranded specific nuclease(s), followed by size determination of the digested fragments. A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment "Control sequence" refers to polynucleotide sequences which are neces¬ sary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this region may represent a portion of a coding sequence or a total coding sequence. A "coding sequence" is a polynucleotide sequence which is translated into a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the δ'-terminus and a translation stop codon at the 3 * -teιminus. A coding sequence can include, but is not limited to, cDNA, and recombinant polynucleotide sequences. As used herein, the term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally oc¬ curring and non-naturally occurring. A polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is inv munologically identifiable with a polypeptide encoded in the sequence. This terminology also includes a polypeptide expressed from a designated nucleic acid sequence. "Immunogenic" refers to the ability of a polypeptide to cause a humoral and/or cellular immune response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. "Neutralization" refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent. "Epitope" refers to an antigenic determinant of a peptide, polypeptide, or protein; an epitope can comprise 3 or more amino acids in a spatial conformation unique to the epitope. Generally, an epitope consists of at least 5 such amino acids and, more usually, consists of at least 8-10 such amino acids. Methods of determining spatial conformation of amino acids are known in the art and include, for example, x- ray crystallography and 2-dimensional nuclear magnetic resonance. Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen. Treatment" as used herein, refers to prophylaxis and/or therapy (i.e., the modulation of any disease symptoms). An "individual" indicates an animal that is susceptible to infection by H. pylori and includes, but is not limited to, primates, including humans. A "vaccine" is an immunogenic, or otherwise capable of eliciting protection against H. pylori, whether partial or complete, composition useful for treatment of an individual. As such, it may include but is not limited to a modified bacterium (e.g., chemical or genetic alterations); bacterial protein subunits, whether recombinantly produced or purified from cell lysates; bacterial genetic material employed in polynucleotide vaccines, etc. H. pylori proteins may be used for producing antibodies, either monoclonal or polyclonal, specific to the proteins. The methods for producing these antibodies are known in the art. "Recombinant host cells", "host cells," "cells," "cell cultures," and other such terms denote, for example, microorganisms, insect cells, and mammalian cells, that can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent due to natural, accidental, or deliberate mutation. Examples for mammalian host cells include Chinese hamster ovary (CHO) and monkey kidney (COS) cells. Specifically, as used herein, "cell line," refers to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants. The term "cell lines" also includes immortalized cells. Preferably, cell lines include nonhybrid cell lines or hybridomas to only two cell types. As used herein, the term "microorganism" includes prokaryotic and eukaryotic microbial species such as bacteria and fungi, the latter including yeast and filamentous fungi. "Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome. By "purified" and "isolated" is meant when referring to a polypeptide or nucleotide sequence, that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type. The term "purified" as used herein preferably means at least 75% by weight more preferably at least 85% by weight, more preferably still at least 95% by weight and most preferably at least 98% by weight of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000, can be present). C. Nucleic Acid Assays Using as a basis the genome of H. pylori, and more particularly, the genetic region of CagI, polynucleotide probes of approximately 8 nucleotides or more can be prepared which hybridize with the positive strand(s) of the RNA or its complement as well as to cDNAs. These polynucleotides serve as probes for the detection, isolation and/or labeling of polynucleotides which contain nucleotide sequences, and/or as primers for the transcription and/or replication of the targeted sequences. Each probe contains a targeting polynucleotide sequence, which is comprised of nucleotides which are complementary to a target nucleotide sequence; the sequence is of sufficient length and complementarily with the sequence to form a duplex which has sufficient stability for the purpose intended. For example, if the purpose is the isolation, via immobilization, of an analyte containing a target sequence, the probes will contain a polynucleotide region which is of sufficient length and complementarily to the targeted sequence to afford sufficient duplex stability to immobilize the analyte on a solid surface under the isolation conditions. For example, also, if the polynucleotide probes are to serve as primers for the transcription and/or replication of target sequences, the probes will contain a polynucleotide region of suf¬ ficient length and complementarily to the targeted sequence to allow for replication. For example, also, if the polynucleotide probes are to be used as label probes, or are to bind to multimers, the targeting polynucleotide region would be of sufficient length and complementarily to form stable hybrid duplex structures with the label probes and or multimers to allow detection of the duplex The probes may contain a minimum of about 4 contiguous nucleotides which are complementary to the targeted sequence; usually the oligomers will contain a minimum of about 8 continuous nucleotides which are complementary to the targeted sequence, and preferably will contain a minimum of about 14 contiguous nucleotides which are complementary to the targeted sequence. The probes, however, need not consist only of the sequence which is complementary to the targeted sequence. They may contain additional nucleotide sequences or other moieties. For example, if the probes are to be used as primers for the amplification of sequences via PCR, they may contain sequences which, when in duplex, form restriction enzyme sites which facilitate the cloning of the amplified sequences. For example, also, if the probes are to be used as "capture probes" in hybridization assays, they will be coupled to a "binding partner" as defined above. Preparation of the probes is by means known in the art, including, for example, by methods which include excision, transcription or chemical synthesis. D. Expression Systems Once the appropriate H. pylori coding sequence is isolated, it can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, bacteria, and yeast i. Mammalian Systems Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation, Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd ed (1989). Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallotheionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells. The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter, Maniatis et al., Science 236:1237 (1989); Alberts et al. Molecular Biology of the Cell. 2nd ed (1989). Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer, Dijkema et al (1985) EMBO J. 4:761, and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, Gorman et al. (1982) Proc. Natl. Acad. Sci. 79:6777, and from human cytomegalovirus, Boshart et al. (1985) Cell 41:5221. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion, Sassone-Corsi et al. (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237. A DNA molecule may be expressed intracellulariy in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide. Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells. Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation, Bimstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) Termination and 3' end processing of eukaryotic RNA. In Transcription and splicing (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from SV40, Sambrook et al (1989). Molecular Cloning: A Laboratory Manual. Some genes may be expressed more efficiently when introns (also called intervening sequences) are present Several cDNAs, however, have been effi¬ ciently expressed from vectors that lack splicing signals (also called splice donor and acceptor sites), see e.g., Gething and Sambrook (1981) Nature 293:620. Introns are intervening noncoding sequences within a coding sequence that contain splice donor and acceptor sites. They are removed by a process called "splicing," following polyadenylation of the primary transcript Nevins (1983) Annu. Rev. Biochem. 52:441; Green (1986) Annu. Rev. Genet 20:671; Padgett et al. (1986) Annu. Rev. Biochem. 55:1119; Krainer and Maniatis (1988) "RNA splicing," In Transcription and splicing (ed. B.D. Hames and D.M. Glover). Usually, the above-described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40, Gluzman ( 981) Cell 23:175, or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replication systems, thus allowing it to be mairv tained, for example, in mammalian cells for expression and in a procaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2, Kaufman et al. (1989) Mol. Cell. Biol. 9:946, and pHEBO, Shimizu et al. (1986) Mol. Cell. Biol. 6:1074. The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei. Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. ii. Baculovirus Systems The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-speciftc fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media. After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia. Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter "Summers and Smith"). Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above-described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification. Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31. The plasmid usually also contains the polyhedron polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a procaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in E. coli. Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present is usually distal to the structural gene. Expression may be either regulated or constitutive. Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) The Regulation of Baculovirus Gene Expression," in: The Molecular Bioloαv of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155476; and the gene encoding the p10 protein, Vlak et al., (1988), J. Gen. Virol. 69:765. DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human a-interferon, Maeda et al., (1985), Nature 315:592; human gastrin-releasing peptide, Lebacq-Verheyden et al., (1988), Molec. Cell. Biol. 8:3129; human IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404; mouse IL-3, (Miyajima et al., (1987) Gene 58:273; and human glucocerebrosidase, Martin et al. (1988) DNA 7:99, can also be used to provide for secretion in insects. A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by vitro incubation with cyanogen bromide. Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum. After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus - usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the ar (See Summers and Smith; Ju et al. (1987); Smith et al., Mol. Cell. Biol. (1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), Bioessays 4:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter. The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15 mm in size, are highly retractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild- type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith; Miller et al. (1989). Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, inter alia: Aedes aegypti , Autoorapha califomica. Bombvx moil. Drosophila melanoαaster. Spodoptera fruαiperda. and Trichoplusia ni (PCT Pub. No. WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al., (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225). Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, e.g., Summers and Smith. The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides. In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art iii. Bacterial Systems Bacterial expression techniques are known in the art A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3") transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in E. coli. Raibaud et al. (1984) Annu. Rev. Genet 18:173. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription. Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac). Chang et al. (1977) Nature 198:1056, and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan ___, Goeddel et al. (1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. 4,738,921; EPO Publ. Nos. 036776 and 121 775. The beta-glacotamase (bla) promoter system, Weissmann (1981) The cloning of interferon and other mistakes." In Interferon 3 (ed. I. Gresser), bacteriophage lambda PL, Shimatake et al. (1981) Nature 292:128, and T5, U.S. 4,689,406, promoter systems also provide useful promoter sequences. In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter, U.S. 4,551,433. For example, the tac promoter is a hybrid trp-lac promoter comprised of both t__ promoter and lac operon sequences that is regulated by the jac repressor, Amann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21. Furthermore, a bacterial promoter can include naturally occurring promoters of non- bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system, Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (EPO Publ. No. 267 851). In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In E. coli. the ribosome binding site is called the Shine-Dalgamo (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon, Shine et al. (1975) Nature 254:34. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' and of E. coli 16S rRNA, Steitz et al. (1979) "Genetic signals and nucleotide sequences in messenger RNA." In Biological Regulation and Development: Gene Expression (ed. R.F. Goldberger). To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site, Sambrook et al. (1989), Molecular Cloning: A Laboratory Manual. A DNA molecule may be expressed intracellulariy. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo on in vitro incubation with a bacterial methionine N-teπminal peptidase (EPO Publ. No. 219237). Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene, Nagai et al. (1984) Nature 309:810. Fusion proteins can also be made with sequences from the jacZ, Jia et al. (1987) Gene 60:197, troE. Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11, and EPO Publ. No. 324 647, genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated. Miller et al. (1989) Bio/Technology 7:698. Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria, U.S. 4,336,336. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene. DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (c_n___). Masui et al. (1983), in: -Experimental Manipulation of Gene Expression: Ghrayeb et al. (1984) EMBO J. 3:2437 and the E. coli alkaline phosphatase signal sequence (βhoA), Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212. As an additional example, the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from B. subtilis. Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. No. 244 042. Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. (Examples include transcription termination sequences derived from genes with strong promoters, such as the t__ gene in E. coli as well as other biosynthetic genes. Usually, the above-described components, comprising a promoter, signal sequence (if desired), coding sequence of interest and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a procaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EPO Publ. No. 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences. Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline. Davies et al. (1978) Annu. Rev. Microbiol. 32:469. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways. Alternatively, some of the above-described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector. Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, inter alia, the following bacteria: Bacillus subtilis. Palv et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541; E. coli. Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol. 189:113; EPO Publ. Nos. 036 776, 136 829 and 136 907; Streptococcus cremoris. Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Streptococcus lividans. Powell et al. (1988) Appl. Environ. Microbiol. 54:655; and Streptomvces lividans. U.S. 4,745,056. Methods of introducing exogenous DNA into bacterial hosts are well- known in the art, and usually include either the transformation of bacteria treated with CaCL or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See, e.g., Masson et al. (1989) FEMS Microbiol. Lett 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036259 and 063 953; PCT Publ. No. WO 84/04541 , for Bacillus: Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, for Campylobacter Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res. 16:6127; Kushner (1978) "An improved method for transformation of E. coli with ColE1-derived plasmids," In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H. W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318, for Escherichia: Chassy et al. (1987) FEMS Microbiol. Lett. 44:173, for Lactobacillus: Fiedler et al. (1988) Anal. Biochem 170:38, for Pseudomonas: Augustin et al. (1990) FEMS Microbiol. Lett 66:203, for Staphylococcus: Barany et al. (1980) J. Bacteriol. 144:698; Hariander (1987) Transformation of Streptococcus lactis by electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981) Infec. Immun. 32:1295; Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Evr. Cong. Biotechnology 1:412, for Streptococcus. iv. Yeast Expression Yeast expression systems are also known to one of ordinary skill in the art A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5 * end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription. Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. .Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehydθ-3-phosphate-dehydrogenasθ (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast PHQ5 gene, encoding acid phosphatase, also provides useful promoter sequences, Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1. In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. .Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. 4,876,197 and U.S. 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2. GAL4. GAL10. or PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EPO Publ. No. 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. EExamples of such promoters include, inter alia. Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) The Expression of Bacterial Antibiotic Resistance Genes in the Yeast Saccharomyces cerevisiae," in: Plasmids of Medical. Environmental and Commercial Importance (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109. A DNA molecule may be expressed intracellulariy in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide. Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (see, e.g., PCT Publ. No. WO 88/024066). Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. 62,096,086) and the A-factor gene (U.S. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EPO Publ. No. 060 057). A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. 4,546,083 and U.S. 4,870,008; EPO Publ. No. 324274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast but a pro-region from a second yeast alphafactor. (See e.g., PCT Publ. No. WO 89/02463.) Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. -Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes. Usually, the above-described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. -Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a procaryotic host for cloning and amplification. -Examples of such yeast-bacteria shuttle vectors include YEp24, Botstein et al. (1979) Gene 8:17- 24; pCI/1 , Brake et al. (1984) Proc. Natl. Acad. Sci USA 81 :4642-4646; and YRp17, Stinchcomb et al. (1982) J. Mol. Biol. 158:157. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. A high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome, Orr- Weaver et al. (1983) Methods in Enzymol. 101:228-245. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced, Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host such as ADE2. HIS4. LEU2. TRP1. and ALG7. and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions. Butt et al. (1987) Microbiol, Rev. 51:351. Alternatively, some of the above-described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector. .Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: Candida albicans. Kurtz, et al. (1986) Mol. Cell. Biol. 6:142; Candida maltosa. Kunze, et al. (1985) J. Basic Microbiol. 25:141; Hansenula polvmoroha. Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet 202:302; Kluweromvces fraoilis. Das, et al. (1984) J. Bacteriol. 158:1165; Kluweromyces lactis. De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology 8:135; Pichia ouillerimondii. Kunze et al. (1985) J. Basic Microbiol. 25:141; Pichia pastoris. Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; U.S. 4,837,148 and U.S. 4,929,555; Saccharomvces cerevisiae. Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163; Schizosaccharomvces pombe. Beach et al. (1981) Nature 300:706; and Yarrowia lipolvtica. Davidow, et al. (1985) Curr. Genet. 10:380471 Gaillardin, et al. (1985) Curr. Genet 10:49. Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See e.g., Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol.25:141, for Candida; Gleeson et al. (1986) J. Gen. Microbioy. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302, for Hansenula: Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et al. (1990) Bio/Technology 8:135, for Kluweromvces: Cregg et al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic Microbiol. 25:141; U.S. 4,837,148 and U.S. 4,929,555, for Pichia: Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75; 1929; Ito et al. (1983) J. Bacteriol. 153:163, for Saccharomvces: Beach et al. (1981) Nature 300:706, for Schizosaccharomvces: Davidow et al. (1985) Curr. Genet. 10:39; Gaillardin et al. (1985) Curr. Genet. 10:49, for Yarrowia. E. Vaccines Proteins encoded by the CagI region (as well as DNA from the region itself in the form of polynucleotide vaccines) may be used as a sole vaccine candidate or in combination with one or more other antigens, the latter either from H. pylori or other pathogenic sources. Preferred are "cocktail" vaccines comprising, for example, the cytotoxin (CT or VacA) antigen, the CagA protein, and the urease. Additionally, the hsp can be added to one or more of these components. These vaccines may either be prophylactic (to prevent infection) or therapeutic (to treat disease after infection). Such vaccines comprise H. pylori antigen or antigens, usually in combination with "pharmaceutically acceptable carriers", which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, etc. pathogens. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (and other submicron oil-in-water emulsions described in PCT Publ. No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfiuidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (3) saponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (IFA); (5) cytokines, such as interieukins (IL-1, IL-2, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59 are preferred. As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl- D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl- r >isoglutaminyl-L-alanine-2-(1'-2 , - dipalmitoyl-sπ-glycero-3-huydroxyphosphoryloxy)-ethylamine (MTP-PE), etc. The immunogenic compositions (e.g., the antigen or polynucleotide, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect as discussed above under pharmaceutically acceptable carriers. Immunogenic compositions used as vaccines comprise an immuno- logically effective amount of the antigenic polypeptides or nucleotides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g., nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. The immunogenic compositions are conventionally administered parenterally, e.g., by injection, either subcutaneously or intramuscularly. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Oral formulations are most preferred for the H. pylori proteins. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents. F. Immunodiaαnostic Assays H. pylori antigens encoded by the CagI regions can be used in immunoassays to detect antibody levels (or conversely H. pylori antibodies can be used to detect antigen levels) and correlation can be made with gastroduodenal disease and with duodenal ulcer in particular. Immunoassays based on well defined, recombinant antigens can be developed to replace the invasive diagnostics methods that are used today. Antibodies to H. pylori proteins within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent chemiluminescent radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays. Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the invention, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutions, etc.) required for the conduct of the assay, as well as suitable set of assay instructions. G. Examples The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art and are not to be construed as limiting the invention in any way. 1. Materials and methods a. Growth of H. pylori and DNA isolation H. pylori strains can be cultured in solid or liquid media for 3 days at 37 β C, both in microaerophilic atmosphere using Oxoid (Basingstoke, England) or Becton and Dickinson (Cockeysville, MD) gas pack generators or in an incubator containing air supplemented with 5% CO2, (26). The bacteria can be harvested and resuspended in STE (NaCI 0.1M, Tris-HCI 10mM pH 8, EDTA 1 mM pH 8) containing lysozyme at a final concentration of 100 micrograms ml and incubated at room temperature for 5 min. To lyse the bacteria SDS can be added to a final concentration 1% and heated at 65 °C. After the addition of proteinase K at final concentration of 25 micrograms/ml, the solution can be incubated at 50° for 2 hours. The DNA can be purified by CsCl gradient in the presence of ethidium bromide, precipitated with 77% ethanol and recovered with a sealed glass capillary. b. Construction and screening of a lambda gt11 expression library To generate a lambda gt11 expression library, genomic DNA from the CCUG 17874 strain partially digested with restriction enzymes can be used. After fractionation on 0.8% agarose gel, the DNA between 0.6 and 8 Kb in size can be eluted using a Costar Spin-X (0.22 micron) microcentrifuge filter. The products from each digestion can be combined, and used to construct an expression library, using the lambda gt11 cloning system kit (Bethesda Research Laboratories) and the Gigapack II Gold packaging kit (Stratagene, La Jolla, CA). c. Cloning Using overlapping libraries of H. pylori DNA from strain CCUG 17874 digested with EcoRI and Hindlll, cloned into vector Bluscript SK+, contiguous clones covering more than 31,000 bases of the H. pylori chromosome were identified, containing a full-length copy of the CagI region. Using random transposon mutagenesis and ad hoc deletions in different subclones, phenotypic variants were produced by allelic exchange. As can be seen from Fig. 1, four clones, E64 (14,500 bases), H12 (4000 bases), 5B (7800 bases), and 11.1 A (5900 bases), generated from the plasmid library, contain the entire CagI region and these four clones have been deposited with the American Type Culture Collection (ATCC), see below. These clones overlap with the CagA region (see PCT Publ. No. WO 93/18150 for the sequence for CagA). If one looks at the sequences on Fig. 1 designated 1, 2, and 3, the following is noted: Sequence 1 (10299 bases) contains the 3'-terminus of CagA, the entire CagA gene, and part of CagI. This sequence starts with nucleotide 1 and terminates at nucleotide 10299. Within this region, from nucleotides 4909 to 10299 is the CagA locus. From nucleotide 1 to 4908 is the 3'-terminus of CagI. Sequence 2 (5599 bases) starts with nucleotide 1 and terminates at 5599; there is a minor gap of 400 base pairs between nucleotide 5599 of sequence 2 and nucleotide 1 of sequence 1. Sequence 3 (1529 bases) starts with nucleotide 1 and terminates at 1529. Again, there is a minor gap of 400 base pairs between nucleotide 1529 of sequence 3 and nucleotide 1 of sequence 2. By assembling sequences 1 , 2, and 3, the CagI region is covered from the 5'- terminus to the 3'-terminus. Furthermore, Fig. 3 is the complete nucleotide sequence of the CagI locus (19,932 base pairs), including the true δ'-terrninus of CagI, contained in clone E64, which is about 2500 bases upstream from the beginning of sequence 3. d. Sequencing The nucleotide sequences of the overlapping clones was determined by manual and automated sequencing using nested deletions and primer walking. The produced data were subjected to computer analysis using the Wisconsin Genetic Group package running on parallel supercomputers. Figs. 2 and 3 show the nucleotide and predicted amino acid sequences of the CagI region, e. Structure of the CagI region The CagI region contains clusters of putative open reading frames (ORFs) with different polarity. Fig. 4 shows the putative open reading frames (ORF) for this region and homologies with known proteins. It is hypothesized that some of these ORFs may encode exporter molecules with homology to the ptl genes of Bordetella pertussis and VIR B4 genes of Aorobacterium tumefaciens and for proteins with motifs shared by purported invasion factors of Salmonella genus. Predicted amino acid sequences for the various frameshifts are shown in Figs. 2 and 4. f. Hybridizations All the clones were tested by Southern blotting on the DNA isolated from 44 well-characterized clinical isolates of H. pylori. The contiguous fragments located in the CagI region were able to recognize homologous sequences in all Type I strains of H. pylori but failed to hybridize with the DNA from Type II strains of H. pylori. It is possible that the approximately 120 base pair DNA segment ("MAK") present at both the 5-' and 3'-terminus of the CagI region may account for evolutionary divergence of Type I and Type II H. pylori bacteria. H. Deposit of Biological Materials The following materials were deposited on 7 April 1995, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, phone (301) 231-5519, under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Purposes of Patent Procedure. ATCC No. 69781 E. coli host strain TG1 containing plasmid 11.1A (CMCC# 4411); ATCC No. 69782 E. coli host strain TG1 containing plasmid 5B (CMCC#4412); ATCC No. 69783 E. coli host strain TG1 containing plasmid H12 (CMCC #4413); and ATCC No. 69784 E. coli host strain DH10B containing plasmid E64 (CMCC #4421). These deposits are provided as convenience to those of skill in the art, and are not an admission that a deposit is required under 35 U.S.C. §112. The nucleic acid sequences of these deposits, as well as the amino acid sequences of the polypeptides encoded thereby, are incorporated herein by reference and should be referred to in the event of any error in the sequences described herein as compared with the sequences of the deposits. A license may be required to make, use, or sell the deposited materials, and no such license is granted hereby. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Biocine SpA (B) STREET: Via Fiorentina 1 (C) CITY: Siena (E) COUNTRY: Italy (F) POSTAL CODE (ZIP) : 53100 Siena (ii) TITLE OF INVENTION: HELICOBACTER PYLORI CAGI REGION (iii) NUMBER OF SEQUENCES: 46 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk 720K (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA: APPLICATION NUMBER: PCT/IB96/00343 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10299 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: TTTGTTCAGT GATTTCGCCT TCCATTTCTT CTTCTATGAA GTCCAATTCT TCTTTCAGTT 60 CAAAAAGATA ATTAGAAAAA CTATCCAAAA TCGTCAAGAC ATCATTTTCA AAATTTCCAA 120 T AATTTTTGT TCACGCAAAT TTTGTTTCAT TTTAATACTC CTCTATTTGT TGATACATTT 180 GTCTCAAGGC CTGATATTTA TCTATGATAC TATGGTTTTG GATAATCTTA TCAATTTCTT 240 TGACAAATAC AGTATCTGTG GATAAAATTT TCAAATATTC TTTAGGAATG CCTCTCAAAT 300 TAAAACTAGC GATAACGCTA GGGCTTCCAT CCTGTTTGTA GAGGATTTTC CTATCTAGTC 360 CCTTAGTGAT GATTTCAAAT TCTTTTTCTG TAACATTAGC CAATCTTTGG TAATCAGAAA 420 RECTIFIED SHEET (RULE 91) GATTGCCCCC ATCGTTTCTC AAAAAAATCT TTGTAGGGCA TTGTTCTCTA ATCGTATCAG 480 CAATAGGGCA AGCCAAAAGA TCAGTGATGC TTTGAGTCGC AAGTCTGACA ATAGCGTTTC 540 TTTTCCTTGC AGTTTTTAGC ATGTCTCTTA CAAAATAAGC GACCTTTGGλ TCGCTAAATA 600 TTTCCAGGCT TCATCAATAT CTAAGACAAA TCTACGCCCA TCCATTGCCT CTTGGATACG 660 AGCGAAAAGG TAAAAACAAA TAAAGGGCGA AACATCATTA TTGTCTAAGA AACTTGACCC 720 ATCAACGCCA ATAATCGTTT TTGAAAAATC TAAGCGATCT GTTGCTTTAT TATCAAAAAG 780 CCATTGAAAT TCACCATTGG TTGATTTGCA AAAAGGCGCT AATCGCGCGA CAAGCCCATT 840 AGGATCATTG TGGTCTTTCC CGAAAGCATT AATAAGTTGA GTGATGGGAT AATCTAGATT 900 CATATTTCCT GTGATAAGGT TGGTTACTGC GCTGCAAGCG TATTAGAATC TGCTAGGCTA 960 AAAGAGATGC TGTTGCCATT TTCATCTTTT TCATCGCTTT TAGTTGCTAA GTTTTTCACA 1020 AGCTCTTTGA CAACAGAAAT AGCTGTTTGT TTTTGCTCCA TTGTTGCATT TCTTTTTTGC 1080 ACACAAGCCG CCCAAGCAAA AGGATTTAAT CCTGTATCTG TCCCTAGCTC AATCTTGACA 1140 TACTCCCCAC CCATTGCGAC AATATTCCCA TAAGCGCCAT AATCTTTATC CATATAAACC 1200 ATAGTGAGCT TTTGCTTGTC TTTGCTGACA TTAGCAGGAA AATTATAGGC AAATTGTCCC 1260 ATAGCGTTCA AGGTCATTGA CATAAACACT GTCTTACCTG AACCGGTTGA GCCAAGTATC 1320 AAAGTGTGTC CTGCTGAAGC TGAACCAAAA TCAGTGGGCA TGTGGAAGTT CAGATAAAAA 1380 GGCGAATTGA TCTCGCTTTT TAGCGTCATC ACACTATTGC CCCAAGCGTT ATTCTCTTGA 1440 TTGCCATCAA AACTCATACC CCTCATAGCG ATGAAATCAG CAAAATTATT AGAAGTTACA 1500 TCAAAAATAA AAGGAAGCGT GATAAAAGAG CAATGTTTGG CAAAAAAGTA ATTTTCCATA 1560 GAGAAAGTCG CTGCGTTGGC TAAAAAACCT TTAGCGTTAA GACTAGAGAC GCATTCCTTA 1620 ACGCTTTGTT TCATTTTTTC JAAGCTATCA GCAAACAGCλ CTAAAGAATT ACCATAACTG 1680 CCTAGCGTAA TATCACCATT ACCCACTAAT TCGCTCAAGC AACCTAAAGT CATGCCCTGT 1740 TCTTTAGAGC CTCCACTAAT AATAATTCTT CTAGAGGTGA AAGCCAGTTT GTCCTTTAAA 1800 ACCTGTGAGT TTTTAGGCGA ATAAGCATGC ATGAAAATAA ATTCGCTGTC TAGGGCGTTG 1860 ATTTTATCAA ACAAATCGCT TTGTGATTTA GGGGCGTATT CACTAATCTC AATAGCGCTA 1920 AAATATTTTT CACTCAAATC GTCATTTAAG ATTTTTCCAT GCTTATTGGC AAAATAAACT 1980 TCTTTCACCC CACCATGCAT TTTTTCCTTG AGATACAAGT CTTTTCGGTT GCAAATAAAA 2040 GGGGCTTCAT TCATTCCCAA AAGAAAATTG TAAAATTCGC ATTGTTTGGλ GTAAATAACG 2100 CCATCTTTAG TGTATTCTTT TAATCTACTG GGGTGGTATT TGCTCAACAG CTCTTCTATG 2160 AGCTCTATCC TATCCTTGAA GTTTTCAAGC TTGGCTCTAA TAATCCTTTG AAACTCTTCA 2220 AAATTATTGT CTGCAAAATG CTTTTTATTC ATAACGGGTT CATTGAGAGT GTCTAATAAA 2280 TCTTGCTCTA TGGTCAGAAA AAAACTAATA TCATAAAAAC TTTCTCTCTT TTGCTTCTCA 2340 TTATAGGCTC GCATGAAATC ATTAGAAAAA ATAAGACCAT AGTCCCTATT GGTTTCATCA 2400 ATAACGATTT TCTTTTTAAT AGTGTGAAAA TAGAATTTGA ATTCAGGGGT AACAAAATTC 2460 CTAAAAACGC TATAAATAGA AGCGTGTAAC TCTATGAGAT CTTTTTTGGA AGTGGTTAAA 2520 AAATCAATGC CCCCCAATTT GATTGTGCCT AAAAGAGAAT AGTTGTTAGT AAGGATCACC 2580 CCATCATCTA AAAAACATTC ATAGTTATTT GCTAGATAGG AGTTTGCAGC GCTCACAAGT 2640 CTGTCTTCTC TGTTTGGATT TAAGTGGATG TCATTAGCCA TTTCTTTACT AGGCTTCATG 2700 GAAAAAATGC TCATGAACGC TTTGTTTTTC ACGCCCTTAA ACAAAAAAGG TTTTTTAAAT 2760 TTCATCGCTC GCTCCATTCT TTGATAAAGC CTATAATCTT TCTTGAATCC AAGAGCTACA 2820 AGCACAATAA CAATCGCTAC AATCAAAACA GGTTCATAGG CTTGAAAAAG AATAACAGAT 2880 AATACAATGG TTACAAACAA TATAAATATA GAGGAATAAA TAAAAGTTTC AGGGAAACCA 2940 AACAACCTAT TCCCCCCATC AAACAAGACT TTAAAAAAGG GATTGACACC CTTTTGCATG 3000 TCTGCTTTAA GTTCTTCTAT TTTTTGAAAC TGCCGCTTTT GAACCTCTTG CTCTATAATT 3060 AGCTTTTTTT GTTCATCAGC CTGCTTGCTT CCCACAAACA CCTCTCTCTT TATAGATATA 3120 CCGCTTCACA TGTAATCGTA TAAAAGATTT TTTTGAGAGA CTCTACGGTG CTAATATGTT 3180 TCAAAAGATC ATTAGGATCA TAAGAATTGA ATACGGCCAA TAAAACATTA TATAACTTAT 3240 CATCGCATAG AATTTCTCTT GTTTCTCCGC GCAATGACAG AAAGCAGCGT TGTTTGTTGG 3300 TCGTGCTGAT GCTTTTGAAA GTAAAAAAGT CTTTCACTTC AGGATTGATC TGTAATTCTA 3360 CATTCAATCC CATTTCCTTA CCCTTTTCAT CAAAGATTTT TTCAATAACT GGATCGTAAT 3420 GCTTCAAATC CTTTATTTTT TTAAGGACTC TATTGACAAT CACGAAGTCA AAAACTTCAT 3480 CTTTGATAAT ATCGGGATTG ACTTCTTTGA AAGTTACTTT CTTGTCTTTC AAATTTTTGA 3540 TAGTCGCTTT GAAACTATCA AAATCTAAAT TTGTATAAAC AAGCCCATTG GGAGTGTTTT 3600 TTTCTTTTTC TTGTGCTTCT TTTTTGGCTT CTTTGTCATC ATTTGCTAAC CCATACGAAC 3660 TGAAAACAAC GAGACTTAAG AGAACTTTCλ AAAAAAAGCC TCTTAGTTTC TTATTGCTAT 3720 TATTATTATT GTTGATCAAC TTAGCTAGCT CCTCCACCCT CGCCAATATT GAAGCCAAAC 3780 TTAGTGCTCA AATAGATAAT ACCGCCTGCC ACCGCTAACA TAGCTATGGG TTGCGCGTAA 3840 GCAAAAACAG TCGCCTGACC TCTTTTAATG TCATCAGAGA TTTTCCAAAT ATCCGCTATG 3900 CCTTTGACCC CTAAAGCGCA ACCACCTACG ATCGCTAGAA CAGAAATGAT CTGAATAACC 3960 AAACCTTTAG TTGCAGTGAC GCCTTCTGTA GGACTGGCGA CCGCCATTAA AGGATTGGTT 4020 GTTACCACTA GCCCTAAAGT TACTACAACT TTCTTGTAGC TGTCAGTGAT TCTTGTAAAA 4080 AATTTCATGC GTTTCCTTTC AAATTGAAAT CAATCGCTTG AGTATATCAA AAAAAAAAGT 4140 ATTTTTATAC TATTCATACA AGCGCTACTT TATAATTTAA ATCAAAACCG ACGCTTTTGC 4200 TCGGCAACTG ACATCATTCA GGAATAGTAA ACCTACTTGT CCCAACCATT TTTCTTTCTC 4260 AAGTCGTTGT AGAATTGTAG ATCTTTAGGA TCTTTGATGT ATTTTTTAAT CGTCTCAGGT 4320 TGAAACCTAA AAACAAGCAA AAACAAACCC AAGCTGATCA GAGTGAGAAT AAAGCTCCAT 4380 TTTAAGCAAC TCCATAGACC ACTAAAGAAA CTTTTTTTGA GGCTATCTTT GAAAATCTGT 4440 CCTATTGATT TGTTTTCCAT TTTGTTTCCC ATGTGGATCT TGTGGATCAC AAACCCTTAA 4500 TTATACATGC TATAGTAAGC ATGACACACA AACCAAACTA TTTTTAGAAC GCTTCATGTG 4560 CTCACCTTGA CTAACCATTT CTCCAACCAT ACTTTAGCGT TGCATTTGAT TTCTTCAAAA 4620 AGATTCATTT CTTATTTCTT GTTCTTATTA AAGTTCTTTC ATTTTAGCAA ATTTTTGTTA 4680 ATTGTGGGTA AAAATGTGAA TCGTCCTAGC CTTTAGACGC CTGCAACGAT CGGGCTTTTT 4740 TCAATATTAA TAATGATTAA TGAAAAAAAA AAAAAATGCT TGATATTGTT GTATAATGAG 4800 AATGTTCAAA GACATGAATT GACTACTCAA GCGTGTAGCG ATTTTTAGCA GTCTTTGACA 4860 CTAACAAGAT ACCGATAGGT ATGAAACTAG GTATAGTAAG GAGAAACAAT GACTAACGAλ 4920 ACCATTGACC AACAACCACA AACCGAAGCG GCTTTTAACC CGCAGCAATT TATCAATAAT 4980 CTTCAAGTAG CTTTTCTTAA AGTTGATAAC GCTGTCGCTT CATACGATCC TGATCAAAAλ 5040 CCAATCGTTG ATAAGAACGA TAGGGATAAC AGGCAAGCTT TTGAAGGAAT CTCGCAATTA 5100 AGGGAAGAAT ACTCCAATAA AGCGATCAAA AATCCTACCA AAAAGAATCA GTATTTTTCA 5160 GACTTTATCA ATAAGAGCAA TGATTTAATC AACAAAGACA ATCTCATTGA TGTAGAATCT 5220 TCCACAAAGA GCTTTCAGAA ATTTGGGGAT CAGCGTTACC GAATTTTCAC AAGTTGGGTG 5280 TCCCATCAAA ACGATCCGTC TAAAATCAAC ACCCGATCGA TCCGAAATTT TATGGAAAAT 5340 ATCATACAAC CCCCTATCCT TGATGATAAA GAGAAAGCGG AGTTTTTGAA ATCTGCCAAA 5400 CAATCTTTTG CAGGAATCAT TATAGGGAAT CAAATCCGAA CGGATCAAAA GTTCATGGGC 5460 GTGTTTGATG AGTCCTTGAA AGAAAGGCAA GAAGCAGAAA AAAATGGAGA GCCTACTGGT 5520 GGGGATTGGT TGGATATTTT TCTCTCATTT ATATTTGACA AAAAACAATC TTCTGATGTC 5580 AAAGAAGCAA TCAATCAAGA ACCAGTTCCC CATGTCCAAC CAGATATAGC CACTACCACC 5640 ACCGACATAC AAGGCTTACC GCCTGAAGCT AGAGATTTAC TTGATGAAAG GGGTAATTTT 5700 TCTAAATTCA CTCTTGGCGA TATGGAAATG TTAGATGTTG AGGGAGTCGC TGACATTGAT 5760 CCCAATTACA AGTTCAATCA ATTATTGATT CACAATAACG CTCTGTCTTC TGTGTTAATG 5820 GGGAGTCATA ATGGCATAGA ACCTGAAAAA GTTTCATTGT TGTATGGGGG CAATGGTGGT 5880 CCTGGAGCTA GGCATGATTG GAACGCCACC GTTGGTTATA AAGACCAACA AGGCAACAAT 5940 GTGGCTACAA TAATTAATGT GCATATGAAA AACGGCAGTG GCTTAGTCAT AGCAGGTGGT 6000 GAGAAAGGGλ TTAACAACCC TAGTTTTTAT CTCTACAAAG AAGACCAACT CACAGGCTCA 6060 CAACGAGCAT TAAGTCAAGA AGAGATCCAA AACAAAATAG ATTTCATGGλ ATTTCTTGCA 6120 CAAAATAATG CTAAATTAGA CAACTTGAGC GAGAAAGAGA AGGAAAAATT CCGAACTGAG 6180 ATTAAAGATT TCCAAAAAGA CTCTAAGGCT TATTTAGACG CCCTAGGGAA TGATCGTATT 6240 GCTTTTGTTT CTAAAAAAGA CACAAAACAT TCAGCTTTAA TTACTGAGTT TGGTAATGGG 6300 GATTTGAGCT ACACTCTCAA AGATTATGGG AAAAAAGCAG ATAAAGCTTT AGATAGGGAG 6360 AAAAATGTTA CTCTTCAAGG TAGCCTAAAA CATGATGGCG TGATGTTTGT TGATTATTCT 6420 AATTTCAAAT ACACCAACGC CTCCAAGAAT CCCAATAAGG GTGTAGGCGT TACGAATGGC 6480 GTTTCCCATT TAGAAGTAGG CTTTAACAAG GTAGCTATCT TTAATTTGCC TGATTTAAAT 6540 AATCTCGCTA TCACTAGTTT CGTAAGGCGG AATTTAGAGG ATAAACTAAC CACTAAAGGA 6600 TTGTCCCCAC AAGAAGCTAA TAACCTTATC AAAGATTTTT TGAGCAGCAA CAAAGAATTG 6660 GTTGGAAAAA CTTTAAACTT CAATAAAGCT GTAGCTGACG CTAAAAACAC AGGCAATTAT 6720 GATGAAGTGA AAAAAGCTCA GAAAGATCTT GAAAAATCTC TAAGGAAACG AGAGCATTTA 6780 GAGAAAGAAG TAGAGAAAAA ATTGGAGAGC AAAAGCGGCA ACAAAAATAA AATGGAAGCA 6840 AAAGCTCAAG CTAACAGCCA AAAAGATGAG ATTTTTGCGT TGATCAATAA AGAGGCTAAT 6900 AGAGACGCAλ GAGCAATCGC TTACGCTCAG AATCTTAAAG GCATCAAAAG GGAATTGTCT 6960 GATAAACTTG AAAATGTCAA CAAGAATTTG AAAGACTTTG ATAAATCTTT TGATGAATTC 7020 AAAAATGGCA AAAATAAGGA TTTCAGCAAG GCAGAAGAAA CACTAAAAGC CCTTAAAGGT 7080 TCGGTGAAAG ATTTAGGTAT CAATCCAGAA TGGATTTCAA AAGTTGAAAA CCTTAATGCA 7140 GCTTTGAATG AATTCAAAAA TGGCAAAAAT AAGGATTTCA GCAAGGTAAC GCAAGCAAAA 7200 AGCGACCTTG AAAATTCCGT TAAAGATGTG ATCATCAATC AAAACGTAAC GGATAAAGTT 7260 GATAATCTCA ATCAAGCGGT ATCAGTGGCT AAAGCAACGG GTGATTTCAG TAGGGTAGAG 7320 CAAGCGTTAG CCGATCTCAA AAATTTCTCA AAGGAGCAAT TGGCCCAACA AGCTCAAAAA 7380 AATGAAAGTC TCAATGCTAG AAAAAAATCT GAAATATATC AATCCGTTAA GAATGGTGTG 7440 AATGGAACCC TAGTCGGTAA TGGGTTATCT CAAGCAGAAG CCACAACTCT TTCTAAAAAC 7500 TTTTCGGACA TCAAGAAAGA GTTGAATGCA AAACTTGGAA ATTTCAATAA CAATAACAAT 7560 AATGGACTCA AAAACGAACC CATTTATGCT AAAGTTAATA AAAAGAAAGC AGGGCAAGCλ 7620 GCTAGCCTTG AAGAACCCAT TTACGCTCAλ GTTGCTAAAA AGGTAAATGC AAAAATTGAC 7680 CGACTCAATC AAATAGCAAG TGGTTTGGGT GTTGTAGGGC AAGCAGCGGG CTTCCCTTTG 7740 AAAAGGCATG ATAAAGTTGA TGATCTCAGT AAGGTAGGGC TTTCAAGGAA TCAAGAATTG 7800 GCTCAGAAAA TTGACAATCT CAATCAAGCG GTATCAGAAG CTAAAGCAGG TTTTTTTGGC 7860 AATCTAGAGC AAACGATAGA CAAGCTCAAA GATTCTACAA AACACAATCC CATGAATCTA 7920 TGGGTTGAAA GTGCAAAAAA AGTACCTGCT AGTTTGTCAG CGAAACTAGA CAATTACGCT 7980 ACTAACAGCC ACATACGCAT TAATAGCAAT ATCAAAAATG GAGCAATCAA TGAAAAAGCG 8040 ACCGGCATGC TAACGCAAAA AAACCCTGAG TGGCTCAAGC TCGTGAATGA TAAGATAGTT 8100 GCGCATAATG TAGGAAGCGT TCCTTTGTCA GAGTATGATA AAATTGGCTT CAACCAGAAG 8160 AATATGAAAG ATTATTCTGA TTCGTTCAAG TTTTCCACCA AGTTGAACAA TGCTGTAAAA 8220 GACACTAATT CTGGCTTTAC GCAATTTTTA ACCAATGCAT TTTCTACAGC ATCTTATTAC 8280 TGCTTGGCGλ GAGAAAATGC GGAGCATGGA ATCAAGAACG TTAATACAAA AGGTGGTTTC 8340 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3289 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Phe Val Gin Phe Arg Leu Pro Phe Leu Leu Leu Ser Pro He Leu Leu 1 5 10 15 Ser Val Gin Lye Aβp Aβn Lye Asn Tyr Pro Lye Ser Ser Arg His Hie 20 25 30 Phβ Gin Aβn Phβ Gin Phe Leu Phe Thr Gin He Leu Phe Hie Phβ Aen 35 40 45 Thr Pro Leu Phe Val Asp Thr Phe Val Ser Arg Pro Aβp He Tyr Leu 50 55 60 Tyr Tyr Gly Phe Gly Ser Tyr Gin Phe Leu Gin He Gin Tyr Leu Trp 65 70 75 80 He Lye Phe Ser Asn He Leu Glu Cyβ Leu Ser Asn Asn Arg Arg Gly 85 90 95 Phe Hie Pro Val Cye Arg Gly Phe Ser Tyr Leu Val Pro Phe Gin He 100 105 110 Leu Phe Leu Hie Pro He Phe Gly Aβn Gin Lye Aβp Cys Pro His Arg 115 120 125 Phβ Ser Lye Lye Ser Leu Gly He Val Leu Ser Tyr Gin Gin Gly Lye 130 135 140 Pro Lye Aβp Gin Cyβ Phe Glu Ser Gin Val Gin Arg Phβ Phβ Sβr Leu 145 150 155 160 Gin Phβ Leu Ala Cye Leu Leu Gin Aen Lye Arg Pro Leu λep Arg He 165 170 175 Phe Pro Gly Phe He Aβn He Aβp Lye Ser Thr Pro He Hie Cye Leu 180 185 190 Lβu λβp Thr Sβr Glu Lye Val Lye Thr Aβn Lye Gly Arg Aen He He 195 200 205 He Val Glu Thr Pro He Asn Ala Aβn Aen Arg Phe Lye He Ala He 210 215 220 Cyβ Cyβ Phe He He Lye Lye Pro Leu Lye Phe Thr He Gly Phe Ala 225 230 235 240 Lye Arg Arg Ser Arg λβp Lye Pro He Arg He He Val Val Phe Pro 245 250 255 Glu Ser He Asn Lye Lβu Sβr λβp Gly He He He Hie He Sβr Cyβ 260 265 270 λβp Lye Val Gly Tyr Cye Ala Ala Ser Val Leu Glu Ser Ala Arg Leu 275 280 285 Lyβ Glu Met Leu Leu Pro Phe Ser Ser Phe Ser Ser Leu Leu Val λla 290 295 300 Lye Phe Phe Thr Ser Sβr Lβu Thr Thr Glu He λla Val Cyβ Phe Cye 305 310 315 320 Ser He Val λla Phβ Val Phβ Cyβ Thr Gin λla λla Gin λla Lye Gly 325 330 335 Phβ λβn Pro Val Ser Val Pro Ser Ser He Leu Thr Tyr Ser Pro Pro 340 345 350 He λla Thr He Phβ Pro λla Pro Ser Leu Ser He Thr He Val Ser 355 360 365 Phe Cyβ Leu Ser Lβu Lβu Thr Leu λla Gly Lye Lβu λla λβn Cyβ Pro 370 375 380 He λla Phe Lye Val He λβp He Aβn Thr Val Leu Pro Glu Pro Val 385 390 395 400 Glu Pro Sβr He Lye Val Cye Pro λla Glu λla Glu Pro Lye Ser Val 405 410 415 Gly Met Trp Lye Phβ Arg Lye Gly Glu Leu He Ser Leu Phe Ser Val 420 425 430 He Thr Leu Leu Pro Gin λla Leu Phe Ser Leu Pro Ser Lye Leu He 435 440 445 λla Leu He λla Met Lye Ser λla Lye Lβu Leu Glu Val Thr Ser Lye 450 455 460 He Lyβ Gly Sβr Val He Lye Glu Gin Cye Leu λla Lye Lye Phβ Ser 465 470 475 480 He Glu Lyβ Val λla λla Leu λla Lyβ Lye Pro Lβu λla Leu Arg Leu 485 490 495 Glu Thr Hie Ser Leu Thr Leu Cye Phe He Phe Ser Lyβ Lβu Ser λla 500 505 510 λsn Ser Thr Lye Glu Leu Pro Lβu Pro Ser Val He Ser Pro Leu Pro 515 520 525 Thr λβn Sβr Lβu Lye Gin Pro Lye Val Met Pro Cye Sβr Lβu Glu Pro 530 535 540 Pro Leu He He He Leu Leu Glu Val Lyβ λla Ser Leu Ser Phe Lyβ 545 550 555 560 Thr Cyβ Glu Phβ Leu Gly Glu λla Cys Met Lye He λβn Ser Leu Ser 565 570 575 Arg λla Leu He Lβu Ser λβn Lye Ser Leu Cyβ Aβp Lβu Gly λla Tyr 580 585 590 Ser Leu He Ser He λla Leu Lyβ Tyr Phβ Ser Leu Lye Ser Ser Phe 595 600 605 Lyβ He Phe Pro Cye Lβu Lβu λla Lye Thr Sβr Phβ Thr Pro Pro Cyβ 610 615 620 He Phe Ser Leu Arg Tyr Lyβ Ser Phe Arg Leu Gin He Lyβ Gly λla 625 630 635 640 Ser Phe He Pro Lyβ λrg Lyβ Leu λβn Ser Hie Cye Lβu Glu He Thr 645 650 655 Pro Ser Leu Val Tyr Ser Phe λβn Leu Val Gly Trp Tyr Lβu Lβu λβn 660 665 670 Ser Ser Ser Met Ser Ser He Leu Ser Leu Lyβ Phe Ser Ser Leu λla 675 680 685 Leu He He Leu λsn Ser Ser Lys Leu Leu Ser λla Lyβ Cyβ Phe Leu 690 695 700 Phe He Thr Gly Ser Leu λrg Val Ser λβn Lyβ Sβr Cyβ Ser Met Val 705 710 715 720 λrg Lye Lyβ Leu He Ser Lyβ Leu Ser Lβu Phe Cyβ Phβ Sβr Leu λla 725 730 735 λrg Met Lyβ Ser Leu Glu Lyβ He λrg Pro Ser Leu Leu Val Ser Ser 740 745 750 He Thr He Phe Phe Leu He Val Lyβ λβn Leu λβn Ser Gly Val Thr 755 760 765 Lyβ Phe Leu Lyβ Thr Leu He Glu λla Cyβ λβn Ser Met λrg Ser Phe 770 775 780 Leu Glu Val Val Lyβ Lyβ Ser Met Pro Pro λβn Leu He Val Pro Lyβ 785 790 795 800 λrg Glu Leu Leu Val λrg He Thr Pro Ser Ser Lye Lye Hie Sβr Lβu 805 810 815 Phe Ala Arg Glu Phe λla λla Leu Thr Ser Leu Ser Ser Leu Phe Gly 820 825 830 Phe Lye Trp Met Ser Leu λla He Ser Leu Leu Gly Phe Met Glu Lye 835 840 845 Met Leu Met λβn λla Lβu Phβ Phe Thr Pro Leu λβn Lye Lye Gly Phβ 850 855 860 Leu λβn Phe He λla λrg Ser He Leu Ser Leu Ser Phe Leu λen Pro 865 870 875 880 λrg λla Thr Ser Thr He Thr He λla Thr He Lyβ Thr Gly Sβr λla 885 890 895 Lyβ λrg He Thr λβp λβn Thr Met Val Thr λen λen He λβn He Glu 900 905 910 Glu He Lyβ Val Ser Gly Lye Pro λβn λβn Leu Phe Pro Pro Ser λen 915 920 925 Lye Thr Leu Lyβ Lyβ Gly Lβu Thr Pro Phβ Cyβ Met Ser λla Leu Ser 930 935 940 Ser Ser He Phe λβn Cye λrg Phβ Thr Ser Cye Sβr He He Ser Phe 945 950 955 960 Phe Cyβ Ser Ser λla Cyβ Leu Leu λla Thr λsn Thr Ser Leu Phe He 965 970 975 λβp He Pro Leu Hie Met Ser Tyr Lyβ λrg Phe Phe Glu Thr Lβu λrg 980 985 990 Cyβ Tyr Val Ser Lyβ λβp Hie λβp Hie Lyβ λβn He λrg Pro He Lye 995 1000 1005 Hie Tyr He Thr Tyr Hie λrg He Glu Phe Leu Leu Phe Leu λrg λla 1010 1015 1020 Met Thr Glu Ser Ser Val Val Cyβ Trp Sβr Cyβ Cyβ Phe Lye Lyβ Ser 1025 1030 1035 1040 Leu Ser Leu Gin Aβp Ser Val He Leu Hie Sβr He Pro Phe Pro Tyr 1045 1050 1055 Pro Phe Hie Gin λrg Phβ Phβ Gin Leu λsp λrg Aβn λla Sβr λβn Pro 1060 1065 1070 Leu Phe Phe Gly Leu Tyr Gin Ser λrg Ser Gin Lyβ Leu Hie Leu Tyr 1075 1080 1085 λrg λβp Leu Lβu Lyβ Leu Leu Ser Cye Leu Ser λβn Phβ Sβr Lβu λβn 1090 1095 1100 Tyr Gin λβn Leu λβn Leu Tyr Lye Gin λla Hie Trp Glu Cyβ Phe Phe 1105 1110 1115 1120 Leu Phe Leu Val Leu Leu Phe Trp Lβu Leu Cyβ Hie Hie Lβu Lβu Thr 1125 1130 1135 Hie Thr λβn Lyβ Gin λrg λβp Leu λrg Glu Leu Ser Lyβ Lyβ Sβr Lβu 1140 1145 1150 Leu Val Ser Tyr Cyβ Tyr Tyr Tyr Tyr Cyβ Ser Thr Leu λla Pro Pro 1155 1160 1165 Pro Ser Pro He Leu Lys Pro λsn Leu Val Leu Lyβ He He Pro Pro 1170 1175 1180 λla Thr λla λβn He λla Met Gly Cyβ λla λla Lyβ Thr Val λla Pro 1185 1190 1195 1200 Lβu Leu Met Ser Ser Glu He Phe Gin He Ser λla Met Pro Leu Thr 1205 1210 1215 Pro Lyβ λla Gin Pro Pro Thr He λla λrg Thr Glu Met He He Thr 1220 1225 1230 Lyβ Pro Leu Val λla Val Thr Pro Ser Val Gly Leu λla Thr λla He 1235 1240 1245 Lya Gly Leu Val Val Thr Thr Ser Pro Lyβ Val Thr Thr Thr Phβ Lβu 1250 1255 1260 Leu Ser Val He Leu Val Lyβ λβn Phe Met λrg Phe Leu Ser λβn λβn 1265 1270 1275 1280 Gin Ser Leu Glu Tyr He Lyβ Lyβ Lyβ Ser He Phe He Leu Phe He 1285 1290 1295 Gin λla Leu Leu Tyr λsn Leu λβn Gin λβn λrg λrg Phβ Cyβ Ser λla 1300 1305 1310 Thr λβp He He Gin Glu Thr Tyr Leu Ser Gin Pro Phe Phβ Phe Leu 1315 1320 1325 Lyβ Ser Leu λsn Cys λrg Ser Leu Gly Ser Leu Met Tyr Phe Leu He 1330 1335 1340 Val Sβr Gly λβn Lβu Lyβ Thr Sβr Lyβ λβn Lyβ Pro Lyβ Lβu He λrg 1345 1350 1355 1360 Val λrg He Lyβ Lβu Hie Phe Lyβ Gin Lβu Hie λrg Pro Leu Lyβ Lyβ 1365 1370 1375 Leu Phe Leu λrg Leu Ser Leu Lye He Cyβ Pro He λβp Leu Phe Ser 1380 1385 1390 He Leu Phe Pro Met Trp He Leu Trp He Thr λβn λla Leu Tyr Met 1395 1400 1405 Leu λla Hie Thr λβn Gin Thr He Phe λrg Thr Lβu Hie Val Leu Thr 1410 1415 1420 Leu Thr λβn Hie Phe Ser λβn Hie Thr Lβu λla Lβu Hie Lβu He Ser 1425 1430 1435 1440 Ser Lyβ λrg Phe He Ser Tyr Phe Leu Phe Leu Leu Lyβ Phe Phe Hie 1445 1450 1455 Phe Ser Lyβ Phβ Leu Leu He Val Gly Lyβ λβn Val λβn λrg Pro Sβr 1460 1465 1470 Leu Thr Pro λla Thr He Gly Leu Phe Ser He Leu He Met He λβn 1475 1480 1485 Glu Lyβ Lyβ Lyβ Lyβ Cyβ Leu He Leu Leu Tyr λβn Glu λβn Val Gin 1490 1495 1500 λrg Hie Glu Lβu Thr Thr Gin λla Cyβ Sβr λβp Phβ Gin Sβr Lβu Thr 1505 1510 1515 1520 Leu Thr Arg Tyr λrg Val λβn Val Gly Glu Thr Met Thr λβn Glu Thr 1525 1530 1535 He λβp Gin Gin Pro Gin Thr Glu λla λla Phβ λen Pro Gin Gin Phe 1540 1545 1550 He Aβn Asn Leu Gin Val λla Phe Leu Lyβ Val Aβp Aβn Ala Val Ala 1555 1560 1565 Ser Tyr Asp Pro Aβp Gin Lyβ Pro He Val λβp Lyβ λβn λβp λrg λβp 1570 1575 1580 λβn λrg Gin λla Phβ Glu Gly He Ser Gin Leu λrg Glu Glu Tyr Ser 1585 1590 1595 1600 λβn Lyβ λla He Lyβ λβn Pro Thr Lyβ Lyβ λβn Gin Tyr Phβ Ser λβp 1605 1610 1615 Phe He λβn Lye Sβr λen λβp Lβu He λβn Lye λβp λβn Leu He λβp 1620 1625 1630 Val Glu Ser Ser Thr Lyβ Ser Phe Gin Lyβ Phβ Gly λβp Gin λrg Tyr 1635 1640 1645 λrg He Phβ Thr Ser Trp Val Ser Hie Gin λβn λsp Pro Ser Lye He 1650 1655 1660 λβn Thr λrg Ser He λrg λβn Phβ Met Glu λβn He He Gin Pro Pro 1665 1670 1675 1680 He Leu λsp λsp Lys Glu Lyβ λla Glu Phβ Leu Lyβ Ser λla Lye Gin 1685 1690 1695 Ser Phe λla Gly He He He Gly Aβn Gin He λrg Thr λβp Gin Lyβ 1700 1705 1710 Phe Met Gly Val Phe λβp Glu Ser Leu Lyβ Glu λrg Gin Glu λla Glu 1715 1720 1725 Lyβ λβn Gly Glu Pro Thr Gly Gly λβp Trp Leu λβp He Phe Leu Sβr 1730 1735 1740 Phe He Phe λβp Lyβ Lyβ Gin Sβr Ser λβp Val Lyβ Glu λla He λβn 1745 1750 1755 1760 Gin Glu Pro Val Pro Hie Val Gin Pro Aβp He λla Thr Thr Thr Thr 1765 1770 1775 Aβp He Gin Gly Leu Pro Pro Glu λla λrg Aβp Leu Leu Asp Glu λrg 1780 1785 1790 Gly λβn Phe Ser Lyβ Phe Thr Leu Gly λβp Met Glu Met Leu λβp Val 1795 1800 1805 Glu Gly Val λla λβp He λβp Pro λβn Tyr Lyβ Phβ λβn Gin Lβu Lβu 1810 1815 1820 He Hie λβn λβn λla Lβu Ser Ser Val Lβu Met Gly Ser Hie λβn Gly 1825 1830 1835 1840 He Glu Pro Glu Lyβ Val Sβr Lβu Leu Tyr Gly Gly λβn Gly Gly Pro 1845 1850 1855 Gly Ala Arg Hie Aβp Trp λβn λla Thr Val Gly Tyr Lyβ λβp Gin Gin 1860 1865 1870 Gly λβn λβn Val λla Thr He He λβn Val Hie Met Lyβ λβn Gly Sβr 1875 1880 1885 Gly Leu Val He λla Gly Gly Glu Lye Gly He Aβn λβn Pro Ser Phe 1890 1895 1900 Tyr Leu Tyr Lye Glu Aβp Gin Lβu Thr Gly Ser Gin Arg λla Lβu Sβr 1905 1910 1915 1920 Gin Glu Glu He Gin λsn Lyβ He λβp Phe Met Glu Phe Leu λla Gin 1925 1930 1935 λβn λβn λla Lyβ Leu λβp λβn Leu Ser Glu Lye Glu Lyβ Glu Lyβ Phe 1940 1945 1950 λrg Thr Glu He Lyβ λβp Phβ Gin Lyβ λβp Ser Lyβ λla Tyr Leu λβp 1955 1960 1965 λla Leu Gly λβn λβp λrg He λla Phe Val Ser Lyβ Lye λβp Thr Lyβ 1970 1975 1980 Hie Ser λla Leu He Thr Glu Phe Gly Aβn Gly λβp Leu Ser Tyr Thr 1985 1990 1995 2000 Leu Lyβ λsp Tyr Gly Lys Lye λla λβp Lys λla Leu λβp λrg Glu Lyβ 2005 2010 201S λβn Val Thr Leu Gin Gly Ser Leu Lyβ Hie λβp Gly Val Met Phe Val 2020 2025 2030 λβp Tyr Ser λβn Phe Lyβ Tyr Thr λβn λla Ser Lyβ λβn Pro λen Lye 2035 2040 2045 Gly Val Gly Val Thr λen Gly Val Sβr Hie Lβu Glu Val Gly Phβ λβn 2050 2055 2060 Lyβ Val λla He Phe λβn Leu Pro λβp Leu λβn λβn Leu λla He Thr 2065 2070 2075 2080 Ser Phe Val λrg λrg λβn Leu Glu λβp Lyβ Lβu Thr Thr Lyβ Gly Lβu 2085 2090 2095 Ser Pro Gin Glu λla λβn Lyβ Lβu He Lys λβp Phβ Leu Ser Ser λβn 2100 2105 2110 Lyβ Glu Leu Val Gly Lyβ Thr Lβu λβn Phβ λβn Lyβ λla Val λla λβp 2115 2120 2125 λla Lyβ λβn Thr Gly λsn Tyr λsp Glu Val Lyβ Lys λla Gin Lyβ λsp 2130 2135 2140 Leu Glu Lyβ Ser Leu λrg Lyβ λrg Glu Hie Leu Glu Lyβ Glu Val Glu 2145 2150 2155 2160 Lyβ Lyβ Leu Glu Ser Lyβ Ser Gly λβn Lys λβn Lye Met Glu λla Lyβ 2165 2170 2175 λla Gin λla λβn Ser Gin Lyβ λβp Glu He Phe λla Leu He λβn Lyβ 2180 2185 2190 Glu λla λsn λrg λβp λla λrg λla He λla Tyr λla Gin λβn Leu Lye 2195 2200 2205 Gly He Lyβ λrg Glu Leu Ser λsp Lyβ Leu Glu λβn Val λβn Lyβ λβn 2210 2215 2220 Leu Lyβ Aβp Phe λβp Lyβ Sβr Phβ λβp Glu Phβ Lyβ λβn Gly Lyβ λβn 2225 2230 2235 2240 Lye λsp Phe Ser Lyβ λla Glu Glu Thr Leu Lyβ λla Leu Lyβ Gly Ser 2245 2250 2255 Val Lyβ λβp Leu Gly He λβn Pro Glu Trp He Ser Lye Val Glu λen 2260 2265 2270 Leu λβn λla λla Leu λβn Glu Phe Lyβ λsn Gly Lys Aβn Lye Aβp Phe 2275 2280 2285 Ser Lyβ Val Thr Gin λla Lyβ Sβr λβp Leu Glu λβn Sβr Val Lyβ λβp 2290 2295 2300 Val He He λβn Gin Lyβ Val Thr λβp Lyβ Val Aβp λβn Lβu λβn Gin 2305 2310 2315 2320 λla Val Ser Val λla Lyβ λla Thr Gly λβp Phβ Sβr λrg Val Glu Gin 2325 2330 2335 λla Leu λla λβp Leu Lyβ λβn Phβ Ser Lyβ Glu Gin Leu λla Gin Gin 2340 2345 2350 λla Gin Lyβ λβn Glu Ser Leu λβn λla λrg Lyβ Lyβ Ser Glu He Tyr 2355 2360 2365 Gin Ser Val Lyβ λen Gly Val λβn Gly Thr Lβu Val Gly λen Gly Leu 2370 2375 2380 Ser Gin λla Glu λla Thr Thr Leu Ser Lyβ λβn Phβ Sβr λβp He Lye 2385 2390 2395 2400 Lyβ Glu Lβu λβn λla Lye Leu Gly λβn Phe λβn λβn λβn λβn λβn λβn 2405 2410 2415 Gly Leu Lyβ λsn Glu Pro He Tyr λla Lyβ Val λsn Lys Lys Lyβ λla 2420 2425 2430 Gly Gin λla λla Ser Leu Glu Glu Pro He Tyr λla Gin Val λla Lyβ 2435 2440 2445 Lyβ Val λβn λla Lyβ He λβp λrg Leu λβn Gin He λla Ser Gly Leu 2450 2455 2460 Gly Val Val Gly Gin λla λla Gly Phe Pro Lβu Lyβ λrg Hie Aβp Lyβ 2465 2470 2475 2480 Val λβp λβp Leu Ser Lyβ Val Gly Leu Ser λrg λβn Gin Glu Leu λla 2485 2490 2495 Gin Lyβ He λβp Aβn Leu λβn Gin λla Val Ser Glu λla Lyβ λla Gly 2500 2505 2510 Phe Phe Gly λβn Leu Glu Gin Thr He λβp Lyβ Lβu Lyβ λβp Ser Thr 2515 2520 2525 Lyβ Hie λβn Pro Met Aβn Leu Trp Val Glu Ser λla Lyβ Lyβ Val Pro 2530 2535 2540 λla Ser Leu Ser λla Lyβ Lβu λβp λβn Tyr λla Thr λβn Ser Hie He 2545 2550 2555 2560 λrg He λβn Ser λβn He Lyβ λβn Gly λla He λβn Glu Lyβ λla Thr 2565 2570 2575 Gly Met Leu Thr Gin Lyβ λβn Pro Glu Trp Lβu Lyβ Leu Val λβn λβp 2580 2585 2590 Lyβ He Val λla Hie λβn Val Gly Sβr Val Pro Lβu Ser Glu Tyr λβp 2595 2600 2605 Lyβ He Gly Phe λβn Gin Lyβ λβn Met Lyβ λep Tyr Sβr λβp Sβr Phe 2610 2615 2620 Lyβ Phe Ser Thr Lye Leu λsn λβn λla Val Lys λβp Thr Aβn Ser Gly 2625 2630 2635 2640 Phe Thr Gin Phe Leu Thr Aβn λla Phe Ser Thr λla Ser Tyr Tyr Cye 2645 2650 2655 Lβu λla λrg Glu λβn λla Glu Hie Gly He Lyβ λβn Val Aβn Thr Lyβ 2660 2665 2670 Gly Gly Phβ Gin Lyβ Ser λrg He Lye Glu Tyr Gin Lyβ λrg Lyβ λβn 2675 2680 2685 Hie Pro Leu Leu Lyβ λla λrg Gly Phe Leu He Leu Leu Ser λrg λβn 2690 2695 2700 Pro λβn λrg Leu Tyr Leu Gly Met Leu Pro He Hie Gly He He Ser 2705 2710 2715 2720 Pro Tyr He λrg He λrg λrg Lyβ Cyβ λla Lye Leu λrg Leu Trp λrg 2725 2730 2735 Tyr λβp Val λsp Leu Gly Met λrg Trp Ser Ser λβn Ser Val Lyβ Ser 2740 2745 2750 Leu Leu Gly Hie Arg Val λrg Thr Lyβ Lβu Ser Leu λrg λla Thr Ser 2755 2760 2765 λla Glu λla Gin Ser Ser Leu λla Val Gly Hie Phβ Thr Leu Lyβ Tyr 2770 2775 2780 Pro λep λrg Hie λrg Lyβ λla Leu Phe Phβ Lye Val Cye Met λep He 2785 2790 2795 2800 Ser Tyr Pro Lyβ Lyβ Thr Pro Phβ λla λen Val Lβu Cyβ Trp Val λrg 2805 2810 2815 λla He Val λrg Lyβ Leu He Lyβ Gly Tyr Lyβ Glu Ser He λsn Lys 2820 2825 2830 Lys Gin Val λla He Thr Lyβ He Lyβ Phβ Lye Lye Sβr Sβr Phβ Sβr 2835 2840 2845 Lyβ Leu He λla Leu Leu Thr Lyβ Glu Lyβ Ser Glu Lyβ Pro Glu Lβu 2850 2855 2860 Ser Hie Lβu He Met Pro Lyβ Lyβ λβp λla Cyβ λβp Gin Lye Trp Lyβ 2865 2870 2875 2880 λβn Thr λla Ser λrg He Leu Met Ser Ser Lyβ Thr Leu Trp Met Pro 2885 2890 2895 Phe Lyβ Val Lyβ λrg Gin He Leu Leu Phe He Pro Pro Lyβ Leu Val 2900 2905 2910 Val He Phe Leu Ser Cye He Leu λβn λla Met Trp Leu Phe Leu Gly 2915 2920 2925 Gin Lyβ Lyβ He Ser Phe Leu Trp Val Lyβ Sβr Leu Ser Leu λrg He 2930 2935 2940 Tyr Glu λla Met λrg λrg He Ser Leu λla Leu Phe Cyβ Lys Ser Val 2945 2950 2955 2960 λβp λrg Ser Phe Pro Lye He He He λrg Hie Ser Ser Leu Gin λen 2965 2970 2975 λla Phe He λsn Leu Ser Lye λla Leu Tyr λβn Gin Hie λβn Thr Leu 2980 2985 2990 He Val λla He λla Pro Phe Trp Glu Leu Ser Tyr Phe λβp Phβ Lyβ 2995 3000 3005 Phe Leu Leu λla Lβu Gin Phe Glu Pro Phe Phe Ser Leu Phe Phe Pro 3010 3015 3020 Aβp Hie He λla λla λrg Met Lyβ Phβ Hie Phβ λrg Glu Cyβ Val Cyβ 3025 3030 3035 3040 He Phe Phe Lyβ Gly Val Phβ Leu Leu Gin He Ser Tyr λβn Ser He 3045 3050 3055 λla λrg Met Aβp Glu Gly Gly Cyβ Lyβ Gly Lyβ Met Leu Hie Lye He 3060 3065 3070 λla Leu λsn Phe Leu Ser λsp Gly Lys Met λrg λla Thr λβn λβn Hie 3075 3080 3085 Phe Gly Lyβ He Phe Lyβ Gly Val Lys λrg Met Gin Val Ser λsn Aβn 3090 3095 3100 Ser Pro Ser Lyβ He Leu Ser Ser He Lyβ Gly Thr Lyβ λrg Glu Val 3105 3110 3115 3120 λla Lyβ Cyβ Glu Thr Phe Lyβ Pro Cyβ Cyβ Phe λrg λla Leu Ser λla 3125 3130 3135 Leu λβp Trp He Val λla Phe Val Pro Sβr Thr Lyβ He Gly λla Phe 3140 3145 3150 Leu Ser Phe Thr Cyβ λrg Lβu He λla Lyβ Met Leu Gly Ser He Thr 3155 3160 3165 Pro Thr He Gly He Leu Glu Cyβ Phe Cyβ He Ser Ser Lyβ λla λrg 3170 3175 3180 λla Leu λla Val Leu Hie λla Thr He λβn λβn Ser He Trp Cyβ Gly 3185 3190 3195 3200 Lβu Lyβ Lyβ Ser Lyβ λla Ser Lyβ Pro λβn Cyβ Leu He Val Val Gly 3205 3210 3215 Ser Leu Val Pro Gly Thr Leu λla Val Ser Pro Met He Ser Ser λβn 3220 3225 3230 λsn Cyβ λla Phβ Lyβ λrg Leu Phe Lyβ Thr Lβu Aβn Pro Pro Thr Pro 3235 3240 3245 Leu Ser Lye Thr Pro He Phe Met Thr Leu Phe Phe λβn Gly He λβn 3250 3255 3260 Gly Phe Tyr Phe Ser Phe He Lye Phβ Lyβ λβn Sβr Ser Leu Ser Leu 3265 3270 3275 3280 Val Cyβ Cye He Leu Glu Thr Lyβ Lβu 3285 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3174 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Leu Phe Ser λβp Phe λla Phe Hie Phβ Phβ Phβ Tyr Glu Val Gin Phe 1 5 10 15 Phe Phe Gin Phβ Lyβ Lyβ He He λrg Lyβ Thr He Gin λβn λrg Gin 20 25 30 λβp He He Phe Lyβ He Ser λβn λen Phβ Cye Sβr λrg Lyβ Phe Cyβ 35 40 45 Phe He Leu He Leu Leu Tyr Leu Leu He Hie Leu Ser Gin Gly Leu 50 55 60 He Phe He Tyr λβp Thr Met Val Leu λβp λsn Leu He λβn Phβ Phβ 65 70 75 80 λβp Lyβ Tyr Ser He Cyβ Gly Aβn Phe Gin He Phe Phe λrg λβn λla 85 90 95 Ser Gin He Lyβ Thr Ser λβp λsn λla λrg λla Ser He Leu Phe Val 100 105 110 Glu λβp Phβ Pro He Ser Leu Ser λep λβp Phβ Lys Phβ Phe Phe Cyβ 115 120 125 λβn He Ser Gin Sβr Leu Val He λrg Lyβ He λla Pro He Val Sβr 130 135 140 Gin Lye λen Lβu Cyβ Arg λla Lβu Phe Ser λβn λrg He Ser λβn λrg 145 150 155 160 λla Ser Gin Lyβ He Ser λβp λla Leu Ser λrg Lyβ Sβr λβp λβn Sβr 165 170 175 Val Ser Phe Pro Cyβ Ser Phe Hie Val Sβr Tyr Lyβ He Ser λβp Lβu 180 185 190 Trp He λla Lye Tyr Phe Gin λla Ser Ser He Ser Lyβ Thr λβn Lβu 195 200 205 λrg Pro Ser He λla Ser Trp He λrg λla Lyβ λrg Lyβ Gin He Lyβ 210 215 220 Gly Glu Thr Ser Leu Leu Ser Lyβ Lyβ Leu Aβp Pro Ser Thr Pro He 225 230 235 240 He Val Phβ Glu Lyβ Sβr Lyβ λrg Ser Val λla Leu Leu Ser Lye Sβr 245 250 255 Hie λβn Ser Pro Leu Val λβp Lβu Gin Lyβ Gly λla λβn λrg λla Thr 260 265 270 Ser Pro Leu Gly Sβr Lβu Trp Sβr Phβ Pro Lyβ λla Leu He Ser Val 275 280 285 Met Gly Ser λrg Phe He Phβ Pro Val He λrg Leu Val Thr λla Lβu 290 295 300 Gin λla Tyr λen Leu Leu Gly Lyβ λrg Cye Cye Cye Hie Phβ Hie Lβu 305 310 315 320 Phe Hie λrg Phe Leu Leu Ser Phe Ser Gin λla Leu Gin Gin Lyβ Leu 325 330 335 Phe Val Phe λla Pro Leu Leu Hie Leu Phe Phe λla Hie Lyβ Pro Pro 340 345 350 Lyβ Gin Lyβ λβp Leu He Leu Tyr Leu Ser Leu λla Gin Ser Hie Thr 355 360 365 Pro Hie Pro Leu λrg Gin Tyr Ser Hie Lye λrg Hie λen Leu Tyr Pro 370 375 380 Tyr Lyβ Pro λla Phe λla Cyβ Lβu Cyβ Hie Gin Glu Aβn Tyr λrg Gin 385 390 395 400 He Val Pro λrg Ser λrg Ser Leu Thr Thr Leu Ser Tyr Lβu λβn λrg 405 410 415 Leu Ser Gin Val Ser Lyβ Cyβ Val Leu Leu Lyβ Leu λβn Gin λβn Gin 420 425 430 Trp λla Cyβ Gly Ser Ser λep Lye Lyβ λla λβn Ser λrg Phe Leu λla 435 440 445 Ser Ser Hie Tyr Cyβ Pro Lyβ λrg Tyr Ser Leu λβp Cyβ Hie Gin λβn 450 455 460 Ser Pro Ser λrg λβn Gin Gin λsn Tyr Lyβ Leu Hie Gin Lyβ Lyβ Glu 465 470 475 480 λla Lyβ Sβr λβn Val Trp Gin Lyβ Sβr λβn Phe Pro λrg Lyβ Sβr Leu 485 490 495 λrg Trp Leu Lyβ λβn Lβu λrg λβp λrg λrg He Pro λrg Phe Val Ser 500 505 510 Phe Phe Gin Ser Tyr Gin Gin Thr λla Leu Lyβ λβn Tyr Hie λβn Cyβ 515 520 525 Leu λla Tyr Hie His Tyr Pro Lβu He λrg Ser Ser λβn Lβu Lyβ Sβr 530 535 540 Cyβ Pro Val Lβu Ser Leu Hie Phβ Phβ λrg Lyβ Pro Val Cyβ Pro Lβu 545 550 555 560 Lyβ Pro Val Ser Phe λla λβn Lye Hie λla Lye He λrg Cyβ Leu Gly 565 570 575 λrg Phe Tyr Gin Thr λβn λrg Phβ Val He Gly λrg He Hie Ser Gin 580 585 590 λrg λβn He Phe Hie Sβr λβn λrg Hie Leu λrg Phe Phe Hie λla Tyr 595 600 605 Trp Gin Asn Lyβ Lβu Lβu Sβr Pro Hie Hie λla Phβ Phβ Pro λβp Thr 610 615 620 Ser Leu Phe Gly Cyβ Lyβ Lyβ Gly Lβu Hie Ser Phe Pro Lye Glu λβn 625 630 635 640 Cyβ Lyβ He λrg He Val Trp Ser Lyβ Arg Hie Lβu Cye He Leu Leu 645 650 655 He Trp Gly Gly He Cyβ Ser Thr λla Leu Leu λla Leu Sβr Tyr Pro 660 665 670 Sβr Phβ Gin λla Trp Leu Ser Phe Glu Thr Lβu Gin λβn Tyr Cye Lβu 675 680 685 Gin λβn λla Phe Tyr Ser λrg Val Hie Glu Cye Leu He λβn Leu λla 690 695 700 Leu Trp Ser Glu Lyβ λβn Tyr Hie Lyβ λβn Phβ Leu Ser Phe λla Ser 705 710 715 720 Hie Tyr λrg Leu λla λβn Hie Lye Lye λβp Hie Sβr Pro Tyr Trp Phβ 725 730 735 Hie Gin λrg Phe Ser Phe Cyβ Glu λβn λrg He He Gin Gly Gin λβn 740 745 750 Ser Lyβ λrg Tyr Lyβ Lyβ λrg Val Thr Lβu λsp Leu Phe Trp Lye Trp 755 760 765 Leu Lyβ λβn Gin Cyβ Pro Pro He Leu Cye Leu Lyβ Glu λβn Ser Cyβ 770 775 780 Gly Ser Pro Hie Hie Leu Lyβ λsn He Hie Ser Tyr Leu Leu Asp λrg 785 790 795 800 Ser Leu Gin λrg Ser Gin Val Cyβ Lβu Leu Cyβ Leu λβp Lβu Sβr Gly 805 810 815 Cyβ Hie Pro Phβ Leu Tyr λla Ser Trp Lyβ Lyβ Cyβ Ser Thr Leu Cyβ 820 825 830 Phe Ser λrg Pro Thr Lyβ Lyβ Val Phe He Sβr Ser Leu λla Pro Phe 835 840 845 Phe λβp Lyβ λla Tyr λβn Leu Ser He Gin Glu Leu Gin λla Gin Gin 850 855 860 Ser Leu Gin Ser Lyβ Gin Val Hie λrg Leu Glu Lyβ Glu Gin He He 865 870 875 880 Gin Trp Leu Gin Thr He He λrg λβn Lyβ Lyβ Phβ Gin Gly λβn Gin 885 890 895 Thr Thr Tyr Ser Pro Hie Gin Thr λrg Leu Lyβ λrg Aβp His Pro Phe 900 905 910 Ala Cyβ Lβu Leu Val Leu Leu Phe Phe Glu Thr Ala λla Phe Glu Pro 915 920 925 Leu λla Leu Leu λla Phβ Phβ Val His Gin Pro λla Cys Lβu Pro Gin 930 935 940 Thr Pro Leu Ser Lβu He Tyr λrg Phe Thr Cyβ λβn λrg He Lyβ λβp 945 950 955 960 Phβ Phβ Glu λrg Leu Tyr Gly λla λβn Met Phe Gin Lyβ He He λrg 965 970 975 He He λrg He Glu Tyr Gly Gin λβn He He Leu He He λla λβn 980 985 990 Phe Ser Cyβ Phe Ser λla Gin Gin Lyβ λla λla Lβu Phe Val Gly λrg 995 1000 1005 λla λβp λla Phβ Glu Ser Lyβ Lyβ Val Phe Hie Phβ λrg He λep Leu 1010 1015 1020 Phe Tyr He Gin Ser Hie Phβ Leu Thr Leu Phe He Lyβ Aβp Phe Phe 1025 1030 1035 1040 Aβn λβn Trp He Val Met Leu Gin He Leu Tyr Phβ Phe Lyβ λβp Ser 1045 1050 1055 He λβp λβn Hie Glu Val Lyβ λβn Phe He Phe λβp Aβn He Gly He 1060 1065 1070 λβp Phβ Phe Glu Ser Tyr Phe Leu Val Phe Gin He Phe λβp Ser λrg 1075 1080 1085 Phe Glu Thr He Lyβ He He Cyβ He λβn Lyβ Pro He Gly Ser Val 1090 1095 1100 Phe Phe Phe Phβ Leu Cye Phe Phe Phe Gly Phe Phe Val He He Cye 1105 1110 1115 1120 Pro He λrg Thr Glu λβn λβn Glu Thr Glu λβn Phβ Gin Lyβ Lye λla 1125 1130 1135 Ser Phe Leu He λla He He He He Val λep Gin Leu Ser Leu Leu 1140 1145 1150 Hiβ Pro λrg Gin Tyr Sβr Gin Thr Cyβ Sβr λβn λrg Tyr λrg Lβu Pro 1155 1160 1165 Pro Leu Thr Leu Trp Val λla λrg Lyβ Gin Lye Gin Ser Pro λep Lβu 1170 1175 1180 Phe Cyβ Hie Gin λrg Phe Ser Lyβ Tyr Pro Leu Cyβ Lβu Pro Leu Lyβ 1185 1190 1195 1200 λrg λβn Hie Lβu λrg Sβr Lβu Glu Gin Lye Sβr Glu Pro λβn Lβu Lβu 1205 1210 1215 Gin λrg Leu Leu λβp Trp λrg Pro Pro Lβu Lyβ λβp Trp Lβu Lβu Pro 1220 1225 1230 Leu λla Leu Lyβ Leu Leu Gin Leu Ser Cyβ Ser Cye Gin Phe Leu Lye 1235 1240 1245 He Ser Cyβ Val Ser Phe Gin He Glu He Aβn λrg Lβu Ser He Sβr 1250 1255 1260 Lyβ Lyβ Lyβ Val Phe Leu Tyr Tyr Ser Tyr Lye λrg Tyr Phe He He 1265 1270 1275 1280 He Lyβ Thr λβp λla Phβ λla λrg Gin Leu Thr Ser Phe λrg Aβn Ser 1285 1290 1295 Lyβ Pro Thr Cyβ Pro Aβn Hie Phβ Ser Phe Ser Ser λrg Cyβ λrg He 1300 1305 1310 Val λβp Leu Aβp Leu Cyβ He Phe Ser Ser Gin Val Glu Thr Lyβ Gin 1315 1320 1325 λla Lyβ Thr λβn Pro Sβr Ser Glu Glu Ser Sβr He Leu Ser λβn Sβr 1330 1335 1340 He λβp Hie λrg Aβn Phe Phe Gly Tyr Leu Lyβ Ser Val Leu Leu He 1345 1350 1355 1360 Cyβ Phβ Pro Phβ Cyβ Phβ Pro Cyβ Gly Ser Cyβ Gly Ser Gin Thr Leu 1365 1370 1375 Aβn Tyr Thr Cys Tyr Ser Lye Hie λsp Thr Gin Thr Lyβ Leu Phe Leu 1380 1385 1390 Glu λrg Phe Met Cyβ Ser Pro Leu Thr He Ser Pro Thr He Leu λrg 1395 1400 1405 Cyβ He Phe Leu Gin Lyβ Aβp Ser Phe Lβu He Ser Cye Ser Tyr Ser 1410 1415 1420 Ser Phe He Leu λla λβn Phe Cye Leu Trp Val Lye Met He Val Leu 1425 1430 1435 1440 λla Phe λrg λrg Leu Gin λrg Ser Gly Phe Phβ Gin Tyr Leu Met Lyβ 1445 1450 1455 Lyβ Lye Lye λβn λla Tyr Cyβ Cyβ He Met λrg Met Phe Lyβ Aβp Met 1460 1465 1470 λβn Leu Leu Lyβ λrg Val λla He Phe Ser Ser Leu Hie Gin λβp Thr 1475 1480 1485 Aβp λrg Tyr Glu Thr λrg Tyr Ser Lyβ Glu Lyβ Gin Leu Thr Lyβ Pro 1490 1495 1500 Leu Thr λβn λβn Hie Lye Pro Lyβ λrg Lβu Lβu Thr λrg Ser λβn Leu 1505 1510 1515 1520 Ser He He Phe Lyβ Leu Phe Leu Lyβ Leu He Thr Leu Ser Leu Hie 1525 1530 1535 Thr He Leu He Lye λβn Gin Sβr Leu He λrg Thr He Gly He Thr 1540 1545 1550 Gly Lyβ Leu Leu Lyβ Glu Ser λrg λβn Gly Lyβ λβn Thr Pro He Lyβ 1555 1560 1565 λrg Ser Lyβ He Leu Pro Lyβ λrg He Ser He Phe Gin Thr Leu Sβr 1570 1575 1580 He λrg λla Met He Ser Thr Lyβ Thr He Ser Leu Met λβn Lβu Pro 1585 1590 1595 1600 Gin λrg λla Phe λrg λβn Lβu Gly He Ser Val Thr Glu Phe Sβr Gin 1605 1610 1615 Val Gly Cyβ Pro He Lye Thr He λrg Leu Lyβ Ser Thr Pro λβp λrg 1620 1625 1630 Ser Glu He Leu Trp Lyβ He Ser Tyr λβn Pro Leu Ser Leu Met He 1635 1640 1645 Lyβ λrg Lyβ λrg Ser Phe λβn Leu Pro λβn λβn Leu Leu Gin Glu Ser 1650 1655 1660 Leu Gly He Lyβ Ser Glu λrg He Lys Ser Ser Trp λla Cye Lβu Met 1665 1670 1675 1680 Ser Pro Lyβ Lyβ Gly Lyβ Lye Gin Lye Lyβ Met Glu Ser Leu Leu Val 1685 1690 1695 Gly He Gly Trp He Phe Phe Ser Hie Leu Tyr Leu Thr Lyβ Aβn λβn 1700 1705 1710 Leu Leu Met Ser Lyβ Lyβ Gin Ser He Lyβ λen Gin Phβ Pro Met Ser 1715 1720 1725 λβn Gin He Pro Leu Pro Pro Pro Thr Tyr Lye λla Tyr λrg Lβu Lye 1730 1735 1740 Leu Glu He Tyr Leu Met Lyβ Gly Val He Phe Leu λβn Ser Leu Leu 1745 1750 1755 1760 λla He Trp Lyβ Cyβ Met Leu λrg Glu Ser Lβu Thr Leu He Pro He 1765 1770 1775 Thr Ser Ser He λβn Tyr Phe Thr He Thr Leu Cyβ Lβu Leu Cye Trp 1780 1785 1790 Gly Val He Met λla λβn Leu Lyβ Lyβ Phe Hie Cye Cyβ Met Gly λla 1795 1800 1805 Met Val Val Leu Glu Leu Gly Met He Gly Thr Pro Pro Leu Val He 1810 1815 1820 Lyβ Thr λβn Lyβ λla Thr Met Trp Leu Gin Leu Met Cyβ He Lyβ Thr 1825 1830 1835 1840 λla Val λla Ser Gin Val Val λrg Lyβ Gly Leu Thr Thr Leu Val Phe 1845 1850 1855 Ile Sβr Thr Lyβ Lyβ Thr λβn Sβr Gin λla Hie λβn Glu Hie Val Lye 1860 1865 1870 Lyβ λrg Ser Lyβ Thr Lyβ He Ser Trp λβn Phβ Lβu Hie Lyβ He Met 1875 1880 1885 Leu λβn Thr Thr λla λrg Lye λrg λrg Lye λβn Ser Glu Leu λrg Leu 1890 1895 1900 Lyβ He Ser Lys Lyβ Thr Leu λrg Leu He Thr Pro Gly Met He Val 1905 1910 1915 1920 Leu Leu Leu Phe Leu Lyβ Lys Thr Gin λβn He Gin Leu Leu Leu Ser 1925 1930 1935 Leu Val Met Gly He λla Thr Leu Ser Lyβ He Met Gly Lyβ Lye Gin 1940 1945 1950 He Lyβ Lβu He Gly λrg Lyβ Met Leu Lβu Phβ Lyβ Val λla λβn Met 1955 1960 1965 Met λla Cyβ Lβu Lβu He He Leu He Ser λβn Thr Pro Thr Pro Pro 1970 1975 1980 λrg He Pro He λrg Val λla Leu λrg Met λla Phβ Pro He Lyβ λla 1985 1990 1995 2000 Leu Thr λrg Leu Ser Leu He Cyβ Leu He He He Sβr Lβu Sβr Lβu 2005 2010 2015 Val Ser Gly Gly He λrg He λβn Pro Leu Lyβ λβp Cyβ Pro Hie Lyβ 2020 2025 2030 Lyβ Lβu He Ser Leu Ser Lyβ He Phe λla λla Thr Lyβ λβn Trp Leu 2035 2040 2045 Glu Lyβ Lβu Thr Ser He Lyβ Lβu Leu Thr Leu Lyβ Thr Gin λla He 2050 2055 2060 Met Met Lyβ Lyβ Lyβ Leu λrg Lyβ He Leu Lyβ λβn Lβu Gly λβn Glu 2065 2070 2075 2080 Ser He λrg Lyβ Lyβ λrg Lyβ λsn Trp λrg λla Lys λla λla Thr Lys 2085 2090 2095 He Lyβ Trp Lyβ Gin Lyβ Lβu Lyβ Leu Thr λla Lyβ Lyβ Met Arg Phe 2100 2105 2110 Leu λrg Ser He Lyβ λrg Leu He Glu Thr Gin Glu Gin Ser Leu Thr 2115 2120 2125 Leu λrg He Lβu Lyβ λla Ser Lyβ Gly λβn Cye Lβu He λβn Lβu Lyβ 2130 2135 2140 Met Ser Thr λrg He Lyβ Thr Lβu He λβn Lβu Leu Met λβn Ser Lyβ 2145 2150 2155 2160 Met λla Lyβ He λrg He Ser λla λrg Gin Lyβ Lyβ Hie Lyβ Pro Lβu 2165 2170 2175 Lyβ Val λrg Lyβ He Val Ser He Gin λβn Gly Phe Gin Lyβ Lβu Lyβ 2180 2185 2190 Thr Leu Met Gin Leu Met λβn Ser Lye Met λla Lye He λrg He Ser 2195 2200 2205 λla λrg λrg Lyβ Gin Lyβ λla Thr Lβu Lyβ He Pro Leu Lyβ Met Ser 2210 2215 2220 Ser He Lyβ λrg λrg He Lyβ Leu He He Ser He Lyβ λrg Tyr Gin 2225 2230 2235 2240 Trp Leu Lyβ Gin λrg Val He Ser Val Gly Ser Lyβ λrg Pro He Ser 2245 2250 2255 Lyβ He Ser Gin λrg Ser λβn Trp Pro λβn Lyβ Lβu Lyβ Lyβ Met Lyβ 2260 2265 2270 Val Sβr Met Leu Glu Lyβ λβn Leu Lyβ Tyr He λβn Pro Lβu λrg Met 2275 2280 2285 Val Met Glu Pro Ser Val Met Gly Tyr Leu Lyβ Gin Lyβ Pro Gin Lβu 2290 2295 2300 Phe Leu Lyβ Thr Phβ λrg Thr Ser λrg Lyβ Ser Met Gin λβn Lβu Glu 2305 2310 2315 2320 He Ser He Thr He Thr He Met λβp Ser Lye Thr Aβn Pro Phβ Met 2325 2330 2335 Leu Lyβ Lβu He Lyβ λrg Lyβ Gin Gly Lyβ Gin Leu λla Leu Lyβ λβn 2340 2345 2350 Pro Phe Thr Leu Lyβ Leu Leu Lyβ λrg Met Gin Lyβ Lβu Thr λβp Sβr 2355 2360 2365 He Lyβ Gin Val Val Trp Val Leu Gly Lyβ Gin λrg λla Ser Leu Lyβ 2370 2375 2380 Gly Met He Lyβ Leu Met He Sβr Val λrg Gly Phe Gin Gly He Lye 2385 2390 2395 2400 λβn Trp Leu λrg Lyβ Lβu Thr He Ser He Lye λrg Tyr Gin Lye Lβu 2405 2410 2415 Lyβ Gin Val Phe Leu λla He Ser Lye λrg Thr Ser Ser Lye He Leu 2420 2425 2430 Gin λβn Thr He Pro He Tyr Gly Leu Lyβ Val Gin Lyβ Lys Tyr Leu 2435 2440 2445 Leu Val Cyβ Gin λrg λβn Thr He Thr Leu Leu Thr λla Thr Tyr λla 2450 2455 2460 Leu He λla He Sβr Lyβ Met Glu Gin Ser Met Lyβ Lyβ λrg Pro λla 2465 2470 2475 2480 Cyβ λrg Lyβ Lyβ Thr Leu Ser Gly Ser Ser Ser Met He λrg Leu λrg 2485 2490 2495 He Met Glu λla Phe Lβu Cyβ Gin Ser Met He Lyβ Leu λla Ser Thr 2500 2505 2510 λrg λrg He Lyβ He He Leu He λrg Ser Ser Phβ Pro Pro Ser Thr 2515 2520 2525 Met Leu Lyβ Thr Leu He Lβu λla Lβu λrg λβn Phβ Pro Met Hie Phe 2530 2535 2540 Leu Gin Hie Lβu He Thr λla Trp λrg Glu Lye Met λrg Ser Met Glu 2545 2550 2555 2560 Ser λrg Thr Leu He Gin Lyβ Val Val Ser Lys λsn Leu Lyβ Gly Leu 2565 2570 2575 λrg λsn Thr Lyβ λβn λla Lyβ Thr Thr Pro Cyβ Lyβ Arg Gly Val Phβ 2580 2585 2590 Tyr Ser Leu Ala Glu He Pro He Val Phe Ser He Trp λβp Glu Cyβ 2595 2600 2605 Tyr Gin Phe Met Val Sβr Tyr Pro Hie Thr Phβ Val Ser Ser Val Gly 2610 2615 2620 Ser Val Gin Ser Tyr λla Phe Gly λβp Met Met Cyβ Glu Thr Cyβ λrg 2625 2630 2635 2640 Glu Cyβ Val Gly λla Gin Thr Leu λβn Pro Tyr Tyr λrg λβp Thr Glu 2645 2650 2655 Glu Pro λβn Ser Pro Tyr Gly Gin Hie Gin Pro λrg Lye Pro Aβn λrg 2660 2665 2670 Lβu λrg Leu Gly Thr Ser Pro λβn He Pro Thr λβp Thr λβn Glu λrg 2675 2680 2685 Lβu Cye Ser Leu Lyβ Ser Ala Trp He Phβ Pro Thr Pro Lyβ Arg Lβu 2690 2695 2700 λβn Pro Lβu Lβu Lye He Lye Phβ λβp Cyβ λla Sβr Gly Phβ Val Lβu 2705 2710 2715 2720 Cyβ Glu λβn Leu λrg Val He Lyβ λrg λla Thr λrg Lyβ λβn Lyβ Lβu 2725 2730 2735 Gin λrg Sβr Ser Ser Lyβ λβn Hie λrg λla Phβ λrg λla λβn Ser λrg 2740 2745 2750 Ser Pro Lye Lyβ λβn Gin Lyβ λβn Hie λrg λβn Tyr Hie Thr Lβu Cyβ 2755 2760 2765 Pro Lyβ Lyβ Thr Leu λla He λrg Ser Gly Lye He λrg Leu Gin Glu 2770 2775 2780 Phe λla Gin λβn λrg Hie Cye Gly Cye Leu Ser Arg λrg Gly λrg Tyr 2785 2790 2795 2800 Tyr Tyr Leu Phe Hie λrg Glu λen Lβu Trp Ser Phe Phe Leu λla λrg 2805 2810 2815 Phe Thr Leu Glu Cyβ Gly Tyr Phβ Gly Lyβ λrg Lyβ Sβr Hie Phβ Cyβ 2820 2825 2830 Gly Lyβ Val Phe Leu Glu Phe Thr Lyβ λrg Glu Glu Tyr Lβu λrg Tyr 2835 2840 2845 Phβ λla Ser Leu He Gly λβn Leu Phe Gin λrg Ser Leu λβp He Leu 2850 2855 2860 λrg Phβ Lye Thr Leu Ser He Ser Leu Lyβ λrg Phβ He He λβn Thr 2865 2870 2875 2880 He Pro Leu Cyβ Glu Leu Pro Leu Phe Gly λβn Val He Leu Thr Leu 2885 2890 2895 λβn Phe Tyr λrg Tyr λβn Lβu Ser Hie Sβr Leu λla Cyβ Phe Ser Ser 2900 2905 2910 Gln He Thr Ser Pro Leu λla λβn Ser Thr Leu Gly λβn λla Cyβ λla 2915 2920 2925 Phe Phe Leu λrg λla Tyr Phβ Cyβ Cyβ Lyβ Tyr Pro Thr He λla Ser 2930 2935 2940 Pro Glu Trp Met Ser λrg Gly Gly Val Glu λrg λla Lyβ Cyβ Sβr He 2945 2950 2955 2960 Lyβ Pro Sβr He Phe λla He Lyβ Gly Lyβ Cyβ Val Gin Pro Lyβ He 2965 2970 2975 He Thr Ser Gly Lyβ Ser Leu λrg Glu λβn Aβn λβn λla Cyβ Lyβ Phe 2980 2985 2990 Leu Thr He λrg Pro Leu Lyβ Tyr Phβ Leu Gin Ser Lyβ λla Gin Lyβ 2995 3000 3005 Glu Lyβ Trp Lβu λβn λla Lyβ Hie Sβr λen Sβr Lβu Val Val Sβr Gly 3010 3015 3020 Hie Cyβ Hie Lyβ λrg Trp He Gly Ser Ser Lβu Lβu Ser Leu λla Leu 3025 3030 3035 3040 Lye Gly λrg Phβ Tyr Lβu Leu Leu Val λla Ser Leu Lyβ Cyβ Leu λla 3045 3050 3055 Gin Ser λrg Pro Gin Gly Phe Trp λβn λla Phe λla Ser Leu Leu Lyβ 3060 306S 3070 Leu Glu λrg Ser Lβu Cyβ Cyβ Met Pro Gin Ser He He Gin Ser Gly 3075 3080 3085 λla Val Lyβ λβn Pro Lyβ Pro Lβu Sβr Gin He λla Ser Trp Gly Leu 3090 3095 3100 Cyβ Hie Lyβ λla Lβu Pro yr λrg Hie λβn λrg Phe Hie Gin He He 3105 3110 3115 3120 λla Leu Leu Lye Gly Phβ Lβu Lyβ λrg Thr Lβu Pro Hie λrg Tyr Gin 3125 3130 3135 Lyβ Arg Leu Phe Ser Hie Phe Phe λan Leu Met Gly Leu He Arg Aβp 3140 3145 3150 Phe He Phe Hie Ser Leu Ser Leu Lyβ He Leu Hie Cye Pro Phe Val 3155 3160 3165 λla Phe λβn λrg Gin (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3177 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βinglβ (D) TOPOLOGY: linear ( ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Cyβ Ser Val He Ser Pro Ser He Ser Ser Ser Met Lyβ Ser λβn Ser 1 5 10 15 Ser Phβ Ser Ser Lyβ λrg Lβu Glu Lyβ Lβu Sβr Lyβ He Val Lyβ Thr 20 25 30 Sβr Phβ Ser Lyβ Phβ Pro He He Phβ Val Hie λla λβn Phe Val Ser 35 40 45 Phβ Tyr Sβr Ser He Cyβ Tyr He Cyβ Leu Lyβ λla Tyr Lβu Ser Met 50 55 60 He Leu Trp Phe Trp He He Leu Ser He Ser Leu Thr λβn Thr Val 65 70 7S 80 Ser Val λβp Lyβ He Phe Lye Tyr Ser Leu Gly Met Pro Leu Lyβ Lβu 85 90 95 Lyβ Leu λla He Thr Leu Gly Leu Pro Sβr Cyβ Lβu λrg He Phe Lβu 100 105 110 Ser Ser Pro Leu Val Met He Ser λβn Ser Phe Ser Val Thr Leu λla 115 120 125 λβn Leu Trp Ser Glu λrg Lβu Pro Pro Ser Phe Leu Lyβ Lyβ He Phe 130 135 140 Val Gly Hie Cyβ Ser Leu He Val Ser λla He Gly Gin λla Lyβ λrg 145 150 155 160 Sβr Val Met Leu Val λla Sβr Lβu Thr He λla Phe Lβu Phe Leu λla 165 170 175 Val Phe Ser Met Ser Leu Thr Lyβ λla Thr Phβ Gly Sβr Lβu λβn He 180 185 190 Ser λrg Leu Hie Gin Tyr Lβu λrg Gin He Tyr λla Hie Pro Lβu Pro 195 200 205 Lβu Gly Tyr Glu λrg Lyβ Gly Lyβ λen Lye λrg λla Lye Hie Hie Tyr 210 215 220 Cyβ Leu λrg Aβn Leu Thr Hie Gin Arg Gin Ser Phβ Leu Lyβ Aβn Leu 225 230 235 240 Ser Asp Leu Leu Leu Tyr Tyr Gin Lyβ Ala He Glu He His His Trp 245 250 255 Leu He Cyβ Lyβ Lyβ λla Leu He λla λrg Gin λla Hie λβp Hie Cyβ 260 265 270 Gly Leu Ser Arg Lyβ Hie Val Glu Trp λβp λβn Lβu λβp Ser Tyr Phe 275 280 285 Leu Gly Trp Leu Leu λrg Cyβ Lyβ λrg He λrg He Cyβ λla Lyβ λrg 290 295 300 λsp λla Val λla He Phe He Phe Phe He λla Phe Ser Cyβ Val Phβ 305 310 315 320 Hie Lyβ Leu Phe λsp λβn λrg λβn Ser Cyβ Leu Phe Leu Leu Hie Cye 325 330 335 Cyβ He Cyβ Phe Leu Hie Thr Ser λrg Pro Ser Lyβ λrg He Ser Cyβ 340 345 350 He Cyβ Pro Leu λsn Leu λsp He Leu Pro Thr Hie Cyβ λβp λβn He 355 360 365 Pro He Ser λla He He Phe He Hie He λβn Hie Sβr Glu Leu Leu 370 375 380 Leu Val Phe λla λβp He Ser λrg Lyβ He He Gly Lyβ Leu Ser Hie 385 390 395 400 Ser Val Gin Gly Hie Hie Lye Hie Cye Leu Thr Thr Gly λla Lyβ Tyr 405 410 415 Gin Ser Val Ser Cyβ Ser Thr Lyβ He Ser Gly Hie Val Glu Val Gin 420 425 430 He Lyβ Arg λrg He λβp Leu λla Phe λrg Hie Hie Thr He λla Pro 435 440 445 Ser Val He Leu Lβu He λla He Lyβ Thr Hie Sβr Pro Hie Sβr λep 450 455 460 Glu He Ser Lyβ He He λrg Sβr Tyr He Lyβ λβn Lyβ λrg Lye λrg 465 470 475 480 λβp Lyβ λrg λla Met Phe Gly Lyβ Lyβ Val He Phe Hie λrg Glu Sβr 485 490 495 λrg Cyβ Val Gly Lyβ Thr Phβ Ser Val Lye Thr λrg λβp λla Phe Lβu 500 505 510 λβn λla Leu Phe Hie Phe Phe Lyβ λla He Ser Lyβ Gin Hie λrg He 515 520 525 Thr He Thr λla λrg λen He Thr He Thr Hie Phβ λla Gin λla Thr 530 535 540 Ser Hie λla Lβu Phβ Phβ λrg λla Ser Thr Aen λβn λβn Ser Ser λrg 545 550 555 560 Gly Glu Ser Gin Phe Val Leu λβn Leu Val Phe λrg λrg He Ser Met 565 570 575 Hie Glu Aβn Lyβ Phβ λla Val Gly Val λβp Phe He Lye Gin He λla 580 585 590 Leu Phe λrg Gly Val Phe Thr λsn Leu λsn Ser λla Lye He Phe Phe 595 600 605 Thr Gin He Val He λep Phe Ser Met Leu He Gly Lyβ He Aβn Phe 610 615 620 Phe Hie Pro Thr Met Hie Phβ Phe Leu Glu He Gin Val Phe Ser Val 625 630 635 640 λla λβn Lyβ λrg Gly Phβ He Hie Ser Gin Lyβ Lyβ He Val Lyβ Phe 645 650 655 λla Leu Phe Gly Val λβn λβn λla He Phe Ser Val Phe Phe Ser Ser 660 665 670 Gly Val Val Phe λla Gin Gin Leu Phe Tyr Glu Leu Tyr Pro He Leu 675 680 685 Glu Val Phe Lyβ Lβu Gly Ser λβn λβn Pro Leu Lyβ Leu Phe Lyβ He 690 695 700 He Val Cyβ Lyβ Met Leu Phe He Hie λβn Gly Phe He Glu Ser Val 705 710 715 720 Ile Leu Leu Tyr Gly Gin Lyβ Lye Thr λβn He He Lyβ Thr Phe Ser 725 730 735 Leu Leu Leu Leu He He Gly Ser Hie Glu He He λrg Lyβ λβn Lyβ 740 745 750 Thr He Val Pro He Gly Phe He λβn λβn λβp Phe Leu Phe λβn Sβr 755 760 765 Val Lyβ He Glu Phe Glu Phβ λrg Gly λβn Lye He Pro Lyβ λβn λla 770 775 780 He λβn λrg Ser Val Leu Tyr Glu He Phe Phe Gly Ser Gly Lye He 785 790 795 800 λen λla Pro Gin Phe λβp Cye λla Lyβ λrg He Val Val Ser Lyβ λβp 805 810 815 Hie Pro He He Lyβ Thr Phe He Val He Cye He Gly Val Cye Ser 820 825 830 λla Hie Lyβ Ser Val Phe Ser Val Trp He Val λβp Val He Ser Hie 835 840 845 Phe Phe Thr λrg Leu Hie Gly Lyβ Aβn λla Hie Glu λrg Phe Val Phe 850 855 860 Hie λla Leu Lyβ Gin Lyβ λrg Phe Phe Lyβ Phβ Hie λrg Ser Leu Hie 865 870 875 880 Ser Leu He Lyβ Pro He He Phe Leu Glu Ser Lyβ Ser Tyr Lys Hie 885 890 895 Aβn λen λen λrg Tyr Aβn Gin λβn λrg Phβ He Gly Leu Lyβ Lye λβn 900 905 910 λβn λrg Tyr λβn Gly Tyr Lyβ Gin Tyr Lye Tyr λrg Gly He Aen Lye 915 920 925 Ser Phe Arg Glu Thr Lye Gin Pro He Pro Pro He Lyβ Gin Aβp Phβ 930 935 940 Lyβ Lyβ Gly He Asp Thr Leu Leu Hie Val Cyβ Phe Lyβ Phe Phβ Tyr 945 950 955 960 Phe Leu Lyβ Leu Pro Leu Leu λβn Leu Leu Leu Tyr λβn Leu Phe Leu 965 970 975 Phe He Ser Leu Leu λla Cyβ Hie Lye Hie Leu Ser Leu Tyr λrg Tyr 980 985 990 Thr λla Ser Hie Val He Val Lyβ He Phe Leu λrg λβp Ser Thr Val 995 1000 1005 Leu He Cyβ Phe Lyβ λrg Ser Leu Gly Ser Glu Leu λen Thr λla λβn 1010 1015 1020 Lyβ Thr Leu Tyr λβn Leu Ser Ser Hie λrg He Ser Leu Val Ser Pro 1025 1030 1035 1040 λrg Aβn λsp λrg Lys Gin λrg Cyβ Leu Leu Val Val Leu Met Leu Leu 1045 1050 1055 Lyβ Val Lye Lyβ Ser Phe Thr Ser Gly Leu He Cyβ λβn Ser Thr Phe 1060 1065 1070 λβn Pro He Ser Leu Pro Phe Ser Ser Lyβ He Phe Ser He Thr Gly 1075 1080 1085 Ser Cyβ Phβ Lyβ Ser Phe He Phβ Lβu λrg Thr Leu Leu Thr He Thr 1090 1095 1100 Lyβ Ser Lyβ Thr Ser Ser Leu He He Ser Gly Leu Thr Ser Leu Lye 1105 1110 1115 1120 Val Thr Phe Leu Ser Phβ Lyβ Phe Leu He Val λla Leu Lyβ Leu Ser 1125 1130 1135 Lyβ Ser Lyβ Phe Val Thr Ser Pro Lβu Gly Val Phe Phe Ser Phe Ser 1140 1145 1150 Cyβ λla Ser Phe Leu λla Ser Leu Ser Sβr Phβ λla λen Pro Tyr Glu 1155 1160 1165 Leu Lyβ Thr Thr λrg Leu Lyβ λrg Thr Phe Lyβ Lye Lyβ Pro Leu Ser 1170 1175 1180 Phe Leu Leu Leu Leu Leu Leu Lβu Lβu He λen Lβu λla Ser Ser Ser 1185 1190 1195 1200 Thr Leu λla λβn He Glu λla Lyβ Leu Ser λla Gin He Aβp Asn Thr 1205 1210 1215 Ala Cys His λrg His Ser Tyr Gly Leu λrg Val Ser Lyβ λβn Ser λrg 1220 1225 1230 Leu Thr Ser Phe λβn Val He λrg λβp Phe Pro λβn He λrg Tyr λla 1235 1240 1245 Phe λsp Pro Ser λla Thr Thr Tyr λsp λrg λβn λrg Aβn λβp Leu λsn 1250 1255 1260 λβn Gin Thr Phe Ser Cyβ Ser λβp λla Phe Cyβ λrg Thr Gly λβp λrg 1265 1270 1275 1280 Hie λrg He Gly Cyβ Tyr Hie Pro Ser Tyr Tyr λβn Phe Leu Val λla 1285 1290 1295 Val Ser λβp Ser Cyβ Lye Lyβ Phe Hie λla Phe Pro Phe Lyβ Leu Lyβ 1300 1305 1310 Ser He λla Val Tyr Gin Lyβ Lyβ Lye Tyr Phβ Tyr Thr He Hie Thr 1315 1320 1325 Ser Ala Thr Leu Phe Lyβ Ser Lyβ Pro Thr Leu Leu Leu Gly λβn Hie 1330 1335 1340 Hie Ser Gly He Val λβn Lβu Leu Val Pro Thr He Phe Leu Ser Gin 1345 1350 1355 1360 Val Val Val Glu Leu He Phe λrg He Phe λβp Val Phe Phe λβn λrg 1365 1370 1375 Leu λrg Leu Lyβ Pro Lyβ λβn Lyβ Gin Lyβ Gin Thr Gin λla λβp Gin 1380 1385 1390 Ser Glu λβn Lyβ λla Pro Phβ λla Thr Pro Thr Thr Lyβ Glu Thr Phe 1395 1400 1405 Phe Glu Ala He Phe Glu Aen Leu Ser Tyr Phe Val Phe Hie Phe Val 1410 1415 1420 Ser Hie Val λβp Leu Val λβp Hie Lye λrg Leu He He Hie λla He 1425 1430 1435 1440 Val Ser Met Thr Hie Lyβ Pro λsn Tyr Phe λsn λla Ser Cys λla His 1445 1450 1455 Leu Aβp Pro Phe Leu Gin Pro Tyr Phe Ser Val Ala Phe λep Phβ Phe 1460 1465 1470 Lyβ Lyβ He Hie Phβ Lβu Phβ Lβu Val Lβu He Lyβ Val Leu Ser Phe 1475 1480 1485 Gin He Phe Val λβn Cye Gly Lyβ Cye Glu Sβr Ser Pro Leu λβp λla 1490 1495 1500 Cyβ λβn λβp λrg λla Phe Phe λen He λβn Aβn λβp Lye Lye Lye Lyβ 1505 1510 1515 1520 Met Leu λsp He Val Val Glu Cyβ Ser Lyβ Thr He λβp Tyr Ser Ser 1525 1530 1535 Val λrg Phe Leu λla Val Phe λβp Thr λβn Lyβ He Pro He Gly Met 1540 1545 1550 Lyβ Lβu Gly He Val λrg λrg λen λβn λβp λrg λen Hie Pro Thr Thr 1555 1560 1565 Thr λβn λrg Ser Gly Phe Pro λla λla He Tyr Gin Ser Ser Ser Ser 1570 1575 1580 Phe Ser Ser λrg Cyβ λrg Phβ He λrg Ser Ser Lys Thr λβn λrg Glu 1585 1590 1595 1600 λrg Gly Gin λla Ser Phe λrg λsn Leu λla He Lyβ Gly λrg He Leu 1605 1610 1615 Gin Ser λβp Gin Lyβ Ser Tyr Gin Lye Glu Sβr Val Phe Phe λrg Leu 1620 1625 1630 Tyr Gin Glu Gin Phe λβn Gin Gin λrg Gin Ser Hie Cyβ λrg He Phe 1635 1640 1645 Hie Lyβ Glu Leu Ser Glu He Trp Gly Ser λla Leu Pro λβn Phe Hie 1650 1655 1660 Lyβ Leu Gly Val Pro Ser Lyβ λrg Ser Val λen Gin Hie Pro He λβp 1665 1670 1675 1680 Pro Lyβ Phe Tyr Gly Lyβ Tyr Hie Thr Thr Pro Tyr Pro λrg Glu Ser 1685 1690 1695 Gly Val Phe Glu He Cyβ Gin Thr He Phe Cyβ λrg λβn Hie Tyr λrg 1700 1705 1710 Glu Ser λβn Pro λsn Gly Ser Lys Val His Gly λrg Val Val Leu Glu 1715 1720 1725 λrg Lyβ λla λrg Sβr λrg Lyβ Lyβ Trp λrg λla Tyr Trp Trp Gly Leu 1730 1735 1740 Val Gly Tyr Phe Ser Leu He Tyr He Gin Lye Thr He Phe Cye Gin 1745 1750 1755 1760 λrg Ser λsn Gin Ser λrg Thr Ser Ser Pro Cys Pro Thr λrg Tyr Ser 1765 1770 1775 Hie Tyr Hie Hie Arg Hie Thr λrg Leu Thr λla Ser λrg Phe Thr Lyβ 1780 1785 1790 Gly Phe Phe He Hie Ser Trp λrg Tyr Gly λen Val λrg Cye Gly Ser 1795 1800 1805 Arg Hie Ser Gin Leu Gin Val Gin Ser He He λβp Ser Gin λrg Ser 1810 1815 1820 Val Phe Cye Val λen Gly Glu Ser Trp Hie λrg Thr Lyβ Sβr Phβ He 1825 1830 1835 1840 Val Val Trp Gly Gin Trp Trp Ser Trp Ser λla Leu Glu λrg Hie λrg 1845 1850 1855 Trp Leu λrg Pro Thr λrg Gin Gin Cyβ Gly Tyr λβn λβn Cyβ λla Tyr 1860 1865 1870 Glu Lyβ λrg Gin Trp Lβu Sβr Hie Ser λrg Trp Glu λrg Aβp Gin Pro 1875 1880 1885 Phe Leu Ser Leu Gin Arg λrg Pro Thr Hie λrg Leu Thr Thr Ser He 1890 1895 1900 Lyβ Ser λrg λrg λep Pro Lye Gin λβn λrg Phe Hie Gly He Ser Cyβ 1905 1910 1915 1920 Thr Lyβ Cyβ He λrg Gin Leu Glu λrg Glu λrg Glu Gly Lyβ He Pro 1925 1930 1935 λβn λβp λrg Phβ Pro Lyβ λrg Leu Gly Leu Phe λrg λrg Pro λrg Glu 1940 1945 1950 Ser Tyr Cyβ Phe Cyβ Phβ Lyβ λrg Hie Lyβ Thr Phe Ser Phβ λen Tyr 1955 1960 1965 Val Trp Trp Gly Phe Glu Leu Hie Ser Gin λrg Leu Trp Glu Lye Ser 1970 1975 1980 λrg Ser Phe λrg Gly Glu Lyβ Cyβ Tyr Sβr Ser λrg Pro Lyβ Thr Trp 1985 1990 1995 2000 Arg Aβp Val Cyβ Leu Phe Phe Gin He Hie Gin λrg Leu Gin Glu Ser 2005 2010 2015 Gin Gly Cyβ λrg λrg Tyr Glu Trp λrg Phβ Pro Phβ λrg Ser λrg Leu 2020 2025 2030 Gin Gly Ser Tyr Leu Phe λla Phe Lyβ Sβr λrg Tyr Hie Phe λrg Lyβ 2035 2040 2045 λla Glu Phβ λrg Gly Thr λβn Hie λrg He Val Pro Thr λrg Ser λla 2050 2055 2060 Tyr Gin λrg Phe Phe Glu Gin Gin Gin λrg He Gly Trp Lyβ λβn Phe 2065 2070 2075 2080 Lyβ Leu Gin Ser Cyβ Ser λrg Lye Hie λrg Gin Leu Ser Glu Lyβ Ser 2085 2090 2095 Ser Glu λrg Ser Lyβ He Ser Lyβ Glu Thr λrg λla Phe λrg Glu λrg 2100 2105 2110 Ser λrg Glu Lyβ He Gly Glu Gin Lyβ λrg Gin Gin Lyβ λβn Gly Ser 2115 2120 2125 Lye Ser Ser Ser Gin Pro Lyβ λrg λsp Phe Cys Val λsp Gin λrg Gly 2130 2135 2140 λrg λrg Lys Ser λsn λrg Leu λrg Ser Glu Ser λrg Hie Gin Lye Gly 2145 2150 2155 2160 He Val Thr Lye Cye Gin Gin Glu Phβ Glu λrg Leu He Phe He Gin 2165 2170 2175 Lyβ Trp Gin Lyβ Gly Phe Gin Gin Gly λrg λrg λβn Thr Lyβ Ser Pro 2180 2185 2190 λrg Phe Gly Glu λrg Phe λrg Tyr Gin Ser λrg Met λβp Phβ Lye Ser 2195 2200 2205 Lyβ Pro Cyβ Ser Phe Glu He Gin Lyβ Trp Gin Lyβ Gly Phβ Gin Gin 2210 2215 2220 Gly λβn λla Ser Lyβ Lyβ λrg Pro Lye Phβ λrg λrg Cyβ λβp Hie Gin 2225 2230 2235 2240 Ser Lyβ Gly λβn Gly Ser Ser Gin Ser Ser Gly He Ser Gly Ser λβn 2245 2250 2255 Gly Phe Gin Gly λrg λla Ser Val Ser λrg Ser Gin Lye Phβ Leu Lye 2260 2265 2270 Gly λla He Gly Pro Thr Ser Ser Lyβ Lye Lyβ Sβr Gin Cyβ Lye Lye 2275 2280 2285 He λβn He Ser He λrg Glu Trp Cyβ Glu Trp λβn Pro Sβr λrg Trp 2290 2295 2300 Val He Ser Ser λrg Ser Hie λen Ser Phe Lyβ Leu Phe Gly Hie Gin 2305 2310 2315 2320 Glu λrg Val Glu Cyβ Lye Thr Trp Lyβ Phβ Gin Gin Gin Trp Thr Gin 2325 2330 2335 Lyβ λrg Thr Hie Leu Cyβ Ser Lyβ Glu Ser λrg λla Ser Ser Pro λrg 2340 2345 2350 Thr Hie Leu λrg Ser Ser Cyβ Lye Gly Lye Cye Lyβ λβn Pro Thr Gin 2355 2360 2365 Ser λβn Ser Lyβ Trp Phe Gly Cyβ Cyβ λrg λla Ser Ser Gly Leu Pro 2370 2375 2380 Phe Glu Lyβ λla Ser Ser Gin Gly λrg λla Phe Lyβ Glu Ser λrg He 2385 2390 2395 2400 Gly Ser Glu λβn Gin Ser Gin Ser Ser Gly He λrg Ser Ser λrg Phe 2405 2410 2415 Phe Trp Gin Ser λrg λla Aβn λsp λrg Gin λla Gin λrg Phe Tyr Lyβ 2420 2425 2430 Thr Gin Ser Hie Glu Sβr Met Gly Lyβ Cyβ Lyβ Lyβ Ser Thr Cyβ Phe 2435 2440 2445 Val Ser Glu Thr λrg Gin Leu λrg Tyr Gin Pro Hie Thr Hie Gin Tyr 2450 2455 2460 Gin Lye Trp Ser Aβn Gin Lye Ser Aβp λrg Hie λla λβn λla Lyβ Lyβ 2465 2470 2475 2480 Pro Val λla Gin λla λrg Glu λβp Ser Cyβ λla Cyβ λrg Lye λrg Ser 2485 2490 2495 Phe Val λrg Val λβn Trp Leu Gin Pro Glu Glu Tyr Glu λrg Leu Phe 2500 2505 2510 Phe Val Gin Val Phe Hie Gin Val Glu Gin Cye Cyβ Lyβ λrg Hie Phe 2515 2520 2525 Trp Leu Tyr λla He Phe λβn Gin Cyβ He Phe Tyr Ser He Leu Leu 2530 2535 2540 Leu Leu Gly Glu λrg Lyβ Cyβ Gly λla Trp λen Gin Glu λrg Tyr Lye 2545 2550 2555 2560 λrg Trp Phe Pro Lys He Leu Lyβ λsp Gly He Pro Lyβ Thr Gin Lyβ 2565 2570 2575 Pro Pro Leu λla Lyβ Ser Glu Gly Phe Phe λβn Thr Pro Gin Lyβ Ser 2580 2585 2590 Gin Ser Ser Leu Val Phe Gly Met λβn λla Thr λβn Ser Trp Tyr Hie 2595 2600 2605 He Pro He Hie Ser Tyr Leu λla Glu Val Cyβ Lye Val Thr Pro Leu 2610 2615 2620 Glu He Cyβ Val λrg Pro Val Gly λβn λla Leu Glu Leu Lyβ Leu Cye 2625 2630 2635 2640 Lye He Pro He He Gly Thr Gin Ser Glu Aβn Gin Thr Leu Pro Thr 2645 2650 2655 Gly Aβn He Ser Leu Gly Ser Pro He Val Phβ Ser Gly Trp λla Leu 2660 2665 2670 Hie Lβu Lyβ He Ser λrg Gin Thr Leu Thr Lye Gly Phe Val Leu Ser 2675 2680 2685 Leu Hie Gly Tyr Phe Leu Pro Gin Lye λβp Lβu Thr Leu Cye Leu Lye 2690 2695 2700 Leu Ser Leu He Val Leu Val Gly Ser Cye Tyr Ser λla Lye He Aβn 2705 2710 2715 2720 Gly Leu Arg Glu Hie Lye Leu Glu Lye Thr Ser Ser Tyr λβn Lye Aβp 2725 2730 2735 Gin Val Gin Lye He He Glu Leu Leu Glu Gin He λβp λrg λla Leu 2740 2745 2750 λβn Gin λrg Lyβ He λrg Lyβ Thr He Gly He He Thr Pro Tyr λβn 2755 2760 2765 λla Gin Lyβ λrg λrg Leu λrg Ser Glu Val Glu Lyβ Tyr Gly Phe Lye 2770 2775 2780 λβn Phe λβp Glu Leu Lye He λβp Thr Val Aβp λla Phe Gin Gly Glu 2785 2790 2795 2800 Glu λla λβp He He He Tyr Ser Thr Val Lyβ Thr Cyβ Gly λβn Leu 2805 2810 2815 Ser Phe Leu Leu λβp Ser Lye λrg Leu λβn Val λla He Ser λrg λla 2820 2825 2830 Lyβ Glu λβn Leu He Phe Val Gly Lye Lye Ser Phe Phe Glu λβn Leu 2835 2840 2845 λrg Ser Aβp Glu Lyβ λβn He Phe Ser λla He Leu Gin Val Cyβ λrg 2850 2855 2860 Val He Phe Ser Lye λβp Aβn Hie Thr Phe Phe λla Ser Lyβ λrg Phe 2865 2870 2875 2880 Hie Lye Ser Leu Ser λla Leu Ser Thr Gin Tyr Pro Tyr Sβr Val Ser 2885 2890 2895 Tyr Ser Pro Phe Leu Gly He Glu Leu Phe Leu He Phe He Ser Val 2900 2905 2910 Thr He λla He Leu Leu Val Phe Leu λla λrg Ser Hie λrg λrg Ser 2915 2920 2925 Hie Glu He Pro Leu Gly Met λrg Val Hie Phe Phe Gly λrg He Phe 2930 2935 2940 λla λla λβn He Leu Gin Hie λrg Pro Aβn Gly Val Gly Gly Val Leu 2945 2950 2955 2960 Lyβ Gly Gin λβn λla Pro λβn Ser Pro Gin Phe Phe Glu λrg Leu λrg 2965 2970 2975 Glu λβn λla Cyβ λβn Leu Lyβ Ser Leu λrg Glu λen Leu Gly Ser Glu 2980 2985 2990 He He Thr Hie λla Ser Phe Gin Phe λla Leu λen Thr Phe Phe λβn 2995 3000 3005 Gin λrg Hie Lye Lyβ λrg Ser Gly Met λrg λen He Gin He λla Leu 3010 3015 3020 Leu Phe Gin Gly He Val He Ser Val Gly Leu λβp λrg λrg Phe Cyβ 3025 3030 3035 3040 Pro Hie Aβn λrg Gly Val Phe He Phe Tyr Leu Ser Leu Aβp λrg λβn 3045 3050 3055 λla Trp Leu λsn His λla His λsn λrg λsp Phβ Gly Met Leu Leu Hie 3060 3065 3070 Leu Phe Ser Ser λla λrg Cyβ Val λla Cyβ Hie λβn Gin Phe λβn Leu 3075 3080 3085 Val λrg Phe Glu Lyβ He Gin Ser Leu λla Lyβ Leu Leu λep λrg Ser 3090 3095 3100 Gly Val Phe Ser λla He Arg Hie Ser Ser Arg He λla He He λβp 3105 3110 3115 3120 λβp Phe He Lyβ Leu λrg Phe Lyβ λla Phβ λβn λla Lyβ Pro Ser Hie 3125 3130 3135 Thr λla He Lyβ λβn λla Tyr Phe Hie λβp Thr Phe Leu He Trp λβp 3140 3145 3150 Leu Gly He Leu Phe Phe He Hie Val Lye Phe Phe He Val Leu Ser 3155 3160 3165 Leu Leu Hie Phe λrg He λβp Lye λla 3170 3175 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10299 baβe pairβ (B) TYPE: nucleic acid (C) STRANDEDNESS: eingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: AAGCTTTGTC TATTCTAAAA TGCAACAAAC TAAGGACAAT GAAGAATTTT TAAACTTAAT 60 GAATGAAAAA TAAAATCCCT AATTAATCCC ATTAAATTAA AAAAGTGTCA TGAAAATAGG 120 CGTTTTTGAT AGCGGTGTGG GAGGGTTTAG CGTTTTAAAA AGCCTTTTλλ AAGCGCAATT 180 ATTTGλTGAA ATCATCTATT ATGGCGλTλG CGCTAGAGTG CCTTATGGCλ CTAAAGACCC 240 CACTACGATC AAGCAATTTG GCTTAGλGGC TTTGGATTTT TTCλλλCCGC ACCAGATTGA 300 ATTATTGATT GTGGCATGCλ ACACAGCGAG CGCTCTAGCT TTAGAAGAGA TGCλAAAGCλ 360 TTCCAAAATC CCTATTGTGG GCGTGATTGA GCCλAGCλTT TTAGCGλTCλ AGCGACAACT 420 AAAAGATAAA AACGCCCCTA TTTTAGTGCT AGGGACAAAA GCGACGATCC AATCCAACGC 480 TTATGλCAAT GCCCTGAλλC AACAAGGCTA TTTGAATGTT TCGCATTTλG CCACTTCTCT 540 TTTTGTGCCT TTGATTGAAG AAAGTATTTT AGAGGGCGAA TTGTTAGAAA CTTGCATGCG 600 TTATTATTTC λCTCCCTTAA λGλTTTTCCC GλλGTGλTTλ TTTTAGGTTG CACGCATTTT 660 CCCTTAATCG CTCAAAAAAT TGAGGGCTλT TTTATGGλGC ATTTTGCCCT TTCAACλCCC 720 CCCCTACTCλ TCCATTCGGG CGATGCTATT GTAGGATATT TGCAGCλλλλ ATλCGCCCTT 780 AAAAAAλλTG CACACGCλTT CCCTAAAGTG GAATTTCλTG CGAGCGGCGλ TCTGATCTGG 840 CTAGAAAAAC AAGCTAAAGA ATGGCTCλλλ TTGTAACGCT AATAAAAATT TAAAGTCAλλ 900 ATAACTCAλT TCCCAAAAAG GGGCTATλGC TCACACTATA AGGGTATTGT GTTGATTATA 960 AAGCGCTTTA GAGAGATTTA TGAAAGCGTT TTGAAGCGλλ GAATGTCTλA TGATTATCTT 1020 TGGAAAAGAT TACCTATCTA CAGACTTGCA AAATAGCGCT AAAGATATTC TTCTCATCGC 1080 TTCGTAAATT CTCAAAGAAA GACTTTTTAC CCACAAAAAT GAGATTTTCT TTTGCCCTAG 1140 AAATAGCCAC ATTCAAGCGT TTAGλλTCTλ GCAAGAAAGλ AAGATTACCA CAAGTTTTCA 1200 CGGTGGAλTλ AATAATAATA TCTGCCTCTT CACCTTGAAA GGCATCCACA GTGTCTATTT 1260 TGAGCTCATC AAAATTCTTG AλGCCGTλTT TTTCC CTTC TGλTCGCΛAG CCTCTTTTTT 1320 GGGCATTATλ AGGTGTGλTλ ATTCCTATGG TTTTTCTGAT TTTTCTTTGG TTAAGAGCGC 1380 GATCAATTTG CTCTAAAλGC TCTATGλTTT TTTGλλCTTG ATCTTTGTTλ TλGCTλCTTG 1440 TTTTTTCTλG TTTλTGCTCT CTTTATAACC CTTλATTAAT TTTCGCλCTA TAGCACGAAC 1500 CCACTAGCλC AATCAAACTT AATTTTAAGC AλλGGGTTλλ GTCTTTTTGG GGTAGGλλλT 1560 ATCCATGCAG ACTTTAAAGA ACAAAGCCTT TCGTTAGTGT CTGTCGGGAT ATTTTAAGGT 1620 GAAGTGCCCA ACCGCTAAAG ACGATTGGGC TTCCTAGGCT GATGTTGCCC GTAGGGAGAG 1680 TTTGGTTCTC ACTCTGTGTC CCTATAATAG GGATTTTACA GAGTTTGAGC TCCλλCGCAT 1740 TCCCTACAGG TCTCλCλCAT CATATCTCCA AAGGCGTAAC TTTGCACACT TCCTACGCTA 1800 GATACGAATG TATGGGGλTλ TGATACCATG λATTGGTAGC λTTCATCCCA AATACTAAAG 1860 ACGATTGGGA TTTCTGCTλλ GGAGTATTAA AλλλCCCCTC GCTTTTAGCλ AGGGGTGGTT 1920 TTTGCGTTTT TGGTATTCCT TλλTCCTTTλ λGATTTTTGG AAACCACCTT TTGTATTλλC 1980 GTTCTTGATT CCATGCTCCG CATTTTCTCT CGCCAAGCAG TAATAAGATG CTGTAGAAAA 2040 TGCATTGGTT AAAAATTGCG TAAAGCCAGA ATTAGTGTCT TTTACAGCAT TGTTCAλCTT 2100 GGTGGAAAAC TTGAACGAAT CAGAATAATC TTTCATATTC TTCTGGTTGλ AGCCλλTTTT 2160 ATCATACTCT GACAAAGGAA CGCTTCCTAC ATTATGCGCA ACTATCTTAT CATTCACGAG 2220 CTTGAGCCAC TCAGGGTTTT TTTGCGTTAG CλTGCCGGTC GCTTTTTCλT TGλTTCCTCC 2280 ATTTTTGATA TTGCTATTλλ TGCGTATGTG GCTGTTAGTA GCGTAATTGT CTAGTTTCGC 2340 TGACλAACTλ GCAGGTACTT TTTTTGCACT TTCAACCCAT AGATTCATGG GATTGTGTTT 2400 TGTAGAATCT TTGAGCTTGT CTATCGTTTG CTCTACATTG CCAAAAAAAC CTGCTTTAGC 2460 TTCTGATACC GCTTGATTGA GATTGTCλλT TTTCTGAGCC AATTCTTGAT TCCTTGAAAG 2520 CCCTACCTTλ CTGAGATCAT CAACTTTATC ATGCCTTTTC AAAGGGAAGC CCGCTGCTTG 2580 CCCTACAACA CCCλλλCCλC TTGCTATTTG ATTGAGTCGG TCAATTTTTG CATTTACCTT 2640 TTTAGCAACT TGAGCGTAAA TGGGTTCTTC λAGGCTAGCT CCTTGCCCTG CTTTCTTTTT 2700 ATTAACTTTA GCATAAATGG GTTCGTTTTT GAGTCCATTA TTGTTATTGT TATTGAAATT 2760 TCCAAGTTTT GCATTCAACT CTTTCTTGAT GTCCGAλλλG TTTTTAGAλλ GAGTTGTGGC 2820 TTCTGCTTGA GATAACCCAT TACCGACTAG GGTTCCATTC ACACCATTCT TAACGGATTG 2880 ATATATTTCλ GATTTTTTTC TAGCATTGAG ACTTTCATTT TTTTGAGCTT GTTGGGCCAA 2940 TTGCTCCTTT GAGAAATTTT TGAGλTCGGC TAλCGCTTGC TCTACCCTAC TGAAATCλCC 3000 CGTTGCTTTA GCCACTGATA CCGCTTGATT GAGATTATCA ACTTTATCCG TTACCTTTTG 3060 ATTGATGATC ACATCTTTAA CGGAATTTTC AAGGTCGCTT TTTGCTTGCG TTACCTTGCT 3120 GAAATCCTTA TTTTTGCCAT TTTTGAATTC ATTCAAAGCT GCATTAAGGT TTTCAACTTT 3180 TGAAATCCAT TCTGGATTGλ TACCTAAATC TTTCλCCGAλ CCTTTλλGGG CTTTTAGTGT 3240 TTCTTCTGCC TTGCTGAAAT CCTTATTTTT GCCλTTTTTG λλTTCATCλλ λλGλTTTλTC 3300 AAAGTCTTTC AAATTCTTGT TGACATTTTC AAGTTTATCA GACAATTCCC TTTTGATGCC 3360 TTTAAGATTC TGAGCGTAAG CGATTGCTCT TGCGTCTCTA TTAGCCTCTT TATTGATCAA 3420 CGCAAAAATC TCATCTTTTT GGCTGTTAGC TTGAGCTTTT GCTTCCATTT TATTTTTGTT 3480 GCCGCTTTTG CTCTCCAATT TTTTCTCTAC TTCTTTCTCT AAATGCTCTC GTTTCCTTλG 3540 λGATTTTTCA λGλTCTTTCT GλGCTTTTTT CλCTTCλTCλ TλλTTGCCTG TGTTTTTλGC 3600 GTCλGCTACA GCTTTATTGλ AGTTTAAAGT TTTTCCλλCC AATTCTTTGT TGCTGCTCλλ 3660 AAAATCTTTG ATAAGCTTAT TAGCTTCTTG TGGGGACAAT CCTTTAGTGG TTAGTTTATC 3720 CTCTAAATTC CGCCTTACGA λACTAGTGAT λGCGAGATTA TTTAAATCAG GCAAATTAAA 3780 GATλGCTλCC TTGTTAAAGC CTACTTCTAA λTGGGAAACG CCATTCGTAA CGCCTACACC 3840 CTTATTGGGλ TTCTTGGAGG CGTTGGTGTλ TTTGAAATTA CAATAATCAA CAAACATCAC 3900 GCCATCATGT TTTAGGCTAC CTTGAAGAGT AACATTTTTC TCCCTATCTA AAGCTTTATC 3960 TGCTTTTTTC CCATAATCTT TGAGλGTGTλ GCTCAAATCC CCλTTACCJ-A ACTCAGTAAT 4020 TAAAGCTGAA TGTTTTGTGT CTTTTTTAGA AACAAAAGCA λTACGATCAT TCCCTAGGGC 4080 GTCTAAATAA GCCTTAGAGT CTTTTTGGAA ATCTTTAATC TCAGTTCGGA ATTTTTCCTT 4140 CTCTTTCTCG CTCAAGTTGT CTAATTTAGC ATTATTTTGT GCAAGAAATT CCATGAAATC 4200 TATTTTGTTT TGGATCTCTT CTTGACTTAA TGCTCGTTGT GAGCCTGTGλ GTTGGTCTTC 4260 TTTGTAGAGA TAAAAACTAG GGTTGTTAAT CCCTTTCTCA CCACCTGCTλ TGACTλλGCC 4320 ACTGCCGTTT TTCATλTGCλ CλTTAATTAT TGTAGCCACA TTGTTGCCTT GTTGGTCTTT 4380 ATAACCAACG GTGGCGTTCC AATCATGCCT AGCTCCAGGA CCλCCATTGC CCCCATλCAA 4440 CAATGAAACT TTTTCAGGTT CTATGCCATT ATGACTCCCC ATTAACACAG AAGλCAGAGC 4500 GTTATTGTGλ ATCAATAATT GATTGAACTT GTAATTGGGA TCAATGTCAC CGACTCCCTC 4560 AλCATCTAAC ATTTCCATAT CGCCAAGAGT GAATTTAGAA AAATTACCCC TTTCATCAAG 4620 TAAATCTCTA GCTTCAGGCβ GTAAGCCTTG TATGTCGGTG GTGGTAGTGG CTATATCTGG 4680 TTGGACλTGG GGλλCTGGTT CTTGλTTGλT TCCTTCTTTG λCλTCAGλAG λTTCTTTTTT 4740 CTCAAATATA AATGAGAGAA AAATATCCAA CCAATCCCCA CCAGTAGGCT CTCC_ATTTTT 4800 TTCTGCTTCT TGCCTTTCTT TCAAGGλCTC λTCλλλCλCG CCCATGAACT TTTGATCCCT 4860 TCGCATTTGλ TTCCCTATAA TGATTCCTGC AAAAGATTGT TTGCCAGATT TCAAAAACTC 4920 CGCTTTCTCT TTATCATCAA GGATλGGGGG TTGTATGλTλ TTTTCCATλλ AATTTCGGAT 4980 CGATCGGGTG TTGATTTTAG ACGGATCGTT TTGATGGGλC ACCCλλCTTG TGAAAATTCG 5040 GTAACGCTGλ TCCCCAAATT TCTGAAAGCT CTTTGTGGAA GATTCTACAT CAATGAGATT 5100 GTCTTTGTTG ATTAλλTCλT TGCTCTTλTT GλTλAλGTCT GλAAAATλCT GλTTCTTTTT 5160 GGTλGGλTTT TTGATCGCTT TATTGGAGTA TTCTTCCCTT AATTGCGAGA TTCCTTCλλλ 5220 AGCTTGCCTG TTλTCCCTλT CGTTCTTλTC AλCGλTTGGT TTTTGλTCλG GATCGTATGλ 5280 λGCGλCAGCG TTATCAACTT TAAGAAAAGC TACTTGAAGA TTATTGATAA ATTGCTGCGG 5340 GTTAAAAGCC GCTTCGGTTT GTGGTTGTTG GTCAATGGTT TCGTTλGTCλ TTGTTTCTCC 5400 TTλCTATACC TλGTTTCλTλ CCTλTCGGTλ TCTTGTTλGT GTCλλλGλCT GCTλλλλλTC 5460 GCTACACGCT TGAGTAGTCA ATTCATGTCT TTGAACATTC TCATTATACA λCAATATCAA 5520 GCATTTTTTT TTTTTTTCAT TλλTCλTTλT TλλTλTTGλλ AAAAGCCCGA TCGTTGCAGG 5580 CGTCTAAAGG CTAGGλCGAT TCACATTTTT ACCCλCAATT AACAAAAATT TGCTAAAATG 5640 AAAGAACTTT AATAAGAACA AGAAATAAGA AATGAATCTT TTTGAAGAAA TCAAATGCAA 5700 CGCTAAAGTA TGGTTGGAGλ AATGGTTAGT CAAGGTGAGC ACATGAAGCG TTCTAAAAAT 5760 AGTTTGGTTT GTGTGTCATG CTTACTATAG CATGTATAAT TAAGCGTTTG TGATCCACAA 5820 GATCCACATG GGAAACAAAA TGGAAAACAA λTCAATAGGA CAGATTTTCA λAGATAGCCT 5880 CAAAAAAAGT TTCTTTAGTG GTCTATGGAG TTGCTTAAAA TGGAGCTTTA TTCTCACTCT 5940 GATCAGCTTG GGTTTGTTTT TGCTTGTTTT TAGGTTTCAA CCTGAGλCGλ TTAAAAAATA 6000 CATCAAAGAT CCTAAAGATC TACAATTCTA CAACGACTTG AGAAAGAAAA ATGGTTGGGλ 6060 CAAGTAGGTT TACTATTCCT GAATGλTGTC AGTTGCCGλG CλλλλGCGTC GGTTTTGATT 6120 TAAATTATAA AGTAGCGCTT GTATGAATAG TATAAAAATA CTTTTTTTTT TGATATACTC 6180 AAGCGATTGA TTTCAATTTG AλλGGλλλCG CATGAAATTT TTTλCλλGλλ TCACTGACAG 6240 CTACAAGAAA GTTGTAGTAA CTTTAGGGCT AGTGGTAACA ACCAATCCTT TAATGGCGGT 6300 CGCCAGTCCT ACAGAAGGCG TCACTGCAAC TAAAGGTTTG GTTATTCAGA TCATTTCTGT 6360 TCTAGCGATC GTAGGTGGTT GCGCTTTλGG GGTCAAAGGC ATAGCGGATA TTTGGAAAAT 6420 CTCTGATGAC ATTAAAAGAG GTCλGGCGAC TGTTTTTGCT TACGCGCAAC CCATAGCTAT 6480 GTTAGCGGTG GCAGGCGGTA TTλTCTλTTT GAGCACTAAG TTTGGCTTCλ ATATTGGCGA 6540 GGGTGGAGGA GCTAGCTAAG TTGATCλλCλ ATAATAATAA TAGCAATλλC λλλCTλAGAG 6600 GCTTTTTTTT GAλλGTTCTC TTλλGTCTCG TTGTTTTCAG TTCGTλTGGG TTAGCAAATG 6660 λTGACAAAGA λGCCAAAAAA GAAGCACAAG AAAAAGAAAA AAACACTCCC AλTGGGCTTG 6720 TTTATACAAA TTTAGATTTT GATλGTTTCλ AAGCGACTAT Cλ λλλTTTG AAAGACAAGA 6780 AAGTAACTTT CAAAGAAGTC AATCCCGATA TTATCAAAGA TGAAGTTTTT GACTTCGTGλ 6840 TTGTCAATAG AGTCCTTAAA AAAATAAAGG ATTTGAAGCA TTACGATCCA GTTATTGAAA 6900 AAATCTTTGA TGAAAAGGGT AAGGAAATGG GATTGAATGT AGλATTACAG ATCAATCCTG 6960 AAGTGAAAGA CTTTTTTACT TTCAAAAGCA TCAGCλCGAC CAACAAACAA CGCTGCTTTC 7020 TGTCATTGCG CGGAGAAACA AGAGAAATTC TATGCGATGA TAAGTTATAT AATGTTTTAT 7080 TGGCCGTATT CAATTCTTAT GATCCTAATG λTCTTTTGλλ λCATATTAGC ACCGTAGAGT 7140 CTCTCAAλλλ AATCTTTTAT ACGATTACAT CTGAAGCGGT λTATCTATAA AGAGAGAGGT 7200 GTTTGTGGCλ AGCAAGCAGG CTGATGλλCλ AAAAAAGCTA ATTATAGAGC AAGAGGTTCA 7260 AAAGCGGCAG TTTCAAAAAA TλGAAGAλCT TAAAGCAGAC ATGCAAAAGG GTGTCAATCC 7320 CTTTTTTAλA GTCTTGTTTG λTGGGGGGAA TAGGTTGTTT GGTTTCCCTG λλλCTTTTλT 7380 TTATTCCTCT ATATTTATAT TGTTTGTAλC CATTGTATTA TCTGTTATTC TTTTTCAAGC 7440 CTATGAACCT GTTTTGATTG TAGCGλTTGT TATTGTGCTT GTAGCTCTTG GATTCAAGAA 7500 AGATTATAGG CTTTATCAAA GAλTGGλGCG AGCGATGAAA TTTAAAAAAC CTTTTTTGTT 7560 TAAGGGCGTG AAAAACAAAG CGTTCATGAG CATTTTTTCC ATGAAGCCTA GTAAAGAAAT 7620 GGCTAATGAC ATCCACTTAA ATCCAAACAG AGAAGACAGA CTTGTGAGCG CTGCAAACTC 7680 CTATCTAGCA AATAACTATG AATGTTTTTT AGATGATGGG GTGATCCTTA CTAACAACTA 7740 TTCTCTTTTA GGCλCλλTCλ AATTGGGGGG CATTGATTTT TTAACCACTT CCAAAAAAGA 7800 TCTCATAGAG TTACACGCTT CTATTTATAG CGTTTTTAGG AATTTTGTTA CCCCTGAATT 7860 CAAATTCTAT TTTCACλCTλ TTAAAAAGAA AATCGTTATT GATGAAACCA ATAGGGACTA 7920 TGGTCTTATT TTTTCTAATG ATTTCATGCG AGCCTATAAT GAGAAGCAAA AGAGAGAAAG 7980 TTTTTATGAT ATTAGTTTTT TTCTGACCAT AGAGCAAGAT TTATTAGACA CTCTCAATGA 8040 ACCCGTTATG AATAAAAAGC ATTTTGCλGλ CAATAATTTT GAAGAGTTTC AAAGGATTAT 8100 TAGAGCCAAG CTTGAAAACT TCAAGGATAG GATAGAGCTC ATAGAAGAGC TGTTGAGCAA 8160 ATACCACCCC ACTAGATTAA AAGAATACAC TλλλGλTGGC GTTATTTACT CCλλλCλλTG 8220 CGAATTTTAC AATTTTCTTG TGGGAATGAA TGAAGCCCCT TTTATTTGCA ACCGAAAAGA 8280 CTTGTATCTC AAGGAAAAAA TGCATGGTGG GGTGAAAGAA GTTTATTTTG CCAATAAGCA 8340 TGGAAAAATC TTAAATGACG ATTTGAGTGA AAAATATTTT AGCGCTATTG AGATTAGTGA 8400 ATλCGCCCCT AAATCACAAA GCGATTTGTT TGATλAAATC AACGCCCTAG ACAGCGAATT 8460 TATTTTCATG CATGCTTATT CGCCTAAAAA CTCACAGGTT TTAAAGGACA AACTGGCTTT 8520 CACCTCTAGA AGAATTATTA TTAGTGGAGG CTCTAAAGAA CAGGGCλTGA CTTTAGGTTG 8580 CTTGAGCGλλ TTAGTGGGTλ ATGGTGATAT TACGCTλCCC AGTTλTGGTλ ATTCTTTAGT 8640 GCTGTTTGCT GATAGCTTTG AAAAAATGAA ACAAAGCGTT AλGGλλTGCG TCTCTAGTCT 8700 TAACGCTAAA GGTTTTTTAG CCAACGCλGC GλCTTTCTCT λTGGAA ATT ACTTTTTTGC 8760 CAAACATTGC TCTTTTλTCλ CGCTTCCTTT TλTTTTTGλT GTAACTTCTA ATAATTTTCC 8820 TGATTTCATC GCTATGλGGG CTATGAGTTT TGATGGCAAT CAAGAGAATA ACGCTTGGGG 8880 CAATAGTGTG ATGACGCTAA AAAGCGAGAT CAATTCGCCT TTTTATCTGλ ACTTCCACAT 8940 GCCCACTGAT TTTGGTTCAG CTTCAGCAGG ACACACTTTG ATλCTTGGCT CλACCGGTTC 9000 λGGTAAGACA GTGTTTATGT CAATGACCTT GAACGCTATG GGλCλλTTTG CCTATAATTT 9060 TCCTGCTAAT GTCAGCAAAG ACAAGCAAAA GCTCACTATG GTTTATλTGG ATAAAGAT A 9120 TGGCGCTTAT GGGAATATTG TCGCAATGGG TGGGGAGTAT GTCAAGATTG AGCTAGGGAC 9180 AGATACAGGA TTAAATCCTT TTGCTTGGGC GGCTTGTGTG CAAAAAACAA ATGCAACAAT 9240 GGAGCAAAAA CAAACAGCTA TTTCTGTTGT CAAAGAGCTT GTGAAAAACT TAGCAACTAA 9300 λAGCGATGAA AAAGATGAAA ATGGCλACAG CATCTCTTTT AGCCTλGCλG ATTCTλATAC 9360 GCTTGCAGCG CAGTAλCCλλ CCTTATCACA GGAAATATGA ATCTAGATTA TCCCATCACT 9420 CAACTTATTA ATGCTTTCGG GAAAGACCAC AATGATCCTA ATGGGCTTGT CGCGCGATTA 9480 GCGCCTTTTT GCAAATCAAC CAATGGTGλλ TTTCAATGGC TTTTTGATAA TAAAGCλλCA 9540 GλTCGCTTλG λTTTTTCAAλ AACGλTTλTT GGCGTTGATG GGTCAAGTTT CTTAGλCAAT 9600 AλTGATGTTT CGCCCTTTAT TTGTTTTTAC CTTTTCGCTC GTλTCCAλGλ GGCλATGGAT 9660 GGGCGTAGAT TTGTCTTAGA TATTGATGAA GCCTGGAAAT ATTTAGCGAT CCλλλGGTCG 9720 CTTATTTTGT AAGAGACATG CTAAAAACTG CAAGGAAAAG AAACGCTATT GTCAGACTTG 9780 CGACTCAAAG CATCACTGAT CTTTTGGCTT GCCCTATTGC TGATACGATT AGAGAACAAT 9840 GCCCTACAAA GATTTTTTTG AGAAACGATG GGGGCAλTCT TTCTGATTAC CAAAGATTGG 9900 CTAATGTTAC AGAAAAAGAA TTTGAAATCA TCλCTAAGGG ACTAGATAGG AAAATCCTCT 9960 ACAAλCAGGλ TGGAAGCCCT AGCGTTλTCG CTAGTTTTAA TTTGAGλGGC ATTCCTAAAG 10020 AATATTTGAA AATTTTATCC ACAGATACTG TATTTGTCAA AGAAATTGAT AAGATTATCC 10080 AAAACCATAG TATCATAGAT AAATATCAGG CCTTGAGACA AATGTATCAA CAAATλGAGG 10140 AGTATTAAAA TGAAACAAAA TTTGCGTGAA CAAAAATTAT GGAAATTTTA GAAAATGATG 10200 TCTTGACGAT TTTGGλTAGT TTTTCTAATT ATCTTTTTGλ λCTGλAAGAA GAλTTGGλCT 10260 TCλTAGAAGA AGAAATGGAλ GGCGAAATCA CTGAACAAA 10299 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3169 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: λla Leu Ser He Leu Lyβ Cyβ λβn Lyβ Leu λrg Thr Met Lye Aβn Phe 1 5 10 15 Thr Met Lyβ Aβn Lyβ He Pro λβn Ser Hie He Lye Lyβ Val Ser Lyβ 20 25 30 λla Phe Leu He λla Val Trp Glu Gly Leu λla Phe Lyβ λla Phe Lyβ 35 40 45 λrg λβn Tyr Leu Met Lyβ Ser Ser He Met λla He λla Leu Glu Cye 50 55 60 Leu Met λla Leu Lyβ Thr Pro Leu λrg Ser Ser λβn Leu λla λrg Leu 65 70 75 80 Trp He Phe Ser λβn λrg Thr λrg Leu λβn Tyr Leu Trp Hie λla Thr 85 90 95 Gin λrg λla Leu Leu Lye λrg Cye Lye Ser He Pro Lye Ser Leu Leu 100 105 110 Trp λla Leu Ser Gin λla Phe λrg Ser Ser λβp Lyβ Lye He Lye Thr 115 120 125 Pro Leu Phe Cyβ Gly Gin Lyβ λrg λrg Ser λβn Pro Thr Leu Met Thr 130 135 140 Met Pro λen λβn Lyβ λla He Met Phe λrg He Pro Leu Leu Phe Leu 145 150 155 160 Cyβ Leu Leu Lyβ Lyβ Val Phe λrg λla λβn Cyβ Lye Leu λla Cys Val 165 170 175 He He Ser Lβu Pro λrg Phe Ser λrg Ser λβp Tyr Phβ λrg Leu Hie 180 185 190 λla Phβ Ser Leu λβn λrg Ser Lyβ λβn Gly Leu Phe Tyr Gly λla Phe 195 200 205 Cys Pro Phe λsn Thr Pro Pro Thr His Pro Phe Gly λrg Cyβ Tyr Cyβ 210 215 220 Arg He Phe λla λla Lyβ He λrg Pro Lyβ Lyβ Cyβ Thr Arg He Pro 225 230 235 240 Ser Gly He Ser Cyβ Glu λrg λrg Cyβ λβp Leu λla λrg Lyβ Thr Ser 245 250 255 λrg Met λla Gin He Val Thr Leu He Lye He Ser Gin λβn λen Ser 260 265 270 He Pro Lyβ Lyβ Gly Leu Leu Thr Leu Gly Tyr Cyβ Val λβp Tyr Lyβ 275 280 285 λla Leu λrg λep Leu Lye λrg Phe Glu λla Lyβ λβn Val Leu Ser Lβu 290 295 300 Glu Lyβ He Thr Tyr Leu Gin Thr Cyβ Lyβ He λla Leu Lyβ He Phe 305 310 315 320 Phe Ser Ser Leu λrg Lyβ Phβ Ser Lyβ Lyβ λβp Phβ Leu Pro Thr Lyβ 325 330 335 Met λrg Phe Ser Phe λla Leu Glu He λla Thr Phe Lyβ λrg Leu Glu 340 345 350 Ser Ser Lyβ Lyβ Glu λrg Leu Pro Gin Val Phe Thr Val Glu He He 355 360 365 He Ser λla Ser Ser Pro Lye λla Ser Thr Val Ser He Leu Ser Ser 370 375 380 Ser Lyβ Phe Leu Lyβ Pro Tyr Phe Ser Thr Ser Aβp Arg Lye Arg Leu 385 390 395 400 Phe Trp λla Leu Gly Val He He Pro Met Val Phe Leu He Phe Leu 405 410 415 Trp Leu λrg λla λrg Ser He Cyβ Ser Lye Ser Ser Met He Phe Thr 420 425 430 Ser Leu Leu Leu Leu Val Phe Ser Ser Leu Cyβ Ser Leu Tyr λβn Pro 435 440 445 Leu He Phe λla Leu Hie Glu Pro Thr Ser Thr He Lye Leu λβn Phe 450 455 460 Lys Gin λrg Val Lys Ser Phe Trp Gly λrg Lyβ Tyr Pro Cyβ λrg Leu 465 470 475 480 λrg Thr Lyβ Pro Phe Val Ser Val Cyβ λrg λβp He Leu λrg Ser λla 485 490 495 Gin Pro Leu Lyβ Thr He Gly Leu Pro λrg Leu Met Leu Pro Val Gly 500 505 510 λrg Val Trp Phe Ser Leu Cyβ Val Pro He He Gly He Leu Gin Ser 515 520 525 Leu Ser Ser λβn λla Phe Pro Thr Gly Leu Thr His His He Ser Lye 530 535 540 Gly Val Thr Leu His Thr Ser Tyr λla λrg Tyr Glu Cyβ Met Gly He 545 550 555 560 Tyr Hie Glu Leu Val λla Phe He Pro λβn Thr Lyβ λβp λβp Trp λβp 565 570 575 Phe Cyβ Gly Val Leu Lyβ λsn Pro Ser Leu Leu λla λrg Gly Gly Phe 580 585 590 Cyβ Val Phe Gly He Pro Ser Phe Lye He Phe Gly λβn Hie Leu Leu 595 600 605 Tyr λrg Ser Phe Hie λla Pro Hie Phe Leu Ser Pro Ser Ser λβn Lyβ 610 615 620 Met Leu Lyβ Met Hie Trp Leu Lye He λla Ser Gin λβn Cye Leu Leu 625 630 635 640 Gin Hie Cye Ser Thr Trp Trp Lyβ Thr Thr λβn Gin Asn λen Lβu Ser 645 650 655 Tyr Ser Ser Gly Ser Gin Phe Tyr Hie Thr Leu Thr Lye Glu λrg Phe 660 665 670 Leu Hie Tyr λla Gin Leu Ser Tyr Hie Ser λrg λla λla Thr Gin Gly 675 680 685 Phe Phe λla Leu λla Cyβ λrg Ser Leu Phe Hie Leu Leu Hie Phe Tyr 690 695 700 Cye Tyr Cye Val Cye Gly Cys λrg λβn Cye Lβu Val Sβr Leu Thr λβn 705 710 715 720 Gin Val Leu Phe Leu Hie Phe Gin Pro He λβp Ser Trp λβp Cyβ Val 725 730 735 Leu λβn Leu λla Cyβ Leu Ser Phe λla Leu λβp Cyβ Gin Lys λβn Leu 740 745 750 Leu Leu Leu He Pro Leu λβp λβp Cye Gin Phe Ser Glu Pro He Leu 755 760 765 λep Ser Leu Lyβ λla Leu Pro Tyr λsp His Gin Leu Tyr His λla Phe 770 775 780 Ser Lys Gly Ser Pro Leu Leu λla Lβu Gin Hie Pro λen Hie Leu Leu 785 790 795 800 Phe λβp Val Gly Gin Phe Leu Hie Leu Pro Phe Gin Leu Glu λrg Lye 805 810 815 Trp Val Leu Gin Gly Leu Leu λla Leu Leu Ser Phe Tyr Leu Hie Lye 820 825 830 Trp Val λrg Phe Val Hie Tyr Cye Tyr Cye Tyr λβn Phe Gin Val Leu 835 840 845 Hie Ser Thr Leu Ser Cyβ Pro Lye Ser Phe Lye Glu Leu Trp Leu Leu 850 855 860 Leu Glu He Thr Hie Tyr λrg Leu Gly Phe Hie Ser Hie Hie Ser λrg 865 870 875 880 He λsp He Phe Gin He Phe Phe Hie λsp Phe Hie Phe Phe Glu Lβu 885 890 895 Val Gly Pro He λla Pro Leu λrg λβn Phe λβp λrg Leu Thr Leu λla 900 905 910 Leu Pro Tyr λβn Hie Pro Leu Leu Pro Leu He Pro Leu λβp λβp Tyr 915 920 925 Gin Leu Tyr Pro Leu Pro Phβ λβp Ser Hie Leu λrg λβn Phβ Gin Gly 930 935 940 λrg Phe Leu Leu λla Leu Pro Cyβ λβn Pro Tyr Phe Cyβ His Phe He 945 950 955 960 His Ser Lyβ Leu His Gly Phe Gin Leu Leu Lys Ser He Leu Asp Tyr 965 970 975 Leu λβn Leu Ser Pro λβn Leu Gly Leu Leu Val Phe Leu Leu Pro Cyβ 980 985 990 λβn Pro Tyr Phe Cyβ Hie Phe He Hie Gin Lye He Tyr Gin Ser Leu 995 1000 1005 Ser λβn Ser Cyβ Hie Phe Gin Val Tyr Gin Thr He Pro Phe Cye Leu 1010 1015 1020 λβp Ser Glu λrg Lyβ λrg Lβu Leu Leu λrg Leu Tyr Pro Lβu Tyr Ser 1025 1030 1035 1040 Thr Gin Lyβ Ser Hie Leu Phe Gly Cyβ Leu Glu Leu Leu Leu Pro Phe 1045 1050 1055 Tyr Phe Cyβ Cye λrg Phe Cye Ser Pro He Phβ Sβr Leu Leu Leu Ser 1060 1065 1070 Leu λsn λla Leu Val Ser Leu Glu He Phe Gin Aβp Leu Ser Glu Leu 1075 1080 1085 Phe Ser Leu Hie Hie λβn Cyβ Leu Cyβ Phe λrg Gin Leu Gin Leu Tyr 1090 1095 1100 Ser Leu Lye Phe Phe Gin Pro He Leu Cye Cyβ Cyβ Ser Lye λβn Leu 1105 1110 1115 1120 λla Tyr Leu Leu Val Gly Thr He Leu Trp Leu Val Tyr Pro Leu λβn 1125 1130 1135 Ser λla Leu λrg λβn λrg λβp Tyr Leu λsn Gin λla λsn λrg Lβu Pro 1140 1145 1150 Cyβ Ser Leu Leu Leu λβn Gly Lye λrg Hie Sβr λrg Leu Hie Pro Tyr 1155 1160 1165 Trp λβp Ser Trp λrg λrg Trp Cyβ He λβn λβn λsn Gin Gin Thr Ser 1170 1175 1180 λrg Hie His Val Leu Gly Tyr Leu Glu Glu Hie Phe Ser Pro Tyr Leu 1185 1190 1195 1200 Lyβ Leu Tyr Leu Leu Phe Ser Hie λβn Leu Glu Cyβ Ser Ser λen Pro 1205 1210 1215 Hie Tyr Gin Thr Gin Leu Lye Leu λβn Val Leu Cyβ Leu Phe Lyβ Gin 1220 1225 1230 Lyβ Gin Tyr Aβp Hie Ser Leu Gly λrg Leu λβn Lye Pro Ser Leu Phe 1235 1240 1245 Gly Aβn Leu Ser Gin Phe Gly He Phe Pro Ser Leu Ser λrg Ser Ser 1250 1255 1260 Cyβ Leu He Hie Tyr Phe Val Gin Glu He Pro λβn Leu Phe Cyβ Phβ 1265 1270 1275 1280 Gly Ser Leu Leu λβp Leu Met Leu Val Val Ser Leu Val Gly Leu Leu 1285 1290 1295 Cyβ λrg λβp Lyβ λβn Gly Cyβ Ser Leu Ser Hie Hie Leu Leu Leu Ser 1300 1305 1310 Hie Cye λrg Phe Ser Tyr λla Hie Leu Leu Pro Hie Cye Cye Leu Val 1315 1320 1325 Gly Leu Tyr λβn Gin λrg Trp λrg Ser λβn Hie λla Leu Gin λep Hie 1330 1335 1340 Hie Cye Pro Hie Thr Thr Met Lyβ Leu Phe Gin Val Leu Cye Hie Tyr 1345 1350 1355 1360 λβp Ser Pro Leu Thr Gin Lyβ Thr Glu λrg Tyr Cye Glu Ser He He 1365 1370 1375 λβp Thr Cye λβn Trp λβp Gin Cye Gin λrg Leu Pro Gin Hie Leu Thr 1380 1385 1390 Phe Pro Tyr λrg Gin Glu He Lyβ Aβn Tyr Pro Phe Hie Gin Val λen 1395 1400 1405 Leu Leu Gin λla Val Ser Leu Val Cyβ λrg Trp Trp Trp Leu Tyr Leu 1410 1415 1420 Val Gly Hie Gly Glu Leu Val Leu Aβp Leu Leu Leu Hie Gin Lye He 1425 1430 1435 1440 Val Phe Cyβ Gin He Met λrg Glu Lye Tyr Pro Thr Aβn Pro Hie Gin 1445 1450 1455 λla Leu Hie Phe Phe Leu Leu Leu λla Phe Leu Ser λrg Thr Hie Gin 1460 1465 1470 Thr λrg Pro Thr Phe Aβp Pro Phe Gly Phe λβp Ser Leu Phe Leu Gin 1475 1480 1485 Lyβ He Val Trp Gin He Ser Lyβ Thr Pro Leu Ser Leu Tyr Hie Gin 1490 1495 1500 Gly Gly Val Val Tyr Phe Pro λβn Phe Gly Ser He Gly Cyβ Phe Thr 1505 1510 1515 1520 λβp λrg Phe λβp Gly Thr Pro λβn Lβu Lyβ Phe Gly λβn λla λβp Pro 1525 1530 1535 Gin He Ser Glu Ser Ser Leu Trp Lyβ He Leu Hie Gin Aβp Cyβ Leu 1540 1545 1550 Cye Leu λsn His Cyβ Ser Tyr Ser Leu Lyβ λsn Thr λsp Ser Phe Trp 1555 1560 1565 λβp Phe Ser Leu Tyr Trp Ser He Leu Pro Leu He λla λrg Phe Leu 1570 1575 1580 Gin Lyβ Leu λla Cye Tyr Pro Tyr λrg Ser Tyr Gin λrg Leu Val Phe 1585 1590 1595 1600 λep Gin λβp λrg Met Lyβ λrg Gin λrg Tyr Gin Leu Glu Lyβ Leu Leu 1605 1610 1615 Glu λβp Tyr He λla λla Gly Lyβ Pro Leu λrg Phe Val Val Val Gly 1620 1625 1630 Gin Trp Phe λrg Ser Leu Phe Leu Leu Thr He Pro Ser Phe He Pro 1635 1640 1645 He Gly He Leu Leu Val Ser Lyβ Thr λla Lye Aβn λrg Tyr Thr Leu 1650 1655 1660 Glu Ser He His Val Phe Glu His Ser Hie Tyr Thr Thr He Ser Ser 1665 1670 1675 1680 He Phe Phe Phe Phe Hie Ser Leu Leu He Leu Lyβ Lyβ λla λrg Ser 1685 1690 1695 Leu Gin λla Ser Lyβ Gly Aβp λβp Ser Hie Phβ Tyr Pro Gin Leu Thr 1700 1705 1710 Lyβ He Cyβ λβn Glu λrg Thr Leu He λrg Thr λrg λen Lye Lye He 1715 1720 1725 Phe Leu Lyβ Lye Ser λen λla Thr Lβu Lyβ Tyr Gly Trp λrg λβn Gly 1730 1735 1740 Ser λrg λla Hie Glu λla Phe Lye Phe Gly Leu Cye Val Met Leu Thr 1745 1750 1755 1760 He λla Cyβ He He Lyβ λrg Lβu Ser Thr λrg Ser Thr Trp Glu Thr 1765 1770 1775 Lyβ Trp Lyβ Thr λβn Gin λβp λrg Phe Ser Lye He λla Ser Lye Lye 1780 1785 1790 Val Ser Leu Val Val Tyr Gly Val λla λβn Gly λla Leu Phe Ser Leu 1795 1800 1805 Ser λla Trp Val Cyβ Phe Cye Leu Phe Leu Gly Phe λsn Leu λrg λrg 1810 1815 1820 Leu Lyβ λen Thr Sβr Lyβ He Leu Lyβ He Tyr λβn Ser Thr Thr Thr 1825 1830 1835 1840 Glu λrg Lye Met Val Gly Thr Ser λrg Phe Thr He Pro Glu Cyβ Gin 1845 1850 1855 Leu Pro Ser Lye Ser Val Gly Phe Aβp Leu Aβn Tyr Lye Val λla Leu 1860 1865 1870 Val He Val Lyβ Tyr Phβ Phe Phe Tyr Thr Gin λla He λβp Phe λβn 1875 1880 1885 Leu Lyβ Gly λβn λla λβn Phe Leu Gin Glu Ser Leu Thr λla Thr λrg 1890 1895 1900 Lys Leu Leu Gly Trp Gin Pro He Leu Trp λrg Ser Pro Val Leu Gin 1905 1910 1915 1920 Lye λla Ser Leu Gin Leu Lyβ Val Trp Leu Phe λrg Ser Phe Leu Phe 1925 1930 1935 λrg Ser Val Val λla Leu Gly Ser Lye λla λrg He Phe Gly Lye Sβr 1940 1945 1950 Leu Met Thr Leu Lyβ Glu Val λrg λrg Leu Phe Leu Leu Thr λrg λβn 1955 1960 1965 Pro Leu Cye Arg Trp Gin λla Val Lβu Ser He λla Leu Ser Leu λla 1970 1975 1980 Ser He Leu λla λrg Val Glu Glu Leu λla Lyβ Leu He λβn λβn λβn 1985 1990 1995 2000 λβn Asn Ser λβn Lyβ Lye Leu λrg Gly Phe Phe Leu Lyβ Val Leu Leu 2005 2010 2015 Ser Leu Val Val Phe Ser Ser Tyr Gly Leu λla λβn λβp Aβp Lyβ Glu 2020 2025 2030 λla Lyβ Lye Glu λla Gin Glu Lye Glu Lyβ λβn Thr Pro λβn Gly Leu 2035 2040 2045 Val Tyr Thr Aβn Leu λβp Phe λep Sβr Phe Lyβ λla Thr He Lye λen 2050 2055 2060 Leu Lyβ λsp Lyβ Lys Val Thr Phe Lye Glu Val Aβn Pro λβp He He 2065 2070 2075 2080 Lyβ λβp Glu Val Phβ λβp Phe Val He Val Aβn λrg Val Leu Lyβ Lye 2085 2090 2095 He Lye λβp Lβu Lyβ Hie Tyr λep Pro Val He Glu Lyβ He Phe λep 2100 2105 2110 Glu Lye Gly Lyβ Glu Met Gly Leu λen Val Glu Lβu Gin He λen Pro 2115 2120 2125 Glu Val Lye λβp Phβ Phβ Thr Phe Lye Ser He Ser Thr Thr λβn Lyβ 2130 2135 2140 Gin λrg Cyβ Phe Leu Ser Leu λrg Gly Glu Thr λrg Glu He Leu Cyβ 2145 2150 2155 2160 Aβp λβp Lyβ Leu Tyr λβn Val Leu Leu λla Val Phe Aβn Ser Tyr λβp 2165 2170 2175 Pro λβn λβp Leu Leu Lye Hie He Ser Thr Val Glu Ser Leu Lye Lyβ 2180 2185 2190 He Phe Tyr Thr He Thr Cye Glu λla Val Tyr Leu λrg Glu λrg Cyβ 2195 2200 2205 Leu Trp Gin λla Ser λrg Leu Met λβn Lye Lye Ser Leu Ser Lye λrg 2210 2215 2220 Phe Lye Ser Gly Ser Phe Lye Lye Lyβ λβn Leu Lyβ Gin Thr Cyβ Lyβ 2225 2230 2235 2240 λrg Val Ser He Pro Phe Leu Lye Ser Cye Leu Met Gly Gly He Gly 2245 2250 2255 Cyβ Leu Val Ser Leu Lyβ Leu Leu Phe He Pro Leu Tyr Leu Tyr Cye 2260 2265 2270 Leu Pro Leu Tyr Tyr Leu Leu Phe Phe Phe Lye Pro Met λβn Leu Phe 2275 2280 2285 Leu λrg Leu Leu Leu Cyβ Leu Leu Leu λep Ser λrg Lyβ He He Gly 2290 2295 2300 Phe He Lyβ Glu Trp Sβr Glu λrg λen Leu Lye Aβn Lβu Phe Cye Leu 2305 2310 2315 2320 Arg Ala Lye Thr Lye Arg Ser λla Phe Phe Pro Ser Leu Val Lyβ Lyβ 2325 2330 2335 Trp Leu Met Thr Ser Thr He Gin Thr Glu Lyβ Thr λβp Leu λla Leu 2340 2345 2350 Gin Thr Pro He Gin He Thr Met Aβn Val Phe Met Met Gly Ser Leu 2355 2360 2365 Leu Thr Thr He Leu Phe λla Gin Ser λβn Trp Gly λla Leu He Phe 2370 2375 2380 Pro Leu Pro Lyβ Lye He Ser Ser Tyr Thr Leu Leu Phe He λla Phe 2385 2390 2395 2400 Leu Gly He Leu Leu Pro Leu λβn Ser λβn Sβr He Phe Thr Leu Lβu 2405 2410 2415 Lyβ λrg Lye Ser Leu Leu Met Lye Pro He Gly Thr Met Val Leu Phe 2420 2425 2430 Phe Leu Met He Ser Cyβ Glu Pro He Met λrg Ser Lye λrg Glu Lye 2435 2440 2445 Val Phe Met He Leu Val Phe Phe Pro Ser Lye He Tyr Thr Leu Ser 2450 2455 2460 Met λβn Pro Leu He Lyβ Ser He Leu Gin Thr He He Leu Lye Ser 2465 2470 2475 2480 Phe Lyβ Gly Leu Leu Glu Pro Ser Leu Lye Thr Ser λrg He Gly Ser 2485 2490 2495 Ser Lyβ Ser Cye λla λsn Thr Thr Pro Leu λep Lye λβn Thr Leu Lyβ 2500 2505 2510 Met λla Leu Phe Thr Pro λen λβn λla λβn Phe Thr He Phe Leu Trp 2515 2520 2525 Glu Met Lyβ Pro Leu Leu Phe λla Thr Glu Lye Thr Cye He Ser λrg 2530 2535 2540 Lyβ Lye Cyβ Met Val Gly Lyβ Lye Phe He Leu Pro He Ser Met Glu 2545 2550 2555 2560 Lyβ Ser Met Thr He Val Lyβ λen He Leu λla Leu Leu λrg Leu Val 2565 2570 2575 λβn Thr Pro Leu λβn Hie Lyβ λla He Cyβ Leu He Lye Ser Thr Pro 2580 2585 2590 Thr λla λsn Leu Phe Ser Cyβ Met Leu He Arg Leu Lyβ Thr Hie λrg 2595 2600 2605 Phe λrg Thr λβn Trp Leu Ser Pro Leu Glu Glu Leu Leu Leu Val Glu 2610 2615 2620 λla Leu Lye λβn λrg λla Leu Val λla λla λβn Trp Val Met Val He 2625 2630 2635 2640 Leu λrg λla Val Met Val He Leu Cyβ Cyβ Leu Leu He λla Leu Lyβ 2645 2650 2655 Lyβ λsn Lye λla Leu λrg λen λla Ser Leu Val Leu Thr Leu Lye Val 2660 2665 2670 Phe Pro Thr Gin λrg Leu Ser Leu Trp Lys He Thr Phe Leu Pro λsn 2675 2680 2685 He λla Leu Leu Ser λrg Phe Leu Leu Phe Leu Met Leu Leu He He 2690 2695 2700 Leu Leu He Ser Ser Leu Gly Leu Val Leu Met λla He Lyβ λrg He 2705 2710 2715 2720 Thr Leu Gly Ala He Val Arg Lyβ Ala Arg Ser He Arg Leu Phe He 2725 2730 2735 Thr Ser Thr Cye Pro Leu He Leu Val Gin Leu Gin Gin λep Thr Leu 2740 2745 2750 Tyr Leu λla Gin Pro Val Gin Val λrg Gin Cyβ Lβu Cyβ Gin Pro Thr 2755 2760 2765 Leu Trp λβp λβn Leu Pro He He Phe Lβu Lβu Met Ser λla Lyβ Thr 2770 2775 2780 Ser Lye Ser Ser Leu Trp Phe He Trp He Lyβ He Met λla Leu Met 2785 2790 2795 2800 Gly He Leu Ser Gin Trp Val Gly Ser Met Ser λrg Leu Ser Gly Gin 2805 2810 2815 He Gin Aβp He Leu Leu Leu Gly λrg Leu Val Cyβ Lye Lyβ Gin Met 2820 2825 2830 Gin Gin Trp Ser Lyβ λβn Lyβ Gin Leu Phe Leu Leu Ser Lyβ Ser Leu 2835 2840 2845 Lyβ Thr Gin Leu Lyβ λla Met Lye Lyβ Met Lys Met λla Thr λla Ser 2850 2855 2860 Leu Leu λla Gin He Leu He λrg Lβu Gin λrg Ser λβn Gin Pro Tyr 2865 2870 2875 2880 Hie λrg Lyβ Tyr Glu Ser λrg Leu Ser Hie Hie Ser Thr Tyr Cyβ Phe 2885 2890 2895 λrg Glu λrg Pro Gin Ser Trp λla Cye λrg λla He Ser λla Phe Leu 2900 2905 2910 Gin He Asn Gin Trp He Ser Met λla Phe Ser λβn λrg Ser Leu λrg 2915 2920 2925 Phe Phe Lyβ λsn λsp Tyr Trp λrg Trp Val Lyβ Phβ Lβu λrg Gin Cyβ 2930 2935 2940 Phe λla Leu Tyr Leu Phe Leu Pro Phe λrg Ser Tyr Pro λrg Gly λβn 2945 2950 2955 2960 Gly Trp λla He Cys Leu λrg Tyr Ser Leu Glu He Phe Ser λβp Pro 2965 2970 2975 Lyβ Val λla Tyr Phe Val Arg λβp Met Leu Lye Thr λla λrg Lye λrg 2980 2985 2990 Asn λla He Val λrg Leu λla Thr Gin Ser He Thr λβp Leu Leu λla 2995 3000 3005 Cyβ Pro He λla λβp Thr He λrg Glu Gin Cyβ Pro Thr Lyβ He Phe 3010 3015 3020 Leu λrg λβn λβp Gly Gly λen Leu Ser λep Tyr Gin λrg Leu λla λβn 3025 3030 3035 3040 Val Thr Glu Lyβ Glu Phβ Glu He He Thr Lye Gly Leu Aβp λrg Lyβ 3045 3050 3055 He Leu Tyr Lyβ Gin λβp Gly Sβr Pro Ser Val He λla Ser Phβ λen 3060 3065 3070 Leu λrg Gly He Pro Lye Glu Tyr Leu Lyβ He Leu Ser Thr Aβp Thr 3075 3080 3085 Val Phe Val Lys Glu He λβp Lye He He Gin λβn Hie Sβr He He 3090 3095 3100 Aβp Lyβ Tyr Gin λla Lβu λrg Gin Met Tyr Gin Gin He Glu Glu Tyr 3105 3110 3115 3120 λβn Glu Thr Lyβ Phe λla Thr Lye He Met Glu He Leu Glu Aβn λep 3125 3130 3135 Val Leu Thr He Leu λβp Sβr Phβ Ser λβn Tyr Leu Phe Glu Leu Lye 3140 3145 3150 Glu Glu Leu λβp Phe He Glu Glu Glu Met Glu Gly Glu He Thr Glu 3155 3160 3165 Gin (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3287 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: eingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Ser Phe Val Tyr Ser Lye Met Gin Gin Thr Lye λβp λβn Glu Glu Phe 1 5 10 15 Leu λβn Leu Met Aβn Glu Lye λen Pro Leu He Pro Leu λβn Lyβ Ser 20 25 30 Val Met Lyβ He Gly Val Phe Aβp Ser Gly Val Gly Gly Phe Ser Val 35 40 45 Leu Lye Ser Leu Leu Lye λla Gin Lβu Phβ λβp Glu He He Tyr Tyr 50 55 60 Gly λβp Ser λla λrg Val Pro Tyr Gly Thr Lyβ λep Pro Thr Thr He 65 70 75 80 Lyβ Gin Phe Gly Leu Glu λla Leu λβp Phe Phe Lyβ Pro Hie Gin He 85 90 95 Glu Leu Leu He Val λla Cye λsn Thr λla Sβr λla Leu λla Leu Glu 100 105 110 Glu Met Gin Lyβ Hie Ser Lye He Pro He Val Gly Val He Glu Pro 115 120 125 Ser He Leu λla He Lyβ λrg Gin Val Lyβ λsp Lyβ λβn λla Pro He 130 135 140 Leu Val Leu Gly Thr Lye λla Thr He Gin Ser λβn λla Tyr λβp λβn 145 150 155 160 λla Leu Lyβ Gin Gin Gly Tyr Leu λβn Val Sβr Hie Leu λla Thr Ser 165 170 175 Leu Phe Val Pro Leu He Glu Glu Ser He Leu Glu Gly Glu Leu Leu 180 185 190 Glu Thr Cyβ Met λrg Tyr Tyr Phe Thr Pro Leu Lyβ He Phe Pro Lye 195 200 205 Leu Phe Val λla λrg He Phe Pro Ser Lβu Lyβ Lyβ Lβu λrg λla He 210 215 220 Leu Trp Ser He Leu Pro Phe Gin Hie Pro Pro Tyr Ser Ser He λrg 225 230 235 240 λla Met Leu Leu λβp He Cyβ Ser Lyβ λen Thr Pro Leu Lyβ Lye Met 245 250 255 Hie Thr Hie Ser Leu Lyβ Trp λβn Phβ Met λrg λla λla Met Sβr Gly 260 265 270 Lyβ λβn Lyβ Leu Lyβ λβn Gly Ser λen Cyβ λβn λla λen Lye λβn Leu 275 280 285 Lyβ Ser Lye Leu λβn Ser Gin Lye Gly λla He λla Hie Thr He λrg 290 295 300 Val Leu Cyβ Leu Ser λla Leu Glu λrg Phe Met Lyβ λla Phe Ser Glu 305 310 315 320 Glu Cyβ Leu Met He He Phe Gly Lyβ λβp Tyr Lβu Sβr Thr λβp Leu 325 330 335 Gin λβn Ser λla Lyβ λβp He Leu Leu He λla Ser He Leu Lye Glu 340 345 350 λrg Leu Phe Thr Hie Lye Aen Glu He Phe Phe Cyβ Pro λrg λen Ser 355 360 365 Hie He Gin λla Phe λrg He Gin Glu λrg Lyβ He Thr Thr Ser Phe 370 375 380 Hie Gly Gly He λβn λsn λsn He Cyβ Leu Phe Thr Leu Lyβ Gly He 385 390 395 400 Hie Ser Val Tyr Phe Glu Leu He Lyβ He Leu Glu λla Val Phe Phe 405 410 415 Hie Phe Ser Gin λla Ser Phe Leu Gly He He λrg Cye Aβp λen Sβr 420 425 430 Tyr Gly Phe Ser λβp Phβ Ser Leu Val Lyβ Ser λla He λsn Leu Leu 435 440 445 Lyβ Leu Tyr λβp Phβ Lβu λβn Leu He Phβ Val He λla Thr Cyβ Phe 450 455 460 Phe Phe Met Leu Ser Leu Pro Leu He λβn Phβ λrg Thr He λla λrg 465 470 475 480 Thr Hie Hie Aβn Gin Thr Phe λla Lys Gly Val Phe Leu Gly Glu He 485 490 495 Ser Met Gin Thr Leu Lye λβn Lyβ λla Phβ λrg Cyβ Leu Ser Gly Tyr 500 505 510 Phe Lyβ Val Lyβ Cye Pro Thr λla Lyβ λβp λβp Trp λla Ser λla λβp 515 520 525 Val λla λrg λrg Glu Sβr Leu Val Leu Thr Leu Cyβ Pro Tyr λβn λrg 530 535 540 λsp Phe Thr Glu Phe Glu Leu Gin λrg He Pro Tyr λrg Ser Hie Thr 545 550 555 560 Ser Tyr Leu Gin λrg λrg λβn Phe λla Hie Phβ Leu λrg He λrg Met 565 570 575 Tyr Gly λep Met He Pro He Gly Ser He Hie Pro Lye Tyr λrg λrg 580 585 590 Leu Gly Phe Leu Leu λrg Ser He Lyβ Lye Pro Leu λla Phe Ser Lyβ 595 600 605 Gly Trp Phe Leu λrg Phe Trp Tyr Ser Leu He Leu λep Phe Trp Lyβ 610 615 620 Pro Pro Phe Val Leu Thr Phe Leu He Pro Cye Ser λla Phe Ser Leu 625 630 635 640 λla Lye Gin λβp λla Val Glu Aβn λla Leu Val Lyβ λβn Cyβ Val Lye 645 650 655 Pro Glu Leu Val Ser Phe Thr λla Leu Phe λβn Leu Val Glu λβn Leu 660 665 670 λβn Glu Ser Glu Ser Phe He Phe Phβ Trp Leu Lyβ Pro He Leu Ser 675 680 685 Tyr Ser λsp Lys Gly Thr Leu Pro Thr Leu Cyβ λla Thr He Leu Ser 690 695 700 Phe Thr Ser Leu Ser Hie Ser Gly Phe Phe Cye Val Ser Met Pro Val 705 710 715 720 λla Phe Ser Leu He λla Pro Phe Leu He Leu Leu Leu Met λrg Met 725 730 735 Trp Leu Leu Val λla Leu Ser Ser Phe λla λβp Lyβ Lβu λla Gly Thr 740 745 750 Phe Phe λla Leu Ser Thr Hie λrg Phβ Met Gly Leu Cyβ Phe Val Glu 755 760 765 Ser Leu Ser Leu Ser He Val Cye Ser λrg Leu Pro Lyβ Lyβ Pro λla 770 775 780 Leu λla Ser λep Thr λla Leu λrg Leu Ser He Phβ λla λβn Ser Phe 785 790 795 800 Leu Glu Ser Pro Thr Leu Leu λrg Ser Ser Thr Leu Ser Cyβ Lβu Phβ 805 810 815 Lyβ Gly Lyβ Pro λla λla Cyβ Pro Thr Thr Pro Lyβ Pro Leu λla He 820 825 830 Leu Ser λrg Ser He Phe λla Phe Thr Phe Leu λla Thr λla Met Gly 835 840 845 Ser Ser λrg Leu λla λla Cyβ Pro λla Phe Phe Leu Leu Thr Leu λla 850 855 860 Met Gly Ser Phe Leu Ser Pro Leu Leu Leu Leu Leu Leu Lye Phe Pro 865 870 875 880 Ser Phe λla Phe λsn Ser Phe Leu Met Ser Glu Lye Phe Leu Glu λrg 885 890 895 Val Val λla Ser λla λβp λβn Pro Leu Pro Thr λrg Val Pro Phe Thr 900 905 910 Pro Phe Leu Thr λβp Tyr He Ser λβp Phβ Phe Leu λla Leu λrg Leu 915 920 925 Ser Phe Phe λla Cye Trp λla λen Cye Ser Phe Glu Lyβ Phβ Leu λrg 930 935 940 Ser λla λβn λla Cyβ Ser Thr Leu Leu Lye Ser Pro Val λla Leu λla 945 950 955 960 Thr λβp Thr λla Leu λrg Leu Ser Thr Leu Ser Val Thr Phe Leu Met 965 970 975 He Thr Ser Leu Thr Glu Phe Ser λrg Ser Leu Phe λla Cye Val Thr 980 985 990 Leu Leu Lyβ Ser Leu Phe Leu Pro Phe Leu λsn Ser Phe Lyβ Ala λla 995 1000 1005 Leu λrg Phe Ser Thr Phe Glu He His Ser Gly Leu He Pro Lys Ser 1010 1015 1020 Phe Thr Glu Pro Leu λrg λla Phe Ser Val Ser Ser λla Leu Leu Lye 1025 1030 1035 1040 Ser Leu Phe Leu Pro Phe Leu λβn Ser Ser Lyβ λβp Leu Ser Lyβ Sβr 1045 1050 1055 Phe Lyβ Phe Leu Leu Thr Phβ Ser Ser Leu Ser λβp λen Ser Leu Leu 1060 1065 1070 Met Pro Leu Arg Phe Ala Ala He λla Leu λla Ser Leu Leu λla Ser 1075 1080 1085 Leu Leu He λβn λla Lyβ He Ser Ser Phe Trp Leu Leu λla λla Phe 1090 1095 1100 λla Ser He Leu Phe Leu Leu Pro Leu Lβu Leu Ser λβn Phβ Phe Ser 1105 1110 1115 1120 Thr Ser Phe Ser Lye Cye Ser λrg Phe Leu λrg λsp Phe Ser λrg Ser 1125 1130 1135 Phe λla Phe Phe Thr Ser Ser Leu Pro Val Phβ Leu λla Ser λla Thr 1140 1145 1150 λla Leu Leu Lye Phe Lys Val Phe Pro Thr λen Ser Leu Leu Leu Leu 1155 1160 1165 Lyβ Lye Ser Leu He Ser Leu Leu λla Ser Cyβ Gly λep λβn Pro Leu 1170 1175 1180 Val Val Ser Leu Ser Ser Lyβ Phβ λrg Leu Thr Lyβ Leu Val He λla 1185 1190 1195 1200 λrg Leu Phe Lyβ Ser Gly Lyβ Lβu Lyβ He λla Thr Leu Leu Lyβ Pro 1205 1210 1215 Thr Ser Lye Trp Glu Thr Pro Phe Val Thr Pro Thr Pro Leu Leu Gly 1220 1225 1230 Phe Leu Glu λla Leu Val Tyr Leu Lyβ Leu Glu Ser Thr λβn He Thr 1235 1240 1245 Pro Ser Cyβ Phe λrg Leu Pro λrg Val Thr Phe Phe Sβr Leu Ser Lyβ 1250 1255 1260 λla Lβu Ser λla Phe Phe Pro Ser Leu λrg Val Leu Lyβ Ser Pro Leu 1265 1270 1275 1280 Pro λβn Ser Val He Lyβ λla Glu Cyβ Phe Val Ser Phe Leu Glu Thr 1285 1290 1295 Lyβ λla He λrg Ser Phe Pro λrg λla Ser Lye λla Leu Glu Ser Phe 1300 1305 1310 Trp Lyβ Ser Leu He Ser Val λrg λβn Phβ Ser Phe Ser Phe Ser Leu 1315 1320 1325 Lye Leu Ser λβn Leu λla Leu Phe Cye λla λrg Aβn Sβr Met Lye Sβr 1330 1335 1340 He Leu Phe Trp He Ser Ser Leu Aβn λla λrg Cye Glu Pro Val Ser 1345 1350 1355 1360 Trp Ser Ser Leu Arg Lyβ Leu Gly Leu Leu He Pro Phe Ser Pro Pro 1365 1370 1375 Ala Met Thr Lyβ Pro Lβu Pro Phe Phe He Cye Thr Leu He He Val 1380 1385 1390 λla Thr Leu Leu Pro Cyβ Trp Ser Leu Pro Thr Val λla Phe Gin Ser 1395 1400 1405 Cyβ Leu λla Pro Gly Pro Pro Leu Pro Pro Tyr λβn λen Glu Thr Phe 1410 1415 1420 Ser Gly Ser Met Pro Leu Leu Pro He λβn Thr Glu λβp λrg λla Lβu 1425 1430 1435 1440 Leu He λβn λβn Leu λsn Leu Leu Gly Ser Met Ser λla Thr Pro Ser 1445 1450 1455 Thr Ser λβn He Ser He Ser Pro λrg Val λβn Leu Glu Lyβ Leu Pro 1460 1465 1470 Leu Ser Ser Ser Lyβ Ser Leu λla Ser Gly Gly Lyβ Pro Cye Met Ser 1475 1480 1485 Val Val Val Val λla He Ser Gly Trp Thr Trp Gly Thr Gly Ser Leu 1490 1495 1500 He λla Ser Leu Thr Ser Glu λβp Cyβ Phe Leu Ser λen He λβn Glu 1505 1510 1515 1520 λrg Lyβ He Ser λβn Gin Ser Pro Pro Val Gly Ser Pro Phe Phβ Sβr 1525 1530 1535 λla Ser Cyβ Leu Ser Phe Lye λsp Ser Ser λsn Thr Pro Met Aβn Phe 1540 1545 1550 Ser Val Arg He Phe Pro He Met He Pro λla Lyβ λsp Cyβ Leu λla 1555 1560 1565 λβp Phe Lys λsn Ser λla Phe Ser Leu Ser Ser λrg He Gly Gly Cyβ 1570 1575 1580 Met He Phe Ser He Lyβ Phe λrg He λβp λrg Val Leu He Leu λep 1585 1590 1595 1600 Gly Ser Phe Trp λβp Thr Gin Leu Val Lyβ He λrg λrg Ser Pro λβn 1605 1610 1615 Phe Lyβ Leu Phe Val Glu λβp Ser Thr Ser Met λrg Leu Ser Leu Leu 1620 1625 1630 He Lyβ Ser Leu Leu Leu Leu He Lyβ Ser Glu Lye Tyr Phe Phe Leu 1635 1640 1645 Val Gly Phe Leu He λla Leu Leu Glu Tyr Ser Ser Leu λβn Cye Glu 1650 1655 1660 He Pro Ser Lyβ λla Cyβ Lβu Leu Ser Leu Ser Phe Lβu Ser Thr He 1665 1670 1675 1680 Gly Phe Ser Gly Ser Tyr Glu λla Thr λla Leu Ser Thr Leu λrg Lyβ 1685 1690 1695 λla Thr λrg Leu Leu He Asn Cye Cyβ Gly Leu Lyβ Ala λla Ser Val 1700 1705 1710 Cye Gly Cyβ Trp Ser Met Val Ser Leu Val He Val Ser Pro Tyr Tyr 1715 1720 1725 Thr Phe Hie Thr Tyr λrg Tyr Leu Val Ser Val Lyβ λβp Cye Lyβ Ser 1730 1735 1740 Leu Hie λla Val Val λβn Ser Cye Lβu Thr Phβ Ser Leu Tyr λβn λβn 1745 1750 1755 1760 He Lyβ Hie Phe Phe Phe Phe Ser Leu He He He λβn He Glu Lyβ 1765 1770 1775 Ser Pro He Val λla Gly Val λrg Leu Gly λrg Phe Thr Phe Leu Pro 1780 1785 1790 Thr He λβn Lye λβn Leu Leu Lye Lye Aβn Phe Aβn Lyβ Aen Lyβ Lye 1795 1800 1805 Glu Met Aβn Leu Phe Glu Glu He Lyβ Cys λsn λla Lyβ Val Trp Leu 1810 1815 1820 Glu Lyβ Trp Leu Val Lyβ Val Ser Thr Ser Val Leu Lye He Val Trp 1825 1830 1835 1840 Phe Val Cys His λla Tyr Tyr Ser Met Tyr λβn λla Phe Val He Hie 1845 1850 1855 Lyβ He Hie Met Gly Aβn Lyβ Met Glu λβn Lye Ser He Gly Gin He 1860 1865 1870 Phe Lye λβp Ser Leu Lyβ Lye Ser Phe Phβ Ser Gly Leu Trp Ser Cyβ 1875 1880 1885 Leu Lyβ Trp Ser Phe He Leu Thr Leu He Ser Leu Gly Leu Phe Leu 1890 1895 1900 Leu Val Phe λrg Phβ Gin Pro Glu Thr He Lyβ Lyβ Tyr He Lyβ λep 1905 1910 1915 1920 Pro Lye λβp Leu Gin Phe Tyr λen λβp Lβu λrg Lyβ Lyβ λβn Gly Trp 1925 1930 1935 λβp Lyβ Val Tyr Tyr Ser Met Met Ser Val λla Glu Gin Lyβ λrg λrg 1940 1945 1950 Phe Phe Lyβ Leu Ser Ser Ala Cyβ Met λβn Ser He Lye He Leu Phe 1955 1960 1965 Phe Leu He Tyr Ser Ser λβp Phe Gin Phe Glu λrg Lyβ λrg Met Lyβ 1970 1975 1980 Phe Phe Thr λrg He Thr λep Sβr Tyr Lyβ Lye Val Val Val Thr Leu 1985 1990 1995 2000 Gly Leu Val Val Thr Thr λen Pro Leu Met λla Val λla Ser Pro Thr 2005 2010 2015 Glu Gly Val Thr λla Thr Lyβ Gly Leu Val He Gin He He Ser Val 2020 2025 2030 Leu λla He Val Gly Gly Cyβ λla Leu Gly Val Lyβ Gly He λla λep 2035 2040 2045 He Trp Lyβ He Ser Aβp Asp He Lyβ λrg Gly Gin λla Thr Val Phβ 2050 2055 2060 λla Tyr λla Gin Pro He λla Met Leu λla Val λla Gly Gly He He 2065 2070 2075 2080 Tyr Leu Ser Thr Lyβ Phe Gly Phe λen He Gly Glu Gly Gly Gly λla 2085 2090 2095 Ser Val λβp Gin Gin Gin Glu Thr Lyβ λrg Leu Phe Phβ Glu Ser Ser 2100 2105 2110 Leu Lyβ Ser λrg Cyβ Phe Gin Phe Val Trp Val Ser Lye Gin λrg Ser 2115 2120 2125 Gin Lys λrg Ser Thr λrg Lyβ λrg Lys Lys His Ser Gin Trp λla Cyβ 2130 2135 2140 Leu Tyr Lyβ Phe λrg Phe Phe Gin Ser λβp Tyr Gin Lye Phβ Glu λrg 2145 2150 2155 2160 Gin Glu Ser λβn Phe Gin λrg Ser Gin Ser λrg Tyr Tyr Gin λrg Ser 2165 2170 2175 Phe Leu λrg λβp Cyβ Gin Ser Pro Lyβ λβn Lyβ Gly Phe Glu λla Leu 2180 2185 2190 λrg Ser Ser Tyr Lye λen Leu Lye Gly Gly λβn Gly He Glu Cyβ λrg 2195 2200 2205 He Thr λβp Gin Ser Ser Glu λrg Leu Phe Tyr Phe Gin Lye Hie Gin 2210 2215 2220 Hie λβp Gin Gin Thr Thr Leu Leu Ser Val He λla λrg λrg λβn Lyβ 2225 2230 2235 2240 λrg λβn Ser Met λrg Val He Cyβ Phe He Gly λrg He Gin Phβ Leu 2245 2250 2255 Ser Ser Phe Glu Thr Tyr Hie λrg λrg Val Ser Gin Lyβ λβn Leu Leu 2260 2265 2270 Tyr Asp Tyr Met Ser Gly He Ser He Lyβ λrg Glu Val Phe Val λla 2275 2280 2285 Ser Lys Gin λla Asp Glu Gin Lys Lys Leu He He Glu Gin Glu Val 2290 2295 2300 Gin Lyβ λrg Gin Phβ Gin Lyβ He Glu Glu Leu Lye λla λep Met Gin 2305 2310 2315 2320 Lye Gly Val λen Pro Phβ Phe Lye Val Leu Phe λep Gly Gly λβn λrg 2325 2330 2335 Leu Phe Gly Phe Pro Glu Thr Phe He Tyr Ser Ser He Phe He Leu 2340 2345 2350 Phe Val Thr He Val Leu Ser Val He Lβu Phe Gin λla Tyr Glu Pro 2355 2360 2365 Val Leu He Val λla He Val He Val Leu Val λla Leu Gly Phe Lye 2370 2375 2380 Lye λβp Tyr λrg Leu Tyr Gin λrg Met Glu λrg λla Met Lye Phe Lye 2385 2390 2395 2400 Lyβ Pro Phe Leu Phe Lye Gly Val Lye λβn Lyβ λla Phβ Met Ser He 2405 2410 2415 Phe Ser Met Lyβ Pro Ser Lye Glu Met λla λβn λβp He Hie Leu λβn 2420 2425 2430 Pro Aβn λrg Glu Aβp Arg Leu Val Ser Ala Ala λen Ser Tyr Leu λla 2435 2440 2445 λβn Aβn Tyr Glu Cye Phe Leu λβp λβp Gly Val He Leu Thr λen λen 2450 2455 2460 Tyr Ser Leu Leu Gly Thr He Lyβ Leu Gly Gly He λβp Phe Leu Thr 2465 2470 2475 2480 Thr Ser Lyβ Lye Aβp Leu He Glu Leu Hie λla Ser He Tyr Ser Val 2485 2490 2495 Phe λrg λβn Phe Val Thr Pro Glu Phe Lyβ Phe Tyr Phe Hie Thr He 2500 2505 2510 Lyβ Lyβ Lyβ He Val He λβp Glu Thr λβn λrg λβp Tyr Gly Leu He 2515 2520 2525 Phe Ser λen λβp Phe Met λrg λla Tyr λβn Glu Lyβ Gin Lyβ λrg Glu 2530 2535 2540 Ser Phe Tyr λβp He Ser Phe Phe Leu Thr He Glu Gin λβp Leu Leu 2545 2550 2555 2560 Asp Thr Leu λβn Glu Pro Val Met λen Lye Lye Hie Phe λla Asp λsn 2565 2570 2575 λsn Phβ Glu Glu Phe Gin λrg He He λrg λla Lye Leu Glu λβn Phe 2580 2585 2590 Lyβ Aβp λrg He Glu Leu He Glu Glu Leu Leu Ser Lyβ Tyr Hie Pro 2595 2600 2605 Thr λrg Leu Lye Glu Tyr Thr Lyβ λsp Gly Val He Tyr Ser Lyβ Gin 2610 2615 2620 Cyβ Glu Phβ Tyr λen Phe Leu Val Gly Met λen Glu λla Pro Phe He 2625 2630 2635 2640 Cyβ λβn λrg Lyβ λβp Leu Tyr Leu Lye Glu Lyβ Met Hie Gly Gly Val 2645 2650 2655 Lys Glu Val Tyr Phe λla λβn Lye His Gly Lye He Leu λβn λβp Aβp 2660 2665 2670 Leu Ser Glu Lye Tyr Phe Ser λla He Glu He Ser Glu Tyr λla Pro 2675 2680 2685 Lyβ Ser Gin Ser λβp Leu Phe λβp Lyβ He Aβn λla Leu λβp Ser Glu 2690 2695 2700 Phe He Phe Met Hie λla Tyr Ser Pro Lyβ Aen Ser Gin Val Leu Lys 2705 2710 2715 2720 Asp Lye Leu λla Phe Thr Ser λrg λrg He He He Ser Gly Gly Ser 2725 2730 2735 Lyβ Glu Gin Gly Met Thr Lea Gly Cye Leu Ser Glu Leu Val Gly λβn 2740 2745 2750 Gly λsp He Thr Leu Gly Ser Tyr Gly λβn Ser Leu Val Leu Phe λla 2755 2760 2765 Asp Ser Phe Glu Lyβ Met Lys Gin Ser Val Lyβ Glu Cyβ Val Ser Ser 2770 2775 2780 Leu λβn λla Lye Gly Phe Leu λla λβn λla λla Thr Phe Ser Met Glu 2785 2790 2795 2800 Aβn Tyr Phe Phe λla Lye Hie Cye Ser Phe He Thr Leu Pro Phe He 2805 2810 2815 Phe λβp Val Thr Ser λsn λsn Phe λla λβp Phe He λla Met λrg λla 2820 2825 2830 Met Ser Phe Aβp Gly λβn Gin Glu λβn λβn λla Trp Gly λβn Ser Val 2835 2840 2845 Met Thr Leu Lyβ Ser Glu He λβn Ser Pro Phe Tyr Leu λβn Phe Hie 2850 2855 2860 Met Pro Thr λsp Phe Gly Ser λla Ser λla Gly His Thr Leu He Leu 2865 2870 2875 2880 Gly Ser Thr Gly Ser Gly Lyβ Thr Val Phe Met Ser Met Thr Leu λβn 2885 2890 2895 λla Met Gly Gin Phe λla Tyr λen Phe Pro λla λsn Val Ser Lyβ λep 2900 2905 2910 Lye Gin Lye Leu Thr Met Val Tyr Met λβp Lye Aβp Tyr Gly λla Tyr 2915 2920 2925 Gly λsn He Val λla Met Gly Gly Glu Tyr Val Lyβ He Glu Leu Gly 2930 2935 2940 Thr λβp Thr Gly Leu λen Pro Phe λla Trp λla λla Cye Val Gin Lye 2945 2950 2955 2960 Thr λβn λla Thr Met Glu Gin Lyβ Gin Thr λla He Ser Val Val Lyβ 2965 2970 2975 Glu Leu Val Lyβ λen Leu λla Thr Lyβ Ser λβp Glu Lyβ λsp Glu λβn 2980 2985 2990 Gly λβn Ser He Ser Phe Ser Leu λla λsp Ser λsn Thr Leu λla λla 2995 3000 3005 Gin Pro Thr Leu Ser Gin Glu He He He He Pro Ser Leu λβn Leu 3010 3015 3020 Leu Met Leu Ser Gly Lys Thr Thr Met He Leu Met Gly Leu Ser λrg 3025 3030 3035 3040 λβp λrg Leu Phe λla λen Gin Pro Met Val λβn Phe λen Gly Phe Leu 3045 3050 3055 He He Lyβ Gin Gin He λla He Phe Gin Lyβ λrg Leu Leu λla Leu 3060 3065 3070 Met Gly Gin Val Ser Thr He Met Met Phe λrg Pro Leu Phe Val Phe 3075 3080 3085 Thr Phe Ser Leu Val Ser Lye λrg Gin Trp Met Gly Val λep Leu Ser 3090 3095 3100 He Leu Met Lye Pro Gly Aβn He λrg Ser Lye Gly λrg Leu Phe Cye 3105 3110 3115 3120 Lyβ λrg Hie λla Lyβ λβn Cye Lyβ Glu Lyβ Lyβ λrg Tyr Cye Gin Thr 3125 3130 3135 Cyβ λβp Ser Lyβ Hie Hie Ser Phe Gly Leu Pro Tyr Cyβ Tyr λsp λrg 3140 3145 3150 Thr Met Pro Tyr Lyβ Aβp Phe Phe Glu Lyβ λrg Trp Gly Gin Ser Phe 3155 3160 3165 Leu Pro Lye He Gly Cyβ Tyr λrg Lyβ λrg He λβn Hie Hie Gly Thr 3170 3175 3180 λrg Glu Aβn Pro Leu Gin Thr Gly Trp Lye Pro λrg Tyr λrg Phe Phβ 3185 3190 3195 3200 Glu λrg Hie Ser λrg He Phe Glu λβn Phe He Hie λrg Tyr Cye He 3205 3210 3215 Cyβ Gin λrg λβn λβp Tyr Pro Lyβ Pro Tyr Hie λrg He Ser Gly Leu 3220 3225 3230 Glu Thr λβn Val Ser Thr λβn λrg Gly Val Leu Lyβ λβn Lye He Cye 3235 3240 3245 Val λβn Lye λβn Tyr Gly λβn Phβ λrg Lye Cye Leu λβp λβp Phβ Gly 3250 3255 3260 Phe Phe Leu Ser Phe Thr Glu λrg λrg He Gly Leu His λrg λrg λrg 3265 3270 3275 3280 λsn Gly λrg λrg λsn His Thr 3285 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3200 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Lyβ Leu Cyβ Leu Phe λsn λla Thr λβn Gly Gin λrg He Phe Lyβ Leu 1 5 10 15 λβn Glu Lyβ He Lyβ Ser Leu He λβn Pro He Lyβ Leu Lyβ Lye Cye 20 25 30 Hie Glu λβn λrg λrg Phe λrg Cyβ Gly λrg Val λrg Phβ Lyβ Lye Pro 35 40 45 Phe Lyβ Ser λla He He λen Hie Leu Leu Trp λrg λrg Ser λla Leu 50 55 60 Trp Hie λrg Pro Hie Tyr λβp Gin λla He Trp Leu λrg Gly Phe Gly 65 70 75 80 Phe Phe Gin Thr λla Pro λβp He He λep Cye Gly Met Gin Hie Ser 85 90 95 Glu λrg Ser Ser Phe λrg λrg Aβp λla Lyβ λla Phe Gin λβn Pro Tyr 100 105 110 Cyβ Gly λrg λβp λla Lyβ Hie Phe Ser λβp Gin λla Thr Ser Lyβ λrg 115 120 125 Lye λrg Pro Tyr Phe Ser λla λrg λβp Lyβ Ser λβp λβp Pro He Gin 130 135 140 λrg Leu Gin Cye Pro Glu Thr Thr λrg Leu Phe Glu Cyβ Phe λla Phe 145 150 155 160 Ser Hie Phe Ser Phe Cyβ λla Phe λβp λrg Lye Tyr Phe λrg Gly λrg 165 170 17S He Val λrg λβn Leu Hie λla Leu Leu Phe Hie Ser Leu Lye λsp Phe 180 185 190 Pro Glu Val He He Leu Gly Cyβ Thr Hie Phβ Pro Leu He λla Gin 195 200 205 Lyβ He Glu Gly Tyr Phe Met Glu Hie Phe λla Leu Ser Thr Pro Pro 210 215 220 Leu Leu He Hie Ser Gly λsp λla He Val Gly Tyr Leu Gin Gin Lye 225 230 235 240 Tyr λla Leu Lyβ Lye Aβn λla Hie λla Phβ Pro Lyβ Val Glu Phe Hie 245 250 255 λla Ser Gly λβp Val He Trp Leu Glu Lyβ Gin λla Lyβ Glu Trp Leu 260 265 270 Lyβ Leu λrg Lye Phe Lyβ Val Lyβ He Thr Gin Phe Pro Lye λrg Gly 275 280 285 Tyr Ser Ser Hie Tyr Lyβ Gly He Val Leu He He Lye λrg Phe λrg 290 295 300 Glu He Tyr Glu Ser Val Leu Lyβ λrg λrg Met Ser λβn λβp Tyr Leu 305 310 315 320 Trp Lyβ λrg Lβu Pro He Tyr λrg Leu λla Lyβ λrg λrg Tyr Ser Ser 325 330 335 Hie λrg Phe Val Aβn Ser Gin λrg Lye Thr Phe Tyr Pro Gin Lye λβp 340 345 350 Phe Leu Leu Pro Lye Pro Hie Ser Ser Val λβn Leu λla λrg Lyβ Lye 355 360 365 λβp Tyr Hie Lyβ Phe Ser λrg Trp λen Lyβ Tyr Leu Pro Leu Hie Leu 370 375 380 Glu λrg Hie Pro Gin Cyβ Leu Phe λla Hie Gin λen Ser Ser λrg He 385 390 395 400 Phe Pro Leu Leu He λla Ser Val Phe Phe Gly Hie Tyr Lye Val Phe 405 410 415 Leu Trp Phe Phe Phe Phβ Phβ Gly Glu λrg λβp Gin Phβ λla Leu Lye 420 425 430 λla Leu Phe Phe Glu Leu Aβp Leu Cye Tyr Ser Tyr Leu Phe Phe Leu 435 440 445 Val Tyr λla Leu Phe He Thr Leu λen Phβ Sβr Hie Tyr Ser Thr λβn 450 455 460 Pro Leu λla Gin Ser λβn Leu He Leu Ser Lye Gly Leu Ser Leu Phe 465 470 475 480 Gly Val Gly λen He Hie λla Aβp Phβ Lye Glu Gin Ser Leu Ser Leu 485 490 495 Val Ser Val Gly He Phe Gly Glu Val Pro λsn λrg λrg λrg Leu Gly 500 505 510 Phe Leu Gly Cyβ Cye Pro Gly Glu Phe Gly Ser Hie Ser Val Ser Leu 515 520 525 Gly Phe Tyr λrg Val λla Pro Thr Hie Ser Leu Gin Val Ser Hie He 530 535 540 He Ser Pro Lyβ λla Lβu Cye Thr Leu Pro Thr Leu λβp Thr λen Val 545 550 555 560 Trp Gly Tyr λβp Thr Met λβn Trp Hie Ser Ser Gin He Leu Lye Thr 565 570 575 He Gly He Ser λla Lyβ Glu Tyr Lyβ Thr Pro λrg Phe Gin Gly Val 580 585 590 Val Phe λla Phe Leu Val Phe Leu λsn Pro Leu λrg Phe Leu Glu Thr 595 600 605 Thr Phe Cys He λβn Val Leu λβp Sβr Met Leu λrg He Phe Ser λrg 610 615 620 Gin λla Val He λrg Cyβ Cyβ λrg Lys Cyβ He Gly Lye Leu λrg Lye 625 630 635 640 λla λrg He Ser Val Phe Tyr Ser He Val Gin Leu Gly Gly Lyβ Leu 645 650 655 Glu λrg He λrg He He Phe Hie He Leu Leu Val Glu λla λen Phe 660 665 670 He He Leu Gin λrg Aβn λla Ser Tyr He Met λrg λen Tyr Leu He 675 680 685 He Hie Glu Leu Glu Pro Leu λrg Val Phe Leu λrg Hie λla Gly λrg 690 695 700 Phe Phe He λβp Cye Ser He Phβ λsp He λla He λsn λla Tyr Val 705 710 715 720 λla Val Ser Ser Val He Val Phe λrg Gin Thr Ser λrg Tyr Phe Phe 725 730 735 Cyβ Thr Phe λβn Pro He Hie Gly He Val Phe Cye λrg He Phe Glu 740 745 750 Leu Val Tyr λrg Leu Leu He λla Lyβ Lye Thr Cye Phβ Ser Phe Tyr 755 760 765 λrg Leu He Glu He Val λsn Phe Leu Ser Gin Phe Leu He Pro Lye 770 775 780 Pro Tyr Leu Thr Glu He He λβn Phe He Met Pro Phe Gin λrg Glu 785 790 795 800 λla λrg Cyβ Leu Pro Tyr λβn Thr Gin Thr Thr Cye Tyr Leu He Glu 805 810 815 Ser Val λβn Phe Cye He Tyr Leu Phe Ser λβn Leu Ser Val λen Gly 820 825 830 Phe Phe Lye λla Ser Cye Leu Pro Cyβ Phβ Leu Phe He λβn Phe Ser 835 840 845 He λen Gly Phe Val Phe Glu Ser He He Val He Val He Glu He 850 855 860 Ser Lyβ Phe Cye He Gin Leu Phe Leu Aβp Val λrg Lye Val Phe λrg 865 870 875 880 Lye Ser Cye Gly Phβ Cye Lβu λrg Pro He Thr λβp Gly Ser He Hie 885 890 895 Thr He Leu λβn Gly Leu He Tyr Phe λrg Phe Phβ Ser Ser He Glu 900 905 910 Thr Phe He Phβ Lβu Ser Leu Leu Gly Gin Leu Leu Lβu Glu He Phe 915 920 925 Glu He Gly λrg Leu Leu Tyr Pro Thr Glu He Thr λrg Cyβ Phβ Ser 930 935 940 Hie Tyr λrg Leu He Glu He He λβn Phβ He λrg Tyr Leu Leu He 945 950 955 960 λβp λβp Hie He Phe λen Gly He Phe Lyβ Val λla Phe Cyβ Leu λrg 965 970 975 Tyr Leu λla Glu He Leu He Phe λla He Phe Glu Phe He Gin Ser 980 985 990 Cyβ He Lye Val Phe λβn Phβ λβn Pro Phe Trp He Aβp Thr He Phe 995 1000 1005 Hie λrg Thr Phe Lye Gly Phe Cyβ Phβ Phe Cyβ Leu λla Glu He Leu 1010 1015 1020 He Phβ λla He Phe Glu Phe He Lyβ λrg Phβ He Lye Val Phe Gin 1025 1030 1035 1040 He Leu Val λβp He Phe Lyβ Phe He λrg Gin Phe Pro Phe λβp λla 1045 1050 1055 Phe Lyβ He Leu Ser Val Ser Aβp Cys Ser Cys Val Ser He Ser Leu 1060 1065 1070 Phe He λβp Gin λrg Lyβ λβn Leu He Phe Leu λla Val Ser Leu Ser 1075 1080 1085 Phe Cyβ Phe Hie Phβ He Phe Val λla λla Phβ λla Leu Gin Phe Phe 1090 1095 1100 Leu Tyr Phe Phe Leu Met Leu Ser Phβ Pro λrg Phe Phe Lye He Phe 1105 1110 1115 1120 Leu Ser Phe Phe Hie Phe He He He λla Cyβ Val Phe Ser Val Ser 1125 1130 1135 Tyr Ser Phe He Glu Val Ser Phe Ser λβn Gin Phe Phe Val λla λla 1140 1145 1150 Gin Lye He Phe λβp Lyβ Leu He Ser Phe Leu Trp Gly Gin Ser Phe 1155 1160 1165 Ser Gly Phe He Leu He Pro Pro Tyr Glu Thr Ser λβp Ser Glu He 1170 1175 1180 He He λrg Gin He Lyβ λβp Ser Tyr Leu Val Lyβ λla Tyr Phe Met 1185 1190 1195 1200 Gly λβn λla He λrg λβn λla Tyr Thr Leu He Gly He Leu Gly Gly 1205 1210 1215 Val Gly Val Phe Glu He λrg He He λβn Lye Hie Hie λla He Met 1220 1225 1230 Phe λla Thr Leu Lyβ Ser λβn He Phβ Leu Pro He Ser Phe He Cyβ 1235 1240 1245 Phe Phe Pro He He Phe Glu Sβr Val λla Gin He Pro He Thr Lyβ 1250 1255 1260 Leu Ser λen Ser Met Phe Cyβ Val Phe Phe λrg λβn Lye Ser λβn Thr 1265 1270 1275 1280 He He Pro Gly Val He Ser Leu λrg Val Phe Leu Glu He Phe λβn 1285 1290 1295 Leu Ser Ser Glu Phe Phe Leu Leu Phβ Leu λla Gin Val Val Phe Ser 1300 1305 1310 He He Leu Cyβ Lyβ Lyβ Phβ Hie Glu He Tyr Phe Val Leu λβp Leu 1315 1320 1325 Phe Leu Thr Cyβ Ser Leu λla Cyβ Glu Leu Val Phe Phe Val Glu He 1330 1335 1340 Lyβ Thr λrg Val Val λsn Pro Phe Leu Thr Thr Cys Tyr λsp λla Thr 1345 1350 1355 1360 λla Val Phe Hie Met Hie He λen Tyr Cye Ser Hie He Val λla Leu 1365 1370 1375 Leu Val Phe He Thr λβn Gly Gly Val Pro He Met Pro Ser Ser λrg 1380 1385 1390 Thr Thr He λla Pro He Gin Gin λβn Phe Phe λrg Phe Tyr λla He 1395 1400 1405 Met Thr Pro Hie Hie λrg λrg Gin Ser Val He Val λβn Gin Leu He 1410 1415 1420 Glu Leu Val He Gly He λsn Val Ser λsp Ser Leu λsn He His Phe 1425 1430 1435 1440 His He λla Lyβ Ser Glu Phe λrg Lye He Thr Pro Phe He Lye He 1445 1450 1455 Ser Ser Phe λrg λrg λla Leu Tyr Val Gly Gly Gly Sβr Gly Tyr He 1460 1465 1470 Trp Leu λβp Met Gly λβn Trp Phe Leu He λβp Cye Phe Phe λβp He 1475 1480 1485 λrg λrg Leu Phe Phe Val Lyβ Tyr Lyβ Glu Lyβ λen He Gin Pro He 1490 1495 1500 Pro Thr Ser λrg Leu Ser He Phe Phe Cyβ Phe Leu Pro Phe Phe Gin 1505 1510 1515 1520 Gly Leu He Lyβ Hie λla Hie Glu Leu Leu He λrg Ser λβp Lβu He 1525 1530 1535 Pro Tyr λen Aβp Ser Cye Lye λrg Lβu Phe Gly λrg Phe Gin Lye Leu 1540 1545 1550 λrg Phe Leu Phe He He Lye λβp λrg Gly Lβu Tyr λβp He Phe Hie 1555 1560 1565 Lyβ He Ser λβp λrg Ser Gly Val λβp Phe λrg λrg He Val Leu Met 1570 1575 1580 Gly Hie Pro Thr Cyβ Glu λen Ser Val Thr Leu He Pro Lyβ Phe Leu 1585 1590 1595 1600 Lyβ λla Leu Cyβ Gly λrg Phe Tyr He λβn Glu He Val Phe Val λep 1605 1610 1615 He He λla Leu He λsp Lyβ Val Lyβ He Leu He Leu Phe Gly λrg 1620 1625 1630 He Phe λβp λrg Phe He Gly Val Phe Phe Pro Leu λrg λβp Ser Phe 1635 1640 1645 Lyβ Ser Leu Pro Val He Pro He Val Leu He λβn λβp Trp Phe Leu 1650 1655 1660 He λrg He Val Ser λβp Ser Val He λen Phe Lyβ Lyβ Ser Tyr Leu 1665 1670 1675 1680 Lye He He λβp Lye Lβu Leu λrg Val Lyβ Sβr λrg Phe Gly Leu Trp 1685 1690 1695 Leu Leu Val λsn Gly Phe Val Ser Hie Cyβ Phe Ser Leu Leu Tyr Leu 1700 1705 1710 Val Ser Tyr Leu Ser Val Ser Cyβ Cyβ Gin λrg Leu Leu Lyβ He λla 1715 1720 1725 Thr λrg Leu Ser Ser Gin Phe Met Ser Leu λβn He Leu He He Gin 1730 1735 1740 Gin Tyr Gin λla Phe Phe Phe Phe Phβ He λβn Hie Tyr Tyr Lye Lye 1745 1750 1755 1760 Pro λβp λrg Cyβ λrg λrg Leu Lyβ λla λrg Thr He Hie He Phe Thr 1765 1770 1775 Hie λβn Gin Lyβ Phe λla Lye Met Lyβ Glu Leu Glu Gin Glu He λrg 1780 1785 1790 λβn Glu Ser Phe λrg Aβn Gin Met Gin λrg Ser Met Val Gly Glu Met 1795 1800 1805 Val Ser Gin Gly Glu Hie Met Lye λrg Ser Lyβ λβn Ser Leu Val Cyβ 1810 1815 1820 Val Ser Cyβ Leu Leu Hie Val Leu Ser Val Cye Aβp Pro Gin Aβp Pro 1825 1830 1835 1840 Hie Gly Lyβ Gin Aβn Gly Lys Gin He λβn λrg Thr λep Phe Gin λrg 1845 1850 1855 Pro Gin Lyβ Lye Phe Leu Trp Ser Met Glu Leu Leu Lye Met Glu Leu 1860 1865 1870 Tyr Ser Hie Ser λβp Gin Leu Gly Phe Val Phe λla Cye Phe Val Ser 1875 1880 1885 Thr λβp λβp Lyβ He Hie Gin λrg Ser λrg Ser Thr He Leu Gin λrg 1890 1895 1900 Leu Glu Lyβ Glu Lyβ Trp Leu Gly Gin Val Gly Leu Leu Phe Leu λβn 1905 1910 1915 1920 λβp Val Ser Cye λrg λla Lye λla Ser Val Leu He He He Lye λrg 1925 1930 1935 Leu Tyr Glu Tyr Lyβ λβn Thr Phe Phe Phe λβp He Leu Lyβ λrg Leu 1940 1945 1950 He Ser He Lyβ Glu Thr Hie Glu He Phe Tyr Lyβ λsn His Gin Leu 1955 1960 1965 Gin Glu Ser Cyβ Ser λsn Phe λrg λla Ser Gly λsn λβn Gin Ser Phe 1970 1975 1980 λβn Gly Gly λrg Gin Ser Tyr λrg λrg λrg Hie Cye Asn λrg Phe Gly 1985 1990 1995 2000 Tyr Ser λβp Hie Phe Cye Ser Ser λep λrg λrg Trp Lβu λrg Phβ λrg 2005 2010 2015 Gly Gin λrg Hie Sβr Gly Tyr Leu Glu λβn Lβu Hie Lye λrg Ser Gly 2020 2025 2030 Aβp Cyβ Phe Cyβ Leu λrg λla Thr Hie Ser Tyr Val Ser Gly Gly λrg 2035 2040 2045 λrg Tyr Tyr Lβu Phe Glu Hie Val Trp Leu Gin Tyr Trp λrg Gly Trp 2050 2055 2060 λrg Ser Leu Ser Ser Thr He He He He λla He λrg λβn Glu λla 2065 2070 2075 2080 Phe Phe Lyβ Phe Ser Val Ser Leu Phe Ser Val λrg Met Gly Gin Met 2085 2090 2095 Met Thr Lyβ Lyβ Pro Lye Lye Lye Hie Lyβ Lyβ Lyβ Lyβ Lye Thr Lβu 2100 2105 2110 Pro Met Gly Leu Phe He Gin He He Lβu He Val Ser Lyβ λrg Leu 2115 2120 2125 Ser Lyβ He Lye Thr λrg Lye Leu Ser Lye Lye Ser He Pro He Leu 2130 2135 2140 Ser Lyβ Met Lye Phe Leu Thr Ser Leu Ser He Glu Ser Leu Lyβ Lye 2145 2150 2155 2160 λrg He Ser He Thr He Gin Leu Leu Lyβ Lyβ Ser Leu Met Lye λrg 2165 2170 2175 Val λrg Lye Trp Aβp Met λβn Tyr λrg Ser He Leu Lyβ Lye Thr Phe 2180 2185 2190 Leu Leu Ser Lyβ λla Sβr λla λrg Pro Thr λen λen λla λla Phe Cye 2195 2200 2205 Hie Cye λla Glu Lyβ Gin Glu Lye Phe Tyr λla Met He Sβr Tyr He 2210 2215 2220 Met Phe Tyr Trp Pro Tyr Ser He Leu Met He Leu Met He Phe Aβn 2225 2230 2235 2240 He Leu λla Pro Ser Leu Ser Lye Lye Ser Phe He λrg Leu Hie Val 2245 2250 2255 Lye λrg Tyr He Tyr Lyβ Glu λrg Gly Val Cye Gly Lye Gin λla Gly 2260 2265 2270 Thr Lyβ Lyβ λla λen Tyr λrg λla λrg Gly Ser Lye λla λla Val Ser 2275 2280 2285 Lye λsn λrg λrg Thr Ser λrg Hie λla Lyβ Gly Cyβ Gin Ser Leu Phe 2290 2295 2300 Ser Leu Val Trp Gly Glu Val Val Trp Phe Pro λen Phe Tyr Leu Phe 2305 2310 2315 2320 Leu Tyr He Tyr He Val Cyβ λβn Hie Cye He He Cyβ Tyr Ser Phe 2325 2330 2335 Ser Ser Leu Thr Cyβ Phβ λsp Cyβ Ser Aβp Cys Tyr Cys λla Cys Sβr 2340 2345 2350 Ser Trp He Gin Glu λrg Leu λla Leu Ser Lye λβn Gly λla Ser λβp 2355 2360 2365 Glu He Lyβ Thr Phe Phe Val Gly λrg Glu Lyβ Gin Ser Val His Glu 2370 2375 2380 His Phe Phe Hie Glu λla λrg Aβn Gly Hie Pro Leu Lye Ser Lye Gin 2385 2390 2395 2400 Arg Arg Gin Thr Cyβ Glu λrg Cyβ Lyβ Leu Leu Ser Ser Lyβ Leu Met 2405 2410 2415 Phe Phe λrg Trp Gly λβp Pro Tyr Gin Leu Phe Ser Phe λrg Hie Aen 2420 2425 2430 Gin He Gly Gly Hie Phe Phe Aβn Hie Phe Gin Lyβ Arg Ser Hie λrg 2435 2440 2445 Val Thr λrg Phe Tyr Lβu λrg Phe Glu Phe Cyβ Tyr Pro He Gin He 2450 2455 2460 Leu Phe Ser Hie Tyr Lyβ Glu λβn λrg Tyr λβn Gin Gly Leu Trp Ser 2465 2470 2475 2480 Tyr Phe Phe Phe Hie λla Ser Leu Glu λla Lye Glu λrg Lyβ Phe Leu 2485 2490 2495 Tyr Phe Phe Ser λβp Hie λrg λla λrg Phe He λrg Hie Ser Gin Thr 2500 2505 2510 λrg Tyr Glu Lye λla Phe Cyβ λrg Gin Phe λrg Val Ser Lye λβp Tyr 2515 2520 2525 Ser Gin λla Lye Leu Gin Gly λβp λrg λla Hie λrg λrg λla Val Glu 2530 2535 2540 Gin He Pro Pro Hie He Lyβ λrg He Hie λrg Trp λrg Tyr Leu Leu 2545 2550 2555 2560 Gin Thr Met λrg He Leu Gin Phe Ser Cye Gly λβn Glu Ser Pro Phe 2565 2570 2575 Tyr Leu Gin Pro Lyβ λrg Leu Val Ser Gin Gly Lyβ λβn λla Trp Trp 2580 2585 2590 Gly Glu λrg Ser Leu Phe Cyβ Gin λla Trp Lyβ λβn Lβu Lyβ λrg Phe 2595 2600 2605 Glu Lyβ He Phe λrg Tyr λβp He λrg Pro He Thr Lyβ λrg Phe Val 2610 2615 2620 Aβn Gin λrg Pro λrg Gin λrg He Tyr Phe Hie λla Cye Leu Phe λla 2625 2630 2635 2640 Lyβ Leu Thr Gly Phe Lyβ Gly Gin Thr Gly Phe Hie Leu Lye Aβn Tyr 2645 2650 2655 Tyr Trp Arg Leu Arg Thr Gly Hie Aβp Phe λrg Leu Leu Glu λrg He 2660 2665 2670 Ser Gly Trp Tyr Tyr λla λrg Gin Leu Trp Phe Phe Ser λla Val Cyβ 2675 2680 2685 Leu Lyβ λβn Glu Thr Lye λrg Gly Met λrg Leu Ser λrg λrg Phe Phe 2690 2695 2700 Ser Gin λrg Ser λsp Phe Leu Tyr Gly Lyβ Leu Leu Phe Cyβ Gin Thr 2705 2710 2715 2720 Leu Leu Phe Tyr Hie λla Ser Phe Tyr Phe Cye λβn Phe Phe Cyβ Phβ 2725 2730 2735 Hie λrg Tyr Glu Gly Tyr Glu Phβ Trp Gin Ser λrg Glu λrg Leu Gly 2740 2745 2750 Gin Cyβ λsp λsp λla Lyβ Lys λrg λsp Gin Phe λla Phe Leu Ser Glu 2755 2760 2765 Leu Pro Hie λla Hie Phe Trp Phe Ser Phe Ser λrg Thr Hie Phe λβp 2770 2775 2780 Thr Trp Leu λβn λrg Phe λrg λsp Ser Val Tyr Val λsn λsp Leu Glu 2785 2790 2795 2800 λrg Tyr Gly Thr He Cye Leu Phe Ser Cyβ Cyβ Gin Gin λrg Gin λla 2805 2810 2815 Lyβ λla Hie Tyr Gly Leu Tyr Gly λrg Leu Trp λrg Lβu Trp Glu Tyr 2820 2825 2830 Cyβ λrg λsn Gly Trp Gly Val Cyβ Gin λβp λla λrg λep λrg Tyr λrg 2835 2840 2845 He Lyβ Ser Phβ Cyβ Leu Gly Gly Leu Cyβ λla Lye λβn Lyβ Cyβ λβn 2850 2855 2860 λβn Gly λla Lyβ Thr λβn Sβr Tyr Phe Cye Cye Gin λrg λla Cye Glu 2865 2870 2875 2880 Lye Leu Ser λβn Lyβ λrg Lye λrg Lyβ Trp Gin Gin Hie Leu Phe Pro 2885 2890 2895 Ser λrg Phe Tyr λla Cyβ Sβr λla Val Thr λβn Lβu He Thr Gly λen 2900 2905 2910 Met λβn Leu λβp Tyr Pro He Thr Gin Leu He λen λla Phe Gly Lye 2915 2920 2925 λsp His λsn λβp Pro λβn Gly Leu Val λla λrg Leu λla Pro Phe Cyβ 2930 2935 2940 Lyβ Ser Thr Aβn Gly Glu Phe Gin Trp Leu Phe λβp λen Lye λla Thr 2945 2950 2955 2960 λβp λrg Leu λβp Phβ Ser Lyβ Thr He He Gly Val λβp Gly Ser Ser 2965 2970 2975 Phe Leu λβp λβn λβn Aβp Val Ser Pro Phe He Cye Phβ Tyr Leu Phe 2980 2985 2990 λla λrg He Gin Glu λla Met λβp Gly λrg λrg Phe Val Lβu λβp He 2995 3000 3005 λβp Glu λla Trp Lye Tyr Leu λla He Gin λrg Ser Leu He Leu Glu 3010 3015 3020 Thr Cyβ Lyβ Leu Gin Gly Lye Glu Thr Leu Leu Ser λep Leu λrg Leu 3025 3030 3035 3040 Lye λla Ser Leu He Phe Trp Leu λla Leu Leu Leu He λrg Leu Glu 3045 3050 3055 λβn λβn λla Leu Gin λrg Phe Phe Glu Thr Met Gly λla He Phe Leu 3060 3065 3070 He Thr Lye Aβp Trp Lβu Met Leu Gin Lyβ Lyβ λβn Leu Lye Ser Ser 3075 3080 3085 Leu λrg λβp He Gly Lyβ Ser Ser Thr λβn λrg Met Glu λla Leu λla 3090 3095 3100 Leu Ser Leu Val Leu He Glu λla Phe Leu Lyβ λβn He Lyβ Phe Tyr 3105 3110 3115 3120 Pro Gin He Leu Tyr Leu Ser Lyβ Lye Leu He λrg Leu Sβr Lye Thr 3125 3130 3135 He Val Ser He λβn He λrg Pro λβp Lye Cyβ He λβn Lye λrg Ser 3140 3145 3150 He Lyβ Met Lyβ Gin λβn Leu λrg Glu Gin Lyβ Leu Trp Lyβ Phe Lyβ 3155 3160 3165 Met Met Ser λrg Phe Trp He Val Phe Leu He He Phe Leu λβn Lyβ 3170 3175 3180 Lyβ λβn Trp Thr Ser Lye Lye Lye Trp Lye λla Lye Ser Leu λβn Lyβ 3185 3190 3195 3200 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5599 baβe pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: AAAAATCAAA GAGCTTλTGG ATCATAGAGC TAλλGTTCTT TCAGACTTAG AAAACAAATA 60 CAAAAAAGλλ AAAGAGGCTC TAGAGAAAGA GACAAGAGGT AAAATCCTTA CTGCTAAGTC 120 AAAGGCTTλT GGGGATCTAG AGCAAGCCTT AAAAGATAAC CCTCTCTATA AGAAACTTCT 180 TCCTAACCCT TATGCCTλTG TTTTAAACCA AGλλλCλTTC ACCAAAGAAG ATAAGGλGCG 240 TTTGAGTTAT TACTACCCCC AGGTGλλAλC GAGCAGTATT TTTAAAAAAA CTλCCGCTλC 300 CACTAAAGAT AAGGCTCAGG CTTTGCTTCλ AATGGGTGTG TTTTCTTTAG ATGAAGAACA 360 AAACAAAAAA GCGAGCCGλT TAGCTTTATC TTACAAGCAA GCGATTGAAG AATATTCCAA 420 TAACATTTCT AATCTGTTGA GCAGAAAAGA ATTGGATAAT ATAGATTATT ACTTACAGCT 480 TGAAAGAAAC AAGTTTGλCT CCAAAGCλAλ AGλTλTTGCT CAAAAGGCTλ CTAλCλCGCT 540 TATTTTTAAC TCGGAλCGCT TGGCGTTTAG CATGGCGATT GATAAGATTA ATGAGAAATA 600 CTTAAAGGGC TATGλGGCTT TTTCTAACTT GTTGAAAAAT GTCAAAGATG ATGTGGAATT 660 GAATACTCTG ACTAAAAACT TTACCAATCλ AAAATTGAGT TTCGCACλλλ AACAAAAATT 720 GTGTTTGTTG GTTTTAGACA GCTTCAATTT TGATACCCAA TCCAAAAAAT CTATATTAAA 780 AAAGACTλλT GAATACAATA TTTTCGTAGA TAGCGATCCT ATCATGAGCG λCλλλλCλλC 840 TATGCAAAλλ GAλCACTλCλ AGATATTTAA TTTCTTCλλλ ACAGTGGTTT CTGCλTACCG 900 AAACAATGTT GCCAAGAATA ATCCCTTTGA ATAGGAAAGG AGλCλCTCTT GAAAAGCATC 960 TTCAAAAλλC TAGGTTCTGT CGCTCTTTAT TCTTTAGTTG TTTλTGGGGG CTTAλλCGCT 1020 ATCAATACλG CATTATTGCC GAGTGAATAC AAAGAATTAG TGGCTTTGGG CTTTAAAAAA 1080 ATCAAλλCλC TCTATCAAAG λCATGATGAC AAAGAAATTA CAAAAGAGGA λAAAGAATTC 1140 GCCACTAλCG CTTTGAGAGA AλλλTTλCGλ AATGATAGGG CGAGAGCAGA GCAAATTCAA 1200 AλGAATATTG AAGCGTTTGλ AAAAAAGAAC AACTCTTCTG TTCAAAAAAA λGCGGCTAAG 1260 CACAAAGGλT TACλAGAλTT AAACGAAATT AACGCTAACC CTTTGAATGA CAACCCTAAT 1320 GGCAATTCTT CCACTGAAAC CAAATCTAAT AAAGATGATλ ACTTTGλTGA GATGATCAAT 1380 AAGGTGλλTG AATCTTTTGT GAλλCCTGCT GCTCCGCTTG TGCCTGATGλ GTGGAGAλCG 1440 CCTGAAATTG AAATCATTAT CAATGAGTGT ATTATTTCAA GCλλCGATTλ TGATGGGTTλ 1500 AGλAAGTGTT TGATCAAAGA CATCAAGGAT C__AAAAATTC TTGCCCCCTT ATTAGAAAAA 1560 ATTCAAGλλλ TAGλGλCλGλ AAATAACAAG TTTTCTAGλC AACACCTAAG TGGTTTAAλλ 1620 CTCACTCTTλ ATAACAGCAA CAATAGAACC TTTCTTATλG CTTCGTGCGC TATTTGTGAG 1680 AAGAGAAAAA AAGAAATGGA GCAAGAAAAT AACTACCλGG ATACTACAAA TGCAAGCGAG 1740 TTTGGCλCTA CTGATλCλλλ AGAAAATGAA GCAAAAGATA CAGCATTCTC AAACAATCGC 1800 TCTAAATCCG λACTGCCCλλ TAGCGTCATT AλTCAAATλG AλCλλλGCλT CGCTCλTGGλ 1860 AAAAAATAGC GATCCAAATT ATTAGATCAA AAAACAACTA GAGλλGCλλλ TCCCAAAGGT 1920 TAGAAATCAT AGCCTλTCGT CTCAGAAAAλ TCATTTλλCλ ATGλTCTTλC TTGATTGCCT 1980 TTCTTGTAGG TATTGTCGCT TλCTTTGTTC TλGGGλTCTT TCTλλTGCGT CCλλCTCCTC 2040 TAAATAATTT AAAAAGACCT TGTTTTGAGC TAACATAAGC TTTCTGATTC CTTTGATGλ 2100 ATTTTTATTC TTTAGGCTTT CTACAAGCGT CTGTGλAGCλ GTGATTλλλG AAGCTGTACC 2160 TCCAλTGTTG CTCTGATACG CCTTTAGGGλ AGTTTCTAAλ CGCTCTCTTλ TATTTTGTTT 2220 TTCTTGCTCG ATTTTCAGCT TCCCTTCλCλ ATλλλGλλCT AAAACTTTAT CGGATATTCC 2280 GCATTGCTGC TCAGCλGTλT TTTGGTCTAλ GGGATTGλTT TTCATATAGG TTAATAAAAG 2340 TTCλGGGCTA GACATATAAG TCTTGAAAAT CACATCTTCT GAGATGAAAA ATAACTCATT 2400 CGCTTCAAAA TTGGCTTTCA ATAACGCTAA ATCTCCTCTC AAAGCAATGG CCGCTTTTTT 2460 GATGTTTλGλ GCλTCTTCTT GλCCTλTTTC λTTλTTλGCG CTλGGGCTλG TGGTTGλAAλ 2520 AATCTCATCT AAGTTTTTAA GCλCTTGTTG GTTGGTCTCT TGGTAGGTGC TATCAAGTTG 2580 CTTTAAACCG CTTGTTATλT CTTCTGCCAT CAAAACAGAC AλTλGCAAAA AAGAAGATAT 2640 GGTATTTTTC ACGλGTGTTT TCλTTTGACλ λTλλCTTTλG λGCTλGCAAT GTTTCTTGCT 2700 GTCGTTTCTC TTTCTλλTTT CλGTTGTTCT TCCCAAλGGT CGGCTTTTTT TTCλλGλTTC 2760 TCTλTλTλGT TTAAATGATT TTCTGCGTTT λλGλTCGCAA CTTCTATGAG CGCATTCAAA 2820 TCTACTGATC CTTTTAAGGT TTTGATTTCT CCATTGATCC CATTCAAATA λGCGATATTT 2880 TGAAAATCTG CATCACTCAG TTTATTTTGA ATAAGGGCTA CAATCATTCT GTAATTCTGA 2940 ATλλCCTGTT CCλTλλGGCλ TGCTGλλλTT TTTλGCCCλT CλλGλTλλGG GCλTTTTGTG 3000 GGCGCTAGAG TGAATGTTTC AATGATTCCA AATGGTCGCC CATGCTTGAA AAAAAACTAA 3060 GAGCλGGCGC ATAGATGGCA CTTTGAAACA AAGCCTGACC TGTTAGGGAA TTATAATCAA 3120 TλλGGGTCGC TTTTTGCλTλ GCTGTTTTCλ λCCATGTCTC λAAλCCTTTT λλGGTTTCTT 3180 CλλλCGCCTT GATACCAATC GTATTGTλλβ CGATGTATTG AGCGTTGTCλ GAAGAACTTC 3240 CTλGλGCTTG λGλAATTTCC ATTTGTGTTT TTλGGGTλλC CCTCGGTTCλ λλGCTGTTTT 3300 TTλλCGCTTC TλλGλGλGCG TTTTGCTGGT TCλTTTTGλG CTTGλTCλTT TCGTTλTTTT 3360 TTTGGλGCGC GATTTGCλTG TTTTGGλTTT CTGTTTGGGT λTTλλTTTTT TGTTTTTCCλ 3420 CGλTCATTTT GACATTCCCC CCCAATGCλC TλλGCGCCGC TTGAATACCC TTCCATGλCG 3480 CCAAGCAAGA TGTCTGλλCC TGCAλλAλλC CCCCCTGTCA TGCCATTGλC ACCATTAATA 3540 ACGCCATTAG CCCCTTTTAλ CATAGCGCTC ATGGTTGCAλ GCTGAGTCCT CAATTCTCCC 3600 TCTATTTGCG CTTGAATGGC TTTTTCTTTG GCλCTλGλTT GλGCTTCTλT GGCTTTTλλT 3660 TCGGCTTGλG CGGTTTTTTG TTTGGCTTGT GCGTCTGCCT GAATGGCTTT TλλGGCλGGT 3720 TCλλGCGTTA TTACTλCCTC TGTACCATTC AGAGACAAAC CλCAλλλλGT CAAGAAAGAA 3780 AλTλTGCTTλ λAAAACATTT C CATCTCTT TCCTCλCTTC λCGλTTλTTT TAGTTTGCAC 3840 CCTTTCTGTT λλGTAGCTAT CTTTTTGCCC CTTλAGCTTG TCTTTGATGT AATCAACGTA 3900 AGTCAAATGC GATTTCAAAλ AAGATTTATT CGCTACTATA TTGTAATTAT ATAGCGAACT 3960 TATGTTAGAA ATCGCTTGλG TGTCATAGGT GCTAGTAGCT AATCCTGλTT GATTAAGTAT 4020 CATTTGAGAλ GCGTTCTGCA ACAAATTGGT ATTλTTTTTC ACAAATTCTA TATλGTλTTC 4080 TCTCAAAATT TCTGCTACTT TTTCAGCATA GCAATAAACA GCAλGλλCCT TGTCCCCλλT 4140 AGGGCATGCA GGAGTGGTCλ TAGGATTAλC GCCTGAAGTT AGGGCλTTλG TGGCTAλCGC 4200 TTGGTATTTλ GCATAAACAG TGGGCλTAGA AλCGCTCλTG GGGCGTCATλ GAAATTTGCλ 4260 TGCλλCTGAλ AAACACTTTT GATGλGCCλλ CAAGCGCACC TAAAGCGGTλ CAGCTATCλλ 4320 GGAATCGGTG TATCATTCAT TGAGCTGTTG CTTGCTTGλG λλCGCλGTTG CTCTTGTAGλ 4380 GCTAGGGCGT ATTTTGGTGC TGCλCTTGTλ ATATTGCCTA ATATACCGTC ATCATTTCAA 4440 CCGTTGTTGG CACGCTAGGA ACλGCGλTTT GATTTGTCGC ATλλGCTTCλ ATλGCλCTGG 4500 GATTTTTλGG GGTGGTGTTA CTCGCTAAAλ TGCTTGCAAT CTGACTATTA ACAGCACCAA 4560 TTTGCGCGCC TTGCGTGTTG CCTTGTGCGT TAλλTTCCCC TGTTAATTTG CTAATλTTTλ 4620 AGλTλTTGTT CCCCACAGCC ATGCTTTGAT CGTTAAAACC TTGAAACAAT TGGTTGTATT 4680 GTTGGTTAGC GGCTTTCλTA GGCλTGCTTλ CGGCTTCλGC GλTGCTTTGλ TTGTλTTGGG 4740 TCλTGλTλGC GGTCλTTTGC GGλTTλGTλλ λCCCAACAAT λλTλGGλλTλ λTCGCTGCTG 4800 TCλTλGCλCC CGCTλCTλTT CCTGCλλλTβ GTCCTGCGλC ACCACTTGTG TTGλGλTGλT 4860 TGAGGAAACT TCCGATAAGA λGCCTGCλGλ λGλTGλTTCλ TλTλTλGCTT GTGTλCCTGC 4920 CλTGTTλλCλ CCCCCTλGTT λλTλCCCTλλ TλTCGGTGGT AAAAACGATG λλTCTGλGTλ 4980 TGTTGGTGCλ TAACCATλCλ TGλλλGGλTT GTTTGGλCCG TλλTCGCCCλ TCλTTTGGCT 5040 CλTGλGλλGλ TTTTGλλTGC CCCλCλTCGC λTTGλTλCCT λGλTTλTCλT TλGGTTGλλλ 5100 λCTCCCTλλλ CTTλTGTCGT CAAATTTGAT λTTλλCλTTT TTλTCλTTλT λGTCλTTGλG 5160 TλTGGCCλCT TTTTGCTCTλ GGGTTTCTTT λGGGλTCTCT λTTTTTλCTT CλTCTCTAGλ 5220 AACAAGCCCC λCGCTλTTTλ GTGCCλTλTC TTCλGGλCTλ λTλTCTTTTλ TλTCλGTGTT 5280 TTGGTCAGCG TTAλCGGλCT GTAAACλTGC CλλTGλTλλG λCλCCAAGCλ λλTAGTAλTT 5340 TAATTTTATA AAAATCCGTT TTCλTACTTT TGACTCCTTT ATTCTTATTT TTAGCλCTλT 5400 TCTλGCGCλT TλλCGCCλCT CλλTCGTTAT TTTTGTTTTG ATTTTTTTGλ TCGAGCATTT 5460 TGTTTGTTλC TTCλTCλλTG TTTTGλλAAT λTTTTTCλλλ λλGCTCTTTC TTTTTλGCTT 5520 CλλCGCTCλT λTCλλTCTGλ λTCCAATTAG GλλTλλTGGλ GTCCλTGλTT AAATGCATGA 5580 AGTCATAGGC ATGλTTTTT 5599 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1727 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Lyβ λsn Gin λrg λla Tyr Gly Ser Ser Ser Ser Phe λrg Leu λrg Lye 1 5 10 15 Gin He Gin Lys λrg Lyβ λrg Gly Ser λrg Glu λrg λsp Lyβ λrg λβn 20 25 30 Pro Tyr Cyβ Val Lyβ Gly Leu Trp Gly Ser λrg λla Ser Leu Lys λrg 35 40 45 Pro Ser Leu Glu Thr Ser Ser Pro Leu Cye Leu Cye Phe Lyβ Pro λrg 50 55 60 λsn He His Gin λrg λrg Gly λla Phe Glu Leu Leu Leu Pro Pro Gly 65 70 75 80 Glu λsn Glu Gin Tyr Phβ Lys λβn Tyr λrg Tyr Hie λrg Gly Ser Gly 85 90 95 Phe λla Ser λβn Gly Cye Val Phe Phe λrg λrg Thr Lye Gin Lyβ Ser 100 105 110 Glu Pro He Ser Phe He Leu Gin λla Ser Asp λrg He Phe Gin Hie 115 120 125 Phe Ser Val Glu Gin Lyβ λrg He Gly Tyr λrg Leu Leu Leu Thr λla 130 135 140 Lyβ Lyβ Gin Val Leu Gin Ser Lyβ λrg Tyr Cyβ Ser Lyβ Gly Tyr Hie 145 150 155 160 λla Tyr Phe Leu Gly Thr Leu Gly Val Hie Gly λβp λβp Glu He Leu 165 170 175 Lyβ Gly Lβu Gly Phe Phe Leu Val Glu Lyβ Cyβ Gin λrg Cyβ Gly He 180 185 190 Glu Tyr Ser Asp Lys Leu Tyr Gin Ser Lye He Glu Phe λrg Thr Lyβ 195 200 205 Thr Lyβ He Val Phe Val Gly Phe λrg Gin Leu Gin Phe Tyr Pro He 210 215 220 Gin Lyβ He Tyr He Lye Lyβ λβp He Gin Tyr Phe λrg λrg λrg Ser 225 230 235 240 Tyr λβp Glu λrg Gin λsn λβn Tyr λla Lys λrg Thr Leu Gin λβp He 245 250 255 Phe Leu Gin λsn Ser Gly Phe Cyβ He Pro Lye Gin Cye Cye Gin Glu 260 265 270 Ser Leu He Gly Lyβ Glu Thr Leu Leu Lyβ Sβr He Phe Lyβ Lyβ Lβu 275 280 285 Gly Ser Val λla Leu Tyr Ser Leu Val Val Tyr Gly Gly Leu λβn λla 290 295 300 He λβn Thr λla Leu Leu Pro Ser Glu Tyr Lyβ Glu Leu Val λla Leu 305 310 315 320 Gly Phe Lye Lye He Lye Thr Leu Tyr Gin λrg Hie λβp λβp Lyβ Glu 325 330 335 He Thr Lyβ Glu Glu Lyβ Glu Phe λla Thr λβn λla Leu λrg Glu Lye 340 345 350 Leu λrg λβn λβp λrg λla λrg λla Glu Gin He Gin Lye Aβn He Glu 355 360 365 λla Phe Glu Lyβ Lyβ λβn λβn Ser Ser Val Gin Lyβ Lyβ λla λla Lyβ 370 375 380 Hie Lyβ Gly Leu Gin Glu Leu λβn Glu He Aβn λla λen Pro Leu λβn 385 390 395 400 λβp λβn Pro Aβn Gly Aen Ser Ser Thr Glu Thr Lye Ser λβn Lyβ λβp 405 410 415 λβp λen Phe λβp Glu Met He λβn Lyβ Val λen Glu Ser Phe Val Lyβ 420 425 430 Pro λla λla Pro Leu Val Pro λβp Glu Trp λrg Thr Pro Glu He Glu 435 440 445 He He He λβn Glu Cyβ He He Ser Ser λβn λsp Tyr λβp Gly Lβu 450 455 460 Arg Lyβ Cyβ Leu He Lye Aβp He Lyβ Asp Gin Lys He Leu λla Pro 465 470 475 480 Leu Leu Glu Lyβ He Gin Glu He Glu Thr Glu λβn λen Lyβ Phe Ser 485 490 495 λrg Gin Hie Leu Ser Gly Leu Lye Leu Thr Leu λβn λβn Sβr λβn λβn 500 505 510 λrg Thr Phe Leu He λla Ser Cyβ λla He Cyβ Glu Lyβ λrg Lyβ Lye 515 520 525 Glu Met Glu Gin Glu λβn λβn Tyr Gin Asp Thr Thr λβn λla Ser Glu 530 535 540 Phe Gly Thr Thr λβp Thr Lyβ Glu λβn Glu λla Lye λep Thr λla Phe 545 550 555 560 Ser λβn λβn λrg Ser Lyβ Ser Glu Leu Pro λβn Ser Val He λβn Gin 565 570 575 He Glu Gin Ser He λla Hie Gly Lye Lyβ λrg Ser Lyβ Leu Leu λβp 580 585 590 Gin Lyβ Thr Thr λrg Glu λla Asn Pro Lye Gly Lyβ Ser Pro He Val 595 600 605 Sβr Glu Lyβ Ser Phe λβn λβn λβp Leu Thr Leu Pro Phe Leu Val Leu 610 615 620 Ser Leu Thr Leu Phe Gly Ser Phe Cye Val Gin Leu Leu He He Lyβ 625 630 635 640 λβp Leu Val Leu Ser Hie Lyβ Leu Ser λβp Ser Phe λβp Glu He Phe 645 650 655 He Leu λla Phe Tyr Lye λrg Leu Ser Ser λβp λrg Ser Cye Thr Ser 660 665 670 Aβn Val Ala Leu He Arg Leu Gly Ser Phe Thr Leu Ser Tyr He Leu 675 680 685 Phe Phe Leu Leu λβp Phβ Gin Leu Pro Phe Thr He Lyβ λβn λβn Phe 690 695 700 He Gly Tyr Ser λla Leu Leu Leu Ser Ser He Leu Val Gly He λβp 705 710 715 720 Phe Hie He Gly Lys Phe λrg λla λrg Hie He Ser Leu Glu λen Hie 725 730 735 He Phe Aβp Glu Lyβ Lβu He λrg Phe Lye He Gly Phe Gin λrg He 740 745 750 Ser Ser Gin Ser λsn Gly λrg Phe Phe λβp Val Ser He Phe Leu Thr 755 760 765 Tyr Phe He He Ser λla λrg λla Ser Gly Lye λβn Leu He Val Phe 770 775 780 Lyβ Hie Leu Leu Val Gly Leu Leu Val Gly λla He Lye Leu Leu Thr 785 790 795 800 λla Cye Tyr He Phe Cyβ Hie Gin Aβn λrg Gin Gin Lyβ λrg λrg Tyr 805 810 815 Gly He Phe Hie Glu Cye Phβ Hie Leu Thr He Thr Leu Glu Leu λla 820 825 830 Met Phe Leu λla Val Val Ser Leu Ser λβn Phe Ser Cyβ Sβr Sβr Gin 835 840 845 λrg Ser λla Phe Phe Ser λrg Phe Sβr He Phe Lyβ Phβ Ser λla Phe 850 855 860 Lyβ He λla Thr Ser Met Ser λla Phe Lyβ Ser Thr λβp Pro Phe Lye 865 870 875 880 Val Leu He Ser Pro Leu He Pro Phe Lyβ λla He Phe Lyβ Ser λla 885 890 895 Ser Leu Ser Leu Phe He λrg λla Thr He He Leu Phe He Thr Cyβ 900 905 910 Ser He λrg Hie λla Glu He Phe Ser Pro Ser λrg Gly Hie Phe Val 915 920 925 Gly λla λrg Val λβn Val Ser Met He Pro λβn Gly λrg Pro Cyβ Lβu 930 935 940 Lyβ Lyβ λsn Glu Gin λla His λrg Trp His Phe Glu Thr Lyβ Pro λβp 945 950 955 960 Leu Leu Gly λsn Tyr λβn Gin Gly Ser Leu Phe λla Leu Phe Ser Thr 965 970 975 Met Ser Gin λen Leu Leu λrg Phe Leu Gin Thr Pro Tyr Gin Sβr Tyr 980 985 990 Cyβ Lyβ λrg Cyβ He Glu λrg Cye Gin Lye λβn Phe Leu Glu Leu Glu 995 1000 1005 Lyβ Phe Pro Phe Val Phβ Leu Gly Pro Ser Val Gin Ser Cyβ Phe Leu 1010 1015 1020 Thr Leu Leu λrg Glu λrg Phe λla Gly Ser Phe λla Ser Phe Arg Tyr 1025 1030 1035 1040 Phe Phe Gly Ala λrg Phe λla Cyβ Phe Gly Phe Leu Phe Gly Tyr Phe 1045 1050 1055 Phe Val Phe Pro λrg Ser Phe Hie Ser Pro Pro Met Hie λla Pro Leu 1060 1065 1070 Glu Tyr Pro Ser Met Thr Pro Ser Lyβ Met Ser Glu Pro λla Lyβ λβn 1075 1080 1085 Pro Pro Val Met Pro Leu Thr Pro Leu He Thr Pro Leu λla Pro Phe 1090 1095 1100 λβn He λla Leu Met Val λla Ser Val Leu λβn Ser Pro Ser He Cyβ 1105 1110 1115 1120 λla Met λla Phe Ser Leu λla Leu λsp λla Ser Met λla Phe λβn Ser 1125 1130 1135 λla λla Val Phe Cye Leu λla Cyβ λla Ser λla Met λla Phe Lye λla 1140 1145 1150 Gly Ser Ser Val He Thr Thr Ser Val Pro Phe λrg Asp Lyβ Pro Gin 1155 1160 1165 Lyβ Val Lyβ Lyβ Glu λβn Met Leu Lyβ Lyβ Hie Phe Thr Ser Leu Ser 1170 1175 1180 Ser Leu Hie λβp Tyr Phe Ser Leu Hie Pro Phe Cye Val λla He Phe 1185 1190 1195 1200 Leu Pro Leu Lyβ Leu Val Phe λβp Val He Lyβ Val Ser Gin Met λrg 1205 1210 1215 Phe Gin Lye λrg Phe He λrg Tyr Tyr He Val He He λrg Thr Tyr 1220 1225 1230 Val λrg λsn λrg Leu Ser Val He Gly λla Ser Ser Ser Leu He Lyβ 1235 1240 1245 Tyr Hie Leu λrg Ser Val Leu Gin Gin He Gly He He Phe Hie Lyβ 1250 1255 1260 Phe Tyr He Val Phe Ser Gin λen Phe Cye Tyr Phβ Phe Ser He λla 1265 1270 1275 1280 He λβn Ser Lyβ λβn Leu Val Pro λβn λrg λla Cyβ λrg Ser Gly Hie 1285 1290 1295 λrg He λβn λla Ser Gly He Ser Gly λrg Leu Val Phe Ser He λβn 1300 1305 1310 Ser Gly Hie λrg λβn λla Hie Gly λla Ser Lyβ Phe λla Cyβ λβn Lye 1315 1320 1325 Thr Leu Leu Met Ser Gin Gin λla Hie Leu Lyβ λrg Tyr Ser Tyr Gin 1330 1335 1340 Gly He Gly Val Ser Phβ He Glu Leu Leu Leu λla Glu λrg Ser Cyβ 1345 1350 1355 1360 Ser Cyβ λrg λla λrg λla Tyr Phe Gly λla λla Leu Val He Leu Pro 1365 1370 1375 λsn He Pro Ser Ser Phe Gin Pro Leu Leu λla λrg Glu Gin λrg Phe 1380 1385 1390 λβp Leu Ser Hie Lyβ Leu Gin Hie Trp Asp Phe Gly Trp Cyβ Tyr Ser 1395 1400 1405 Leu Lye Cye Leu Gin Ser λβp Tyr Gin Hie Gin Phe λla λrg Leu λla 1410 1415 1420 Cyβ Cyβ Leu Val λrg He Pro Leu Leu He Cyβ Tyr Leu λrg Tyr Cyβ 1425 1430 1435 1440 Ser Pro Gin Pro Cyβ Phe λβp λrg λsn Leu Glu Thr He Gly Cyβ He 1445 1450 1455 Val Gly λrg Leu Ser λla Cye Leu λrg Leu Gin λrg Cye Phe λβp Cyβ 1460 1465 1470 He Gly Ser λrg Ser Phe λla λβp Thr Gin Gin Glu Ser Leu Leu Ser 1475 1480 1485 Hie Pro Leu Leu Phe Leu Gin Met Val Leu λrg Hie Hie Lβu Cyβ λβp 1490 1495 1500 λsp Gly λβn Phe λrg Glu λla Cyβ λrg λrg Phe He Tyr Ser Leu Cyβ 1505 1510 1515 1520 - I l l - Thr Cyβ Hie Val λsn Thr Pro Leu He Pro Tyr λrg Trp Lyβ λrg He 1525 1530 1535 Val Cyβ Trp Cyβ He Thr He Hie Glu λrg He Val Trp Thr Val He 1540 1545 1550 λla Hie Hie Leu λla Hie Glu Lyβ He Leu λβn λla Pro Hie λrg He 1555 1560 1565 λβp Thr He He He λrg Leu Lye Thr Pro Thr Tyr Val Val Lyβ Phe 1570 1575 1580 λβp He λen He Phe He He He Val He Glu Tyr Gly Hie Phe Leu 1585 1590 1595 1600 Leu Gly Phe Phe λrg λβp Leu Tyr Phe Leu He Ser λrg λβn Lye Pro 1605 1610 1615 Hie λla He Cyβ Hie He Phe λrg Thr λβn He Phe Tyr He Ser Val 1620 1625 1630 Leu Val Ser Val λβn Gly Leu Thr Cye Gin λep Thr Lye Gin He Val 1635 1640 1645 He Phe Tyr Lyβ λsn Pro Phe Ser Tyr Phe Leu Leu Tyr Ser Tyr Phe 1650 1655 1660 Hie Tyr Ser Ser λla Leu Thr Pro Leu λβn λrg Tyr Phe Cyβ Phβ λβp 1665 1670 1675 1680 Phe Phe λβp λrg λla Phe Cyβ Leu Leu Leu Hie Gin Cye Phβ Glu λβn 1685 1690 1695 He Phe Gin Lyβ λla Leu Ser Phβ Leu Gin λrg Ser Tyr Gin Ser Glu 1700 1705 1710 Ser λβn Glu Trp Ser Pro Leu λβn λla Ser Hie λrg Hie λβp Phe 1715 1720 1725 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1781 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Lyβ He Lye Glu Leu Met λβp Hie λrg λla Lye Val Leu Ser Aβp Leu 1 5 10 15 Glu Aβn Lyβ Tyr Lyβ Lyβ Glu Lye Glu λla Leu Glu Lyβ Glu Thr λrg 20 25 30 Gly Lyβ He Leu Thr λla Lyβ Ser Lyβ λla Tyr Gly Aβp Leu Glu Gin 35 40 45 Ala Leu Lyβ λβp λβn Pro Leu Tyr Lye Lye Leu Leu Pro λen Pro Tyr 50 55 60 λla Tyr Val Leu λβn Gin Glu Thr Phe Thr Lye Glu λβp Lyβ Glu λrg 65 70 75 80 Leu Ser Tyr Tyr Tyr Pro Gin Val Lyβ Thr Ser Ser He Phe Lyβ Lye 85 90 95 Thr Thr λla Thr Thr Lyβ λβp Lye λla Gin λla Leu Leu Gin Met Gly 100 105 110 Val Phe Ser Leu λβp Glu Glu Gin λen Lye Lye λla Ser λrg Leu λla 115 120 125 Leu Ser Tyr Lyβ Gin λla He Glu Glu Tyr Ser λβn λβn He Ser λβn 130 135 140 Leu Leu Ser λrg Lyβ Glu Leu λsp λsn He Asp Tyr Tyr Leu Gin Leu 145 150 155 160 Glu λrg λβn Lyβ Phe λβp Ser Lyβ λla Lyβ λsp He λla Gin Lyβ λla 165 170 175 Thr λβn Thr Leu He Phe λsn Ser Glu λrg Leu λla Phe Ser Met λla 180 185 190 He λsp Lye He λen Glu Lye Tyr Leu Lye Gly Tyr Glu λla Phe Ser 195 200 205 λβn Leu Leu Lyβ λβn Val Lyβ λep Aβp Val Glu Leu λβn Thr Leu Thr 210 215 220 Lye λβn Phβ Thr λβn Gin Lyβ Leu Ser Phe λla Gin Lyβ Gin Lyβ Leu 225 230 235 240 Cyβ Leu Leu Val Leu Aβp Ser Phe λen Phe λβp Thr Gin Ser Lyβ Lye 245 250 255 Ser He Leu Lyβ Lyβ Thr Aβn Glu Tyr λβn He Phe Val λβp Ser λβp 260 265 270 Pro Met Met Ser λβp Lyβ Thr Thr Met Gin Lye Glu Hie Tyr Lyβ He 275 280 285 Phe λβn Phe Phe Lyβ Thr Val Val Ser λla Tyr λrg λen Aβn Val λla 290 295 300 Lyβ λβn λβn Pro Phe Glu Glu λrg λrg Hie Ser Lyβ λla Ser Ser Lyβ 305 310 315 320 λsn Val Leu Ser Leu Phe He Leu Leu Phe Met Gly λla Thr Leu Ser 325 330 335 He Gin Hie Tyr Cye λrg Val λβn Thr Lyβ λβn Trp Leu Trp λla Leu 340 345 350 Lyβ Lyβ Ser Lyβ Hie Sβr He Lyβ λβp Met Met Thr Lye Lye Leu Gin 355 360 365 Lyβ λrg Lyβ Lyβ λβn Ser Pro Leu Thr Leu Glu Lyβ λβn Tyr Glu Met 370 375 380 He Gly λrg Glu Gin Ser Lyβ Phe Lyβ λrg He Leu Lye λrg Leu Lye 385 390 395 400 Lyβ λrg Thr Thr Leu Leu Phe Lyβ Lyβ Lyβ λrg Leu Ser Thr Lye Aβp 405 410 415 Tyr Lyβ λβn Thr Lyβ Leu Thr Leu Thr Leu Met Thr Thr Leu Met λla 420 425 430 Ile Leu Pro Leu Lyβ Pro λβn Leu He Lyβ Met He Thr Leu Met λrg 435 440 445 Ser He λrg Met λβn Lβu Leu Aβn Leu Leu Leu λrg Leu Cye Leu Met 450 455 460 Ser Gly Glu λrg Leu Lyβ Leu Lye Ser Leu Ser Met Ser Val Leu Phe 465 470 475 480 Gin λla Thr He Met Met Gly Glu Sβr Val Sβr Lye Thr Ser λrg He 485 490 495 Lyβ Lye Phe Leu Pro Pro Tyr Lye Lye Phe Lyβ Lyβ λrg Gin Lye He 500 505 510 Thr Ser Phe Leu λβp Aβn Thr Val Val λβn Ser Leu Leu He Thr λla 515 520 525 Thr He Glu Pro Phe Leu Leu λrg λla Leu Phe Val λrg λrg Glu Lyβ 530 535 540 Lye Lyβ Trp Ser Lyβ Lyβ He Thr Thr λrg He Leu Gin Met Gin λla 545 550 555 560 Ser Leu λla Leu Leu He Gin Lyβ Lyβ Met Lye Gin Lye He Gin Hie 565 570 575 Sβr Gin Thr He λla Leu Aβn Pro Asn Cyβ Pro He λla Ser Leu He 580 585 590 Lyβ λβn Lyβ λla Ser Leu Met Glu Lyβ Aβn Ser Asp Pro λβn Tyr He 595 600 605 Lyβ Lye Gin Leu Glu Lye Gin He Pro Lye Val λrg λβn Hie Ser Leu 610 615 620 Ser Ser Gin Lyβ λβn Hie Leu Thr Met He Leu Leu λβp Cye Leu Ser 625 630 635 640 Cye λrg Tyr Cyβ λrg Leu Leu Cyβ Ser λrg λβp Leu Ser λen λla Ser 645 650 655 λβn Ser Ser Lyβ Phe Lye Lyβ Thr Leu Phe λla λβn He Ser Phe Leu 660 665 670 He Pro Leu Met Lye Phe Leu Phe Phe λrg Leu Ser Thr Ser Val Cyβ 675 680 685 Glu λla Val He Lye Glu λla Val Pro Pro Met Leu Leu Tyr λla Phe 690 695 700 λrg Glu Val Ser Lyβ λrg Ser Leu He Phe Cyβ Phβ Ser Cyβ Ser He 705 710 715 720 Phe Ser Phe Pro Ser Gin λrg Thr Lye Thr Leu Ser λβp He Pro Hie 725 730 735 Cyβ Cyβ Ser λla Val Phe Trp Ser Lyβ Gly Leu He Phe He Val λβn 740 745 750 Lyβ Ser Ser Gly Leu λβp He Val Leu Lyβ He Thr Ser Ser Glu Met 755 760 765 Lye λβn λβn Ser Phe λla Ser Lye Leu λla Phe λβn λβn λla Lyβ Ser 770 775 780 Pro Leu Lyβ λla Met λla λla Phe Leu Met Phe λrg λla Ser Ser Pro 785 790 795 800 He Ser Leu Leu λla Leu Gly Leu Val Val Glu Lye He Ser Ser Lyβ 805 810 815 Phe Leu Ser Thr Cyβ Trp Lβu Val Ser Trp Val Leu Ser Ser Cyβ Phe 820 825 830 Lyβ Pro Leu Val He Ser Ser λla He Lyβ Thr λβp λβn Ser Lyβ Lyβ 835 840 845 Glu λep Met Val Phe Phe Thr Ser Val Phe He Gin Leu Ser Gin Cyβ 850 855 860 Phe Leu Leu Ser Phe Leu Phe Leu He Ser Val Val Leu Pro Lye Gly 865 870 875 880 λrg Leu Phe Phe Gin λβp Ser Leu Tyr Ser Leu λβn λβp Phe Leu λrg 885 890 895 Leu λrg Ser Gin Leu Leu λla Hie Ser Aβn Leu Leu He Leu Leu λrg 900 905 910 Phe Phe Leu Hie Ser Hie Ser Aβn Lys λrg Tyr Phe Glu λβn Leu Hie 915 920 925 Hie Ser Val Tyr Phe Glu Gly Leu Gin Ser Phβ Cyβ λen Ser Glu Pro 930 935 940 Val Pro Gly Met Leu Lye Phβ Leu λla Hie Gin λβp Lye Gly He Leu 945 950 955 960 Trp λla Leu Glu Met Phe Gin Phβ Gin Met Val λla Hie λla Lye Lye 965 970 975 Thr Lye Ser λrg λrg He λβp Gly Thr Leu Lye Gin Ser Leu Thr Cyβ 980 985 990 Gly He He He λβn Lye Gly λrg Phβ Leu Hie Ser Cyβ Phe Gin Pro 995 1000 1005 Cyβ Leu Lyβ Thr Phe Gly Phe Phe Lyβ λrg Leu Aβp Thr λβn λrg He 1010 1015 1020 Val Ser λβp Val Leu Ser Val Val λrg λrg Thr Ser Ser Leu λrg λβn 1025 1030 1035 1040 Phe Hie Leu Cyβ Phβ Gly λen Pro λrg Phe Lyβ λla Val Phe λrg Phe 1045 1050 1055 Glu Ser Val Leu Leu Val Hie Phe Glu Leu Aβp Hie Phe Val He Phe 1060 1065 1070 Leu Glu λrg λβp Leu Hie Val Lβu λep Phe Cyβ Leu Gly He λβn Phe 1075 1080 1085 Leu Phe Phe Hie λβp Hie Phe λβp He Pro Pro Gin Cyβ Thr Lye λrg 1090 1095 1100 λrg Leu Asn Thr Leu Pro λrg Gin λla λrg Cys Leu λβn Leu Gin Lye 1105 1110 1115 1120 Thr Pro Leu Ser Cyβ Hie Hie Hie λrg Hie Pro Leu Leu Thr λrg Ser 1125 1130 1135 Trp Leu Gin λla Glu Ser Ser He Leu Pro Leu Phe λla Leu Glu Trp 1140 1145 1150 Leu Phe Leu Trp His He Glu Leu Leu Trp Leu Leu He λrg Leu Glu 1155 1160 1165 λrg Phe Phe Val Trp Leu Val λrg Lβu Pro Glu Trp Leu Leu λrg Gin 1170 1175 1180 Val Gin λla Leu Leu Leu Pro Leu Tyr Hie Ser Glu Thr λβn Hie Lyβ 1185 1190 1195 1200 Lyβ Ser λrg Lyβ Lyβ He Cye Leu Lye λβn He Ser Hie Leu Phe Pro 1205 1210 1215 Hie Phe Thr He He Leu Val Cye Thr Lβu Sβr Val Lyβ Leu Ser Phe 1220 1225 1230 Cyβ Pro Leu Ser Leu Ser Leu Met Ser λrg Val Lyβ Cyβ λβp Phβ Lyβ 1235 1240 1245 Lyβ λsp Leu Phe λla Thr He Leu Leu Tyr Ser Glu Leu Met Lβu Glu 1250 1255 1260 He λla Val Ser Val Leu Val λla λβn Pro λsp Leu Ser He He Glu 1265 1270 1275 1280 λla Phe Cyβ λsn Lys Lβu Val Lβu Phe Phe Thr λβn Ser He Tyr Ser 1285 1290 1295 Leu Lye He Ser λla Thr Phe Ser λla Gin Thr λla λrg Thr Leu Ser 1300 1305 1310 Pro He Gly Hie λla Gly Val Val He Gly Leu Thr Pro Glu Val λrg 1315 1320 1325 λla Leu Val λla λβn λla Trp Tyr Leu λla Thr Val Gly He Glu Thr 1330 1335 1340 Leu Met Gly λrg His λrg λsn Leu His λla Thr Glu Lyβ Hie Phe λla 1345 1350 1355 1360 λsn Lyβ λrg Thr Ser Gly Thr λla He Lyβ Glu Ser Val Tyr Hie Ser 1365 1370 1375 Leu Ser Cyβ Cyβ Leu Leu Glu λβn λla Val λla Leu Val Glu Leu Gly 1380 1385 1390 λrg He Leu Val Leu Hie Lβu Tyr Cyβ Leu He Tyr λrg Hie Hie Phβ 1395 1400 1405 λβn λrg Cyβ Trp Hie λla λrg λen Sβr λβp Leu He Cyβ λrg He Ser 1410 1415 1420 Phe λβn Ser Thr Gly He Phe λrg Gly Gly Val Thr λrg λβn λla Cyβ 1425 1430 1435 1440 λβn Leu Thr He λβn Ser Thr λβn Leu λrg λla Leu λrg Val λla Leu 1445 1450 1455 Cyβ Val Lye Phe Pro Cye Phe λla λβn He λβp He Val Pro Hie Ser 1460 1465 1470 His λla Leu He Val Lys Thr Leu Lys Gin Leu Val Val Leu Leu Val 1475 1480 1485 Ser Gly Phβ Hie λrg Hie λla Tyr Gly Phe Ser λβp λla Leu He Val 1490 1495 1500 Leu Gly Hie Aβp Ser Gly Hie Leu λrg He Ser Lyβ Pro λβn λβn λβn 1505 1510 1515 1520 λrg λβn λβn λrg Cyβ Cyβ Hie Sβr Thr λrg Tyr Tyr Sβr Cyβ Lyβ Trp 1525 1530 1535 Ser Cyβ λβp Thr Thr Cye Val Glu Met He Glu Glu Thr Ser λβp Lyβ 1540 1545 1550 Lye Pro λla Glu λβp λβp Ser Tyr He λla Cyβ Val Pro λla Met Leu 1555 1560 1565 Thr Pro Pro Ser Tyr Pro λβn He Gly Gly Lyβ λen λep Glu Ser Glu 1570 1575 1580 Tyr Val Gly λla Pro Tyr Met Lyβ Gly Leu Phe Gly Pro Ser Pro He 1585 1590 1595 1600 He Trp Leu Met λrg λrg Phe Met Pro Hie He λla Leu He Pro λrg 1605 1610 1615 Leu Ser Leu Gly Lyβ Leu Pro Lyβ Leu Met Ser Ser λβn Leu He Leu 1620 1625 1630 Thr Phe Leu Sβr Leu Ser Leu Ser Met λla Thr Phe Cye Ser λrg Val 1635 1640 1645 Ser Leu Gly He Ser He Phe Ser Ser Leu Glu Thr Ser Pro Thr Leu 1650 1655 1660 Phe Ser λla He Ser Ser Gly Leu He Ser Phe He Ser Val Phe Trp 1665 1670 1675 1680 Ser λla Leu Thr λβp Cyβ Lyβ Hie λla λβn λβp Lye Thr Pro Ser Lye 1685 1690 1695 Phe λβn Phe He Lye He λrg Phe Hie Thr Phβ Aβp Ser Phe He Leu 1700 1705 1710 He Phe Ser Thr He Leu λla Hie λrg Hie Ser He Val He Phe Val 1715 1720 1725 Leu He Phe Leu He Glu Hie Phe Val Cye Tyr Phe He λβn Val Lβu 1730 1735 1740 Lyβ He Phe Phe Lye Lyβ Leu Phe Leu Phe Ser Phe λβn λla Hie He 1745 1750 1755 1760 λβn Leu λβn Pro He λrg λβn λβn Gly Val Hie λep Met Hie Glu Val 1765 1770 1775 He Gly Met He Phe 1780 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1720 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: eingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Lyβ Ser Lyβ Sβr Lβu Trp He He Glu Lβu Lyβ Phβ Phe Gin Thr Lye 1 5 10 15 Thr λβn Thr Lyβ Lyβ Lyβ Lyβ λrg Leu λrg Lyβ λrg Gin Glu Val Lyβ 20 25 30 Ser Leu Lβu Lβu Ser Gin λrg Leu Met Gly He Sβr Lyβ Pro Lyβ He 35 40 45 Thr Leu Ser He λrg λen Phe Phe Lβu Thr Leu Met Pro Met Phe Thr 50 55 60 Lyβ Lyβ Hie Sβr Pro Lyβ Lyβ He λrg Ser Val Val He Thr Thr Pro 65 70 75 80 λrg Lyβ λrg λla Val Phe Leu Lye Lyβ Leu Pro Leu Pro Lβu Lye He 85 90 95 λrg Leu λrg Leu Cyβ Phe Lyβ Trp Val Cyβ Phe Leu Met Lyβ λsn Lyβ 100 105 110 Thr Lyβ Lyβ λrg λla λβp Leu Tyr Leu Thr Ser Lye λrg Lβu Lyβ λβn 115 120 125 He Pro He Thr Phe Leu He Cyβ λla Glu Lyβ λβn Trp He He He 130 135 140 He Thr Tyr Ser Leu Lye Glu Thr Ser Leu Thr Pro Lyβ Gin Lyβ He 145 150 155 160 Leu Leu Lyβ λrg Leu Leu Thr λrg Leu Phe Leu Thr λrg λβn λla Trp 165 170 175 λrg Leu λla Trp λrg Leu He λrg Leu Met λrg λβn Thr λrg λla Met 180 185 190 λrg Leu Phe Leu Thr Cye Lyβ Met Ser Lyβ Met Met Trp λen He Leu 195 200 205 Leu Lye Thr Leu Pro He Lye λβn Val Ser Hie Lye λβn Lyβ λβn Cye 210 215 220 Val Cyβ Trp Phe Thr λla Ser He Leu He Pro λβn Pro Lyβ Aβn Leu 225 230 235 240 Tyr Lyβ Arg Leu Met λβn Thr He Phe Ser He λla He Leu λla Thr 245 250 255 Lyβ Gin Leu Cyβ Lye Lyβ λβn Thr Thr λrg Tyr Leu He Ser Ser Lyβ 260 265 270 Gin Trp Phe Leu Hie Thr Glu Thr Met Leu Pro λrg He He Pro Leu 275 280 285 λβn λrg Lyβ Gly λβp Thr Leu Glu Lyβ Hie Leu Gin Lye Thr λrg Phe 290 295 300 Cye λrg Ser Leu Phe Phe Ser Cye Leu Trp Gly Leu Lyβ λrg Tyr Gin 305 310 315 320 Tyr Ser He He λla Glu He Gin λrg He Ser Gly Phe Gly Leu Lyβ 325 330 335 λsn Gin λβn Thr Leu Ser Lyβ Thr Gin λrg λsn Tyr Lys λrg Gly Lyβ 340 345 350 λrg He λrg Hie λrg Phe Glu λrg Lye He Thr Lyβ Gly Glu Ser λrg 355 360 365 λla λen Ser Lye Glu Tyr Ser Val Lyβ Lye Glu Gin Leu Phe Cye Ser 370 375 380 Lye Lyβ Ser Gly λla Gin λrg He Thr λrg He Lyβ λrg λen λrg Pro 385 390 395 400 Phe Glu Gin Pro Trp Gin Phe Phe Hie λβn Gin He λrg Leu λβp λep 405 410 415 Gin Gly Glu He Phe Cye Glu Thr Cye Cyβ Ser λla Cyβ λla Val Glu 420 425 430 λsn λla λsn λen Hie Tyr Gin Val Tyr Tyr Phβ Lyβ Gin λrg Leu Trp 435 440 445 Val Lyβ Lyβ Val Phe λsp Gin λrg His Gin Gly Ser Lyβ λβn Ser Cye 450 455 460 Pro Leu He λrg Lyβ λβn Ser λrg λβn λrg λβp λrg Lye Gin Val Phe 465 470 475 480 Thr Thr Pro Lyβ Trp Phe Lyβ Thr Hie Ser Gin Gin Gin λen Leu Ser 485 490 495 Tyr Ser Phe Val λrg Tyr Lβu Glu Glu Lyβ Lyβ λrg λen Gly λla λrg 500 505 510 Lye Leu Pro Gly Tyr Tyr Lye Cye Lye λrg Val Trp Hie Tyr Tyr Lye 515 520 525 λrg Lye Ser Lyβ λrg Tyr Ser He Leu Lye Gin Ser Leu He λrg Thr 530 535 540 λla Gin λrg Hie Ser λβn λrg Thr Lye Hie λrg Ser Trp Lye Lyβ He 545 550 555 560 λla He Gin He He λrg Ser Lyβ λβn Asn λrg Ser Lyβ Ser Gin Arg 565 570 575 Leu Glu He He λla Tyr λrg Leu λrg Lyβ He He Gin Ser Tyr Leu 580 585 590 He λla Phe Leu Val Gly He Val λla Tyr Phe Val Leu Gly He Phe 595 600 605 Leu Met λrg Pro Thr Pro Leu λβn λβn Leu Lye λrg Pro Cyβ Phe Glu 610 615 620 Leu Thr λla Phe Phe Leu λβn Phe Tyr Ser Leu Gly Phβ Leu Gin λla 625 630 635 640 Ser Val Lyβ Gin Leu Lyβ Lyβ Leu Tyr Leu Gin Cyβ Cye Sβr λβp Thr 645 650 655 Pro Leu Gly Lyβ Phe Leu λβn λla Leu Leu Tyr Phe Val Phe Leu λla 660 665 670 λrg Phe Ser λla Ser Leu Hie λβn Lye Glu Leu Lyβ Leu Tyr λrg He 675 680 685 Phe λrg He λla λla Gin Gin Tyr Phe Gly Leu λrg λsp Phe Ser Tyr 690 695 700 λrg Leu He Lyβ Val Gin Gly Thr Tyr Lyβ Sβr Lyβ Ser Hie Leu Leu 705 710 715 720 λrg Lyβ He Thr Hie Ser Leu Gin λβn Trp Leu Ser He Thr Leu λβn 725 730 735 Leu Leu Ser Lyβ Gin Trp Pro Leu Phe Cyβ Leu Glu Hie Leu Leu λβp 740 745 750 Leu Phe Hie Tyr λrg Gly Trp Leu Lye Lyβ Ser Hie Leu Ser Phe λla 755 760 765 Leu Val Gly Trp Ser Leu Gly λrg Cyβ Tyr Gin Val λla Leu λβn λrg 770 775 780 Leu Leu Tyr Leu Leu Pro Ser Lye Gin Thr He λla Lyβ Lyβ Lye He 785 790 795 800 Trp Tyr Phe Ser λrg Val Phe Ser Phe Aβp λβn λen Phe λrg λla Ser 805 810 815 λβn Val Ser Cyβ Cyβ λrg Phe Ser Phe Phβ Gin Leu Phe Phe Pro Lyβ 820 825 830 Val Gly Phe Phe Phe Lye He Leu Tyr He Val Met He Phe Cye Val 835 840 845 Aβp λrg λβn Phe Tyr Glu λrg He Gin He Tyr Ser Phe Gly Phe λβp 850 855 860 Phe Ser He λβp Pro He Gin He Ser λsp He Leu Lyβ He Cye He 865 870 875 880 Thr Gin Phe He Leu λβn Lyβ Gly Tyr Asn Hie Ser Val He Leu Aen 885 890 895 λβn Leu Phe Hie Lyβ λla Cye λβn Phe Pro He Lye He Arg Ala Phe 900 905 910 Cye Gly λrg Ser Glu Cyβ Phe Asn λsp Ser Lyβ Trp Ser Pro Met Leu 915 920 925 Glu Lys Lye Leu λrg λla Gly λla Met λla Leu λβn Lyβ λla Pro Val 930 935 940 λrg Glu Leu Ser He Arg Val λla Phe Cyβ He λla Val Phe λen Hie 945 950 955 960 Val Ser Lyβ Pro Phe Lye Val Ser Ser Aβn λla Leu He Pro He Val 965 970 975 Leu λla Met Tyr λla Leu Ser Glu Glu Leu Pro λrg λla Glu He Ser 980 985 990 He Cyβ Val Phe λrg Val Thr Leu Gly Ser Lyβ Leu Phe Phe λen λla 995 1000 1005 Ser Lyβ λrg λla Phβ Cyβ Trp Phe He Lβu Ser Leu He He Ser Leu 1010 1015 1020 Phe Phe Trp Ser λla He Cyβ Met Phe Trp He Ser Val Trp Val Leu 1025 1030 1035 1040 Ile Phe Cyβ Phβ Ser Thr He He Leu Thr Phe Pro Pro λβn λla Lβu 1045 1050 1055 Ser λla λla He Pro Phe Hie λβp λla Lye Gin λsp Val Thr Cys Lyβ 1060 1065 1070 Lyβ Pro Pro Cyβ Hie λla He λβp Thr He λen λβn λla He Ser Pro 1075 1080 1085 Phe Hie Ser λla Hie Gly Cye Lye Leu Ser Pro Gin Phβ Ser Leu Tyr 1090 1095 1100 Leu λrg Leu λen Gly Phe Phe Phe Gly Thr λrg Leu Ser Phe Tyr Gly 1105 1110 1115 1120 Phe Phe Gly Leu Ser Gly Phe Leu Phe Gly Leu Cyβ Val Cye Leu λβn 1125 1130 1135 Gly Phe Gly λrg Phe Lye λrg Tyr Tyr Tyr Leu Cyβ Thr He Gin λrg 1140 1145 1150 Gin Thr Thr Lyβ Ser Gin Glu λrg Lyβ Tyr λla Lye Thr Phe Hie He 1155 1160 1165 Ser Phe Leu Thr Ser λrg Leu Phe Phe λla Pro Phe Leu Leu Ser Ser 1170 1175 1180 Tyr Leu Phe λla Pro λla Cyβ Leu Cyβ λsn Gin Gly Lys Ser λβn λla 1185 1190 1195 1200 He Ser Lyβ Lyβ He Tyr Ser Leu Lβu Tyr Cye Aβn Tyr He λla λβn 1205 1210 1215 Leu Cyβ Lyβ Ser Leu Glu Cye Hie λrg Cyβ Leu He Leu He Aβp Val 1220 1225 1230 Sβr Phe Glu Lyβ λrg Ser λla Thr λen Trp Tyr Tyr Phe Ser Gin He 1235 1240 1245 Leu Tyr Ser He Leu Ser Lyβ Phe Leu Leu Leu Phe Gin Hie Ser λen 1250 1255 1260 Lyβ Gin Gin Glu Pro Cye Pro Gin Gly Met Gin Glu Trp Ser λβp λrg 1265 1270 1275 1280 Leu Lyβ Leu Gly Hie Trp Leu Thr Leu Gly He Hie Lye Gin Trp λla 1285 1290 1295 Lyβ λrg Ser Trp Gly Val He Glu He Cyβ Met Gin Leu Lye Aβn Thr 1300 1305 1310 Phe λβp Glu Pro Thr Ser λla Pro Lyβ λla Val Gin Leu Ser λrg λβn 1315 1320 1325 λrg Cyβ He He Hie λla Val λla Cyβ Leu λrg Thr Gin Lβu Leu Leu 1330 1335 1340 Ser Gly Val Phe Trp Cyβ Cyβ Thr Cys λsn He λla Tyr Thr Val He 1345 1350 1355 1360 He Ser Thr Val Val Gly Thr Leu Gly Thr λla He Phe Val λla λla 1365 1370 1375 Ser He λla Leu Gly Phe Leu Gly Val Val Leu Leu λla Lys Met Leu 1380 1385 1390 λla He Leu Leu Thr λla Pro He Cyβ λla Pro Cyβ Val Leu Pro Cyβ 1395 1400 1405 λla Leu λsn Ser Pro Val λsn Leu Leu He Phβ Lyβ He Leu Phe Pro 1410 1415 1420 Thr λla Met Leu Ser Leu Lyβ Pro λβn λβn Trp Leu Tyr Cye Trp Lβu 1425 1430 1435 1440 λla λla Phe He Gly Met Leu Thr λla Ser λla Met Leu Leu Tyr Trp 1445 1450 1455 Val Met He λla Val He Cyβ Gly Leu Val λen Pro Thr He He Gly 1460 1465 1470 He He λla λla Val He λla Pro λla Thr He Pro λla λen Gly Pro 1475 1480 1485 λla Thr Pro Lβu Val Leu λrg Leu λrg Lye Leu Pro He λrg Ser Leu 1490 1495 1500 Gin Lyβ Met He Hie He Leu Val Tyr Leu Pro Cyβ Hie Pro Leu Val 1505 1510 1515 1520 λβn Thr Leu He Ser Val Val Lyβ Thr Met λβn Leu Ser Met Leu Val 1525 1530 1535 Hie Aβn Hie Thr Lyβ λβp Cyβ Lβu λβp λrg λβn λrg Pro Ser Phe Gly 1540 1545 1550 Ser Glu λβp Phe Glu Cys Pro Thr Ser His Tyr Leu λβp Tyr Hie Val 1555 1560 1565 Glu λβn Ser Leu λβn Leu Cyβ λrg Gin He Tyr Hie Phe Tyr Hie Tyr 1570 1575 1580 Ser Hie Val Trp Pro Leu Phe λla Leu Gly Phe Leu Gly Ser Leu Phe 1585 1590 1595 1600 Leu Val λβp Leu Lyβ Gin λla Pro λrg Tyr Leu Val Pro Tyr Leu Gin 1605 1610 1615 λβp Tyr Leu Leu Tyr Gin Cye Phe Gly Gin λrg λrg Thr Val Aβn Met 1620 1625 1630 Pro Met He λrg Hie Gin λla λen Ser λβn Leu He Leu Lyβ Ser Val 1635 1640 1645 Phe He Leu Leu Thr Pro Leu Phe Lβu Phβ Lβu λla Lβu Phβ λrg He 1650 1655 1660 λen λla Thr Gin Ser Leu Phe Leu Phe Phe Phe Ser Ser He Leu Phe 1665 1670 1675 1680 Val Thr Ser Ser Met Phe Lyβ Tyr Phe Ser Lye Ser Ser Phe Phe Leu 1685 1690 1695 λla Sβr Thr Leu He Ser He He Gin Leu Gly He Met Glu Ser Met 1700 1705 1710 He Lyβ Cyβ Met Lyβ Ser λla Phe 1715 1720 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (λ) LENGTH: 5599 baβe pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: AAAAATCλTG CCTATGλCTT CATGCATTTA ATCλTGGλCT CCλTTλTTCC TλλTTGGλTT 60 CAGATTGATλ TGλGCGTTGλ AGCTAAAAAG λλλGλGCTTT TTGλλλλλTλ TTTTCAAAAC 120 ATTGATGAAG TλλCλλλCλλ λλTGCTCGλT CAAAAAAATC λAAACAAAAA TλλCGλTTGλ 180 GTGGCGTTλλ TGCGCTλGλλ TλGTGCTλλλ λλTλλGλλTλ λλGGλGTCλλ λλGTλTGλλλ 240 λCGGλTTTTT ATAAAATTAA ATTACTATTT GCTTGGTGTC TTλTCλTTGG CλTGTTTλCλ 300 GTCCGTTAAC GCTGACCAAA ACACTGATAT AAAAGATATT λGTCCTGλλG λTλTGGCλCT 360 AAATAGCGTG GGGCTTGTTT CTAGAGATCA ACTAAAAATA GλGλTCCCTλ λλGλλλCCCT 420 AGAGCAAAAA GTGGCCATAC TCλλTGλCTλ TλλTGλTλλλ λλTGTTλλTλ TCλλλTTTGλ 480 CGACATAAGT TTAGGGAGTT TTCAACCTAA TGATAATCTA GGTATCAATG CGλTGTGGGG 540 CλTTCλλλλT CTTCTCλTGλ GCCAAATGAT GGGCGATTλC GGTCCAλλCλ λTCCTTTCλT 600 GTλTGGTTλT GCλCCλλCλT λCTCλGλTTC λTCGTTTTTλ CCλCCGλTλT TλGGGTλTTλ 660 λCTλGGGGGT GTTλλCλTGG CλGGTλCλCλ λGCTλTλTλT GλλTCλTCTT CTGCλGGCTT 720 CTTλTCGGλλ GTTTCCTCλλ TCATCTCλλC ACAAGTGGTG TCGCλGGλCC λTTTGCλGGλ 780 λTλGTλGCGG GTGCTλTGλC λGCλGCGλTT λTTCCTλTTλ TTGTTGGGTT TACTλλTCCG 840 CAAATGACCG CTATCATGλC CCAATACAAT CλλλGC TCG CTGAλGCCGT AAGCATGCCT 900 ATGAAAGCCG CTAACCAACA ATACAACCAA TTGTTTCAAG GTTTTAλCGλ TCAAλGCATG 960 GCTGTGGGGA ACAATATCTT AAATATTAGC AAATTAACAG GGGAATTTAA CGCACAAGGC 1020 AACACGCAAG GCGCGCλλλT TGGTGCTGTT AATAGTCAGA TTGCAAGCAT TTTAGCGAGT 1080 AλCλCCACCC CTAAAAATCC CAGTGCTATT GAAGCTTATG CGACAAATCA AATCGCTGTT 1140 CCTAGCGTGC CAACλλCGGT TGAAλTGλTG ACGGTλTλTT AGGCAλTATT ACAAGTGCAG 1200 CACCAλAATλ CGCCCTAGCT CTACAAGAGC AλCTGCGTTC TCAAGCAAGC AλCAGCTCλλ 1260 TGλATGATλC λCCGλTTCCT TGλTλGCTGT λCCGCTTTλG GTGCGCTTGT TGGCTCλTCλ 1320 AAAGTGTTTT TCλGTTGCAT GCλλATTTCT λTGλCGCCCC λTGAGCGTTT CTλTGCCCλC 1380 TGTTTλTGCT AAATACCAAG CGTTAGCCλC TAATGCCCTA ACTTCλGGCG TTAλTCCTλT 1440 GACCλCTCCT GCλTGCCCTλ TTGGGGλCλλ GGTTCTTGCT GTTTλTTGCT λTGCTGλλλλ 1500 AGTAGCAGAA ATTTTGAGAG AATACTATAT AGAATTTGTG AAAAATAλTλ CCAATTTGTT 1560 GCAGAACGCT TCTCAAATGA TACTTAATCA ATCAGGATTA GCTACTAGCA CCTATGACAC 1620 TCAAGCGATT TCTAACATAA GTTCGCTATλ TAATTACAAT ATAGTAGCGA λTAAATCTTT 1680 TTTGAAλTCG CATTTGACTT ACCTTGATTA CλTCAAλGλC AAGCTTAAGG GGCAAAAAGA 1740 TAGCTACTTA ACAGAAAGGG TGCAAACTAA AATAATCGTG AAGTGAGGAA AGAGATGTGA 1800 λλTGTTTTTT AAGCATATTT TCTTTCTTGA CTTTTTGTGG TTTGTCTCTG λATGGTACAG 1860 AGGTAGTAAT λλCGCTTGλλ CCTGCCTTλλ λλGCCλTTCλ GGCλGλCGCλ CλλGCCλλλC 1920 λλλλλλCCGC TCλλGCCGλλ TTλλλλGCCλ TλGλλGCTCλ λTCTλGTGCC λλλGλλλλλG 1980 CCATTCAAGC GCAAATAGAG GGAGAATTGA GGACTCAGCT TGCAACCATG λGCGCTATGT 2040 TAλAAGGGGC TAλTGGCGTT ATTAATGGTG TCλλTGGCλT GACλGGGGGG TTTTTTGCAG 2100 GTTCAGACAT CTTGCTTGGC GTCATGGAAG GGTATTCAAG CGGCGCTTAG TGCλTTGGGG 2160 GGGAATGTCA AAATGATCGT GGAAAAACAA AAAATTAATA CCCAAACAGA AATCCAAAAC 2220 ATGCAAATCG CGCTCCAAAA AAATAACGAA ATGATCAAGC TCAAAATGAA CCAGCAAAAC 2280 GCTCTCTTAG AAGCGTTAAA AAACAGCTTT GAACCGAGGG TTACCCTAAA λACACAAATG 2340 GAAATTTCTC AAGCTCTAGG AAGTTCTTCT GACAACGCTC AλTλCλTCGC TTACAATACG 2400 ATTGGTATCA AGGCGTTTGλ AGAAACCTTA AAAGGTTTTG AGλCλTGGTT GλλλλCλGCT 2460 ATGCAAAAAG CGACCCTTAT TGATTATAAT TCCCTAACAG GTCAGGCTTT GTTTCAAAGT 2520 GCCλTCTATG CGCCTGCTCT TAGTTTTTTT TCAAGCATGG GCGACCATTT GGAATCATTG 2580 AAACATTCAC TCTAGCGCCC ACAAAATGCC CTTATCTTGλ TGGGCTAAAA λTTTCAGCAT 2640 GCCTTATGGλ λCACGTTATT CAGAATTACA GAATGATTGT AGCCCTTATT CAAAATAAAC 2700 TGAGTGλTGC AGATTTTCAA AATATCGCTT λTTTGAATGG GATCAATGGA GAAATCAAAA 2760 CCTTAAAAGG λTCAGTAGAT TTGAATGCGC TCATAGAAGT TGCCATCTTA λACGCAGAAA 2820 ATCATTTAAA CTATATAGAG AATCTTGAAA AAAAAGCCGA CCTTTGGGλλ GAλCλλCTGλ 2880 AATTAGAAAG AGAAACGACA GCAAGAAACA TTGCTAGCTC TAAAGTTATT GTCAAATGλλ 2940 AACACTCGTG AAAAATACCA TλTCTTCTTT TTTGCTATTG TCTGTTTTGA TGGCAGAAGA 3000 TATAACλAGC GGTTTAAAGC AACTTGATAG CACCTACCλλ GAGλCCAACC AACAAGTGCT 3060 TAAAAACTTA GATGAGλTTT TTTCAλCCλC TAGCCCTAGC CCTAATAATG AAATAGGTCA 3120 AGAAGATGCT CTAAACATCA AAAAAGCGGC CATTGCTTTG ACAGGAGATT TAGCGTTATT 3180 GAAAGCCAAT TTTGAAGCGA ATGAGTTATT TTTCλTCTCλ GAAGATGTGA TTTTCλλGλC 3240 TTATATGTCT λGCCCTGAAC TTTTATTAAC CTATATGAAA ATCAATCCCT TAGACCAAAA 3300 TACTGCTGλG CAGCλλTGCG GAATATCCGA TAAAGTTTTA GTTCTTTATT GTGλλGGGλλ 3360 GCTGAAAATC GAGCAAGAAA AACAAAATAT AAGAGAGCGT TTAGAAACTT CCCTAAAGGC 3420 GTATCAGAGC AACATTGGAG GTACAGCTTC TTTAATCACT GCTTCACAGA CGCTTGTAGλ 3480 AAGCCTAAAG AATAAAAATT TCATCAAAGG AATCAGAAAG CTTATGTTAG CTCAλλλCλλ 3540 GGTCTTTTTA AATTATTTAG AGGAGTTGGA CGCATTAGAA AGATCCCTAG λACAAAGTAA 3600 GCGACAATAC CTACAAGAAA GGCAATCAAG TAAGATCATT GTTAAATGAT TTTTCTGAGA 3660 CGATAGGCTλ TGλTTTCTAA CCTTTGGGλT TTGCTTCTCT AGTTGTTTTT TGλTCTλλTλ 3720 ATTTGGλTCG CTλTTTTTTT CCATGλGCGλ TGCTTTGTTC TATTTGλTTλ λTGλCGCTλT 3780 TGGGCλGTTC GGλTTTλGλG CGλTTGTTTG λGλλTGCTGT λTCTTTTGCT TCλTTTTCTT 3840 TTGTATCAGT AGTGCCAAAC TCGCTTGCAT TTGTAGTATC CTGGTAGTTA TTTTCTTGCT 3900 CCATTTCTTT TTTTCTCTTC TCACAAATAG CGCACGAAGC TATAAGAAAG GTTCTATTGT 3960 TGCTGTTATT AAGAGTGAGT TTTAAACCλC TTAGGTGTTG TCTAGAAAAC TTGTTATTTT 4020 CTGTCTCTAT TTCTTGAATT TTTTCTAλTλ AGGGGGCAAG AλTTTTTTGλ TCCTTGλTGT 4080 CTTTGλTCAA ACλCTTTCTT AλCCCλTCAT AATCGTTGCT TGAAATAATA CACTCATTGA 4140 TAATGATTTC AATTTCAGGC GTTCTCCλCT CATCAGGCAC AAGCGGAGCA GCAGGTTTCA 4200 CAAAAGλTTC ATTCACCTTA TTGATCATCT CATCAAAGTT ATCATCTTTA TTAGλTTTGG 4260 TTTCAGTGGA AGAATTGCCA TTAGGGTTGT CATTCAAAGG GTTAGCGTTA ATTTCGTTTA 4320 ATTCTTGTAA TCCTTTGTGC TTAGCCGCTT TTTTTTGλλC λGAλGλGTTG TTCTTTTTTT 4380 CAAACGCTTC AλTλTTCTTT TGλλTTTGCT CTGCTCTCGC CCTλTCλTTT CGTλλTTTTT 4440 CTCTCAAAGC GTTAGTGGCG AATTCTTTTT CCTCTTTTGT AλTTTCTTTG TCλTCλTGTC 4500 TTTGATAGλG TGTTTTGλTT TTTTTAAAGC CCAAAGCCλC TAATTCTTTG TATTCλCTCG 4560 GCAATAATGC TGTATTGATA GCGTTTAAGC CCCCATAAAC AACTAAAGAA TAλAGAGCGλ 4620 CAGAACCTλG TTTTTTGAAG ATGCTTTTCA AGAGTGTCTC CTTTCCTATT CλλAGGGλTT 4680 ATTCTTGGCλ ACλTTGTTTC GGTATGCAGA AACCACTGTT TTGAAGAAAT TAAATATCTT 4740 GTλGTGTTCT TTTTGCλTλG TTGTTTTGTC GCTCATCATA GGATCGCTAT CTACGAAAAT 4800 ATTGTATTCA TTAGTCTTTT TTAATATAGA TTTTTTGGAT TGGGTATCAλ AATTGAAGCT 4860 GTCTAAAACC AACAAACACA ATTTTTGTTT TTCTGCGλλλ CTCλλTTTTT GATTGGTAAA 4920 GTTTTTAGTC AGλGTλTTCλ λTTCCλCλTC λTCTTTGACA TTTTTCAACA AGTTAGAAAA 4980 AGCCTCATAG CCCTTTλAGT ATTTCTCATT AλTCTTλTCλ λTCGCCλTGC TAAACGCCAA 5040 GCGTTCCGAG TTAAAAATAA GCGTGTTAGT AGCCTTTTGλ GCAATATCTT TTGCTTTGGA 5100 GTCAAACTTG TTTCTTTCλλ GCTGTλAGTA ATλλTCTλTλ TTλTCCAATT CTTTTCTGCT 5160 CAACλGATTA GAAATGTTAT TGGAATATTC TTCλλTCGCT TGCTTGTλλG ATAAAGCTAA 5220 TCGGCTCGCT TTTTTGTTTT GTTCTTCATC TλλλGλλ λC λCλCCCλTTT GAAGCAAAGC 5280 CTGAGCCTTA TCTTTAGTGG TAGCGGTλGT TTTTTTλAAA λTλCTGCTCG TTTTCλCCTG 5340 GGGGTλGTAλ TλλCTCAAAC GCTCCTTλTC TTCTTTGGTG λATGTTTCTT GGTTTAλλλC 5400 λTAGGCATAλ GGGTTAGGλλ GAAGTTTCTT ATAGAGλGGG TTATCTTTTλ AGGCTTGCTC 5460 TAGATCCCCA TAAGCCTTTG ACTTλGCAGT AAGGλTTTTλ CCTCTTGTCT CTTTCTCTAG 5520 AGCCTCTTTT TCTTTTTTGT λTTTGTTTTC TλλGTCTGλλ λGλλCTTTλG CTCTλTGλTC 5580 CATAAGCTCT TTGATTTTT 5599 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1732 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Lyβ λβn Hie λla Tyr λβp Phe Met Hie Leu He Met λβp Sβr He He 1 5 10 15 Pro λβn Trp He Gin He λsp Met Ser Val Glu λla Lye Lyβ Lye Glu 20 25 30 Leu Phe Glu Lye Tyr Phe Gin Asn He λβp Glu Val Thr λβn Lyβ Met 35 40 45 Leu Aβp Gin Lye Aβn Gin Aβn Lye λβn λβn λβp Val λla Leu Met λrg 50 55 60 λβn Ser λla Lyβ λen Lyβ λβn Lyβ Gly Val Lyβ Ser Met Lyβ Thr λβp 65 70 75 80 Phe Tyr Lyβ He Lyβ Leu Leu Phe λla Trp Cyβ Lβu He He Gly Met 85 90 95 Phe Thr Val λrg λrg Pro Lyβ Hie Tyr Lye λrg Tyr Ser λrg Tyr Gly 100 105 110 Thr Lyβ λrg Gly λla Cyβ Phe λrg Ser Thr Lyβ λβn λrg λβp Pro λrg 115 120 125 λβn Pro λrg λla Lyβ Ser Gly Hie Thr Gin Leu Lye Cye Tyr Gin He 130 135 140 λrg Hie Lye Phβ λrg Glu Phe Ser Thr Ser λrg Tyr Gin Cyβ Aβp Val 145 150 155 160 Gly Hie Ser Lye Ser Ser Hie Glu Pro λsn λβp Gly λrg Lβu λrg Ser 165 170 175 Lyβ Gin Ser Phe Hie Val Trp Leu Cyβ Thr λβn He Leu λrg Phe He 180 185 190 Val Phe Thr Thr λβp He λrg Val Leu Thr λrg Gly Cyβ Hie Gly λrg 195 200 205 Tyr Thr Ser Tyr He He He Phe Cyβ λrg Leu Lβu He Gly Ser Phe 210 215 220 Leu λsn His Leu λβn Thr Ser Gly Val λla Gly Pro Phe λla Gly He 225 230 235 240 Val λla Gly λla Met Thr λla λla He He Pro He He Val Gly Phe 245 250 255 Thr λβn Pro Gin Met Thr λla He Met Thr Gin Tyr Aβn Gin Ser He 260 265 270 λla Glu λla Val Ser Met Pro Met Lyβ λla λla λβn Gin Gin Tyr λβn 275 280 285 Gin Leu Phe Gin Gly Phe λβn Aβp Gin Ser Met λla Val Gly λβn λβn 290 295 300 He Leu λβn He Ser Lye Leu Thr Gly Glu Phe Aβn λla Gin Gly λβn 305 310 315 320 Thr Gin Gly λla Gin He Gly λla Val Aβn Ser Gin He λla Ser He 325 330 335 Leu λla Ser λen Thr Thr Pro Lyβ λβn Pro Ser λla He Glu λla Tyr 340 345 350 λla Thr λβn Gin He λla Val Pro Ser Val Pro Thr Thr Val Glu Met 355 360 365 Met Thr Val Tyr λla He Leu Gin Val Gin Hie Gin Aβn Thr Pro Leu 370 375 380 Tyr Lyβ Ser λβn Cyβ Val Lβu Lye Gin λla Thr λla Gin Met He Hie 385 390 395 400 λrg Phe Leu λsp Ser Cys Thr λla Leu Gly λla Leu Val Gly Ser Ser 405 410 415 Lyβ Val Phe Phe Ser Cyβ Met Gin He Ser Met Thr Pro Hie Glu λrg 420 425 430 Phe Tyr λla Hie Cyβ Leu Cyβ He Pro Ser Val Ser Hie Cyβ Pro λβn 435 440 445 Phe λrg λrg Ser Tyr λβp Hie Ser Cyβ Met Pro Tyr Trp Gly Gin Gly 450 455 460 Ser Cyβ Cyβ Lβu Leu Leu Cyβ Lyβ Ser Ser λrg λβn Phβ Glu λrg He 465 470 475 480 Leu Tyr λrg He Cyβ Glu Lye Tyr Gin Phβ Val λla Glu λrg Phe Ser 485 490 495 λβn λβp Thr Ser He λrg He Ser Tyr Hie Leu Hie Sβr Ser λβp Phe 500 505 510 Hie Lye Phe λla He Leu Gin Tyr Ser Ser Glu He Phe Phe Glu He 515 520 525 λla Phe λsp Leu Pro Leu Hie Gin λrg Gin λla Gly λla Lyβ λrg Leu 530 535 540 Leu λsn λrg Lyβ Gly λla Aβn λβn λβn λrg Glu Val λrg Lyβ Glu Met 545 550 555 560 λβn Val Phe λla Tyr Phe Leu Ser Leu Phe Val Val Cyβ Lβu Met Val 565 570 575 Gin λrg λrg Leu Aβn Leu Pro Lye Pro Phe λrg Gin Thr Hie Lye Pro 580 585 590 λβn Lyβ Lyβ Pro Leu Lyβ Pro λβn Lyβ Pro Lyβ Leu λβn Leu Val Pro 595 600 605 Lys Lyβ Lye Pro Phe Lyβ λrg Lyβ λrg Glu λβn Gly Leu Ser Leu Gin 610 615 620 Pro λla Leu Cyβ Lyβ Gly Leu Met λla Leu Leu Met Val Ser Met λla 625 630 635 640 Gin Gly Gly Phe Leu Gin Val Gin Thr Ser Cyβ Leu λla Ser Trp Lye 645 650 655 Gly He Gin λla λla Leu Ser λla Leu Gly Gly λβn Val Lyβ Met He 660 665 670 Val Glu Lyβ Gin Lye He λβn Thr Gin Thr Glu He Gin λβn Met Gin 675 680 685 He λla Leu Gin Lyβ λβn λβn Glu Met He Lye Leu Lyβ Met λen Gin 690 695 700 Gin λen λla Leu Leu Glu λla Leu Lyβ λβn Ser Phe Glu Pro λrg Val 705 710 715 720 Thr Leu Lyβ Thr Gin Met Glu He Ser Gin λla Leu Gly Ser Ser Ser 725 730 735 λβp λβn λla Gin Tyr He λla Tyr λβn Thr He Gly He Lye λla Phe 740 745 750 Glu Glu Thr Leu Lye Gly Phe Glu Thr Trp Leu Lye Thr λla Met Gin 755 760 765 Lyβ λla Thr Leu He Aβp Tyr λβn Ser Leu Thr Gly Gin λla Leu Phe 770 775 780 Gin Ser λla He Tyr λla Pro λla Leu Ser Phe Phe Ser Ser Met Gly 785 790 795 800 λsp His Leu Glu Ser Leu Lye Hie Ser Leu λrg Pro Gin λen λla Leu 805 810 815 He Leu Met Gly Lyβ Phe Gin Hie λla Leu Trp λβn λrg Leu Phe λrg 820 825 830 He Thr Glu Leu Pro Leu Phe Lyβ He λβn Val Met Gin He Phe Lye 835 840 845 He Ser Lβu He Met Gly Sβr Met Glu Lye Ser Lye Pro Lyβ λep Gin 850 855 860 He Met λrg Ser Lye Leu λrg Ser Thr Gin Lye He He Thr He λrg 865 870 875 880 He Leu Lye Lye Lyβ Pro Thr Phe Gly Lye Aβn λβn λβn Lyβ Glu Lyβ 885 890 895 λrg Gin Gin Glu Thr Leu Leu λla Leu Lyβ Leu Leu Ser λβn Glu λβn 900 905 910 Thr λrg Glu Lyβ Tyr Hie He Phe Phe Phe λla He Val Cye Phe λβp 915 920 925 Gly λrg λrg Tyr λβn Lyβ λrg Phβ Lye λla Thr Hie Leu Pro λrg λβp 930 935 940 Gin Pro Thr Ser λla Lyβ Leu λrg λβp Phe Phe λsn His Pro λrg λsn 945 950 955 960 λrg Ser λrg λrg Cye Ser Lye His Gin Lye Ser Gly Hie Cye Phe Glu 965 970 975 λrg λrg Phe Ser Val He Glu Ser Gin Phe Ser Glu Val He Phe Hie 980 985 990 Leu λrg λrg Cyβ λβp Phe Gin λβp Leu Tyr Val Pro Thr Phe He λβn 995 1000 1005 Leu Tyr Glu λβn Gin Ser Leu λrg Pro Lyβ Tyr Cyβ λla λla Met λrg 1010 1015 1020 λβn He Arg Ser Phe Ser Ser Leu Leu Arg Glu Ala Glu Aβn Arg Ala 1025 1030 1035 1040 Arg Lyβ Thr Lye Tyr Lye λrg λla Phβ λrg λβn Phβ Pro Lyβ Gly Val 1045 1050 1055 Ser Glu Gin Hie Trp λrg Tyr Ser Phe Phe λβn Hie Cye Phe Thr λβp 1060 1065 1070 λla Cyβ λrg Lyβ Pro Lyβ Glu Lye Phe Hie Gin λrg λβn Gin Lyβ λla 1075 1080 1085 Tyr Val Ser Ser Lye Gin Gly Leu Phe Lye Leu Phe λrg Gly Val Gly 1090 1095 1100 λrg He λrg Lyβ He Pro λrg Thr Lye λla Thr He Pro Thr λrg Lye 1105 1110 1115 1120 λla He Lyβ Aβp Hie Cye Met He Phe Leu λrg λrg λla Met He Ser 1125 1130 1135 λβn Leu Trp λβp Leu Leu Leu Leu Phe Phe λβp Leu He He Trp He 1140 1145 1150 λla He Phe Phe Hie Glu λrg Cye Phe Val Leu Phe Aβp λrg Tyr Trp 1155 1160 1165 λla Val λrg He Ser λβp Cyβ Leu λrg Met Leu Tyr Leu Leu Leu Hie 1170 1175 1180 Phe Leu Leu Tyr Gin Cyβ Gin Thr λrg Lβu Hie Leu Tyr Pro Gly Ser 1185 1190 1195 1200 Tyr Phe Leu λla Pro Phe Leu Phe Phβ Ser Ser Hie Lye λrg T r Lye 1205 1210 1215 Lβu Glu λrg Phe Tyr Cyβ Cyβ Cyβ Tyr Glu Val Leu λen Hie Lβu Gly 1220 1225 1230 Val Val Lyβ Thr Cye Tyr Phe Leu Ser Leu Phe Leu Glu Phe Phe Leu 1235 1240 1245 He λrg Gly Gin Glu Phe Phe λβp Pro Cyβ Leu Ser λen Thr Phe Leu 1250 1255 1260 Thr Hie Hie λβn λrg Cyβ Leu Lyβ Tyr Thr Hie Phβ Gin Phe Gin λla 1265 1270 1275 1280 Phe Ser Thr Hie Gin λla Gin λla Glu Gin Gin Val Sβr Gin Lyβ He 1285 1290 1295 Hie Ser Pro Tyr Ser Ser Hie Gin Ser Tyr Hie Lβu Tyr He Trp Phe 1300 1305 1310 Gin Trp Lyβ λsn Cys Hie Gly Cyβ Hie Ser Lye Gly λrg Phe λrg Leu 1315 1320 1325 He Leu Val He Leu Cyβ λla Pro Leu Phe Phe Glu Gin Lyβ Ser Cyβ 1330 1335 1340 Ser Phe Phe Gin Thr Leu Gin Tyr Ser Phe Glu Phe λla Leu Leu Ser 1345 1350 1355 1360 Pro Tyr Hie Phe Val He Phe Leu Ser Lyβ λrg Trp λrg He Leu Phe 1365 1370 1375 Pro Leu Leu Phe Leu Cyβ Hie Hie Val Phβ λβp λrg Val Phe Phe Phe 1380 1385 1390 Ser Pro Lyβ Pro Leu He Leu Cye He Hie Ser λla He Met Leu Tyr 1395 1400 1405 λrg Leu Ser Pro Hie Lye Gin Leu Lye λβn Lyβ Glu λrg Gin λβn Leu 1410 1415 1420 Val Phe λrg Cyβ Phe Ser λrg Val Ser Pro Phe Leu Phe Lyβ Gly He 1425 1430 1435 1440 He Leu Gly λβn He Val Ser Val Cyβ λrg Aβn Hie Cye Phe Glu Glu 1445 1450 1455 He Lyβ Tyr Leu Val Val Phe Phe Leu Hie Ser Cyβ Phe Val λla Hie 1460 1465 1470 Hie λrg He λla He Tyr Glu λβn He Val Phe He Ser Leu Phe Tyr 1475 1480 1485 λrg Phe Phe Gly Leu Gly He Lyβ He Glu λla Val λβn Gin Gin Thr 1490 1495 1500 Gin Phe Leu Phe Leu Cyβ Glu Thr Gin Phe Leu He Gly Lyβ Val Phe 1505 1510 1515 1520 Ser Gin Ser He Gin Phβ Hie He He Phe λβp He Phe Gin Gin Val 1525 1530 1535 λrg Lyβ Ser Leu He λla Leu Val Phe Leu He λen Lβu He λβn λrg 1540 1545 1550 Hie λla Lyβ λrg Gin λla Phe λrg Val Lyβ λβn Lyβ λrg Val Ser Ser 1555 1560 1565 Leu Leu Ser Aβn He Phe Cye Phe Gly Val Lye Leu Val Ser Phe Lye 1570 1575 1580 Leu Val He He Tyr He He Gin Phe Phe Ser λla Gin Gin He λrg 1585 1590 1595 1600 λβn Val He Gly He Phe Phe λen λrg Leu Leu Val λrg Ser Ser λla 1605 1610 1615 λrg Phe Phe Val Leu Phe Phe He λrg Lyβ Hie Thr Hie Leu Lyβ Gin 1620 1625 1630 Ser Leu Ser Leu He Phβ Ser Gly Ser Gly Ser Phβ Phe Lyβ λen Thr 1635 1640 1645 λla λrg Phe Hie Leu Gly Val Val He Thr Gin Thr Leu Leu He Phe 1650 1655 1660 Phe Gly Glu Cyβ Phe Leu Val λen He Gly He λrg Val λrg Lyβ Lye 1665 1670 1675 1680 Phe Leu He Glu λrg Val He Phe Gly Leu Leu He Pro He Ser Leu 1685 1690 1695 Leu Ser Ser Lyβ λβp Phe Thr Ser Cyβ Leu Phe Leu Ser Leu Phe Phe 1700 1705 1710 Phe Phe Val Phe Val Phe Val Lyβ λβn Phe Ser Ser Met He Hie Lye 1715 1720 1725 Leu Phe λep Phe 1730 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1724 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Lyβ Ser Cyβ Leu Leu Hie Ala Phe λβn Hie Gly Leu Hie Tyr Ser Leu 1 5 10 15 λβp Ser λβp Tyr Glu λrg Ser Lyβ Glu λrg λla Phβ Lye He Phe Ser 20 25 30 Lyβ Hie Ser λβn Lyβ Gin λβn λla λrg Sβr Lyβ Lyβ Sβr Lyβ Gin Lye 35 40 45 λrg Leu Ser Gly Val λβn λla Leu Glu Cyβ Lyβ Glu λrg Sβr Gin Lye 50 55 60 Tyr Glu λβn Gly Phe Leu λβn He Thr He Cyβ Leu Val Ser Tyr Hie 65 70 75 80 Trp Hie Val Tyr Ser Pro Leu Thr Lβu Thr Lyβ Thr Leu He Lyβ He 85 90 95 Leu Val Leu Lye He Trp Hie He λla Trp Gly Leu Phe Leu Glu He 100 105 110 λβn Lyβ λrg Ser Leu Lyβ Lyβ Pro Sβr Lyβ Lye Trp Pro Tyr Ser Met 115 120 125 Thr He Met He Lye Met Leu He Ser λβn Leu Thr Thr Val Gly Val 130 135 140 Phe λβn Leu Met He He Val Ser Met λrg Cyβ Gly λla Phe Lye He 145 150 155 160 Phe Ser λla Lyβ Trp λla He Thr Val Gin Thr He Leu Ser Cye Met 165 170 175 Val Met Hie Gin Hie Thr Gin He Hie λrg Phβ Tyr Hie λrg Tyr Gly 180 185 190 He Aβn Gly Val Leu Thr Trp Gin Val Hie Lye Leu Tyr Met λβn Hie 195 200 205 Leu Leu Gin λla Ser Tyr λrg Lye Phe Pro Gin Ser Ser Gin Hie Lye 210 215 220 Trp Cye λrg λrg Thr He Cyβ λrg λβn Ser Ser Gly Cye Tyr λβp Ser 225 230 235 240 Ser Aβp Tyr Ser Tyr Tyr Cye Trp Val Tyr Ser λla Aβn λep λrg Tyr 245 250 255 His λsp Pro He Gin Ser Lyβ Hie λrg Ser λrg Lyβ Hie λla Tyr Glu 260 265 270 Ser λrg Pro Thr He Gin Pro He Val Ser λrg Phβ λrg Ser Lyβ Hie 275 280 285 Gly Cye Gly Glu Gin Tyr Leu Lyβ Tyr Gin He λβn λrg Gly He λrg 290 295 300 Thr λrg Gin Hie λla λrg λrg λla λβn Trp Cyβ Cyβ Ser λβp Cye Lye 305 310 315 320 Hie Phe Ser Glu Hie Hie Pro Lye Sβr Gin Cyβ Tyr Ser Leu Cyβ λβp 325 330 335 Lyβ Ser λβn λrg Cyβ Ser λrg λla λβn λβn Gly λβn λβp λβp Gly He 340 345 350 Leu Gly λβn He Thr Ser λla λla Pro Lyβ Tyr λla Leu λla Leu Gin 355 360 365 Glu Gin Leu λrg Ser Gin λla Ser λen Ser Ser Met λβn λβp Thr Pro 370 375 380 He Pro Leu Tyr λrg Phe λrg Cyβ λla Cyβ Trp Leu He Lyβ Ser Val 385 390 395 400 Phe Gin Leu Hie λla λen Phβ Tyr λβp λla Pro λla Phe Leu Cye Pro 405 410 415 Lβu Phe Met Leu λβn Thr Lyβ λrg Pro Leu Met Pro Leu Gin λla Leu 420 425 430 He Leu Pro Leu Leu Hie λla Leu Leu Gly Thr λrg Phe Leu Leu Phe 435 440 445 He λla Met Leu Lyβ Lyβ Gin Lyβ Phe Glu Asn Thr He Aβn Leu Lyβ 450 455 460 He He Pro He Cyβ Cyβ λrg Thr Leu Leu Lye Tyr Leu He λβn Gin 465 470 475 480 λβp Leu Leu λla Pro Met Thr Leu Lyβ λrg Phβ Leu Thr Val λrg Tyr 485 490 495 He He Thr He λrg He λβn Leu Phe λβn λrg He Leu Thr Leu He 500 505 510 Thr Ser Lyβ Thr Ser Leu λrg Gly Lyβ Lyβ He λla Thr Gin Lyβ Gly 515 520 525 Cyβ Lyβ Leu Lye Ser Ser Glu Glu λrg λβp Val Lye Cye Phe Leu Ser 530 535 540 He Phe Ser Phe Leu Thr Phe Cye Gly Leu Ser Leu λβn Gly Thr Glu 545 550 555 560 Val Val He Thr Leu Glu Pro λla Leu Lyβ λla He Gin λla λβp λla 565 570 575 Gin λla Lye Gin Lye Thr λla Gin λla Glu Leu Lye λla He Glu λla 580 585 590 Gin Ser Ser λla Lye Glu Lye λla He Gin λla Gin He Glu Gly Glu 595 600 605 Lβu λrg Thr Gin Leu λla Thr Met Ser λla Met Leu Lyβ Gly λla λβn 610 615 620 Gly Val He λβn Gly Val λen Gly Met Thr Gly Gly Phe Phe λla Gly 625 630 635 640 Ser λβp He Leu Leu Gly Val Met Glu Gly Tyr Ser Ser Gly λla Cyβ 645 650 655 He Gly Gly Glu Cyβ Gin λβn λβp λrg Gly Lye Thr Lye Aβn Tyr Pro 660 665 670 λβn λrg λβn Pro Lyβ Hie λla λβn λrg λla Pro Lyβ Lyβ λrg λβn λβp 675 680 685 Gin λla Gin λβn Glu Pro λla Lye λrg Sβr Leu λrg Ser Val Lyβ Lyβ 690 695 700 Gin Leu Thr Glu Gly Tyr Pro Lyβ λβn Thr λβn Gly λβn Phe Ser Sβr 705 710 715 720 Ser λrg Lyβ Phe Phe Gin λrg Ser He Hie λrg Leu Gin Tyr Aβp Trp 725 730 735 Tyr Gin Gly Val λrg λβn Leu Lyβ λrg Phβ λβp Met Val Glu λβn Ser 740 745 750 Tyr λla Lyβ Ser λβp Pro Tyr Leu Phβ Pro λβn λrg Ser Gly Phe Val 755 760 765 Ser Lyβ Cyβ Hie Leu Cye λla Cye Sβr Phβ Phe Phe Lyβ Hie Gly λrg 770 775 780 Pro Phe Gly He He Glu Thr Phe Thr Leu λla Pro Thr Lyβ Cyβ Pro 785 790 795 800 Tyr Leu λsp Gly Leu Lyβ He Ser λla Cyβ Leu Met Glu Gin Val He 805 810 815 Gin λβn Tyr λrg Met He Val λla Leu He Gin λen Lye Leu Ser λβp 820 825 830 λla λβp Phe Gin λβn He λla Tyr Leu λβn Gly He λen Gly Glu He 835 840 845 Lyβ Thr Leu Lyβ Gly Ser Val λβp Leu λβn λla Leu He Glu Val λla 850 855 860 He Leu λsn λla Glu λsn His Leu λβn Tyr He Glu λβn Leu Glu Lye 865 870 875 880 Lyβ λla λβp Leu Trp Glu Glu Gin Leu Lyβ Leu Glu λrg Glu Thr Thr 885 890 895 λla λrg λβn He λla Ser Ser Lyβ Val He Val Lyβ Lye Hie Ser Lye 900 905 910 He Pro Tyr Leu Leu Phe Cye Tyr Cye Leu Phe Trp Gin Lyβ He Gin 915 920 925 λla Val Ser λβn Leu He λla Pro Thr Lyβ λrg Pro Thr λen Lyβ Cyβ 930 935 940 Leu Lyβ Thr Met λrg Phe Phe Gin Pro Leu λla Leu λla Leu He Met 945 950 955 960 Lyβ Val Lyβ Lye Met Leu Thr Ser Lye Lye λrg Pro Leu Leu Glu Glu 965 970 975 He λrg Tyr Lyβ Pro He Leu Lye λrg Met Ser Tyr Phe Ser Ser Gin 980 985 990 Lye Met Phe Ser λrg Leu He Cyβ Leu λla Leu λβn Phe Tyr Pro He 995 1000 1005 Lyβ Ser He Pro Thr Lyβ He Leu Lβu Ser Ser λβn λla Glu Tyr Pro 1010 1015 1020 He Lyβ Phe Phe Phe He Val Lye Gly Ser Lye Ser Ser Lyβ Lye λen 1025 1030 1035 1040 Lyβ He Glu Ser Val Lye Leu Pro λrg λrg He λrg λla Thr Leu Glu 1045 1050 1055 Val Gin Leu Leu Ser Leu Leu Hie λrg λrg Leu Lye λla λrg He Lyβ 1060 1065 1070 He Ser Ser Lyβ Glu Ser Glu Ser Leu Cyβ Lβu Lye Thr λrg Sβr Phe 1075 1080 1085 He He λrg Ser Trp Thr Hie Lye λβp Pro λβn Lyβ Val Ser λβp λβn 1090 1095 1100 Thr Tyr Lyβ Lye Gly λβn Gin Val λrg Ser Leu Lβu λβn Aβp Phβ Sβr 1105 1110 1115 1120 Glu Thr He Gly Tyr λsp Phe Pro Lβu Gly Phe λla Ser Lβu Val Val 1125 1130 1135 Phe Ser λβn λβn Leu λβp λrg Tyr Phβ Phβ Pro λla Met Leu Cyβ Sβr 1140 1145 1150 He Leu Met Thr Leu Leu Gly Ser Ser λβp Leu Glu λrg Lβu Phβ Glu 1155 1160 1165 λβn λla Val Ser Phe λla Ser Phe Ser Phe Val Ser Val Val Pro λβn 1170 1175 1180 Ser Leu λla Phe Val Val Ser Trp Leu Phe Ser Cyβ Ser He Ser Phe 1185 1190 1195 1200 Phe Leu Phe Ser Gin He λla Hie Glu λla He λrg Lyβ Val Leu Leu 1205 1210 1215 Leu Leu Leu Leu λrg Val Ser Phe Lyβ Pro Leu λrg Cyβ Cyβ Leu Glu 1220 1225 1230 λβn Leu Leu Phe Ser Val Ser He Ser He Phe Ser λen Lye Gly λla 1235 1240 1245 λrg He Phe Ser Leu Met Ser Lβu He Lye Hie Phe Leu λβn Pro Sβr 1250 1255 1260 Ser Leu Leu Glu He He Hie Ser Leu He Met He Ser He Ser Gly 1265 1270 1275 1280 Val Leu Hie Ser Ser Gly Thr Ser Gly λla λla Gly Phe Thr Lyβ λβp 1285 1290 1295 Ser Phe Thr Leu Leu He He Ser Ser Lye Lβu Ser Ser Leu Leu λβp 1300 1305 1310 Leu Val Ser Val Glu Glu Leu Pro Leu Gly Leu Ser Phe Lyβ Gly Leu 1315 1320 1325 λla Leu He Ser Phe λβn Ser Cyβ λβn Pro Leu Cyβ Leu λla λla Phe 1330 1335 1340 Phe Thr Glu Glu Leu Phe Phe Phe Ser λen λla Ser He Phe Phβ He 1345 1350 1355 1360 Cyβ Ser λla Leu λla Leu Ser Phe λrg Aβn Phβ Ser Leu Lyβ λla Leu 1365 1370 1375 Val λla λβn Ser Phe Ser Ser Phe Val He Ser Leu Ser Ser Cyβ Leu 1380 1385 1390 Ser Val Leu He Phe Leu Lyβ Pro Lyβ λla Thr λβn Ser Leu Tyr Ser 1395 1400 1405 Leu Gly λβn λβn λla Val Leu He λla Phe Lyβ Pro Pro Thr Thr Lye 1410 1415 1420 Glu λrg λla Thr Glu Pro Sβr Phe Leu Lyβ Met Leu Phe Lye Ser Val 1425 1430 1435 1440 Ser Phe Pro He Gin λrg λsp Tyr Ser Trp Gin His Cye Phe Gly Met 1445 1450 1455 Gin Lye Pro Lβu Phe λrg λβn He Ser Cyβ Ser Val Leu Phe λla Leu 1460 1465 1470 Phe Cye λrg Ser Ser λsp λrg Tyr Leu λrg Lys Tyr Cys He His Ser 1475 1480 1485 Phe Leu He He Phe Trp He Gly Tyr Gin λen Ser Cye Leu Lye Pro 1490 1495 1500 Thr λβn Thr He Phe Val Phe Val λrg λβn Ser He Phe Asp Trp Ser 1505 1510 1515 1520 Phe Ser Glu Tyr Ser He Pro Hie Hie Leu Hie Phe Ser Thr Ser Lyβ 1525 1530 1535 Lyβ Pro Hie Ser Pro Leu Ser He Ser Hie Ser Tyr Gin Ser Pro Cye 1540 1545 1550 Thr Pro Ser Val Pro Ser Lyβ λla Cyβ Pro Phβ Glu Gin Tyr Lβu Leu 1555 1560 1565 Leu Trp Ser Gin Thr Cye Phe Phe Gin λla Val Ser λβn λβn Leu Tyr 1570 1575 1580 Tyr Pro He Leu Phe Cye Ser Thr λβp Lyβ Cye Tyr Trp λβn He Leu 1585 1590 1595 1600 Gin Ser Leu λla Cyβ Lye He Lye Leu He Gly Ser Leu Phe Cyβ Phe 1605 1610 1615 Val Leu Hie Leu Lye Lye Thr Hie Pro Phβ Glu λla Lyβ Pro Glu Pro 1620 1625 1630 Tyr Leu Trp λrg Phe Phe Lye Tyr Cyβ Ser Phe Ser Pro Gly Gly Ser 1635 1640 1645 λsn λsn Ser λβn λla Pro Tyr Leu Leu Trp Met Phe Leu Gly Leu Lys 1650 1655 1660 Hie λrg Hie Lyβ Gly Glu Glu Val Ser Tyr λrg Glu Gly Tyr Leu Leu 1665 1670 1675 1680 λrg Leu λla Leu λβp Pro Hie Lyβ Pro Leu Thr Gin Gly Phe Tyr Leu 1685 1690 1695 Leu Ser Leu Ser Leu Glu Pro Lβu Phe Lβu Phβ Cyβ He Cyβ Phe Leu 1700 1705 1710 Ser Leu Lyβ Glu Leu Leu Tyr λβp Pro λla Lβu Phβ 1715 1720 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1786 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Lyβ He Met Pro Met Thr Ser Cye He Ser Trp Thr Pro Leu Phe Leu 1 5 10 15 He Gly Phe λrg Leu He λla Leu Lye Leu Lye λrg Lye Ser Phe Leu 20 25 30 Lyβ λβn He Phe Lye Thr Lβu Met Lyβ Gin Thr Lyβ Cye Sβr He Lye 35 40 45 Lyβ He Lyβ Thr Lyβ He Thr He Glu Trp λrg Cyβ λla λrg He Val 50 55 60 Leu Lyβ He λrg He Lyβ Glu Ser Lyβ Val Lye λrg He Phe He Lye 65 70 75 80 Leu λβn Tyr Tyr Leu Leu Gly Val Leu Ser Leu λla Cyβ Leu Gin Ser 85 90 95 Val λβn λla λsp Gin λβn Thr λβp He Lyβ λβp He Ser Pro Glu λsp 100 105 110 Met λla Leu λβn Ser Val Gly Lβu Val Sβr λrg λβp Gin Lβu Lye He 115 120 125 Glu He Pro Lyβ Glu Thr Leu Glu Gin Lye Val λla He Leu Aβn λep 130 135 140 Tyr λβn λβp Lyβ λβn Val λβn He Lyβ Phβ λβp λβp He Ser Leu Gly 145 150 155 160 Ser Phe Gin Pro λβn λβp λβn Leu Gly He λβn λla Met Trp Gly He 165 170 175 Gin λβn Leu Leu Met Sβr Gin Met Met Gly λep Tyr Gly Pro Aβn λβn 180 185 190 Pro Phe Met Tyr Gly Tyr λla Pro Thr Tyr Ser λβp Ser Ser Phe Lβu 195 200 205 Pro Pro He Leu Gly Tyr Leu Gly Gly Val λβn Met λla Gly Thr Gin 210 215 220 λla He Tyr Glu Ser Ser Ser λla Gly Phe Leu Ser Glu Val Ser Ser 225 230 235 240 He He Ser Thr Gin Val Val Ser Gin λβp Hie Leu Gin Glu λrg Val 245 250 255 Leu Gin Gin λrg Leu Phe Leu Leu Leu Leu Gly Leu Leu He λrg Lyβ 260 265 270 Pro Leu Ser Pro λβn Thr He Lyβ λla Sβr Leu Lyβ Pro λla Cye Leu 275 280 285 Lye Pro Leu Thr λβn λen Thr Thr λβn Cyβ Phβ Lyβ Val Leu Thr He 290 295 300 Lye λla Trp Leu Trp Gly Thr He Ser He Leu λla λβn Gin Gly λβn 305 310 315 320 Leu Thr Hie Lyβ λla Thr λrg Lys λla λrg Lyβ Leu Val Leu Leu He 325 330 335 Val λrg Leu Gin λla Phe λrg Val Thr Pro Pro Leu Lyβ He Pro Val 340 345 350 Leu Leu Lyβ Lβu Met λrg Gin He Lyβ Ser Leu Phe Leu λla Cye Gin 355 360 365 Gin λrg Leu Lyβ λrg Tyr He λrg Gin Tyr Tyr Lyβ Cyβ Ser Thr Lyβ 370 375 380 He λrg Pro Ser Ser Thr λrg λla Thr λla Phe Ser Ser Lye Gin Gin 385 390 395 400 Leu λβn Glu Tyr Thr λβp Sβr Leu He λla Val Pro Leu Val λrg Leu 405 410 415 Leu λla Hie Gin Lye Cye Phβ Ser Val λla Cye Lye Phβ Leu λrg Pro 420 425 430 Met Ser Val Ser Met Pro Thr Val Tyr λla Lyβ Tyr Gin λla Leu λla 435 440 445 Thr λβn λla Leu Thr Ser Gly Val λβn Pro Met Thr Thr Pro λla Cyβ 450 455 460 Pro He Gly λβp Lyβ Val Leu λla Val Tyr Cyβ Tyr λla Glu Lyβ Val 465 470 475 480 λla Glu He Leu λrg Glu Tyr Tyr He Glu Phe Val Lyβ λβn λβn Thr 485 490 495 λβn Leu Leu Gin λen λla Ser Gin Met He Leu λβn Gin Ser Gly Leu 500 505 510 λla Thr Ser Thr Tyr λsp Thr Gin λla He Ser λsn He Ser Ser Leu 515 520 525 Tyr λsn Tyr λsn He Val λla λβn Lyβ Ser Phe Leu Lye Ser Hie Leu 530 535 540 Thr Tyr Leu λβp Tyr He Lyβ λβp Lyβ Lβu Lyβ Gly Gin Lyβ λβp Sβr 545 550 555 560 Tyr Leu Thr Glu λrg Val Gin Thr Lye He He Val Lye Gly Lyβ λrg 565 570 575 Cyβ Glu Met Phe Phe Lyβ Hie He Phe Phe Leu λβp Phe Leu Trp Phe 580 585 590 Val Ser Glu Trp Tyr λrg Gly Ser λβn λβn λla Thr Cyβ Leu Lyβ Ser 595 600 605 Hie Ser Gly λrg λrg Thr Ser Gin Thr Lyβ λβn λrg Ser Ser λrg He 610 615 620 Lyβ Ser Hie λrg Ser Ser He Cyβ Gin λrg Lyβ Ser Hie Sβr Sβr λla 625 630 635 640 λβn λrg Gly λrg He Glu λβp Ser λla Cyβ λβn Hie Glu λrg Tyr Val 645 650 655 Lyβ λrg Gly Trp λrg Tyr Trp Cyβ Gin Trp Hie Aβp Arg Gly Val Phe 660 665 670 Cyβ λrg Phe λrg Hie Leu λla Trp λrg Hie Gly λrg Val Phe Lyβ λrg 675 680 685 λrg Leu Val Hie Trp Gly Gly Met Ser Lyβ Ser Trp Lyβ λβn Lyβ Lyβ 690 695 700 Leu He Pro Lye Gin Lys Ser Lys Thr Cyβ Lye Ser λrg Ser Lye Lyβ 705 710 715 720 He Thr Lyβ Ser Ser Ser Lyβ Thr Ser Lye Thr Leu Ser Lye λrg Lyβ 725 730 735 Thr λla Leu λβn λrg Gly Leu Pro Lyβ Hie Lye Trp Lye Phβ Leu Lye 740 745 750 Lβu Glu Val Leu Leu Thr Thr Leu λβn Thr Sβr Leu Thr He λrg Leu 755 760 765 Val Ser λrg λrg Leu Lye Lye Pro Lys Val Leu λrg Hie Gly Lye Gin 770 775 780 Leu Cyβ Lyβ Lye λrg Pro Leu Leu He He He Pro Gin Val λrg Leu 785 790 795 800 Cyβ Phβ Lyβ Val Pro Ser Met λrg Leu Leu Leu Val Phe Phe Gin λla 805 810 815 Trp λla Thr He Trp λβn Hie λen He Hie Ser Ser λla Hie Lyβ Met 820 825 830 Pro Leu Ser Trp λla Lye λβn Phe Ser Met Pro Tyr Gly Thr Gly Tyr 835 840 845 Ser Glu Leu Gin λβn λsp Cye Ser Pro Tyr Ser Lyβ Thr Glu Cyβ λrg 850 855 860 Phe Ser Lye Tyr λrg Leu Phe Glu Trp λβp Gin Trp λrg λβn Gin λβn 865 870 875 880 Leu Lyβ λrg He Ser λrg Phβ Glu Cye λla Hie λrg Ser Cyβ λβp Leu 885 890 895 Lys λrg λrg Lys Ser Phe Lyβ Leu Tyr λrg Glu Ser Lye Lyβ Ser λrg 900 905 910 Pro Leu Gly λrg Thr Thr Glu He λrg Lye λrg λβn Aβp Ser Lyβ Lys 915 920 925 Hie Cye Leu Ser Tyr Cye Gin Met Lyβ Thr Leu Val Lye Aβn Thr He 930 935 940 Ser Ser Phe Leu Leu Leu Ser Val Leu Met λla Glu λβp He Thr Ser 945 950 955 960 Gly Leu Lyβ Gin Leu λβp Ser Thr Tyr Gin Glu Thr λβn Gin Gin Val 965 970 975 Leu Lyβ λβn Leu λβp Glu He Phe Ser Thr Thr Ser Pro Ser λla λβn 980 985 990 λβn Glu He Gly Gin Glu Aβp λla Leu Aβn He Lyβ Lyβ λla λla He 995 1000 1005 λla Leu λrg Gly λβp Lβu λla Lβu Leu Lye λla λβn Phe Glu λla λβn 1010 1015 1020 Glu Leu Phe Phe He Ser Glu Aβp Val He Phe Lyβ Thr Tyr Met Ser 1025 1030 1035 1040 Ser Pro Glu Leu Leu Leu Thr Tyr Met Lyβ He λβn Pro Leu λβp Gin 1045 1050 1055 λβn Thr λla Glu Gin Gin Cys Gly He Ser λsp Lys Val Leu Val Leu 1060 1065 1070 Tyr Cyβ Glu Gly Lyβ Lβu Lyβ He Glu Gin Glu Lye Gin Aβn He Arg 1075 1080 1085 Glu λrg Leu Glu Thr Ser Leu Lyβ λla Tyr Gin Ser λβn He Gly Gly 1090 1095 1100 Thr λla Ser Leu He Thr λla Ser Gin Thr Leu Val Glu Ser Leu Lye 1105 1110 1115 1120 Aβn Lyβ λβn Phβ He Lyβ Gly He λrg Lye Leu Met Leu λla Gin λen 1125 1130 1135 Lye Val Phe Leu λβn Tyr Lβu Glu Glu Leu Aβp λla Leu Glu λrg Ser 1140 1145 1150 Leu Glu Gin Ser Lye Arg Gin Tyr Leu Gin Glu Arg Gin Ser Ser Lye 1155 1160 1165 He He Val Lye Phβ Phe λβp λβp λrg Leu Phe Leu Thr Phe Gly He 1170 1175 1180 Cyβ Phe Ser Ser Cye Phe Leu He Phe Gly Ser Leu Phe Phe Ser Met 1185 1190 1195 1200 Ser λβp λla Leu Phe Tyr Leu He Aβn λβp λla He Gly Gin Phe Gly 1205 1210 1215 Phe λrg λla He Val Glu Cyβ Cyβ He Phe Cyβ Phe He Phe Phe Cye 1220 1225 1230 He Ser Ser λla Lyβ Leu λla Cyβ He Cyβ Ser He Leu Val Val He 1235 1240 1245 Phe Leu Leu Hie Phe Phe Phe Ser Leu Leu Thr λβn Ser λla λrg Ser 1250 1255 1260 Tyr Lye Lye Gly Ser He Val λla Val He Lyβ Ser Glu Phe Thr Thr 1265 1270 1275 1280 Val Leu Ser λrg Lye Leu Val He Phe Cyβ Leu Tyr Phe Leu λβn Phe 1285 1290 1295 Phe Gly Gly Lye λβn Phe Leu He Leu λβp Val Phβ λep Gin Thr Leu 1300 1305 1310 Ser Pro He He He Val λla Aβn λβn Thr Leu He λβp λβn λβp Phe 1315 1320 1325 λβn Phe λrg λrg Ser Pro Leu He λrg Hie Lyβ λrg Ser Ser λrg Phe 1330 1335 1340 Hie Lyβ λrg Phe He Hie Leu He λep Hie Leu He Lye Val He He 1345 1350 1355 1360 Phe He λrg Phe Gly Phe Ser Gly λrg He λla He λrg Val Val He 1365 1370 1375 Gin λrg Val Ser Val Aβn Phe Val Phe Leu Ser Phe Val Leu Ser λrg 1380 1385 1390 Phe Phe Leu λsn λrg λrg Val Val Leu Phe Phe Lyβ λrg Phe λsn He 1395 1400 1405 Leu Leu λβn Leu Leu Cyβ Ser λrg Pro He He Ser Phe Phe Ser Gin 1410 1415 1420 Ser Val Ser Gly Glu Phe Phe Phβ Leu Phe Cyβ λβn Phβ Phe Val He 1425 1430 1435 1440 Met Ser Leu He Glu Cyβ Phe λβp Phe Phe Lyβ λla Gin Ser Hie Phe 1445 1450 1455 Phe Val Phe Thr λrg Gin Cyβ Cye He λep Sβr Val λla Pro He λβn 1460 1465 1470 λβn λrg He Lye Sβr Asp λrg Thr Phe Phe Glu λep λla Phe Gin Glu 1475 1480 1485 Cyβ Leu Leu Ser Tyr Ser Lyβ Gly Leu Phe Leu λla Thr Leu Phe λrg 1490 1495 1500 Tyr λla Glu Thr Thr Val Leu Lyβ Lyβ Leu λβn He Leu Cyβ Ser Phe 1505 1510 1515 1520 Cyβ He Val Val Leu Ser Leu He He Gly Ser Leu Ser Thr Lyβ He 1525 1530 1535 Leu Tyr Ser Leu Val Phe Phe λβn He λsp Phβ Leu λβp Trp Val Ser 1540 1545 1550 Lyβ Leu Lyβ Leu Ser Lye Thr λβn Lye Hie λβn Phe Cyβ Phe Cye λla 1555 1560 1565 Lyβ Leu λβn Phe Leu Val Lyβ Phe Leu Val λrg Val Phe λβn Ser Thr 1570 1575 1580 Ser Ser Leu Thr Phe Phe λβn Lye Leu Glu Lyβ λla Ser Pro Phe Lyβ 1585 1590 1595 1600 Tyr Phβ Ser Leu He Leu Ser He λla Met Leu λen λla Lyβ λrg Ser 1605 1610 1615 Glu Leu Lye He Ser Val Leu Val λla Phβ λla He Ser Phe λla Leu 1620 1625 1630 Glu Ser λβn Leu Phe Leu Ser Ser Cye Lye Ser He Leu Ser λβn Ser 1635 1640 1645 Phe Leu Leu λβn λrg Leu Glu Met Leu Leu Glu Tyr Ser Ser He λla 1650 1655 1660 Cyβ Leu λsp Lyβ λla λsn λrg Leu λla Phe Leu Phe Cyβ Ser Ser Ser 1665 1670 1675 1680 Lyβ Glu λβn Thr Pro He Sβr Lyβ λla λla Leu Ser Leu Val Val λla 1685 1690 1695 Val Val Phe Leu Lyβ He Leu Leu Val Phe Thr Trp Gly Leu Lyβ λrg 1700 1705 1710 Ser Leu Ser Ser Leu Val λβn Val Ser Trp Phe Lye Thr λla Gly Leu 1715 1720 1725 Gly λrg Ser Phe Leu λrg Gly Leu Ser Phe Lyβ λla Cyβ Ser λrg Ser 1730 1735 1740 Pro λla Phe Asp Leu λla Val λrg He Leu Pro Leu Val Ser Phβ Ser 1745 1750 1755 1760 λrg λla Ser Phβ Sβr Phe Leu Tyr Lβu Phβ Ser Lye Sβr Glu λrg Thr 1765 1770 1775 Leu λla Leu Ser He Ser Ser Leu He Phβ 1780 1785 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1529 baee pairβ (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: AGGCAAAAAλ CATGλAAACλ TCACTAAATT CλCTTGTCCT CATTGCAATA TCλCACλCCλ 60 CAGAGATTAC AATGCGAGCG TCAATATTAG AλλCTλCGCT TTAGGCλTGC TAGATGACAG 120 GCATAAAATA AAGATAGATA AAAGTλGGGT AGGGATTATC CGAACTGATT ACGCTCATTA 180 CACTGATGAG CGCATCAAAG CTTGTGGAGC TTCCTCTAAT GGGGTTATTT CTAAATATGG 240 CAACATATTG GATCTAGCTA GTTATGGλGC GATGAAGCλλ GAλλλAGCCC λλTCGCTTTλ 300 GCGTTGGTAA TTCACλλλλλ GCAAGATCGG TTGTAAAAAT GCGTTACλλC TAAAATAAAG 360 GGTCAAGATλ ACTCλTTTTC AAAAAGGAGT CTTAAGTAAT AAAATCATAA TGTTCAGCTA 420 GTAATCTATT GCCTCGTTGA TCAAACAAAG CTCTGCGTGλ AAGλTGλλλλ AATTTCACCT 480 TTAGλTλGTT λATλCACCλC TλCλGTCTTλ CTTGλGλGλC λCTCλTTTTλ TTλGCGGTTT 540 TGTCTGATTT GCTGCTACCλ λAλCCλTTλC CAACCAAλGC λGλTCCCλTG TTTTTGλTλC 600 TATCGAλTCC λTTCTTCλGC λCTTCTGCCλ TAAAATTCTT GλTλTTGTCC λTλGGCAλGT 660 TAAATTTTTT CCCTAATGCT TCATTAλGTC CCATCATTAA CATCAGAAAG AACAAAAAAT 720 TTAATATCAT AGAAAACAAA TCACTGGλTλ AACCTGTAAλ λλGλTTTGTT CCGCCλCCCλ 780 λCAAAGAAGC TAAAATTTTT CCCλTGλTCλ GTCCTTTTλT TTTTGGTTGT GTλλGTTCTT 840 GCTTGTTCGG λTCTCTλλTG CGTGTTTTλG TAGGAAGCAT TTCλCAATλG CλTλCCTλλλ 900 GCTACTAAGA AAATTCTTGA ATCTATTGGT AAGATTACTC ATGAAATCAA GCGATAAGTA 960 GCCACCAATC GCAAACAAAT CAAATATTTT GCCACCλλλC AAGCCATATC CT- TTGTTT 1020 TTATCTCCTA ATTATAGCAA ATTTTTATCA ATATTAATTT GGAλλλCCλC CACCATATCA 1080 AAAACAAATT ACTAACACAC TAGATGCAGA ATTATTTTTA AλλλλCGCTC ACTTAAATTT 1140 AAAATCATGG GGTTTTAGGA TTTGAATACC AAAAATAGAT TGGTTTTTTC AAATAAGCTA 1200 GCTTTGTGTA TGCGCTTλ λ AλGATTTTAG TTTTTAGTCA GTAAGGTTTT ATGCTAATGT 1260 TTGGAAATAA AGAAATTTCT CTAAATCAAG TCTTGAGAAA TTTTTGAλCG AATCATλλCλ 1320 ACCAATTTTG CCATTGAGTC ATAAGTATGA TTAGCTTCAT TGTGAATTTT GCGTGGCTTλ 1380 AGAGATAGTA TTTGCTTATT ATGCTGAGAG AAACGAGTAG TAAAAGATAA GTAGTGTλAT 1440 AAAAAAAGCT AGGTTTTATT ATAAGAGCGA ATAAGAATAA TATTGGλTλλ ACTAAAATCA 1500 CCCCTGCCCC ATAAGAAAAA AGCCCTATT 1529 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 464 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Arg Gin Lyβ Thr Lye Hie Hie He Hie Leu Ser Ser Leu Gin Tyr Hie 1 5 10 15 Thr Pro Gin λrg Leu Gin Cyβ Glu λrg Gin Tyr Lye Leu λrg Phe λrg 20 25 30 Hie λla λrg Gin λla Aβn Lye λβp λrg Lyβ Gly λrg λβp Tyr Pro λβn 35 40 45 Leu λrg Ser Lβu Hie λla Hie Gin Sβr Lβu Trp Ser Phe Lβu Trp Gly 50 55 60 Tyr Phe He Trp Gin Hie He Gly Ser Ser Leu Trp Ser Aβp Glu λla 65 70 75 80 λrg Lyβ Ser Pro He λla Leu λla Leu Val He Hie Lye Lyβ Gin λβp 85 90 95 λrg Leu Lyβ Cyβ Val Thr Thr Lyβ He Lyβ Gly Gin λβp λβn Ser Phe 100 105 110 Ser Lyβ λrg Ser Leu Lys λsn His λsn Val Gin Leu Val He Tyr Cys 115 120 125 Leu Val λβp Gin Thr Lys Leu Cyβ Val Lyβ λβp Glu Lyβ He Ser Pro 130 135 140 Leu λβp Ser Tyr Thr Thr Thr Val Leu Leu Glu λrg Hie Sβr Phe Tyr 145 150 155 160 λrg Phe Cye Lβu He Cyβ Cyβ Tyr Gin Aβn Hie Tyr Gin Pro Lye Gin 165 170 175 He Pro Cyβ Phe Tyr Tyr λrg He Hie Ser Ser λla Leu Leu Pro λβn 180 185 190 Ser Tyr Cye Pro λla Ser He Phe Ser Lβu Met Leu Hie Val Pro Ser 195 200 205 Leu Thr Ser Glu λrg Thr Lyβ λβn Leu He Ser Lyβ Thr λβn Hie Trp 210 215 220 He λβn Leu Lyβ λβp Leu Phe λrg Hie Pro Thr Lye Lys Leu Lyβ Phe 225 230 235 240 Phe Pro Ser Val Leu Leu Phe Leu Val Val Val Leu λla Cyβ Ser λep 245 250 255 Leu Cyβ Val Phe Glu λla Phe Hie λβn Ser He Pro Lyβ λla Thr Lys 260 265 270 Lys He Leu Glu Ser He Gly Lye He Thr Hie Glu He Lyβ λrg Val 275 280 285 λla Thr λβn λrg Lyβ Gin He Lye Tyr Phe λla Thr Lyβ Gin λla He 290 295 300 Ser Phe Leu Phe Lβu Ser Pro λen Tyr Ser Lyβ Phβ Leu Ser He Leu 305 310 315 320 He Trp Lye Thr Thr Thr He Ser Lye Thr Aβn Tyr Hie Thr λrg Cye 325 330 335 λrg He He Phe Lyβ Lye λrg Ser Leu Lyβ Phe Lye He Met Gly Phe 340 345 350 λβp Leu λβn Thr Lyβ λβn λrg Leu Val Phe Ser λen Lyβ Leu λla Leu 355 360 365 Cyβ Met λrg Leu Lyβ λrg Phβ Phβ Leu Val Ser Lyβ Val Leu Cye Cye 370 375 380 Leu Glu He Lye Lyβ Phe Leu He Lye Ser Glu He Phe Glu λrg He 385 390 395 400 He λrg Thr λβn Phe λla He Glu Ser Val Leu λla Ser Leu He Leu 405 410 415 λrg Gly Leu λrg Aβp Ser He Cyβ Leu Leu Cye Glu Lye Arg Val Val 420 425 430 Lyβ Asp Lyβ Cyβ λβn Lyβ Lyβ Ser Val Leu Leu Glu λrg He λrg He 435 440 445 He Leu λep Lye Leu Lyβ Ser Pro Leu Pro Hie Lye Lyβ Lyβ λla Leu 450 455 460 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 481 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: βinglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Gly Lyβ Lyβ Hie Glu Aβn He Thr Lyβ Phe Thr Cyβ Pro Hie Cye λβn 1 5 10 15 He Thr Hie Hie λrg λβp Tyr λen λla Ser Val λβn He λrg λβn Tyr 20 25 30 λla Leu Gly Met Leu λβp λβp λrg Hie Lyβ He Lye He Aβp Lye Ser 35 40 45 λrg Val Gly He He λrg Thr λβp Tyr λla Hie Tyr Thr λβp Glu λrg 50 55 60 He Lyβ λla Cyβ Gly λla Ser Ser λβn Gly Val He Ser Lye Tyr Gly 65 70 75 80 λβn He Leu λβp Leu λla Ser Tyr Gly λla Met Lyβ Gin Glu Lye λla 85 90 95 Gin Ser Leu λrg Trp Phe Thr Lyβ Ser Lyβ He Gly Cyβ Lyβ λβn λla 100 105 110 Leu Gin Leu Lye λrg Val Lye He Thr Hie Phβ Gin Lyβ Gly Val Leu 115 120 125 Ser λβn Lyβ He He Met Phe Ser Ser He λla Ser Leu He Lyβ Gin 130 135 140 Ser Ser λla Lyβ Met Lye Lye Phe Hie Leu He Val λβn Thr Pro Leu 145 150 155 160 Gin Ser Tyr Leu λrg λβp Thr Hie Phβ He Ser Gly Phe Val Phe λla 165 170 175 λla Thr Lyβ Thr He Thr λsn Gin Ser λrg Ser Hie Val Phe λβp Thr 180 185 190 He Glu Ser He Leu Gin Hie Phe Cye Hie Lyβ He Leu λsp He Val 195 200 205 Hie λrg Gin Val Lyβ Phe Phe Pro Cye Phe He Lyβ Ser Hie Hie Hie 210 215 220 Gin Lyβ Glu Gin Lyβ He Tyr Hie λrg Lys Gin He Thr Gly Thr Cyβ 225 230 235 240 Lyβ Lye He Cyβ Ser λla Thr Gin Gin λrg Ser λen Phe Ser Hie λβp 245 250 255 Gin Ser Phe Tyr Phe Trp Leu Cyβ Lyβ Phe Leu Leu Val λrg He Ser 260 265 270 λβn λla Cyβ Phβ Ser λrg Lyβ Hie Phβ Thr He λla Tyr Leu Lye Leu 275 280 285 Leu λrg Lyβ Phe Leu λsn Leu Leu Val λrg Leu Leu Met Lys Ser Ser 290 295 300 λsp Lys Pro Pro He λla λsn Lyβ Ser λen He Leu Pro Pro λβn Lyβ 305 310 315 320 Pro Tyr Pro Phe Cye Phβ Tyr Leu Leu He He λla λβn Phβ Tyr Gin 325 330 335 Tyr Phe Gly Lye Pro Pro Pro Tyr Gin Lye Gin He Thr λβn Thr Leu 340 345 350 λβp λla Glu Lβu Phe Leu Lyβ λβn λla Hie Leu Aβn Leu Lyβ Sβr Trp 355 360 365 Gly Phe λrg He He Pro Lyβ He λsp Trp Phe Phe Gin He Ser Leu 370 375 380 Cyβ Val Cyβ λla Lye λβp Phe Ser Phe Ser Val λrg Phe Tyr λla λβn 385 390 395 400 Val Trp Lyβ λrg λsn Phe Ser Lyβ Ser Ser Leu Glu Lyβ Phe Leu λen 405 410 415 Glu Ser Glu Pro He Leu Pro Leu Ser Hie Lye Tyr λβp Leu Hie Cye 420 425 430 Glu Phe Cyβ Val λla Glu He Val Phe λla Tyr Tyr λla Glu λrg λen 435 440 445 Glu Lyβ He Ser Ser Val He Lyβ Lye λla λrg Phe Tyr Tyr Lyβ Ser 450 455 460 Glu Glu Tyr Trp He λβn λβn Hie Pro Cye Pro He λrg Lye Lye Pro 465 470 475 480 Tyr (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 471 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Ala Lyβ λβn Met Lyβ Thr Ser Leu λβn Ser Leu Val Leu He λla He 1 5 10 15 Ser Hie Thr Thr Glu He Thr Met λrg λla Ser He Leu Glu Thr Thr 20 25 30 Leu λla Cyβ Met Thr Gly He Lyβ λrg He Lyβ Val Gly Gly Leu Ser 35 40 45 Glu Leu He Thr Lβu He Thr Leu Met Ser λla Ser Lyβ Leu Val Glu SO 55 60 Leu Pro Leu Met Gly Leu Phe Leu λsn Met λla Thr Tyr Trp He Leu 65 70 75 80 Val Met Glu λrg Ser Lyβ Lye Lye Pro λβn λrg Phe Ser Val Gly λβn 85 90 95 Ser Gin Lyβ λla λrg Sβr Val Val Lyβ Met λrg Tyr λβn λβn Lyβ Gly 100 105 110 Ser λrg Leu He Phe Lyβ Lye Glu Sβr Val He Lyβ Ser Cyβ Sβr λla 115 120 125 Ser λβn Leu Leu Pro λrg Ser λβn Lye λla Leu λrg Glu λrg Lyβ λβn , 130 135 140 Phe Thr Phe λrg Leu He Hie Hie Tyr Ser Leu Thr Glu Thr Leu He 145 150 155 160 Leu Leu λla Val Leu Ser λβp Leu Leu Leu Pro Lyβ Pro Leu Pro Thr 165 170 175 Lyβ λla Aβp Pro Met Phβ Leu He Leu Ser λen Pro Phβ Phe Ser Thr 180 185 190 Ser λla He Lye Phe Leu He Leu Ser He Gly Lye Lβu λβn Phe Phe 195 200 205 Pro λβn λla Ser Leu Ser Pro He He λsn He λrg Lys λsn Lys Lye 210 215 220 Phe λβn He He Glu λβn Lyβ Ser Leu λβp Lyβ Pro Val Lyβ λrg Phe 225 230 235 240 Val Pro Pro Pro λβn Lye Glu λla Lye He Phe Pro Met He Sβr Pro 245 250 255 Phe He Phe Gly Cyβ Val Ser Ser Cyβ Leu Phe Gly Ser Leu Met λrg 260 265 270 Val Leu Val Gly Ser He Ser Gin Hie Thr Ser Tyr Glu λβn Ser He 275 280 285 Tyr Trp λβp Tyr Ser λβn Gin λla He Ser Ser Hie Gin Ser Gin Thr 290 295 300 Asn Gin He Phe Cyβ Hie Gin Thr Ser Hie He Leu Phe Val Phe He 305 310 315 320 Ser Leu Gin He Phe He Asn He λβn Leu Glu λβn Hie Hie Hie He 325 330 335 Lye λβn Lye Leu Leu Thr Hie Met Gin λβn Tyr Phe Lye Thr Leu Thr 340 345 350 He λβn Hie Gly Val Leu Gly Phe Glu Tyr Gin Lye He Gly Phe Phe 355 360 365 Lyβ λla Ser Phe Val Tyr λla Lβu Lyβ Lyβ He Leu Val Phβ Ser Gin 370 375 380 Gly Phe Met Leu Met Phβ Gly λβn Lye Glu He Ser Lβu Aβn Gin Val 385 390 395 400 Leu Arg λβn Phe Thr λβn Hie Lyβ λβn Gin Phβ Cyβ Hie Val He Ser 405 410 415 Met He Ser Phe He Val λsn Phe λla Trp Leu Lyβ λrg Tyr Leu Leu 420 425 430 Ile Met Leu λrg Glu Thr Ser Ser Lyβ λrg Val Val Lyβ Lyβ Leu Gly 435 440 445 Phe He He λrg λla λβn Lyβ λβn λen He Gly Thr Lye He Thr Pro 450 455 460 λla Pro Glu Lye Ser Pro He 465 470 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1529 baβe pairβ (B) TYPE: nucleic acid (C) STRANDEDNESS: einglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: AATAGGGCTT TTTTCTTATG GGGCAGGGGT GATTTTλGTT TλTCCAATAT TATTCTTATT 60 CGCTCTTλTλ λTλλλλCCTλ GCTTTTTTTλ TTλCACTλCT TATCTTTTAC TACTCGTTTC 120 TCTCAGCATA ATAAGCAAAT λCTλTCTCTT λλGCCλCGCλ AAATTCACAA TGAAGCTAAT 180 CλTλCTTλTG λCTCλλTGGC AAAATTGGTT CTTATGATTC GTTCAAAAAT TTCTCAAGAC 240 TTGATTTAGλ GλλλTTTCTT TλTTTCCλλλ CλTTλGCλTλ AAACCTTACT GλCTAAAAλC 300 TAAAATCTTT TTAAGCGCλT ACACAAAGCT λGCTTλTTTG AAAAAACCAA TCTλTTTTTG 360 GTATTCAAAT CCTAAAλCCC CλTGATTTTλ AATTTAAGTG λGCGTTTTTT λAAAATAATT 420 CTGCATCTλG TGTGTTλGTλ λTTTGTTTTT GλTλTGGTGG TGGTTTTCCλ λATTAATATT 480 GATAAAAATT TGCTATAATT λGGAGATAAA AλCAλλλλGG λTλTGGCTTG TTTGGTGGCA 540 AAATλTTTGλ TTTGTTTGCG ATTGGTGGCT λCTTλTCGCT TGλTTTCλTG λGTAATCTTA 600 CCλλTλGλTT CAλGλATTTT CTTλGTλGCT TTλGGTλTGC TλTTGTGAAλ TGCTTCCTAC 660 TAAAACACGC ATTAGAGATC CGAACAλGCλ AGAACTTACA CAACCAAAAλ TAAAAGGACT 720 GATCATGGGA AAAATTTTAG CTTCTTTGTT GGGTGGCGGA ACλλλTCTTT TTλCλGGTTT 780 ATCCAGTGλT TTGTTTTCTλ TGATATTAAA TTTTTTGTTC TTTCTGATGT TλλTGλTGGG 840 λCTTλATGAA GCATTAGGGA AAAAATTTAA CTTGCCTATG GACAATATCA AGAATTTTAT 900 GGCAGAAGTG CTGAAGAATG GATTCGATAG TATCAAAAAC ATGGGATCTG CTTTGGTTGG 960 TAATGGTTTT GGTAGCλGCλ AλTCAGACAλ AλCCGCTAAT AAAATGAGTG TCTCTCλλGT 1020 AAGACTGTAG TGGTGTATTλ ACTATCTAAA GGTGAAλTTT TTTCATCTTT CλCGCAGAGC 1080 TTTGTTTGAT CAACGλGGCλ λTλGλTTλCT λGCTGλλCλT TATGλTTTTλ TTλCTTλλGλ 1140 CTCCTTTTTG λλAλTGλGTT ATCTTGλCCC TTTλTTTTλG TTGTλλCGCλ TTTTTλCλλC 1200 CGλTCTTGCT TTTTGTGAλT TλCCAACGCT AλλGCGλTTG GGCTTTTTCT TGCTTCATCG 1260 CTCCATAACT AGCTAGATCC λλTλTGTTGC CλTλTTTλGλ AATAACCCCA TTλGλGGλλG 1320 CTCCACAAGC TTTGATGCGC TCλTCAGTGT AATGAGCGTA λTCλGTTCGG λTλλTCCCTλ 1380 CCCTλCTTTT λTCTλTCTTT λTTTTλTGCC TGTCλTCTλG CλTGCCTAλλ GCGTλGTTTC 1440 TλλTλTTGλC GCTCGCλTTG TλλTCTCTGT GGTGTGTGλT λTTGCλλTGλ GGλCλλGTGλ 1500 λTTTλGTGλT GTTTTCλTGT TTTTTGCCT 1529 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 485 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: He Gly Leu Phe Ser Tyr Gly λla Gly Val He Leu Val Tyr Pro He 1 5 10 15 Leu Phe Leu Phe λla Leu He He Lyβ Pro Ser Phe Phe Tyr Tyr Thr 20 25 30 Thr Tyr Leu Leu Leu Leu Val Ser Leu Ser He He Ser Lyβ Tyr Tyr 35 40 45 Leu Leu Ser Hie λla Lyβ Phe Thr Met Lyβ Lβu He He Leu Met Thr 50 55 60 Gin Trp Gin λβn Trp Phe Lβu Phe Val Gin Lyβ Phβ Leu Lyβ Thr Phβ 65 70 75 80 λrg Glu He Ser Leu Phe Pro Aβn He Ser He Lyβ Pro Tyr Leu Lye 85 90 95 Thr Lyβ He Phe Leu Ser λla Tyr Thr Lye Leu λla Tyr Lβu Lyβ Lyβ 100 105 110 Pro He Tyr Phe Trp Tyr Ser λβn Pro Lyβ Thr Pro Phe He Val Ser 115 120 125 Val Phe Lya Phe Cye He Cye Val Ser Aβn Leu Phe Leu He Trp Trp 130 135 140 Trp Phe Ser Lyβ Leu He Lβu He Lyβ He Cyβ Tyr λβn Glu He Lye 145 150 155 160 Thr Lye λrg He Trp Leu Val Trp Trp Gin λen He Phe Val Cyβ λβp 165 170 175 Trp Trp Leu Leu He λla Phe Hie Glu Ser Tyr Gin He Gin Glu Phe 180 185 190 Ser Leu Val Cye Tyr Cyβ Glu Met Leu Pro Thr Lyβ Thr λrg He λrg 195 200 205 λβp Pro λβn Lyβ Gin Glu Leu Thr Gin Pro Lyβ He Lyβ Gly Leu He 210 215 220 Met Gly Lyβ He Leu λla Ser Leu Leu Gly Gly Gly Thr λen Leu Phe 225 230 235 240 Thr Gly Leu Ser Ser λsp Leu Phe Ser Met He Leu λsn Phe Leu Phe 245 250 255 Phe Leu Met Leu Met Met Gly Leu λβn Glu λla Leu Gly Lyβ Lyβ Phe 260 265 270 λβn Leu Pro Met λβp λβn He Lyβ λβn Phe Met λla Glu Val Leu Lye 275 280 285 λsn Gly Phe λsp Ser He Lys λβn Met Gly Ser λla Leu Val Gly λen 290 295 300 Gly Phe Gly Ser Ser Lye Ser λβp Lye Thr λla Aβn Lye Met Ser Val 305 310 315 320 Ser Gin Val λrg Leu Trp Cye He λen Tyr Lβu Lye Val Lye Phe Phe 325 330 335 Hie Leu Ser λrg λrg λla Leu Phe λβp Gin λrg Gly λβn λrg Leu Leu 340 345 350 λla Glu His Tyr λsp Phe He Thr λsp Ser Phe Leu Lye Met Ser Tyr 355 360 365 Leu λsp Pro Leu Phe Leu λrg He Phe Thr Thr λβp Leu λla Phe Cyβ 370 375 380 Glu Leu Pro Thr Leu Lyβ λrg Leu Gly Phe Phe Leu Leu Hie λrg Ser 385 390 395 400 He Thr Ser He Gin Tyr Val λla He Phe λrg λβn Aβn Pro He Arg 405 410 415 Gly Ser Ser Thr Ser Phe λβp λla Leu He Ser Val Met Ser Val He 420 425 430 Ser Ser λβp λβn Pro Tyr Pro Thr Phβ He Tyr Leu Tyr Phe Met Pro 435 440 445 Val He Hie λla Ser Val Val Ser λβn He Aβp λla λrg He Val He 450 455 460 Ser Val Val Cys λβp He λla Met λrg Thr Ser Glu Phe Ser Asp Val 465 470 475 480 Phe Met Phe Phe λla 485 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 469 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: aingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Aβn λrg λla Phe Phe Leu Trp Gly λrg Gly λβp Phe Ser Leu Ser λβn 1 5 10 15 He He Leu He λrg Ser Tyr λβn Lye Thr Leu Phe Leu Leu Hie Tyr 20 25 30 λrg Phe Ser Gin Hie Aβn Lyβ Gin He Leu Ser 40 45 He Hie Aen Glu λla λβn Hie Thr Tyr λβp Ser 55 60 Leu Met He λrg Ser Lyβ He Ser Gin λep Leu 70 75 80 He Ser Lye Hie Hie Lye Thr Leu Leu Thr Lye 90 95 λrg He Hie Lyβ λla Ser Leu Phe Glu Lyβ Thr 105 110 Phβ Lyβ Ser λβn Pro Met He Lβu λβn Lβu Ser 120 125 He He Leu Hie Leu Val Cyβ Phe Val Phe λβp 135 140 Gin He λβn He λβp Lyβ λβn Leu Leu Leu Gly 150 155 160 λβp Met λla Cye Leu Val λla Lyβ Tyr Leu He 170 175 λla Thr Tyr λrg Leu He Ser Val He Leu Pro 185 190 Phe Leu Val λla Leu Gly Met Leu Leu Aβn λla 200 205 λrg Ser Glu Gin λla λrg Thr Tyr Thr Thr Lyβ 215 220 Hie Gly Lyβ λβn Phe Ser Phe Phe Val Gly Trp 230 235 240 Tyr λrg Phe He Gin Phe Val Phe Tyr λβp He 250 255 Ser Aβp Val λβn λβp Gly Thr Ser He λrg Glu 265 270 Gly Gin Tyr Gin Glu Phe Tyr Gly λrg Ser λla 280 285 Tyr Gin Lyβ Hie Gly He Cyβ Phβ Gly Trp Trp 295 300 λrg Gin λβn λrg λen Glu Cye Leu Ser Ser Lye 310 315 320 Leu Ser Lyβ Gly Glu He Phe Ser Ser Phe Thr 330 335 Thr λrg Gin He Thr Ser Thr Leu Phe Tyr Tyr 345 350 Glu λβn Glu Leu Ser Pro Phe He Leu Val Val 360 365 λrg Ser Cye Phe Leu He Thr λβn λla Lyβ λla 375 380 Ile Gly Leu Phe Leu λla Ser Ser Leu Hie λβn Leu λβp Pro He Cye 385 390 395 400 Cye Hie He Lyβ Pro Hie λrg Lye Leu Hie Lye Leu Cyβ λla Hie Gin 405 410 415 Cye λβn Glu λrg λβn Gin Phe Gly Ser Leu Pro Tyr Phe Tyr Leu Ser 420 425 430 Leu Phe Tyr λla Cyβ Hie Leu λla Cyβ Leu Lyβ λrg Ser Phe Tyr λrg 435 440 445 Ser Hie Cye λβn Leu Cye Gly Val Tyr Cyβ λen Glu λβp Lye He Cye 450 455 460 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 462 amino acidβ (B) TYPE: amino acid , (C) STRANDEDNESS: einglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Gly Phe Phe Leu Met Gly Gin Gly Phe Phe He Gin Tyr Tyr Ser Tyr 1 5 10 15 Ser Leu Leu λβn Leu λla Phe Phβ He Thr Leu Leu He Phe Tyr Tyr 20 25 30 Ser Phe Leu Ser λla λla λβn Thr He Ser λla Thr Gin λβn Ser Gin 35 40 45 Ser Ser Tyr Leu Leu λβn Gly Lyβ He Gly Ser Tyr λβp Ser Phe Lyβ 50 55 60 λβn Phe Ser λrg Leu λsp Leu Glu Lye Phe Leu Tyr Phe Gin Thr Leu 65 70 75 80 λla λβn Leu Thr λβp Lyβ Leu Lyβ Ser Phe λla Hie Thr Gin Ser Leu 85 90 95 He Lyβ λβn Gin Ser He Phe Gly He Gin He Leu Lye Pro Hie λep 100 105 110 Phβ Lyβ Phe Lye λla Phβ Phe Lyβ Aβn Aen Ser λla Ser Ser Val Leu 115 120 125 Val He Cye Phe Tyr Gly Gly Gly Phe Pro λβn Tyr Lye Phe λla He 130 135 140 He Arg λrg Lyβ Gin Lyβ Gly Tyr Gly Leu Phe Gly Gly Lyβ He Phe 145 150 155 160 Aβp Leu Phe λla He Gly Gly Tyr Leu Ser Leu λβp Phe Met Ser λen 165 170 175 Leu Thr Aen λrg Phe Lys Asn Phe Leu Ser Ser Phe λrg Tyr λla He 180 185 190 Val Lyβ Cyβ Phe Leu Leu Lyβ Hie λla Leu Glu He λrg Thr Ser Lyβ 195 200 205 λen Leu Hie λen Gin Lye Lyβ λβp Ser Trp Glu Lyβ Phe Leu Leu Cyβ 210 215 220 Trp Val λla Glu Gin He Phe Leu Gin Val Tyr Pro Val He Cyβ Phe 225 230 235 240 Leu Tyr He Phe Cyβ Ser Phe Cye Trp λβp Leu Met Lyβ Hie Gly Lye 245 250 255 λβn Leu Thr Cye Leu Trp Thr He Ser λrg He Leu Trp Gin Lyβ Cye 260 265 270 λrg Met λβp Ser He Val Ser Lye Thr Trp λβp Leu Leu Trp Leu Val 275 280 285 Met Val Leu Val λla λla λsn Gin Thr Lyβ Pro Leu He Lyβ Val Ser 290 295 300 Leu Lyβ λβp Cyβ Ser Gly Val Leu Thr He λrg λβn Phe Phe He Phe 305 310 315 320 Hie λla Glu Leu Cye Lβu He λβn Glu λla He λep Tyr Leu λβn He 325 330 335 Met He Leu Leu Leu Lyβ Thr Pro Phβ Lyβ Val He Leu Thr Leu Tyr 340 345 350 Phe Ser Cye λβn λla Phe Leu Gin Pro He Lβu Leu Phe Val λen Tyr 355 360 365 Gin λrg Ser Aβp Trp Ala Phe Ser Cyβ Phe He λla Pro Leu λla λrg 370 375 380 Ser λsn Met Leu Pro Tyr Leu Glu He Thr Pro Leu Glu Glu λla Pro 385 390 395 400 Gin λla Leu Met λrg Ser Ser Val λla Ser Val λrg He He Pro Thr 405 410 415 Leu Leu Leu Ser He Phe He Leu Cys Leu Ser Ser Ser Met Pro Lys 420 425 430 λla Phe Leu He Leu Thr Leu λla Leu Ser Leu Trp Cyβ Val He Leu 435 440 445 Gin Gly Gin Val Aβn Leu Val Met Phe Ser Cye Phe Leu Pro 450 455 460 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19932 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: βinglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GGATλTλTTG λλCCλTTλλG TGCAAATGAT CTλTλTCGCT TCCATCGCAA TGλTλλTGλλ 60 ATGACTTTGG GTGGCTATCT CATCTλTλλC λGλCTTAATλ λλGTTλTTCλ AλTCCCCTTG 120 CAACAACTTT TTTCTATλCT TλCλCλCTλλ λATCAAATGG GCTTTTλGλT TλTGCTTGCT 180 TCGGTTGGTT GλλλTλTλCC CCCTTλλTGG GTλλTGGTTT TTTCTCλTTC CTCTλTCCTT 240 ATTCATTATT TATAAAAACA TTCTATAATA ATACAAGATA AAGATAAGGA GTTλTTTTTC 300 TTλλCGCTλT CλλGTTTλGλ λTTTλTCCTλ λCGCTCλλCλ λλλλGλGCTT λTTTCTλλλC 360 λTTTTGGCTG TTCTλGGGTC GTGTλTλλCT λCTTTTTλGλ TTλCCGλCλλ λλGCλλTλCG 420 CAAAAGGCTT AAAGAAλCTT ACTTCλCCλT GCAAAλλGTC TTAACCCAAA TCλλGCλCCλ 480 λGAAAAλTλC CATTACCTCA ATGλλTGCλλ TTCTCAAAGC TTGCAAATGG CGTTAAGλCλ 540 GCTTGTGAGT GCTTATGλTλ λTTTCTTTλG CλAAAGλGCG λGλTλCCCTλ λλTTCλλλTC 600 TAAAAAAAAλ GCTλλACAλT CTTTTGCAAT CCCCCAλλλC ATAGAAATCA AAACAGAGAC 660 TCAAACCATC GCTCTCCCTA AATTCAAAGA GGGCATTAAG GCTAAATTAC ACAGAGAATT 720 GCCTAAAGλT λGCGTTλTCλ λλCλGGCTTT TλTTTCTTGC λTAGCCGGTC AATλTTTTTG 780 TTCTATATCC TATGλλλCCλ AAGAGCCTAT CCCTAAλCCT ACCATCATTA λλλλλGCGGT 840 AGGTTTAGAC ATGGGCTTAA GAACGCTCAT TGTTACAAGC GATAAAATAG AATACCCACA 900 CATCCGTTTT TATCAAAAAT TAGAAAAGλλ ACTCACTAAA GCGGAAAGGA GGTTAAGTAA 960 AAAAGTAAAA GGCTCCλλCλ λCλGGλλλλλ ACAAGCTAAA AλGGTAGCTA GATTGCλTCT 1020 λGCTTGTTCλ AACACTAGAG λTGACTACTT GCATAAAATC AGTAATGAGA TAλCCAATCA 1080 ATACGATTTG ATAGGGGTAG λλλCTTTGλλ TGTTλλGGGG CTTATGAGAA CCTλTCλTTC 1140 TλAAλGCCTT GCTAATGCGA GTTGGGGGAλ ATTCCTTλCT ATGCTλλλλT ACλAAGCCCλ 1200 AAGAAAAGCT AAAACCCTλT TAGGCATAGA CλGATTTTTC CCTAGCTCTC AATTCTGTTC 1260 TTATTGTGGG TTCAATACAG GCAAAAAACA TGAλλλCλTC ACTλAATTCλ CTTCTCCTCλ 1320 TTGCAATATC ACACλCCACA GAGATTACAA TGCGAGCGTC AATATTAGAA ACTACGCTTT 1380 AGGCATGCTA GATGACλGGC λTAAAATAAA GATAGATAAA AGTAGGGTAG GGATTATCCG 1440 AλCTGλTTλC GCTCATTACA CTGATGλGCG CATCAAAGCT TGTGGAGCTT CCTCTAATGG 1500 GGTTλTTTCT AAATATGGCA ACATATTGGA TCTAGCTAGT TATGGAGCGA TGAAGCAAGA 1560 AAAAGCCCAλ TCGCTTTAGC GTTGGTAATT CACAAAAAGC AAGATCGGTT GTAAAAATCC 1620 GTTACAACTA AAATAAAGGG TCAAGATAAC TCATTTTCλλ AAAGGAGTCT TAAGTAATAA 1680 AATCATAATG TTCλGCTAGT AATCTATTGC CTCGTTGATC AAACAAAGCT CTGCGTGλλλ 1740 GATGλAAAAA TTTCACCTTT AGATAGTTAA TACACCACTA CAGTCTTλCT TGAGλGλCλC 1800 TCATTTTλTT AGCGGTTTTG TCTGATTTGC TGCTλCCAAλ λCCATTλCCλ ACCAAAGCAG 1860 ATCCCλTGTT TTTGλTλCTλ TCGAATCCAT TCTTCAGCλC TTCTGCCλTA λλATTCTTGA 1920 TATTGTCCAT AGGCAλGTTλ AATTTTTTCC CTAATGCTTC ATTAAGTCCC ATCATTAACA 1980 TCλGAAAGAA CAAAAAATTT AATATCATAG AAAACAAATC ACTGGATAAA CCTGTAAAAA 2040 GATTTGTTCC CCCACCCλλC AAAGAAGCTA AAATTTTTCC CATGATCAGT CCTTTTATTT 2100 TTGGTTGTGT AλGTTCTTGC TTGTTCTTλT CTCTAATGCG TGTTTTAGTλ GGλAGCATTT 2160 CACAATAGCA TACCTAAAGC TACTAAGAAA ATTCTTGAAT CTATTGGTAA GATTACTCAT 2220 GAAATCAAGC GATAAGTAGC CACCAATCGC AAACAAATCA AATATTTTGC CACCAAACAA 2280 GCCATATCCT TTTTGTTTTT λTCTCCTλλT TλTλGCλλλT TTTTλTCλλT λTTλλTTTGG 2340 λAAACCACCA CCATATCAAA AACAAATTAC TλλCλCλCTλ GATGCAGAAT TATTTTTTλλ 2400 AAACGCGCAC TTAAATTTAA AATCATGGGG TTTTAGGATT TGAATACCAA λAATAGATTG 2460 GTTTTTTCAA ATAAGCTAGC TTTGTGTATG CGCTTAAAAA GATTTTGGTT TTTAGTCAGT 2520 AAGGTTTTAT GCTλλTGTTT GGAAATAAAG AAATTTCTCT AAATCAAGTC TTGAGAAATT 2580 TTTGAACGAA TCATAAGAAC CAATTTTGCC ATTGAGTCAT AAGTATGATT AGCTTCATTG 2640 TGAATTTTGC GTGGCTTAAG AGATAGTATT TGCTTATTAT GCTGAGAGAA ACGAGTAGTA 2700 AAAGATAAGT AGTGTAATAA AAAAAGCTAG GTTTTATTAT AAGAGCGAAT AAGAATAATA 2760 TTGGATAAAC TAAAATCACC CCTGCCCCAT AAGAAAAAAG CCCTATTAAA AAACCTATAA 2820 CGATAGAGCT GATATTGAAC AGCCTATAAT AAAGGCTGTA CTTATCTλλλ TGTTTGTTGA 2880 AAGAATATTT GAATTGTAAG AAGTTTTGTT TTAATTTGCT λλTTTGGTTG GTTCCATTTT 2940 GGTTTTTAAλ GAAATAGTTC AGGGCGGTGλ ACTTATAAAG GAGCATAAAA TAATAAATAT 3000 TTTACAAAAC CACCCTAATC TAλCTCCλλλ TCTCAAAGAλ TACCCCλCTT GCTGATACTλ 3060 GCATGTGGTλ TAGCλCλλAC CλλCGATTTG TTTGTTTATG CCAAACAAAG AACλGAAAAC 3120 ATCTGTTλλλ GAATAAAGGA GTTTTCCATC TAAAAAACAC AAATCTATTA TATλGAAATλ 3180 ATCTTAAGAG AAACTTAAAA AATACCAACA AGCCGCATAC AAGCAAGAAA AACATAACAC 3240 TATAλGACCT GGATTTTATT TACCTTTTGG λTλTGGAAAA λTCTTGλTTC λTλGTTTTGT 3300 AAAAATTGTG GTAAAATGCA TTGATλTTCT TTGλAATTTT AλGGTTλCAA AAACTATAλG 3360 ATGCTTGCλλ λAATTGTTTT TλGCTCATTG GTTGCGTTTG GAGTTTTGTC GGCTλATGTG 3420 GAGCAGTTTG GTTCATTTTT CAACGAGATA AAAAλAGAAC AλGλλGAAGT GGCTGCAAAA 3480 GAAGACGCTC TTAλGGCTCG CAAGAAGCTC TTAAACAATA CGCATGATTT CTTAGAAGAC 3540 TTGATTTTTλ GAAAACAAAA AATCAAAGAG CTTATGGλTC ATAGAGCTAA AGTTCTTTCA 3600 GACTTAGAAA ACAAATACAA AAAAGAAAAA GAGGCTCTAG AGAAAGAGAC AAGAGGTAAA 3660 ATCCTTACTG CTAAGTCAAA GGCTTATGGG GATCTAGAGC AAGCCTTAAA AGλTλλCCCT 3720 CTCTATAAGA AλCTTCTTCC TAACCCTTAT GCCTATGTTT TλλλCCAAGλ AACATTCACC 3780 AAAGAAGATA AGGAGCGTTT GAGTTATTAC TACCCCCAGG TGAAAACGAG CAGTATTTTT 3840 GAAAAAACTA CCGCTACCλC TAAAGATAAG GCTCAGGCTT TGCTTCAAAT GGGTGTGTTT 3900 TCTTTAGλTG AAGAλCλAAA CAAAAAAGCG AGCCGATTAG CTTTATCTTλ CAAGCAAGCG 3960 ATTGλAGAAT ATTCCAATλλ CATTTCTλλT CTGTTGAGCλ GAAAAGAATT GGATAATATA 4020 GATTATTACT TACAGCTTGA AAGAAACAAG TTTGACTCCA AAGCAAAAGA TATTGCTCAA 4080 AAGGCTλCTλ ACACGCTTAT TTTTAλCTCG GAACGCTTGG CGTTTAGCAT GGCGATTGAT 4140 AλGλTTAATG AGAAATACTT AAAGGGCTAT GAGGCTTTTT CTAλCTTGTT GAAAAATGTC 4200 AAAGATGATG TGGAATTGAA TACTCTGACT AAAAACTTTA CCAATCAAAA λTTGAGTTTC 4260 GCACAλAAAC AAAAATTGTG TTTGTTGGTT TTAGACAGCT TCAATTTTGA TACCCAATCC 4320 AAAAAATCTA TATTAAAAAA GACTAATCAA TACAATATTT TCGTAGATAG CGATCCTATG 4380 ATGλGCGλCλ AAACAACTAT GCλλλλλGλλ CACTACAAGA TATTTAATTT CTTCAAAACA 4440 GTGGTTTCTG CATACCGλλλ CAATGTTGCC AAGAATAATC CCTTTGAATA GGAAAGGAGA 4500 CACTCTTGAA AAGCATCTTC λAAA λCTλG GTTCTGTCGC TCTTTλTTCT TTAGTTGTTT 4560 λTGGGGGCTT AAACGCTATC AATACAGCAT TATTGCCGλG TGAATACAAA GAATTAGTGG 4620 CTTTGGGCTT TAAAAAAλTC AλλλCλCTCT ATCAAAGACA TGATGACAAA GAλATTACAA 4680 AAGAGGAAAA AGAATTCGCC ACTAACGCTT TGAGAGAAAA ATTACGAAAT GATAGGGCGA 4740 GAGCAGAGCA AATTCAAAAG AATATTGAAG CGTTTGλλλλ AAAGAACAAC TCTTCTGTTC 4800 AAAλAAAλGC GGCTAAGCAC AAAGGATTAC AAGAATTAAA CGAAATTAAC GCTAλCCCTT 4860 TGAATGACAA CCCTAATGGC AATTCTTCCA CTGAAACCAA ATCTAATAAA GATGATAACT 4920 TTGATGAGAT GATCAATAAG GTGAATGAAT CTTTTGTGAA ACCTGCTGCT CCGCTTGTGC 4980 CTGATGAGTG GλGλλCGCCT GAAATTGλλλ TCATTATCAA TGAGTGTλTT ATTTCAλGCA 5040 ACGλTTλTGλ TGGGTTAλGA AAGTGTTTGA TCλAAGλCλT CAAGGATCAλ AλλλTTCTTG 5100 CCCCCTTATT AGAAAAAATT CAAGAAATAG AGACAGAAAA TAACAAGTTT TCTAGACλλC 5160 ACCTAAGTGG TTTAAAACTC ACTCTTAATA ACAGCAACAA TAGAACCTTT CTTATAGCTT 5220 CGTGCGCTAT TTGTGAGAAG AGAAAAAAAG AAATGGAGCA AGAAAATAAC TACCAGGλTλ 5280 CTACAAATGC AAGCGλGTTT GGCACTλCTG ΑTλCAAAAGλ λAATGAAGCλ AAAGλTλCAG 5340 CATTCTCAAA CAATCGCTCT AAATCCGAAC TGCCCAATAG CGTCATTAAT CAAATAGAAC 5400 AAAGCATCGC TCλTGGAAAλ AAATAGCGAT CCλ λTTλTT AGATCAAAAA ACAACTAGAG 5460 AAGCAAATCC CAAAGGTTAG AAATCATAGC CTATCATCTC AGAAAAATCA TTTAλCλλTG 5520 ATCTTλCTTG λTTGCCTTTC TTGTAGGTλT TGTCGCTTλC TTTGTTCTλG GGλTCTTTCT 5580 AATGCGTCCA ACTCCTCTAA ATAATTTAAA AAGACCTTGT TTTGAGCTAA CATAAGCTTT 5640 CTGATTCCTT TGATGAAATT TTTATTCTTT AGGCTTTCTλ CAAGCGTCTG TGAAGCAGTG 5700 ATTAAAGAAG CTGTACCTCC AATGTTGCTC TGATλCGCCT TTAGGGAAGT TTCTAλλCGC 5760 TCTCTTATAT TTTGTTTTTC TTGCTCGATT TTCAGCTTCC CTTCACλλTλ AAGAACTAAA 5820 ACTTTλTCGG λTλTTCCGCλ TTGCTGCTCλ GCλGTλTTTT GGTCTλλGGG λTTGλTTTTC 5880 ATATAGGTTA ATAAAAGTTC AGGGCTAGAC ATATAAGTCT TGAAAATCAC ATCTTCTGAG 5940 ATGAAAAATA ACTCATTCGC TTCAAAATTG GCTTTCAATλ ACGCTAAATC TCCTCTCAAA 6000 GCλλTGGCCG CTTTTTTGλT GTTTλGλGCλ TCTTCTTGλC CTλTTTCλTT λTTλGCGCTλ 6060 GGGCTλGTGG TTGAAAAAAT CTCλTCTλλG TTTTTλλGCλ CTTGTTGGTT GGTCTCTTGG 6120 TλGGTGCTλT CλλGTTGCTT TλλλCCGCTT GTTλTλTCTT CTCCCλTCλλ λACAGACAAT 6180 AGCAAAAAAG λλGλTλTGGT λTTTTTCλCG λGTGTTTTCλ TTTGλCλλTλ λCTTTλGλGC 6240 TλGCλλTGTT TCTTGCTGTC GTTTCTCTTT CTAATTTCAG TTGTTCTTCC CAAAGGTCGG 6300 CTTTTTTTTC λλGλTTCTCT λTλTλGTTTλ λλTGλTTTTC TGCGTTTλλβ λTCGCλλCTT 6360 CTλTGλGCGC λTTCλλλTCT λCTGλTCCTT TTλλGGTTTT GλTTTCTCCλ TTGλTCCCλT 6420 TCλλλTλλGC GλTλTTTTGλ AAATCTGCAT CλCTCλGTTT λTTTTGλλTλ λGGGCTλCλλ 6480 TCλTTCTGTλ λTTCTGλλTλ λCCTGTTCCλ TλλGGCλTGC TGλλλTTTTT λGCCCλTCλλ 6540 GλTλλGGGCλ TTTTGTGGGC GCTλGλGTGλ λTGTTTCλλT GATTCCAAAT GGTCGCCCλT 6600 GCTTGAAAAA AAACTAAGAG CλGGCGCλTλ GλTGGCλCTT TGλλλCλλλG CCTGλCCTGT 6660 TAGGGAATTA TAATCAATAA GGGTCGCTTT TTGCλTλGCT GTTTTCλλCC λTGTCTCλλλ 6720 λCCTTTTAAG GTTTCTTCAλ λCGCCTTGλT λCCλλTCGTλ TTGTλλGCGλ TGTλTTGλGC 6780 GTTGTCAGAA GAACTTCCTA GAGCTTGAGA AATTTCCATT TGTGTTTTTA GGGTAλCCCT 6840 CGGTTCAAAG CTGTTTTTTλ ACGCTTCTAA GAGAGCGTTT TGCTGGTTCA TTTTGAGCTT 6900 GATCλTTTCβ TTλTTTTTTT GGλGCGCGλT TTGCλTGTTT TGGλTTTCTG TTTGGGTλTT 6960 AλTTTTTTGT TTTTCCλCGλ TCλTTTTGλC λTTCCCCCCC λλTGCλCTλλ GCGCCGCTTG 7020 AATλCCCTTC CλTGλCGCCλ λGCλλGλTGT CTGλλCCTGC AAAAAACCCC CCTGTCλTGC 7080 CATTGACACC ATTAATAACG CCATTAGCCC CTTTTAλCλT AGCGCTCλTG GTTGCλAGCT 7140 GAGTCCTCAA TTCTCCCTCT ATTTGCGCTT GAλTGGCTTT TTCTTTGGCA CTAGλTTGλG 7200 CTTCTATGGC TTTTAATTCG GCGTGλGCGG TTTTTTGTTT GGCTTGTGCG TCTGCCTGAA 7260 TGGCTTTTλλ GGCAGGTTCA AGCGTTATTA CTACCTCTGT ACCATTCAGA GACAAACCAC 7320 AλλλλGTCλλ GAAAGAAAAT ATGCTTAAAA AλCλTTTCAC ATCTCTTTCC TCλCTTCACG 7380 ATTλTTTTλG TTTGCACCCT TTCTGTTλλG TλGCTλTCTT TTTGCCCCTT λλGCTTGTCT 7440 TTGATGTAAT CAAGGTAAGT CAAATGCGAT TTCAAAAAAG ATTTATTCGC TACTATATTG 7500 TAATTATATA GCGAACTTAT GTTAGAAATC GCTTGAGTGT CATAGGTGCT AGTAGCTAAT 7560 CCTGATTGAT TAAGTATCAT TTGAGAAGCG TTCTGCλλCλ AATTGGTATT ATTTTTCACλ 7620 AλTTCTATλT λGTλTTCTCT CλλλλTTTCT GCTACTTTTT CAGCATAGCA ATλλλCλGCλ 7680 AGAACCTTGT CCCCλλTAGG GCλTGCλGGA GTGGTTATAG GATTAACCCC TGAAGTTAGG 7740 GCATTAGTGC GTAACGCTTG GTATTTAGCA TAAACAGTGG GCATAGAAAC GCTCATGGGG 7800 CGTCATAGAA ATTTGCATGC λλCTGλλλλλ CλCTTTTGAT GAGCCλλCAλ GCGCACCTAA 7860 AGCGGTλCλG CTATCAAGGA ATCGGTGTAT CATTCλTTGλ GCTGTTGCTT GCTTGAGAAG 7920 CCAGTTGCTC TTGTλGλGCT λGGGCGTλTT TTGGTGCTGC λCTTGTλλTλ TTGCCTλλTλ 7980 TACCGTCATC ATTTCAACCG TTGTTGGCλC GCTAGGAACA GCGATTTGAT TTGTCGCATA 8040 AGCTTCλλTλ GCACTGGGAT TTTTλGGGGT GGTGTTλCTC GCTλλλλTGC TTGCλλTCTG 8100 ACTλTTλλCλ GCλCCλλTTT GCGCGCCTTG GCTGTTGCCT TGAGCGTTAA λTTCCCCTGT 8160 TλλTTTGCTλ ATATTTAAGA TATTGTTCCC CACAGCCATG CTTTGATCGT TAAAACCTTG 8220 ATACAATTGG TTGTATTGTT GGTTAGCGGC TTTCATAGGC ATGCTTACGG CTTCAGCGAT 8280 GCTTTGATTG TλTTGGGTCλ TGATAGCGGT CATTTGCGGA TTAGTλλλCC CAACAATAAT 8340 AGGAATλATC GCTGCTGTCλ TAGCλCCCGC TACTATTCCT GCAAATGGTC CTGCGACACC 8400 ACTTGTGTTG AGATGATTGA GGAAACTTCC GATAAGAAGC CTGCAGAAGA TGATTCATAT 8460 ATAGCTTGTG TλCCTGCCAT GTTλλCλCCC CCTλGTTλλT λCCCTλλTλT CGGTGGTλλλ 8520 AACGATGAAT CTGAGTATGT TGGTGCATAA CCATACATGA AAGGATTGTT TGGACCGTλλ 8580 TCGCCCATCA TTTGGCTCAT GAGAAGATTT TGAATGCCCC ACATCGCATT GATACCTAGA 8640 TTATCATTAG GTTGAAλλCT CCCTAAACTT λTGTCGTCAA ATTTGATATT AλCλTTTTTλ 8700 TCλTTλTλGT CλTTGλGTλT GGCCλCTTTT TGCTCTλGGG TTTCTTTλGG GλTCTCTλTT 8760 TTTAGTTGAT CTCTAGAAAC AAGCCCCACG CTATTTAGTG CCATλTCTTC AGGλCTλλTλ 8820 TCTTTTATAT CAGTGTTTTG GTCλGCGTTλ ACGGλCTGTλ AλCλTGCCAA TGATAAGACA 8880 CCAAGCAAAT λGTλλTTTλλ TTTTλTλλλλ λTCCGTTTTC λTλCTTTTGλ CTCCTTTλTT 8940 CTTλTTTTTλ GCλCTATTCT λGCGCλTTλλ CGCCACTCAA TCGTTATTTT TGTTTTGATT 9000 TTTTTGATCG AGCλTTTTGT TTGTTλCTTC λTCAATGTTT TGAAAATλTT TTTCAAAAAG 9060 CTCTTTCTTT TTAGCTTCλλ CGCTCATλTC AATCTGAATC CAATTAGGAλ TAΛTCCλCTC 9120 CATGATTAAA TGCATGλλGT CATAGGCATG ATTTTTTGGG TATλTTTTGT TCTGAACλTA 9180 GTATTCTAAA AAATTCGCTT GAACAAAAAA λATCTCTATA TCGCTCTGCλ TATCCTCCCT 9240 TATGTTGTTλ TTGλTλGGTT TTTCTλGTλλ TCTGλGλλTC CTλTλCGλCT GCATCλTAGT 9300 TTCTAGCATG AAGTAAGCAT AλλCλTλλλC TAATGAGACA AAAGAATTGT TTGCTTTAAλ 9360 CGAGCTTGCG TCATTTTTCC CλCTTTGλλG λGGλλTTλλT CTTGλTλλTG TTTTTTGGGG 9420 ATCTTGCCCλ TCGTTTATTT CTTTAAAAAA GCGGAλλTCT AAATCCTGAT TACTGλGλλλ 9480 TGACTTGACA AAGTGAAGAT TAGCATTGAG ACTATCTATG AGACCTGAAT AAAGGTGCTC 9540 TGTTTTGACA TCATCTATAT TTAAAACATT CTCATAAAAC ACATTGACAT GGTCTTCTλλ 9600 GAAATTAGAA AAGTCATAAA GAGTGGTAAG GTTTTGTTCA GTGATTTCGC CTTCCATTTC 9660 TTCTTCTATG AAGTCCAATT CTTCTTTCAG TTCλλλλλGλ TAATTAGAAA AACTATCCAA 9720 AATCGTCAAG ACATCATTTT CAλλλTTTCC λλTλλTTTTT GTTCλCGCλλ ATTTTGTTTC 9780 λTTTTAATAC TCCTCTATTT GTTGλTλCλT TTGTCTCλλG GCCTGλTλTT TλTCTλTGλT 9840 λCTλTGGTTT TGGλTλλTCT TλTCλATTTC TTTGACλAAT λCλGTλTCTG TGGλTλλλλT 9900 TTTCAAATAT TCTTTAGGAA TGCCTCTCAλ λTTλAAACTλ GCGATAACGC TAGGGCTTCC 9960 ATCCTGTTTG TλGλGGλTTT TCCTλTCTλβ TCCCTTλGTG λTGλTTTCλλ λTTCTTTTTC 10020 TGTλλCλTTλ GCCAATCTTT GGTAλTCλGλ λλGλTTGCCC CCλTCGTTTC TCλλλλλλλT 10080 CTTTGTλGGG CλTTGTTCTC TλλTCGTλTC λGCλλTλGGG CλλGCCλλλλ GλTCλGTGλT 10140 GCTTTGλGTC GCλλGTCTGλ CλλTλGCGTT TCTTTTCCTT GCλGTTTTTλ GCλTGTCTCT 10200 TACAAAATAA GCGλCCTTTG GATCGCCTAλ ATATTTCCAG GCTTCλTCλλ TλTCTλλGλC 10260 AλλTCTλCGC CCATCCATTG CCTCTTGGλT ACGAGCGAAA λGGTλλλλλC λλλTλλλβββ 10320 CGAAACATCA TTATTGTCTA AGAAACTTGA CCCλTCλλCG CCλλTλλTCG TTTTTGλλλλ 10380 ATCTλλGCGλ TCTGTTGCTT TATTATCAAA AAGCCATTGA λATTCACCAT TGGTTGATTT 10440 GCAAAAAGGC GCTAATCGCG CGACAAGCCC λTTAGGATCA TTGTGGTCTT TCCCGλλλGC 10500 ATTAATAAGT TGλGTGλTGG GλTλλTCTλG λTTCλTλTTT CCTGTGATAA GGTTGGTTλC 10560 TGCGCTGCAA GCGTATTAGλ λTCTGCTλGG CTAAAAGAGA TGCTGTTGCC λTTTTCλTCT 10620 TTTTCλTCGC TTTTAGTTGC TAAGTTTTTC ACAAGCTCTT TGACAACAGA AATλGCTGTT 10680 TGTTTTTGCT CCATTGTTGC λTTTGTTTTT TGCACACAAG CCGCCCλλGC AAAAGGATTT 10740 λλTCCTGTλT CTGTCCCTλG CTCλλTCTTG λCATACTCCC CλCCCλTTGC GλCλλTλTTC 10800 CCATAAGCGC CATAATCTTT ATCCATATAA ACCATAGTGA GCTTTTGCTT GTCTTTGCTG 10860 ACATTAGCAG GAAAATTATA GGCAAATTGT CCCATAGCGT TCAAGGTCAT TGACATAAAC 10920 ACTGTCTTAC CTGλλCCGGT TGλGCCλλGT ATCAAAGTGT GTCCTGCTGλ λGCTGλλCCλ 10980 AAATCAGTGG GCλTGTGGAλ GTTCAGATAA AAAGGCGAAT TGATCTCGCT TTTTAGCGTC 11040 ATCλCACTAT TGCCCCAAGC GTTATTCTCT TGATTGCCλT CλλλλCTCAT AGCCCTCATA 11100 GCGATGAAAT CAGCAAAATT ATTλGAAGTT ACATCAAAAA TAAAAGGAλG CGTGATλλλλ 11160 GAGCAATGTT TGGCAAAAλλ GTλλTTTTCC ATAGAGAAAG TCGCTGCGTT GGCTAAAAAA 11220 CCTTTAGCGT TAλGACTAGλ GACGCATTCC TTAλCGCTTT GTTTCλTTTT TTCAAλGCTλ 11280 TCAGCAAACA GCACTAAAGA ATTλCCATAλ CTGCCTAGCG TAATATCλCC ATTACCCACT 11340 AATTCGCTCA AGCAACCTAA AGTCATGCCC TGTTCTTTAG AGCCTCCACT AATAATAATT 11400 CTTCTAGAGG TGAAAGCCAG TTTGTCCTTT AAAACCTGTG AGTTTTTAGG CGAATAAGCA 11460 TGCATGAAAA TAAATTCGCT GTCTAGGGCG TTGATTTTAT CAAACAAATC GCTTTGTGAT 11520 TTAGGGGCGT ATTCACTAAT CTCλATAGCG CTAAAATATT TTTCACTCAA ATCGTCATTT 11580 AλGλTTTTTC CATGCTTATT GGCAAAATAA ACTTCTTTCλ CCCCλCCATG CATTTTTTCC 11640 TTGAGλTλCλ AGTCTTTTCG GTTGCAAATλ AAλGGGGCTT CATTCλTTCC CACAAGAAAA 11700 TTGTAAAATT CGCATTGTTT GGAGTAAATA ACGCCATCTT TAGTGTATTC TTTTAATCTA 11760 GTGGGGTGGT ATTTGCTCλλ CλGCTCTTCT ATGAGCTCTA TCCTATCCTT GAλGTTTTCλ 11820 AGCTTGGCTC TAATAATCCT TTGAAACTCT TCAAAATTAT TGTCTGCAAA ATGCTTTTTA 11880 TTCATAACGG GTTCATTGAG AGTGTCTAλT AλλTCTTGCT CTATGGTCAG AAAAAAACTA 11940 TATTTTTCλT TCATTAAGTT TAAAAATTCT TCATTGTCCT TAGTTTGTTG CATTTTλGλA 19920 TAGACλAλGC TT 19932 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 396 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: βinglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Leu Leu Phe λrg Leu Pro Thr Lyβ λla He λrg Lyβ λrg Leu Lye Glu 1 5 10 15 Thr Tyr Phe Thr Met Gin Lyβ Val Leu Thr Gin He Lye Hie Gin Glu 20 25 30 Lye Tyr Hie Tyr Leu λβn Glu Cye λsn Ser Gin Ser Leu Gin Met λla 35 40 45 Leu λrg Gin Leu Val Ser λla Tyr λβp λsn Phe Phe Ser Lyβ λrg λla 50 55 60 λrg Tyr Pro Lys Phe Lyβ Ser Lye Lyβ Lyβ λla Lye Gin Ser Phe λla 65 70 75 80 He Pro Gin λβn He Glu He Lyβ Thr Glu Thr Gin Thr He λla Leu 85 90 95 Pro Lyβ Phe Lyβ Glu Gly He Lyβ λla Lyβ Leu Hie λrg Glu Leu Pro 100 105 110 Lye λep Ser Val He Lyβ Gin λla Phe He Ser Cye He λla Gly Gin 115 120 125 Tyr Phe Cyβ Ser He Ser Tyr Glu Thr Lyβ Glu Pro He Pro Lyβ Pro 130 135 140 Thr He He Lyβ Lyβ λla Val Gly Leu λβp Met Gly Leu λrg Thr Leu 145 150 155 160 He Val Thr Ser λsp Lyβ He Glu Tyr Pro Hie He λrg Phe Tyr Gin 165 170 17S Lyβ Leu Glu Lyβ Lyβ Leu Thr Lyβ λla Glu λrg λrg Leu Ser Lyβ Lyβ 180 185 190 Val Lye Gly Ser Aβn λβn λrg Lyβ Lyβ Gin λla Lyβ Lye Val λla λrg 195 200 205 Leu Hie Leu λla Cye Ser λβn Thr λrg λsp Asp Tyr Leu Hie Lye He 210 215 220 Ser λβn Glu He Thr λβn Gin Tyr λβp Leu He Gly Val Glu Thr Leu 225 230 235 240 λβn Val Lyβ Gly Leu Met λrg Thr Tyr Hie Ser Lyβ Ser Leu λla λβn 245 250 255 λla Ser Trp Gly Lyβ Phe Leu Thr Met Leu Lyβ Tyr Lye λla Gin λrg 260 265 270 Lyβ λla Lyβ Thr Leu Leu Gly He λsp λrg Phe Phe Pro Ser Ser Gin 275 280 285 Leu Cyβ Ser Tyr Cyβ Gly Phe λβn Thr Gly Lyβ Lyβ Hie Glu Aβn He 290 295 300 Thr Lyβ Phβ Thr Cye Pro Hie Cyβ λβn He Thr Hie Hie λrg Aβp Tyr 305 310 315 320 λβn λla Ser Val λβn He λrg λβn Tyr λla Leu Gly Met Leu λβp λep 325 330 335 λrg Hie Lyβ He Lyβ He λβp Lyβ Ser λrg Val Gly He He λrg Thr 340 345 350 λβp Tyr λla Hie Tyr Thr λsp Glu λrg He Lys λla Cys Gly λla Ser 355 360 365 Ser λβn Gly Val He Ser Lyβ Tyr Gly Aβn He Leu Aβp Leu λla Ser 370 375 380 Tyr Gly λla Met Lye Gin Glu Lyβ λla βln Ser Leu 385 390 395 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 124 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Glu Thr Leu He Leu Leu λla Val Leu Ser λβp Leu Leu Leu Pro Lyβ 1 5 10 15 Pro Lβu Pro Thr Lyβ λla λβp Pro Met Phe Leu He Leu Ser λβn Pro 20 25 30 Phe Phe Ser Thr Ser Ser λla He Lyβ Phe Leu He Leu Ser He Gly 35 40 45 Lyβ Leu λβn Phe Phe Pro λβn λla Ser Leu Ser Pro He He Asn He 50 55 60 λrg Lyβ λβn Lyβ Lyβ Phβ λβn He He Glu λβn Lyβ Ser Leu λβp Lyβ 65 70 75 80 Pro Val Lyβ λrg Phe Val Pro Pro λβn Lyβ Glu λla Lyβ He Phe Pro 85 90 95 Met He Ser Pro Phe He Phe Gly Cyβ Val Ser Ser Cyβ Leu Phe Leu 100 105 110 Ser Leu Met λrg Val Leu Val Gly Ser He Ser Gin 115 120 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 382 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Gly Tyr Lyβ λβn Tyr Lyβ Met Leu λla Lye He Val Phe Ser Ser Leu 1 5 10 15 Val λla Phe Gly Val Lβu Sβr λla λβn Val Glu Gin Phβ Gly Sβr Phe 20 25 30 Phe λβn Glu He Lyβ Lyβ Glu Gin Glu Glu Val λla λla Lyβ Glu λβp 35 40 45 λla Leu Lyβ λla λrg Lye Lye Leu Leu λβn λβn Thr Hie λβp Phe Leu 50 55 60 Glu λβp Leu He Phe λrg Lye Gin Lye He Lyβ Glu Leu Met λβp Hie 65 70 75 80 λrg λla Lyβ Val Leu Ser Aβp Leu Glu λen Lye Tyr Lyβ Lye Glu Lyβ 85 90 95 Glu λla Leu Glu Lyβ Glu Thr λrg Gly Lyβ He Leu Thr λla Lyβ Sβr 100 105 110 Lyβ λla Tyr Gly λβp Leu Glu Gin λla Leu Lyβ λβp λβn Pro Leu Tyr 115 120 125 Lyβ Lys Leu Leu Pro λen Pro Tyr λla Tyr Val Leu Aβn Gin Glu Thr 130 135 140 Phe Thr Lyβ Glu λβp Lyβ Glu λrg Leu Ser Tyr Tyr Tyr Pro Gin Val 145 150 155 160 Lyβ Thr Ser Ser He Phe Glu Lyβ Thr Thr λla Thr Thr Lyβ λep Lyβ 165 170 175 λla Gin λla Leu Leu Gin Met Gly Val Phe Ser Leu λβp Glu Glu Gin 180 185 190 λβn Lyβ Lye λla Ser λrg Leu λla Leu Ser Tyr Lye Gin λla He Glu 195 200 205 Glu Tyr Ser Aβn Aen He Ser Aβn Leu Leu Ser λrg Lyβ Glu Leu λβp 210 215 220 λβn He λβp Tyr Tyr Leu Gin Leu Glu λrg λβn Lyβ Phβ λβp Ser Lyβ 225 230 235 240 λla Lyβ λβp He λla Gin Lye λla Thr λβn Thr Lβu He Phe λβn Sβr 245 250 255 Glu λrg Lβu λla Phβ Ser Met λla He Aβp Lye He λβn Glu Lyβ Tyr 260 265 270 Leu Lyβ Gly Tyr Glu λla Phβ Ser λβn Leu Leu Lye λβn Val Lye Aβp 275 280 285 Aβp Val Glu Leu Aβn Thr Leu Thr Lye λβn Phe Thr λβn Gin Lyβ Leu 290 295 300 Ser Phe λla Gin Lye Gin Lyβ Leu Cyβ Leu Leu Val Leu λβp Ser Phe 305 310 315 320 λβn Phe λsp Thr Gin Ser Lyβ Lyβ Ser He Leu Lyβ Lyβ Thr λen Glu 325 330 335 Tyr λβn He Phe Val Aβp Ser λep Pro Met Met Ser λβp Lye Thr Thr 340 345 350 Met Gin Lye Glu Hie Tyr Lye He Phe λβn Phe Phe Lyβ Thr Val Val 355 360 365 Sβr λla Tyr λrg λen λβn Val λla Lyβ λβn λβn Pro Phβ Glu 370 375 380 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 312 amino acide (B) TYPE: amino acid (C) STRλNDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: He Gly Lyβ Glu Thr Leu Leu Lye Ser He Phe Lyβ Lyβ Leu Gly Ser 1 5 10 15 Val λla Leu Tyr Ser Leu Val Val Tyr Gly Gly Leu λβn λla He Aβn 20 25 30 Thr λla Leu Leu Pro Ser Glu Tyr Lye Glu Leu Val λla Leu Gly Phe 35 40 45 Lyβ Lyβ He Lye Thr Leu Tyr Gin λrg Hie Aβp λβp Lye Glu He Thr 50 55 60 Lyβ Glu Glu Lyβ Glu Phe λla Thr λβn λla Lβu λrg Glu Lye Leu λrg 65 70 75 80 λen λβp λrg λla λrg λla Glu Gin He Gin Lye λβn He Glu λla Phe 85 90 95 Glu Lyβ Lyβ Aβn Aβn Ser Ser Val Gin Lys Lye Ala λla Lye Hie Lye 100 105 110 Gly Leu Gin Glu Leu λen Glu He λβn λla λβn Pro Leu λβn λβp λβn 115 120 125 Pro λβn Gly λβn Sβr Ser Thr βlu Thr Lye Sβr λβn Lyβ λβp λβp λβn 130 135 140 Phβ λβp Glu Met He λβn Lyβ Val λβn Glu Ser Phe Val Lyβ Pro λla 145 150 155 160 λla Pro Lβu Val Pro λβp Glu Trp λrg Thr Pro Glu He Glu He He 165 170 175 He λsn Glu Cys He He Ser Ser λsn λsp Tyr λsp Gly Leu λrg Lyβ 180 185 190 Cyβ Leu He Lyβ Aβp He Lyβ λβp Gin Lyβ He Leu λla Pro Leu Leu 195 200 205 Glu Lye He Gin Glu He Glu Thr Glu λβn λsn Lyβ Phe Ser λrg Gin 210 215 220 His Leu Ser Gly Leu Lyβ Leu Thr Leu λβn λβn Sβr λβn λβn λrg Thr 225 230 235 240 Phe Leu He λla Ser Cyβ λla He Cyβ Glu Lyβ λrg Lyβ Lyβ Glu Met 245 250 255 Glu Gin Glu λsn λsn Tyr Gin λsp Thr Thr λβn λla Ser Glu Phe Gly 260 265 270 Thr Thr λβp Thr Lyβ Glu λβn Glu λla Lyβ λβp Thr λla Phe Ser λβn 275 280 285 λβn λrg Ser Lye Ser Glu Leu Pro λβn Ser Val He λβn Gin He Glu 290 295 300 Gin Ser He λla Hie Gly Lye Lye 305 310 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Val Cyβ Tyr Cyβ Glu Met Leu Pro Thr Lyβ Thr λrg He λrg λβp Lye 1 5 10 15 λβn Lyβ Gin Glu Leu Thr Gin Pro Lyβ He Lyβ Gly Leu He Met Gly 20 25 30 Lye He Leu λla Ser Leu Leu Gly Gly Gly Thr λβn Leu Phe Thr Gly 35 40 45 Leu Ser Ser λβp Leu Phe Ser Met He Leu λβn Phβ Leu Phe Phe Leu 50 55 60 Met Leu Met Met Gly Leu λβn Glu λla Leu Gly Lyβ Lyβ Phe λβn Leu 65 70 75 80 Pro Met λβp Met He Lye λβn Phβ Met λla Glu Val Leu Lyβ Aβn Gly 85 90 95 Phe Aβp Ser He Lyβ λsn Met Gly Ser λla Leu Val Gly λβn Gly Phβ 100 105 110 Gly Ser Ser Lye Ser λep Lye Thr λla λβn Lyβ Met Ser Val Ser βln 115 120 125 Val λrg Leu 130 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 136 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Aβn He Tyr Tyr Phe Met Leu Leu Tyr Lye Phβ Thr λla Leu λβn Tyr 1 5 10 15 Phβ Phβ Lyβ λen Gin λβn Gly Thr λen Gin He Ser Lye Lβu Lyβ Gin 20 25 30 λβn Phe Leu Gin Phβ Lyβ Tyr Ser Phe λβn Lye Hie Leu λβp Lye Tyr 35 40 45 Ser Leu Tyr Tyr λrg Leu Phβ λβn He Ser Ser He Val He Gly Phe 50 55 60 Leu He Gly Leu Phe Ser Tyr Gly λla Gly Val He Leu Val Tyr Pro 65 70 75 80 He Leu Phe Leu Phe λla Leu He He Lyβ Pro Ser Phe Phe Tyr Tyr 85 90 95 Thr Thr Tyr Leu Leu Leu Lβu Val Ser Leu Ser He He Ser Lyβ Tyr 100 105 110 Tyr Lβu Leu Ser Hie λla Lye Phe Thr Met Lyβ Leu He He Leu Met 115 120 125 Thr Gin Trp Gin λβn Trp Phβ Lβu 130 135 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 79 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: He Lye Ser λrg Ser Tyr Ser Val Met Phe Phe Leu Leu Val Cyβ Gly 1 5 10 15 Leu Leu Val Phe Phe Lye Phe Leu Leu λrg Leu Phe Leu Tyr λβn λrg 20 25 30 Phe Val Phe Phe λrg Trp Lye Thr Pro Leu Phe Phe Aβn λrg Cye Phe 35 40 45 Leu Phe Phe Val Trp Hie Lyβ Gin Thr λβn λrg Trp Phe Val Leu Tyr 50 55 60 Hie Met Leu Val Ser λla Ser Gly Val Phe Phe Glu He Trp Sβr 65 70 75 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 241 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βinglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Ser Tyr Cyβ Gin Met Lyβ Thr Leu Val Lyβ λβn Thr He Ser Sβr Phe 1 5 10 15 Leu Leu Leu Ser Val Leu Met Gly Glu λβp He Thr Ser Gly Leu Lye 20 25 30 Gin Leu λβp Ser Thr Tyr Gin Glu Thr λβn Gin Gin Val Lβu Lye Aβn 35 40 45 Leu Aβp Glu He Phe Ser Thr Thr Ser Pro Ser λla λβn λβn Glu He 50 55 60 Gly Gin Glu λβp λla Leu λβn He Lye Lye λla λla He λla Leu λrg 65 70 75 80 Gly λβp Leu λla Leu Leu Lyβ λla λen Phe Glu λla λβn Glu Leu Phe 85 90 95 Phe He Ser Glu λβp Val He Phe Lyβ Thr Tyr Met Ser Ser Pro Glu 100 105 110 Leu Leu Leu Thr Tyr Met Lyβ He λβn Pro Leu Aβp Gin λβn Thr λla 115 120 125 Glu Gin Gin Cyβ Gly He Ser λβp Lyβ Val Lβu Val Leu Tyr Cyβ Glu 130 135 140 Gly Lyβ Leu Lye He Glu Gin Glu Lye Gin Aβn He λrg Glu λrg Leu 145 150 155 160 Glu Thr Ser Leu Lyβ λla Tyr Gin Ser λβn He Gly Gly Thr λla Ser 165 170 175 Leu He Thr λla Ser Gin Thr Leu Val Glu Ser Leu Lye λβn Lye λβn 180 185 190 Phe He Lyβ Gly He λrg Lyβ Leu Met Leu λla Gin λβn Lyβ Val Phe 195 200 205 Leu λβn Tyr Leu Glu Glu Leu λβp λla Lβu Glu λrg Sβr Leu Glu Gin 210 215 220 Ser Lyβ λrg Gin Tyr Leu Gin Glu λrg Gin Ser Ser Lyβ He He Val 225 230 235 240 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: eingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Phe Phe Phe Lyβ Hie Gly λrg Pro Phβ Gly He He Glu Thr Phe Thr 1 5 10 15 Leu λla Pro Thr Lye Cyβ Pro Tyr Lβu λβp Gly Leu Lyβ He Ser λla 20 25 30 Cyβ Leu Met Glu Gin Val He Gin λsn Tyr λrg Met He Val λla Leu 35 40 45 He Gin λβn Lyβ Leu Ser λβp λla λsp Phe Gin λβn He λla Tyr Leu 50 55 60 λβn Gly He λβn Gly Glu He Lyβ Thr Lβu Lyβ Gly Ser Val λβp Lβu 65 70 75 80 λβn λla Leu He Glu Val λla He Leu λβn λla Glu λen Hie Leu λβn 85 90 95 Tyr He Glu λβn Leu Glu Lyβ Lyβ λla λep Leu Trp Glu Glu Gin Leu 100 105 110 Lyβ Leu Glu λrg Glu Thr Thr λla λrg λβn He λla Ser Ser Lyβ Val 115 120 125 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 170 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: aingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: Gin Gly Gly Phe Leu Gin Val Gin Thr Ser Cye Lβu λla Ser Trp Lye 1 5 10 15 Gly He Gin λla λla Leu Ser λla Leu Gly Gly λβn Val Lye Met He 20 25 30 Val Glu Lye Gin Lye He λen Thr Gin Thr Glu He Gin λβn Met Gin 35 40 45 He λla Leu Gin Lye λβn λβn Glu Met He Lyβ Leu Lyβ Met λβn Gin 50 55 60 Gin λsn λla Leu Leu Glu λla Leu Lyβ λβn Ser Phe Glu Pro λrg Val 65 70 75 80 Thr Leu Lyβ Thr Gin Met Glu He Ser Gin λla Leu Gly Ser Ser Ser 85 90 95 λβp Aen λla Gin Tyr He λla Tyr λβn Thr He Gly He Lye λla Phβ 100 105 110 Glu Glu Thr Leu Lyβ Gly Phβ Glu Thr Trp Leu Lye Thr λla Met Gin 115 120 125 Lye λla Thr Leu He λβp Tyr λβn Ser Leu Thr Gly Gin λla Leu Phe 130 135 140 βln Sβr λla He Tyr λla Pro λla Leu Ser Phe Phe Ser Ser Met βly 145 150 155 160 λβp Hie Leu Glu Ser Leu Lyβ Hie Ser Leu 165 170 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 122 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: Ser Glu Glu λrg Aβp Val Lye Cye Phβ Leu Ser He Phe Ser Phe Leu 1 5 10 15 Thr Phe Cyβ Gly Leu Ser Leu Aen Gly Thr Glu Val Val He Thr Leu 20 25 30 Glu Pro λla Leu Lye λla He Gin λla λβp λla Gin λla Lyβ Gin Lye 35 40 45 Thr λla Hie λla Glu Leu Lye λla He Glu λla Gin Ser Ser λla Lyβ 50 55 60 Glu Lyβ λla He Gin λla Gin He Glu Gly Glu Leu λrg Thr βln Leu 65 70 75 80 λla Thr Met Ser λla Met Leu Lyβ Gly λla λβn Gly Val He Aβn Gly 85 90 95 Val λβn Gly Met Thr Gly Gly Phe Phe λla Gly Ser λβp He Leu Leu 100 105 110 Gly Val Met Glu Gly Tyr Ser Ser Gly λla 115 120 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 143 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: eingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: Arg Pro Met Ser Val Ser Met Pro Thr Val Tyr λla Lyβ Tyr Gin λla 1 5 10 15 Leu λrg Thr λβn λla Leu Thr Ser Gly Val λen Pro He Thr Thr Pro 20 25 30 λla Cye Pro He Gly λep Lye Val Lβu λla Val Tyr Cyβ Tyr λla Glu 35 40 45 Lyβ Val λla Glu He Leu λrg Glu Tyr Tyr He Glu Phe Val Lys λβn 50 55 60 λsn Thr λsn Leu Leu Gin λβn λla Ser Gin Met He Leu λβn Gin Ser 65 70 75 80 Gly Leu λla Thr Ser Thr Tyr λβp Thr Gin λla He Ser λβn He Ser 85 90 95 Ser Leu Tyr λβn Tyr λβn He Val λla λβn Lyβ Ser Phe Leu Lyβ Ser 100 105 110 Hie Leu Thr Tyr Leu λβp Tyr He Lyβ λβp Lyβ Leu Lye Gly Gin Lye 115 120 125 λsp Ser Tyr Leu Thr Glu λrg Val Gin Thr Lys He He Val Lys 130 135 140 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 159 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: He He Phe Cyβ Arg Leu Leu He Gly Ser Phe Leu λβn Hie Leu λen 1 5 10 IS Thr Ser Gly Val λla Gly Pro Phe λla Gly He Val λla Gly λla Met 20 25 30 Thr λla λla He He Pro He He Val Gly Phβ Thr λβn Pro Gin Met 35 40 45 Thr λla He Met Thr Gin Tyr λβn Gin Sβr He λla Glu λla Val Ser 50 55 60 Met Pro Met Lye λla λla Aβn Gin Gin Tyr Aβn Gin Leu Tyr Gin Gly 65 70 75 80 Phe Aβn Aβp Gin Ser Met λla Val Gly λβn λβn He Leu λβn He Ser 85 90 95 Lyβ Leu Thr Gly Glu Phe λβn λla Gin Gly λβn Ser Gin Gly λla Gin 100 105 110 He Gly λla Val λβn Ser Gin He λla Ser He Leu λla Ser λβn Thr 115 120 125 Thr Pro Lyβ λβn Pro Ser λla He Glu λla Tyr λla Thr λβn Gin He 130 135 140 λla Val Pro Ser Val Pro Thr Thr Val Glu Met Met Thr Val Tyr 145 150 155 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 140 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βinglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: Lyβ λrg He Phe He Lyβ Leu λβn Tyr Tyr Leu Leu Gly Val Leu Sβr 1 5 10 15 Leu λla Cyβ Lβu Gin Ser Val λen λla λβp Gin λβn Thr λβp He Lye 20 25 30 λβp He Ser Pro Glu λβp Met λla Leu λβn Ser Val Gly Leu Val Ser 35 40 45 λrg λβp Gin Leu Lyβ He Glu He Pro Lyβ Glu Thr Leu Glu Gin Lyβ 50 55 60 Val λla He Leu λβn λep Tyr λen λep Lye λen Val λen He Lye Phe 65 70 75 80 λsp λsp He Ser Leu Gly Ser Phe Gin Pro λsn λβp λβn Leu Gly He 85 90 95 Asn Ala Met Trp Gly He Gin λsn Leu Leu Met Ser Gin Met Met Gly 100 105 110 λsp Tyr Gly Pro λβn λβn Pro Phe Met Tyr Gly Tyr λla Pro Thr Tyr 115 120 125 Ser λsp Ser Ser Phe Leu Pro Pro He Leu Gly Tyr 130 135 140 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 261 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: eingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 0: Thr Lyβ He He Gly λβn Phe Glu Aβn λβp Val Leu Thr He Leu λβp 1 5 10 15 Ser Phe Ser λsn Tyr Leu Phe Glu Leu Lys Glu Glu Leu λβp Phe He 20 25 30 Glu Glu Glu Met Glu Gly Glu He Thr Glu Gin λβn Lβu Thr Thr Leu 35 40 45 Tyr λsp Phe Ser λβn Phe Leu Glu λep Hie Val λβn Val Phe Tyr Glu 50 55 60 λen Val Leu λβn He λβp λβp Val Lyβ Thr Glu Hie Leu Tyr Ser Gly 65 70 75 80 Leu He Asp Ser Leu Asn λla λβn Leu Hie Phe Val Lye Ser Phe Leu 85 90 95 Ser λβn Gin λsp Leu λsp Phe λrg Phe Phe Lye Glu He λen λβp Gly 100 105 110 Gin λep Pro Gin Lye Thr Leu Ser λrg Leu He Pro Leu Gin Ser Gly 115 120 125 Lyβ λβn λβp λla Ser Ser Phe Lyβ λla λβn λβn Ser Phe Val Ser Leu 130 135 140 Val Tyr Val Tyr λla Tyr Phβ Met Leu Glu Thr He Met Gin Ser Tyr 145 150 155 160 λrg He Leu λrg Leu Leu Glu Lyβ Pro He λβn λen λβn He Ser Glu 165 170 175 λβp Met Gin Ser λsp He Glu He Phe Phe Val Gin λla λβn Phe Leu 180 185 190 Glu Tyr Tyr Val Gin λβn Lyβ He Tyr Pro Lyβ λβn Hie λla Tyr λβp 195 200 205 Phe Met Hie Leu He Met λsp Ser He He Pro λβn Trp He Gin He 210 215 220 λβp Met Ser Val Glu λla Lyβ Lye Lye Glu Leu Phe Glu Lyβ Tyr Phe 225 230 235 240 Gin λβn He λsp Glu Val Thr λsn Lye Met Leu λβp Gin Lyβ λsn Gin 245 250 255 λβn Lyβ λsn λsn λsp (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 263 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : Tyr λla Cyβ Ser λla Val Thr λβn Leu He Thr Gly λβn Met λβn Leu 1 5 10 15 Aβp Tyr Pro He Thr Gin Leu He Aβn λla Phe Gly Lyβ λβp Hie λβn 20 25 30 λβp Pro λβn Gly Leu Val λla λrg Leu λla Pro Phe Cyβ Lyβ Ser Thr 35 40 45 λen Gly Glu Phβ Gin Trp Leu Phe λβp λen Lyβ λla Thr λβp λrg Leu 50 55 60 λβp Phe Ser Lyβ Thr He He Gly Val λβp Gly Sβr Sβr Phe Leu λβp 65 70 75 80 Asn Asn λβp Val Ser Pro Phe He Cyβ Phe Tyr Leu Phe λla λrg He 85 90 95 Gin Glu λla Met λβp Gly λrg λrg Phβ Val Leu λβp He λβp Glu λla 100 105 110 Trp Lyβ Tyr Leu Gly Aβp Pro Lye Val λla Tyr Phe Val λrg λβp Met 115 120 125 Leu Lys Thr λla λrg Lyβ λrg Aβn λla He Val λrg Leu λla Thr Gin 130 135 140 Ser He Thr λβp Leu Leu λla Cyβ Pro He λla λβp Thr He λrg Glu 145 150 155 160 Gin Cyβ Pro Thr Lyβ He Phe Leu λrg λβn λβp Gly Gly λβn Leu Ser 165 170 175 λβp Tyr βln λrg Leu λla λβn Val Thr βlu Lyβ βlu Phβ βlu He He 180 185 190 Thr Lyβ Gly Lβu λβp λrg Lyβ He Leu Tyr Lyβ Gin λep Gly Sβr Pro 195 200 205 Ser Val He λla Ser Phe λβn Leu λrg Gly He Pro Lyβ Glu Tyr Leu 210 215 220 Lyβ He Leu Ser Thr λβp Thr Val Phβ Val Lyβ Glu He λβp Lyβ He 225 230 235 240 He Gin Aβn Hie Ser He He λep Lye Tyr Gin λla Lβu λrg Gin Met 245 250 255 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 683 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: eingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: Ser Gly He Ser He Lyβ λrg βlu Val Phe Val λla Ser Lye Gin λla 1 5 10 15 λsp Glu Gin Lys Lys Leu He He Glu Gin Glu Val Gin Lyβ λrg Gin 20 25 30 Phe Gin Lyβ He Glu Glu Leu Lye λla λβp Met βln Lyβ Gly Val λβn 35 40 45 Pro Phe Phe Lye Val Leu Phe λβp Gly Gly λβn λrg Leu Phe Gly Phe 50 55 60 Pro Glu Thr Phe He Tyr Ser Ser He Phβ He Leu Phβ Val Thr He 65 70 75 80 Val Leu Ser Val He Lβu Phβ Gin λla Tyr Glu Pro Val Lβu He Val 85 90 95 λla He Val He Val Leu Val λla Leu Gly Phe Lyβ Lye Aβp Tyr λrg 100 105 110 Leu Tyr Gin λrg Met Glu λrg λla Met Lye Phβ Lyβ Lye Pro Phe Leu 115 120 125 Phe Lyβ Gly Val Lyβ λen Lye λla Phe Met Ser He Phe Ser Met Ly β 130 135 140 Pro Ser Lyβ Glu Met λla Aβn λβp He Hie Leu λβn Pro λβn λrg Glu 145 150 155 160 Leu Val Ser λla λla λβn Ser Tyr Leu λla λβn λβn Tyr Glu 165 170 175 Leu λβp λβp Gly Val He Leu Thr λen λen Tyr Ser Leu Leu 180 185 190 He Lye Leu βly βly He λβp Phe Leu Thr Thr Ser Lyβ Lyβ 195 200 205 He βlu Leu Hie λla Sβr He Tyr Ser Val Phe λrg λβn Phe 215 220 Pro βlu Phe Lyβ Phe Tyr Phe Hie Thr He Lyβ Lyβ Lye He 230 235 240 λβp βlu Thr λβn λrg λβp Tyr βly Lβu He Phe Ser λβn λep 245 250 255 λrg λla Tyr λβn βlu Lys βln Lyβ λrg βlu Ser Phe Tyr λβp 260 265 270 Phe Phe Leu Thr He βlu βln λβp Leu Leu Aβp Thr Leu Aβn 275 280 285 Val Met Aβn Lye Lyβ Hie Phe λla Aβp λβn λβn Phe βlu βlu 295 300 λrg He He λrg λla Lyβ Leu βlu λsn Phe Lyβ λβp λrg He 310 315 320 He βlu βlu Lβu Lβu Ser Lyβ Tyr His Pro Thr λrg Leu Lye 325 330 335 Thr Lye Aβp βly Val He Tyr Ser Lyβ βln Cyβ Glu Phβ Tyr 340 345 350 Leu Val Gly Met λβn Glu λla Pro Phβ He Cye λen λrg Lyβ 355 360 365 Tyr Leu Lyβ Glu Lyβ Met Hie Gly βly Val Lye βlu Val Tyr 375 380 λsn Lyβ Hie Gly Lyβ He Leu λβn λβp λβp Leu Ser Glu Lyβ 390 395 400 Ser λla He Glu He Ser Glu Tyr λla Pro Lyβ Sβr Gin Sβr 405 410 415 Phe Aβp Lys He λβn λla Leu λβp Ser Glu Phe He Phe Met 420 425 430 Tyr Ser Pro Lye λβn Ser Gin Val Leu Lyβ λβp Lyβ Lβu λla 435 440 445 Ser λrg λrg He He He Ser Gly βly Ser Lyβ βlu βln βly 455 460 Leu βly Cyβ Leu Ser Clu Leu Val βly λβn βly λβp He Thr 470 475 480 Ser Tyr βly λβn Ser Leu Val Leu Phe λla λsp Ser Phe βlu 485 490 495 Lyβ βln Ser Val Lyβ βlu Cye Val Ser Ser Leu λβn λla Lye 500 505 510 βly Phβ Leu λla λβn λla λla Thr Phβ Ser Met βlu λβn Tyr Phe Phe 515 520 525 λla Lyβ Hie Cye Sβr Phe He Thr Leu Pro Phe He Phe λβp Val Thr 530 535 540 Ser λβn λβn Phβ λla λβp Phβ He λla Met λrg λla Met Ser Phe λβp 545 550 555 560 Cly λβn βln βlu λβn λen λla Trp βly λβn Sβr Val Met Thr Leu Lyβ 565 570 575 Ser βlu He λβn Ser Pro Phe Tyr Leu λen Phe Hie Met Pro Thr Aβp 580 585 590 Phe βly Ser λla Ser λla βly Hie λla Tyr βly Aβn He Val λla Met 595 600 605 βly βly βlu Tyr Val Lyβ He βlu Leu βly Thr λβp Thr βly Leu λβn 610 615 620 Pro Phβ λla Trp λla λla Cyβ Val Cln Lyβ Thr λβn λla Thr Met βlu 625 630 635 640 βln Lyβ βln Thr λla He Ser Val Val Lyβ βlu Leu Val Lyβ λen Leu 645 650 655 λla Thr Lyβ Ser Aβp βlu Lye λβp βlu λβn βly λβn Ser He Ser Phe 660 665 670 Ser Leu λla λβp Ser λen Thr Lβu λla λla βln 675 680 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: Ala Leu Ser Leu λla Ser He Leu λla λrg Val Glu Glu Leu λla Lyβ 1 5 10 15 Leu He λen λen λβn λβn λβn Ser λβn Lyβ Lye Leu λrg Gly Phe Phe 20 25 30 Leu Lyβ Val Leu Leu Ser Leu Val Val Phβ Ser Ser Tyr Gly Leu λla 35 40 45 λβn λβp Asp Lyβ Glu λla Lya Lys Glu λla Gin Glu Lyβ Glu Lyβ λβn 50 55 60 Thr Pro λβn Gly Leu Val Tyr Thr λsn Leu λsp Phe λsp Ser Phe Lys 65 70 75 80 λla Thr He Lyβ λβn Leu Lyβ λβp Lyβ Lyβ Val Thr Phβ Lyβ Glu Val 85 90 95 λβn Pro Asp He He Lyβ λsp Glu Val Phe λsp Phe Val He Val λβn 100 105 110 Arg Val Leu Lyβ Lyβ He Lyβ λsp Leu Lys Hie Tyr λβp Pro Val He 115 120 125 βlu Lye He Phe λβp βlu Lyβ βly Lyβ βlu Met βly Leu λβn Val βlu 130 135 140 Leu βln He λen Pro βlu Val Lye λsp Phe Phe Thr Phe Lyβ Sβr He 145 150 155 160 Ser Thr Thr λen Lye βln λrg Cye Phe Leu Ser Leu λrg βly βlu Thr 165 170 175 λrg βlu He Leu Cyβ λβp λep Lye Lβu Tyr λβn Val Leu Leu λla Val 180 185 190 Phe λβn Ser Tyr λep Pro λβn Aβp Leu Leu Lyβ Hie He Ser Thr Val 195 200 205 Clu Ser Leu Lyβ Lyβ He Phe Tyr Thr He Thr Cyβ Clu λla Val Tyr 210 215 220 Leu 225 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 122 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: einglβ (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: Phe Gin Phe Glu λrg Lyβ λrg Met Lye Phβ Phe Thr λrg He Thr λβp 1 5 10 15 Ser Tyr Lyβ Lyβ Val Val Val Thr Leu Gly Leu Val Val Thr Thr λβn 20 25 30 Pro Leu λβn λla Val λla Ser Pro Thr Glu Gly Val Thr λla Thr Lye 35 40 45 Gly Leu Val He Gin He He Ser Val Leu λla He Val Gly Gly Cye 50 55 60 λla Leu Gly Val Lyβ Gly He λla λβp He Trp Lye He Ser λβp λβp 65 70 75 80 He Lyβ λrg Gly Gin λla Thr Val Phe λrg Tyr λla βln Pro He λla 85 90 95 Met Leu λla Val λla Gly Gly He He Tyr Leu Ser Thr Lye Phe βly 100 105 110 Phe λβn He βly βlu βly βly βly λla Ser 115 120 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: λla Phe Val He Hie Lye He Hie Met βly λβn Lye Met βlu λen Lye 1 5 10 15 Ser He βly βln He Phe Lye λβp Ser Leu Lyβ Lye Ser Phe Phe Ser 20 25 30 βly Leu Trp Ser Cyβ Lβu Lye Trp Sβr Phβ He Leu Thr Leu He Ser 35 40 45 Leu Cly Leu Phe Leu Leu Val Phe λrg Phe βln Pro βlu Thr He Lyβ 50 55 60 Lyβ Tyr He Lye λβp Pro Lye λβp Leu βln Phe Tyr λβn λβp Leu λrg 65 70 75 80 Lyβ Lyβ λβn βly Trp λβp Lye 85 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 amino acide (B) TYPE: amino acid (C) STRANDEDNESS: βingle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Lye Ser Val Met Lye He Cly Val Phe λβp Ser βly Val βly βly Phe I S 10 15 Ser Val Leu Lyβ Ser Leu Leu Lye λla βln Leu Phe λβp βlu He He 20 25 30 Tyr Tyr βly λβp Thr λla λrg Val Pro Tyr βly Thr Lye λβp Pro Thr 35 40 45 Thr He Lyβ βln Phe βly Leu βlu λla Leu λβp Phe Phe Lyβ Pro His 50 55 60 βln He βlu Leu Leu He Val λla Cyβ λβn Thr λla Sβr λla Leu λla 65 70 75 80 Leu Clu βlu Met βln Lyβ Hie Ser Lye He Pro He Val βly Val He 85 90 95 βlu Pro Ser He Leu λla He Lyβ λrg βln Val Lyβ λβp Lyβ λen λla 100 105 110 Pro He Leu Val Leu βly Thr Lyβ λla Thr He βln Ser λβn λla Tyr 115 120 125 λsp λβn λla Leu Lys βln βln Gly Tyr Leu λsn Val Ser Hie Leu λla 130 135 140 Thr Ser Leu Phe Val Pro Leu He Glu Glu Ser He Leu Glu Gly Glu 145 150 155 160 Leu Lβu Clu Thr Cye Met λrg Tyr Tyr Phe Thr Pro Leu Lyβ He Phe 165 170 175 Pro Lyβ

Claims: CLAIMS What is claimed is: 1. A composition comprising an isolated Helicobacter pylori CagI polynucleotide or fragment thereof. 2. The composition of claim 1 comprising all or part of the nucleotide sequence shown in Fig. 3. 3. A composition comprising a probe comprising the polynucleotide of claim 1. 4. A composition comprising a nucleic acid diagnostic kit comprising the probe of claim 3. 5. A composition comprising a vaccine comprising the polynucleotide of claim 1. 6. A composition comprising a vector comprising the polynucleotide of claim 1. 7. A composition comprising a host cell transformed with the vector of claim 6. 8. A composition comprising a purified protein or fragment thereof encoded by the polynucleotide of claim 1. 9. The composition of claim 8 wherein the protein is recombinantly produced. 10. The composition of claim 8 wherein the protein is labelled or coupled to a solid support. 11. A composition comprising an immunodiagnostic kit comprising the protein of claim 10. 12. A composition comprising a vaccine comprising a protein of claim 8 and a pharmaceutically acceptable carrier. 13. The composition of claim 12 further comprising an adjuvant. 14. A method for preparing an H. pylori vaccine comprising mixing the protein of claim 8 with a pharmaceutically acceptable carrier. 15. A method of diagnosing H. pylori comprising bringing the protein of claim 8 in contact with a biological sample and detecting antibody-antigen complexes. 16. A method of treating an individual infected with Helicobacter pylori comprising administering an effective amount of the vaccine of claim 12. 17. A method of diagnosing H. pylori comprising contacting the probe of claim 3 with a biological sample and detecting hybridization with a target sequence. 18. A method for recombinantly producing an H. pylori protein comprising culturing the host cell of claim 7 and isolating the recombinant polypeptide. 19. A method for diagnosing a pathogenic Type I strain of H. pylori comprising contacting the probe of claim 3 with a biological sample and detecting hybridization with a target sequence.

Inventors: COVACCI ANTONELLO, COVACCI, ANTONELLO
Applicants: BIOCINE SPA, BIOCINE S.P.A.
Application year: 1996
Main classification: C12N15
IPC codes: A61K36, A61K39, A61P31, C07K14, C12N15, C12P21, C12Q1, C12R1, G01N33